

## **Statistical Analysis Plan**

**Study ID:** 217710

**Official Title of Study:** A Phase 4, randomized, open-label, two-arm study evaluating implementation strategies for the delivery of Cabotegravir in low and high-volume pre-exposure prophylaxis (PrEP) sites in the U.S. for HIV uninfected MSM and transgender men  $\geq 18$

**NCT number:** NCT05374525

**Date of Document:** 04 Oct 2024

# A Phase 4, Randomized, Open-label, Two-arm Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low- and High-volume Pre-exposure Prophylaxis (PrEP) Sites in the US for HIV Uninfected MSM and Transgender Men ≥18: 217710 PILLAR

## Statistical Analysis Plan: Patient Study Participants Questionnaires

**EVA-32399 | October 4, 2024 | Version 2.0**

Prepared For:

PPD | Study Delivery Lead—Respiratory & Specialty, GSK

PPD, PhD, MPH | PPD, Global Implementation Science, ViiV Healthcare



Prepared By:

PPD, MA | Senior Research Scientist, Patient Centered Research | PPD

PPD, MPH | Research Scientist, Patient Centered Research | PPD

PPD, MSc | Lead Data Analyst, Patient Centered Research | PPD

PPD, MPH | Research Associate III, Patient Centered Research | PPD

Project Contact:

PPD, MS, PMP | Tel: PPD



# Table of Contents

<b>1</b>	<b>INTRODUCTION.....</b>	<b>1</b>
<b>2</b>	<b>PILLAR STUDY DESIGN .....</b>	<b>1</b>
2.1	Feasibility of Intervention Measure .....	3
2.2	Acceptability of Intervention Measure .....	3
2.3	Analysis Population.....	4
2.4	Missing Data Handling Scheme.....	4
2.5	Significance Levels and Multiplicity .....	4
<b>3</b>	<b>STATISTICAL METHODS .....</b>	<b>4</b>
3.1	Cross-sectional Distributional Characteristics of Study Variables and Features of Score Distributions .....	5
3.1.1	PSP Demographics, Behavioral History, and Attitudes/Knowledge about PrEP and APRETUDE .....	5
3.2	Feasibility and Acceptability of APRETUDE and Telehealth .....	5
3.2.1	Cross sectional Descriptive Statistics by Visits.....	5
3.2.2	Assessment of Variability Within vs. Between Clusters.....	<b>Error! Bookmark not defined.</b>
3.2.3	Mixed-effects Models at M6/7 and M12/13 .....	5
3.2.4	Change from Baseline Mixed Models.....	6
3.3	PSP Perception of Facilitators and Barriers to Feasibility and Acceptability of APRETUDE .....	7
3.4	Acceptability and Utility of DI Compared to RI for APRETUDE Administration .....	7
3.5	PSP Perceptions of Sexual Health Assessment .....	7
3.6	Experience of Implementation .....	7
3.7	HIV Knowledge, Stigma, and Quality of Care .....	7
3.8	Differences by Implementation Arm and Site Volume, FIM APRETUDE and FIM Telehealth .....	8
<b>4</b>	<b>REFERENCES.....</b>	<b>9</b>
	TABLE SHELLS FOR BASELINE ANALYSIS .....	10
	TABLE SHELLS FOR MONTH 6/7 ANALYSIS .....	205
	TABLE SHELLS FOR MONTH 12/13 ANALYSIS .....	420

## List of Abbreviations

Abbreviation	Definition
AIM	Acceptability of Intervention Measure
BL	Baseline
CAB	Cabotegravir
DI	Dynamic implementation
DTI	Direct to injection
FIM	Feasibility of Intervention Measure
HIV	Human immunodeficiency virus
ISQ	Implementation Science Questionnaire
LA	Long-acting
MSM	Men who have sex with men
OLI	Oral lead-in
PrEP	Pre-exposure prophylaxis
PSP	Patient Study Participant
REML	Residual maximum likelihood
RI	Routine implementation
SAP	Statistical analysis plan
SD	Standard deviation
SSP	Staff study participant
TGM	Transgender men
US	United States



# 1 Introduction

---

This study is being conducted following the Food and Drug Administration approval and commercial availability of cabotegravir (CAB) long-acting (LA) for pre-exposure prophylaxis (PrEP, also known as of APRETUDE) in the United States (US). This is an open-label, phase IV, two-arm (dynamic implementation and routine implementation) study of the delivery of APRETUDE in low- and high-volume sites in the US for men who have sex with men (MSM) and transgender men (TGM)  $\geq 18$  years of age, referred to herein as patient study participants (PSPs). Eighteen clinics (~9 high and ~9 low volume) were randomized 2:1 to dynamic implementation (DI) or routine implementation (RI) (protocol # 217710/ Amendment 2.0), and one site was lost in the DI arm.

This statistical analysis plan (SAP) describes the analysis of the PSP questionnaires, which includes the analyses assessing PSP responses to questions regarding the acceptability and feasibility of receiving cabotegravir (GKS1265744) long-acting (APRETUDE).

# 2 Pillar Study Design

---

The phase 4 study is designed to evaluate DI versus RI strategies on the feasibility of delivering APRETUDE at high- and low-volume PrEP centers over 12 months. The patient population includes approximately 220 human immunodeficiency virus (HIV)-negative PSPs across sites who will be prescribed CAB PrEP and enrolled in the study. At least 50% of the PSPs will be Black or Latino. While the primary objective and associated endpoints are aimed at assessing the feasibility of the administration of APRETUDE from the site perspective, secondary and tertiary objectives/endpoints will address the perspective of PSPs, including the feasibility and acceptability for APRETUDE and telehealth. The comparison of DI vs. RI at the site level with PSPs nested within the randomization (i.e., cluster-randomized) will also be performed in the same way as has been described for the staff study participants (SSPs) SAP. As was stated in the SSP SAP, this design may affect the interpretation of certain outcomes as the independence of responses of PSPs within the same site may not hold.

Objectives/endpoints relevant to the current SAP are listed in [Table A](#).

Table A. Study Objectives for PSP Data

Objective Type	Objectives	Endpoints
Secondary	To evaluate feasibility and acceptability of APRETUDE for MSM and TGM.	PSPs mean FIM and AIM scores as well as ISQ responses at BL, M7(OLI)/M6(DTI) and M13(OLI)/M12(DTI).
		Change from baseline in PSPs' AIM and FIM scores as well as ISQ responses FIM score at M7(OLI)/M6(DTI) and M13(OLI)/M12(DTI)
		PSPs perception of facilitators and barriers to feasibility and acceptability of APRETUDE through M13(OLI)/M12(DTI).
	To evaluate feasibility and acceptability of telehealth delivery for APRETUDE administration by clinical staff.	PSPs' mean FIM and AIM scores as well as ISQ responses for telehealth delivery at BL, M7(OLI)/M6(DTI) and M13(OLI)/M12(DTI)
		Change from baseline in PSPs' FIM and AIM scores as well as ISQ responses for telehealth delivery at M7(OLI)/M6(DTI) and M13(OLI)/M12(DTI).
		PSPs perception of facilitators and barriers to feasibility and acceptability of telehealth use through M13(OLI)/M12(DTI)
	To evaluate acceptability and utility of DI compared to RI for APRETUDE administration	PSPs' mean AIM score and ISQ responses by implementation strategy at BL, M7(OLI)/M6(DTI). and M13(OLI)/M12(DTI)
		Change from baseline in PSPs' mean AIM score and ISQ responses by implementation strategy at M7(OLI)/M6(DTI) and M13(OLI)/M12(DTI)
		Proportion of PSPs who respond in agreement on relevant items on the ISQ that each implementation strategy is fit for use through M13(OLI)/M12(DTI)
	To evaluate fidelity to injection and dosing window	PSPs perception of barriers and facilitators to fidelity to injections through M13
	To evaluate fidelity and reach of client Sexual Health Assessment	Proportion of eligible PSPs for which Sexual Health Assessment are administered through M13 and by clinic characteristics, patient subgroups, and service delivery method (e.g., telehealth vs. face-to-face in clinic)
		Proportion of MSM and TGM who take the Sexual Health Assessment through M13
		Proportion of MSM and TGM who expressed interest in PrEP or never heard of PrEP out of those who report having had sex in the last 6 months through M13
		Proportion of PSPs who initiate APRETUDE after taking the Sexual Health Assessment through M13
		PSPs perceptions of Sexual Health Assessment through M13
	To evaluate switch from oral PrEP to APRETUDE	Proportion of PSPs with history of PrEP use that complete the Sexual Health Assessment and ISQ and start APRETUDE through M13
		PSPs reasons for choosing APRETUDE, including switching, as assessed by SSIs and ISQ
	To evaluate perceptions, barriers, and facilitators with PSPs	PSPs perception of barriers and facilitators through M13.
Tertiary		

Objective Type	Objectives	Endpoints
	CCI	

## 2.1 Feasibility of Intervention Measure

The Feasibility of Intervention Measure (FIM) is employed to evaluate the extent to which an intervention can be carried out. This four-item measure assesses perceived intervention feasibility by employing a standard item stem to various aspects of feasibility. The items are measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The FIM has been validated with other implementation outcome measures.<sup>1</sup> Higher scores for FIM indicate greater feasibility and there are no reverse-scored items on the FIM. The FIM has been adapted to measure PSPs' assessments of implementation of APRETUDE and telehealth. Mean scores for the FIM are derived by averaging the four items at each administration where at least two of four item responses are available. This mechanism for handling scoring in the presence of missing item-level responses has been used widely in patient- and clinician-reported outcomes.<sup>2</sup>

## 2.2 Acceptability of Intervention Measure

The Acceptability of Intervention Measure (AIM) is employed to evaluate the perception that a given intervention or treatment is satisfactory. It is similar to the FIM as it is a four-item measure, but it assesses perceived intervention acceptability instead of feasibility. The items are measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The AIM was validated with a suite of implementation outcome measures.<sup>1</sup> Higher scores for AIM indicate greater acceptability. As with the FIM, there are no reverse-scored items on the AIM, and the mean score for acceptability of the intervention is calculated by averaging the responses from four items, provided at least two of the four items have viable responses.<sup>2</sup> The AIM has been

adapted to measure PSPs' assessments of the implementation of: APRETUDE, implementation support, and telehealth.

## 2.3 Analysis Population

The study population in this analysis will be all respondents who complete any item on the PSP questionnaire at any timepoint.

## 2.4 Missing Data Handling Scheme

Missing data at the item level are anticipated to be rare. However, in some cases, the PSP may terminate before completing the survey in its entirety. The scoring algorithm and handling of missing values for FIM and AIM are described in Sections 2.1, 2.2, and 3.2.1. If a participant decides to withdraw from the study, the data will be handled according to the protocol: "If the PSP withdraws consent for disclosure of future information, the sponsor may retain and continue to use any data collected before such a withdrawal of consent." PSPs will be analyzed according to the data as given, and no data imputation will be implemented.

## 2.5 Significance Levels and Multiplicity

Any statistical significance tests will be two-tailed and will be conducted with type I error probability fixed at 0.05. Statistical significance, then, will be determined if the p-value is less than 0.05. No multiplicity adjustment will be performed. The general null and alternative hypotheses for statistical tests will be for a given parameter ( $\theta$ )—e.g., mean:

$$H_0: \theta = 0$$

Versus

$$H_A: \theta \neq 0$$

# 3 Statistical Methods

---

Continuous and interval-like variables will be summarized using descriptive statistics (e.g., n, mean, standard deviation [SD], minimum, first quartile, median, third quartile, and maximum). Means and quartiles will be summarized to one decimal place beyond the data values, SD will be reported to two decimal places more than the source data, and minima and maxima will be reported to the same precision level as the source data. Categorical variables will be reported as frequency counts: the percentage of PSPs in corresponding categories, expressed as whole numbers and percentages with one decimal (e.g., 10.1%). Continuous outcomes will be evaluated depending on the number of group comparisons being made. Grouping variables with two levels will be compared with t-tests. Grouping variables with three or more categories, or which have more than one independent variable (see sections 3.2.3 or 3.2.4 below), or analyses which include a stratification factor, will be evaluated with F-tests and pairwise comparisons will be calculated to aid in interpretation of main effects. Categorical variables will be analyzed with Cochran-Mantel-Haenszel test or Fisher's Exact Test depending on data availability per

category, i.e., if any cell of a given contingency table has a cell with incidence of five or less the Fisher test will be used.

### 3.1 Cross-sectional Distributional Characteristics of Study Variables and Features of Score Distributions

For questions with ordinal responses, a univariate distribution of every item will be tabulated. Standard distributional statistics will be tabulated for interval-like (ordinal) variables, including mean, SD, median, percentage missing, minimum, and maximum of responses, percentage of the sample at the ceiling and floor, first and third quartiles, and 95% confidence intervals around means. For questions with categorical responses, a frequency distribution of all responses will be presented with the number and percentage of a given response.

CCI

### 3.2 Feasibility and Acceptability of APRETUDE and Telehealth

#### 3.2.1 Cross sectional Descriptive Statistics by Visits

PSP mean FIM and AIM scores focusing on APRETUDE and Telehealth at baseline, M6/M7, and M12/M13 will be evaluated by the study arms using descriptive statistics and mixed-effects modeling approaches described below. Descriptive statistics of scores and coded item response will include those listed in Section 3.1 for continuous variables. Additionally, item response frequencies and percentages will be produced for individual items to further assess the distribution of responses.

#### 3.2.2 Mixed-effects Models at M6/7 and M12/13

Cross-sectional mixed-effects models will be fit to the FIM and AIM mean scores at M6/7 and M12/13. These mixed-effects models will be fit using residual maximum likelihood (REML) and will assume data are missing at random. All data will be included regardless of early cessation from the implementation arm. The dependent variables will be the FIM and AIM mean scores. In the model, implementation arm (DI vs. RI), site volume (high vs. low), and the implementation arm by site volume interaction will be fitted as fixed terms, with separate random intercepts fitted to allow for clustering within sites, and for variability within the sites. Site volume was categorized as high versus low according to the reported estimate of PrEP patient seen monthly. These data were split at the median of 50; values above 50 were considered high and those below 50 were considered low. The baseline scores centered around their site mean will be fitted as fixed and random covariates. An unstructured covariance structure will be fitted to account

for the dependence of the residuals within the patient. Should the unstructured covariance structure cause model fitting problems (e.g., nonconvergence), heterogenous compound symmetry will be considered followed by homogenous compound symmetry. Should model fitting problems persist, the random effect on centered mean baseline score will be removed and models will be fit according to the same order of covariance structures (unstructured, then heterogenous compound symmetry, then homogenous compound symmetry).

The corresponding multilevel model for the FIM and AIM scores,  $Y_{ij}$ , for the  $i^{th}$  individual at the  $j^{th}$  site is expressed as:

$$Y_{ij} = \beta_{00} + \beta_{01}I_j + \beta_{02}V_j + \beta_{03}I_jV_j + \beta_{10}(B_{ij} - \bar{B}_j) + u_{0j} + u_{1j}(B_{ij} - \bar{B}_j) + e_{ij}$$

$$e_{ij} \sim N(0, \sigma^2)$$

$$\begin{pmatrix} u_{0j} \\ u_{1j} \end{pmatrix} \sim N \left[ \begin{pmatrix} 0 \\ 0 \end{pmatrix}, \begin{pmatrix} \tau_{00} & \tau_{01} \\ \tau_{10} & \tau_{11} \end{pmatrix} \right]$$

With fixed effects for baseline score ( $B_{ij} - \bar{B}_j$ ), implementation arm ( $I_j$ ), site volume ( $V_j$ ), and the arm by volume interaction. The parameter  $\beta_{00}$  is the fixed mean for the RI arm with low volume. The parameters  $\beta_{01}$ ,  $\beta_{02}$ ,  $\beta_{03}$ , and  $\beta_{10}$  are regression weights for the fixed effects of DI arm, high volume, arm by volume, and baseline score, respectively. Random effects for sites ( $u_{0j}$ ), baseline scores across sites ( $u_{1j}$ ), and the residual error ( $e_{ij}$ ) are also included. All random effects and the error term are assumed to be independent. Coding of the mixed-effects models will be done as suggested by Singer (1998).<sup>3</sup> It is worth noting that there is likely a range restriction on FIM and AIM endpoints given that the measures are fairly discrete (i.e., on a 1–5 scale with 0.25 increments) and adjustment of the mixed-effects models may be necessary if the model fits are determined to be affected by this range restriction. The study implementation arms and specific timepoint contrasts will be calculated within the mixed-effects modeling framework.

### 3.2.3 Change from Baseline Mixed Models

Change from baseline in PSPs' AIM and FIM scores at M6/7, and M12/M13 will be modeled similarly to those described in Section **Error! Reference source not found.**. The dependent variables in this case, however, will be the change from baseline in FIM and AIM mean scores.

The corresponding multilevel model for the changes from baseline in FIM and AIM scores,  $(Y_{ij} - B_{ij})$ , for the  $i^{th}$  individual at the  $j^{th}$  site is expressed as:

$$(Y_{ij} - B_{ij}) = \beta_{00} + \beta_{01}I_j + \beta_{02}V_j + \beta_{03}I_jV_j + \beta_{10}(B_{ij} - \bar{B}_j) + u_{0j} + u_{1j}(B_{ij} - \bar{B}_j) + e_{ij}$$

$$e_{ij} \sim N(0, \sigma^2)$$

$$\begin{pmatrix} u_{0j} \\ u_{1j} \end{pmatrix} \sim N \left[ \begin{pmatrix} 0 \\ 0 \end{pmatrix}, \begin{pmatrix} \tau_{00} & \tau_{01} \\ \tau_{10} & \tau_{11} \end{pmatrix} \right]$$

Similar to the model in Section **Error! Reference source not found.**, we include the same fixed and random effects. All random effects and the error term are assumed to be independent and random effects will be fit with an unstructured covariance matrix. Model fitting will be attempted until an adequately fitting model is found according to the hierarchy of covariance structures and model specifications described in section 3.2.2. REML will be used to estimate the model's parameters.

### **3.3 PSP Perception of Facilitators and Barriers to Feasibility and Acceptability of APRETUDE**

The PSP perception of facilitators and barriers to feasibility and acceptability of APRETUDE will be tabulated by gender (MSM, TGM), implementation arm (RI, DI), and site volume (high, low). For select items tabulation will also be performed by race, ethnicity, as well as race and ethnicity by implementation arm (RI, DI). Descriptive analyses of the facilitators and barriers will be conducted at all timepoints.

### **3.4 Acceptability and Utility of DI Compared to RI for APRETUDE Administration**

The proportion of PSPs responding in agreement on relevant items that the respective implementation strategy that they experienced is fit for use at M12/M13 will be estimated.

### **3.5 PSP Perceptions of Sexual Health Assessment**

PSP perceptions of the Sexual Health Assessment through M6/7 and M12/M13 will be tabulated by subgroup (MSM, TGM), implementation arm, and site volume. For select items tabulation will also be performed by race, ethnicity, as well as race and ethnicity by implementation arm (RI, DI). All analyses will be conducted at each timepoint.

### **3.6 Experience of Implementation**

Attitudes regarding aspects of the experience of implementation, including regarding oral lead-in vs. direct-to-injection, missed doses and following steps, injections and injection reactions, scheduling/appointments, clinics, and quality of care will be tabulated by gender timepoint, implementation arm, and site volume. For select items tabulation will also be performed by race, ethnicity, as well as race and ethnicity by implementation arm (RI, DI). All analyses will be conducted at each timepoint.

### **3.7 HIV Knowledge, Stigma, and Quality of Care**

Three subscales regarding HIV Knowledge,<sup>4</sup> Stigma,<sup>5</sup> and Quality of Care<sup>6</sup> are included at all three timepoints. The items of these scales will be tabulated by gender (MSM, TGM), implementation arm (RI, DI), and site volume (high, low); tabulation by race, ethnicity, as well as race and ethnicity by implementation arm will, will be conducted for select items.

For scale scores, distributional characteristics will be summarized by subgroup (MSM, TGM), implementation arm (RI, DI), site volume (high, low), race, ethnicity, as well as race and ethnicity by implementation arm. Cronbach's alpha will also be calculated for items comprising scale scores across the available sample. All analyses will be conducted at each timepoint.

### **3.8 Differences by Implementation Arm and Site Volume, FIM/AIM APRETUDE, and FIM/AIM Telehealth**

Difference for FIM/AIM means scores in PSP by implementation arm (RI, DI), site volume (high, low), and the interaction of these variables will be tested using a 2 x 2 between-subjects analysis of variance. The FIM/AIM for APRETUDE and telehealth will be tested, separately, in all analyses all factors will be fixed. Significant interactions will be followed up with appropriate simple effects.



## 4 References

---

1. Weiner BJ, Lewis CC, Stanick C, et al. Psychometric assessment of three newly developed implementation outcome measures. *Implement Sci.* 2017;12(1):108. doi:10.1186/s13012-017-0635-3
2. Cella D. *Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System—Version 4.* Center on Outcomes, Research & Education (CORE), Evanston Northwestern Healthcare and Northwestern University; 1997.
3. Singer JD. Using SAS PROC MIXED to fit multilevel models, hierarchical models, and individual growth models. *J Educational Behavioral Stat.* 1998;24(4):323-355.
4. Janulis P, Newcomb ME, Sullivan P, Mustanski B. Evaluating HIV Knowledge Questionnaires Among Men Who Have Sex with Men: A Multi-Study Item Response Theory Analysis. *Arch Sex Behav.* 2018;47(1):107-119. doi:10.1007/s10508-016-0910-4
5. Siegler AJ, Wiatrek S, Mouhanna F, et al. Validation of the HIV Pre-exposure Prophylaxis Stigma Scale: Performance of Likert and Semantic Differential Scale Versions. *AIDS Behav.* 2020;24(9):2637-2649. doi:10.1007/s10461-020-02820-6
6. Pilgrim N, Jani N, Mathur S, et al. Provider perspectives on PrEP for adolescent girls and young women in Tanzania: The role of provider biases and quality of care. *PLoS One.* 2018;13(4):e0196280. doi:10.1371/journal.pone.0196280

## Table Shells for Baseline Analysis

Table 5.001. Demographic Characteristics of New Patient Study Participants (Baseline), N=XX .....	15
Table 5.003. Summary of Behaviors of Patient Study Participants (Baseline), N=XX .....	18
Table 5.004. Summary of Patient Study Participants' Sexual History and Behaviors (Baseline), N=XX, Study Arms .....	20
Table 5.005. Summary of Patient Study Participants' Sexual History and Behaviors (Baseline), N=XX, Race, Dynamic Implementation.....	23
Table 5.006. Summary of Patient Study Participants' Sexual History and Behaviors (Baseline), N=XX, Race, Routine Implementation .....	26
Table 5.007. Summary of Patient Study Participants' Sexual History and Behaviors (Baseline), N=XX, Race, Total .....	29
Table 5.008. Summary of Patient Study Participants' Sexual History and Behaviors (Baseline), N=XX, Ethnicity, Study Arms.....	32
Table 5.009. Summary of Patient Study Participants' Sexual History and Behaviors (Baseline), N=XX, Ethnicity, Total.....	35
Table 5.0010. Summary of Patient Study Participants' Sexual History and Behaviors (Baseline), N=XX, Gender, Total .....	38
Table 5.101. Summary of Patient Study Participants' HIV and PrEP Knowledge (Baseline), N=XX .....	41
Table 5.102. Summary of Patient Study Participants' HIV and PrEP Knowledge (Baseline), N=XX, Scale Questions, Study Arms .....	42
Table 5.103. Distributional Characteristics of Patient Study Participants' HIV and PrEP Knowledge (Baseline), N=XX, Scale Questions, Overall Score .....	44
Table 5.104. Summary of Patient Study Participants' Perception of Stigma Associated with PrEP Usage (Baseline), N=XX, Stigma, Study Arms .....	46
Table 5.105. Distributional Characteristics of Patient Study Participants' History and Perception of PrEP Usage (Baseline), N=XX, Stigma, Overall Score.....	50
Table 5.106. Summary of Patient Study Participants' Choice of APRETUDE (Baseline), N=XX .....	52
Table 5.107. Summary of Knowledge of APRETUDE and Utility of Implementation Strategies (Baseline), N=XX .....	56
Table 5.108. Attitude Regarding APRETUDE and Utility of Implementation Strategies (Baseline), N=XX ...	60
Table 5.109. Summary of Patient Study Participant Acquisition Process (Baseline), N=XX .....	62
Table 5.110. Summary of Patient Study Participant Acquisition Process, Insurance (Baseline), N=XX .....	63
Table 5.111. Summary of Patient Study Participants' Perception of Stigma Associated with PrEP Usage (Baseline), N=XX.....	67
Table 5.112. Summary of Patient Study Participants' History and Perception of PrEP Usage (Baseline), N=XX, Study Arms .....	70
Table 5.113. Summary of Patient Study Participants' History and Perception of PrEP Usage (Baseline), N=XX, Race, Dynamic Implementation .....	71
Table 5.114. Summary of Patient Study Participants' History and Perception of PrEP Usage (Baseline), N=XX, Race, Routine Implementation .....	73

Table 5.115. Summary of Patient Study Participants' History and Perception of PrEP Usage (Baseline), N=XX, Race, Total.....	75
Table 5.116. Summary of Patient Study Participants' History and Perception of PrEP Usage (Baseline), N=XX, Ethnicity, Study Arms .....	77
Table 5.117. Summary of Patient Study Participants' History and Perception of PrEP Usage (Baseline), N=XX, Ethnicity, Total .....	79
Table 5.118. Summary of Patient Study Participants' History and Perception of PrEP Usage (Baseline), N=XX, Gender, Total .....	81
Table 5.201. Distributional Characteristics of Acceptability of Intervention (AIM) (APREUDE) (PSP) (Baseline), N=XX .....	82
Table 5.202. Distributional Characteristics of Feasibility of Intervention (FIM) (APREUDE) (PSP) (Baseline), N=XX .....	84
Table 5.203. Distributional Characteristics of Accessibility of Intervention (AIM) (Telehealth) (PSP) (Baseline), N=XX .....	86
Table 5.204. Distributional Characteristics of Feasibility of Intervention (FIM) (Telehealth) (PSP) (Baseline), N=XX .....	88
Table 5.205. Summary of Acceptability of Intervention (AIM) (APREUDE) (PSP) (Baseline), N=XX .....	90
Table 5.206. Summary of Feasibility of Intervention (FIM) (APREUDE) (PSP) (Baseline), N=XX .....	92
Table 5.207. Summary of Acceptability of Intervention (AIM) (Telehealth) (PSP) (Baseline), N=XX.....	94
Table 5.208. Summary of Feasibility of Intervention (FIM) (Telehealth) (PSP) (Baseline), N=XX.....	96
Table 5.301. Summary of Feasibility and Acceptability of Telehealth (Baseline), N=XX .....	98
Table 5.302. Summary of Quality of Care for Patient Study Participants (Baseline), N=XX .....	102
Table 5.303. Summary of Quality of Care for Patient Study Participants (Baseline), N=XX, Non-Score Questions .....	106
Table 5.304. Summary of Quality of Care for Patient Study Participants (Baseline), N=XX, Score Questions .....	121
Table 5.305. Distributional Characteristics of Quality of Care for Patient Study Participants (Baseline), N=XX, Score Questions, Overall Score .....	138
Table 5.306. Summary of Utility of Proposed Implementation Strategies (Baseline), N=XX .....	141
Table 5.307. Summary of Patient Study Participants' Preferences/Acceptability of APREUDE Information, Appointment Reminders, and Locations (Baseline), N=XX .....	146
Table 5.401. Summary of Acceptability and Feasibility of APREUDE Injection Visits (Baseline), N=XX, Study Arms .....	149
Table 5.402. Summary of Acceptability and Feasibility of APREUDE Injection Visits (Baseline), N=XX, Race, Dynamic Implementation.....	152
Table 5.403. Summary of Acceptability and Feasibility of APREUDE Injection Visits (Baseline), N=XX, Race, Routine Implementation.....	155
Table 5.404. Summary of Acceptability and Feasibility of APREUDE Injection Visits (Baseline), N=XX, Race, Total .....	158
Table 5.405. Summary of Acceptability and Feasibility of APREUDE Injection Visits (Baseline), N=XX, Ethnicity, Study Arms.....	161

Table 5.406. Summary of Acceptability and Feasibility of APRETUDE Injection Visits (Baseline), N=XX, Ethnicity, Total.....	164
Table 5.407. Summary of Acceptability and Feasibility of APRETUDE Injection Visits (Baseline), N=XX, Gender, Total.....	167
Table 5.408. Summary of Reach and Perceptions of Sexual Health Assessment Tool (Baseline), N=XX, Study Arms .....	170
Table 5.409. Summary of Reach and Perceptions of Sexual Health Assessment Tool (Baseline), N=XX, Race, Dynamic Implementation.....	174
Table 5.410. Summary of Reach and Perceptions of Sexual Health Assessment Tool (Baseline), N=XX, Race, Routine Implementation .....	178
Table 5.411. Summary of Reach and Perceptions of Sexual Health Assessment Tool (Baseline), N=XX, Race, Total .....	182
Table 5.412. Summary of Reach and Perceptions of Sexual Health Assessment Tool (Baseline), N=XX, Ethnicity, Study Arms.....	186
Table 5.413. Summary of Reach and Perceptions of Sexual Health Assessment Tool (Baseline), N=XX, Ethnicity, Total.....	190
Table 5.414. Summary of Reach and Perceptions of Sexual Health Assessment Tool (Baseline), N=XX, Gender.....	194
Table 5.415. Summary of Reach and Perceptions of Sexual Health Assessment Tool (Baseline), N=XX, Site Volume .....	198
Table 5.416. Distributional Characteristics of Estimated Amount of Money Spent on Transportation for Each Injection Visit (Baseline), N=XX.....	202
Table 5.417 Summary of Optional Oral Lead-In vs. Direct to Injection (Baseline), N=XX .....	203

Table 5.000. Demographic Characteristics of New Patient Study Participants (Baseline), N=XX

Question Number	Question	Response	Total (N=XX) n (%)	Dynamic Implementation (N=XX) n (%)	Routine Implementation (N=XX) n (%)
DM1	Age (years)	N	XX	XX	XX
		Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)
		Median	XX.X	XX.X	XX.X
		Q1, Q3	XX, XX	XX, XX	XX, XX
		Min-Max	XX.X, XX.X	XX.X, XX.X	XX.X, XX.X
DM2	Age (years), High Volume	N	XX	XX	XX
		Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)
		Median	XX.X	XX.X	XX.X
		Q1, Q3	XX, XX	XX, XX	XX, XX
		Min-Max	XX.X, XX.X	XX.X, XX.X	XX.X, XX.X
DM3	Age (years), Low Volume	N	XX	XX	XX
		Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)
		Median	XX.X	XX.X	XX.X
		Q1, Q3	XX, XX	XX, XX	XX, XX
		Min-Max	XX.X, XX.X	XX.X, XX.X	XX.X, XX.X
DM4	Age				
		18-25	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		26-35	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		36-49	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		50+	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
DM5	Study Arm				
		Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
DM6	Site Volume				
		High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
DM7	Gender				
		Men who have sex with men	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Transgender men	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
DM8	Race				
		Asian	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Black or African American	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		White	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Missing/Unknown	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N=XX) n (%)	Dynamic Implementation (N=XX) n (%)	Routine Implementation (N=XX) n (%)
DM9	Ethnicity				
		Hispanic or Latino	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not Hispanic or Latino	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Missing/Unknown	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 5.001. Demographic Characteristics of New Patient Study Participants (Baseline), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
1	How would you describe your current sexual orientation?	Heterosexual or straight	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Gay or lesbian	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Bisexual	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Asexual	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Pansexual and/or questioning	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Same gender loving	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Queer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other gender	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
2	Which of the following best describes your <u>current</u> relationship status?	Single, never married	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Single, widowed	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Single, separated or divorced	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Dating, but not living with a partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Dating and living with a partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Domestic partnership/civil union	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Married	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
3	How would you describe your current living situation?	I live in my own house or apartment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I live in my parent's house or apartment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		I live in a family member's house or apartment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I live in a friend's house or apartment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I sleep on various friends' or relatives' couches	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I am homeless or am living in a shelter	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I live in motel(s)/hotel(s)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
4	What is the highest level of education you have completed?	Never attended school	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Less than high school	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Some high school; no diploma	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Regular high school diploma/GED or alternative	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Some college; no degree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Associate's or technical degree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		College degree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Postgraduate or professional degree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
5	What <u>best</u> describes your current employment status?	Employed for wages full-time (1 employer)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Employed for wages full-time (2 or more employers)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Employed for wages part-time (1 employer)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Employed for wages part-time (2 or more employers)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Self-employed	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A homemaker	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Student	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Retired	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not employed	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Unable to work (disabled)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
6	What type of medical insurance do you currently have?	My parents' insurance	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		My partner's/spouse's insurance	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Private insurance provided by my workplace	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Private insurance I purchased through an exchange (e.g., Obamacare, Affordable Care Act)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Federal Insurance (e.g., VA, TRICARE)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Medicare or Medicaid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Some other health care plan	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't have any health insurance currently	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 5.002. Summary of Behaviors of Patient Study Participants (Baseline), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
76	How often do you have a drink containing alcohol?				
		Never	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Monthly or less	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		2 to 4 times a month	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		2 to 3 times a week	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		4 or more times a week	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
77	On days when you drink alcohol, how many drinks containing alcohol do you typically have? (1 drink, 1 standard bottle/ can of beer, 1 glass of wine, 1 mixed drink, or 1 shot of liquor)				
		1 or 2	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		3 to 4	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		5 to 6	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		7 to 9	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		10 or more	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
78	In the last 6 months, have you shot up or injected any drugs that were not prescribed for you by a healthcare provider, such as speedball, heroin, or crack? By shooting up, we mean anytime you might have used drugs with a needle, either by mainlining, skin popping, or muscling.				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
79	In the last 6 months, have you used any non-injection drugs (drugs you did not inject like pills, patches, or inhaled substances), <u>that</u> were not prescribed for you by a healthcare provider, such as marijuana, X, downers, or crack cocaine?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 5.003. Summary of Patient Study Participants' Sexual History and Behaviors (Baseline), N=XX, Study Arms**

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
14	Have you had sex in the last 6 months? <i>This could be vaginal sex (penis in vagina) OR anal sex (penis in butt) OR oral sex.</i>				
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
15	How would you describe your sexual behaviors in the last 6 months?				
		I have had vaginal sex (penis in vagina) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had vaginal sex (penis in vagina) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a bottom (penis in butt as a bottom) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a bottom (penis in butt as a bottom) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a top (penis in butt as a top) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a top (penis in butt as a top) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had oral sex (mouth, tongue, or lips on a vagina, penis, or butt) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had oral sex (mouth, tongue, or lips on a vagina, penis, or butt) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
16	How often did you use a condom when you had sex in the last 6 months?				
		All of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Most of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Some of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		None of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
17	In the last 6 months, how would you describe the HIV status of your sexual partner(s)?				
		I know that none of my sexual partners from the last 6 months have HIV/AIDS	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I know that at least one sexual partner from the last 6 months is living with HIV/AIDS	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I do not know my sexual partners' HIV status	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
18	As far as you know, were any of your sexual partner(s) from the last 6 months taking PrEP to prevent HIV infection? PrEP is a medication that prevents HIV.				
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
19	You mentioned that you had a least one partner in the last 6 months who is living with HIV/AIDS. As far as you know, were any of your partners taking HIV medications (antiretrovirals) to treat their HIV infection?				
		Yes, my partner(s) was/were taking HIV medications	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes, my partner(s) was/were taking HIV medications and was/were undetectable, meaning HIV tests were not finding the virus	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No, my partner(s) was/were not taking HIV medications	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I do not know whether my partner(s) was/were taking HIV medications	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
20	Have you had sex in the last 12 months? <i>This could be vaginal sex (penis in vagina) OR anal sex (penis in butt) OR oral sex.</i>				
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
21	In the last 12 months, have you experienced any incidents of sexual violence, physical abuse, or any other type of trauma from a partner?				

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
22	In the last 12 months, have you exchanged things like money or drugs for sex with a sexual partner?				
		Yes, I have a sexual partner things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes, a sexual partner gave me things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No, I have not exchanged things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 5.004. Summary of Patient Study Participants' Sexual History and Behaviors (Baseline), N=XX, Race, Dynamic Implementation**

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
14	Have you had sex in the last 6 months? <i>This could be vaginal sex (penis in vagina) OR anal sex (penis in butt) OR oral sex.</i>					
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
15	How would you describe your sexual behaviors in the last 6 months?					
		I have had vaginal sex (penis in vagina) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had vaginal sex (penis in vagina) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a bottom (penis in butt as a bottom) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a bottom (penis in butt as a bottom) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a top (penis in butt as a top) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a top (penis in butt as a top) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had oral sex (mouth, tongue, or lips on a vagina, penis, or butt) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had oral sex (mouth, tongue, or lips on a vagina, penis, or butt) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
16	How often did you use a condom when you had sex in the last 6 months?					

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
		All of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Most of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Some of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		None of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
17	In the last 6 months, how would you describe the HIV status of your sexual partner(s)?					
		I know that none of my sexual partners from the last 6 months have HIV/AIDS	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I know that at least one sexual partner from the last 6 months is living with HIV/AIDS	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I do not know my sexual partners' HIV status	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
18	As far as you know, were any of your sexual partner(s) from the last 6 months taking PrEP to prevent HIV infection? PrEP is a medication that prevents HIV.					
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
19	You mentioned that you had a least one partner in the last 6 months who is living with HIV/AIDS. As far as you know, were any of your partners taking HIV medications (antiretrovirals) to treat their HIV infection?					
		Yes, my partner(s) was/were taking HIV medications	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes, my partner(s) was/were taking HIV medications and was/were undetectable,	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
		meaning HIV tests were not finding the virus				
		No, my partner(s) was/were not taking HIV medications	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I do not know whether my partner(s) was/were taking HIV medications	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
20	Have you had sex in the last 12 months? <i>This could be vaginal sex (penis in vagina) OR anal sex (penis in butt) OR oral sex.</i>					
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
21	In the last 12 months, have you experienced any incidents of sexual violence, physical abuse, or any other type of trauma form a partner?					
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
22	In the last 12 months, have you exchanged things like money or drugs for sex with a sexual partner?					
		Yes, I have a sexual partner things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes, a sexual partner gave me things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No, I have not exchanged things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 5.005. Summary of Patient Study Participants' Sexual History and Behaviors (Baseline), N=XX, Race, Routine Implementation**

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
14	Have you had sex in the last 6 months? <i>This could be vaginal sex (penis in vagina) OR anal sex (penis in butt) OR oral sex.</i>					
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
15	How would you describe your sexual behaviors in the last 6 months?					
		I have had vaginal sex (penis in vagina) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had vaginal sex (penis in vagina) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a bottom (penis in butt as a bottom) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a bottom (penis in butt as a bottom) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a top (penis in butt as a top) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a top (penis in butt as a top) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had oral sex (mouth, tongue, or lips on a vagina, penis, or butt) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had oral sex (mouth, tongue, or lips on a vagina, penis, or butt) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
16	How often did you use a condom when you had sex in the last 6 months?					
		All of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Most of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Some of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		None of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
17	In the last 6 months, how would you describe the HIV status of your sexual partner(s)?					
		I know that none of my sexual partners from the last 6 months have HIV/AIDS	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I know that at least one sexual partner from the last 6 months is living with HIV/AIDS	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I do not know my sexual partners' HIV status	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
18	As far as you know, were any of your sexual partner(s) from the last 6 months taking PrEP to prevent HIV infection? PrEP is a medication that prevents HIV.					
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
19	You mentioned that you had a least one partner in the last 6 months who is living with HIV/AIDS. As far as you know, were any of your partners taking HIV medications (antiretrovirals) to treat their HIV infection?					
		Yes, my partner(s) was/were taking HIV medications	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes, my partner(s) was/were taking HIV medications and	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
		was/were undetectable, meaning HIV tests were not finding the virus				
		No, my partner(s) was/were not taking HIV medications	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I do not know whether my partner(s) was/were taking HIV medications	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
20	Have you had sex in the last 12 months? <i>This could be vaginal sex (penis in vagina) OR anal sex (penis in butt) OR oral sex.</i>					
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
21	In the last 12 months, have you experienced any incidents of sexual violence, physical abuse, or any other type of trauma from a partner?					
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
22	In the last 12 months, have you exchanged things like money or drugs for sex with a sexual partner?					
		Yes, I have a sexual partner things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes, a sexual partner gave me things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No, I have not exchanged things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 5.006. Summary of Patient Study Participants' Sexual History and Behaviors (Baseline), N=XX, Race, Total**

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
14	Have you had sex in the last 6 months? <i>This could be vaginal sex (penis in vagina) OR anal sex (penis in butt) OR oral sex.</i>					
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
15	How would you describe your sexual behaviors in the last 6 months?					
		I have had vaginal sex (penis in vagina) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had vaginal sex (penis in vagina) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a bottom (penis in butt as a bottom) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a bottom (penis in butt as a bottom) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a top (penis in butt as a top) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a top (penis in butt as a top) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had oral sex (mouth, tongue, or lips on a vagina, penis, or butt) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had oral sex (mouth, tongue, or lips on a vagina, penis, or butt) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
16	How often did you use a condom when you had sex in the last 6 months?					
		All of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Most of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Some of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		None of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
17	In the last 6 months, how would you describe the HIV status of your sexual partner(s)?					
		I know that none of my sexual partners from the last 6 months have HIV/AIDS	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I know that at least one sexual partner from the last 6 months is living with HIV/AIDS	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I do not know my sexual partners' HIV status	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
18	As far as you know, were any of your sexual partner(s) from the last 6 months taking PrEP to prevent HIV infection? PrEP is a medication that prevents HIV.					
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
19	You mentioned that you had a least one partner in the last 6 months who is living with HIV/AIDS. As far as you know, were any of your partners taking HIV medications (antiretrovirals) to treat their HIV infection?					
		Yes, my partner(s) was/were taking HIV medications	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes, my partner(s) was/were taking HIV medications and	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
		was/were undetectable, meaning HIV tests were not finding the virus				
		No, my partner(s) was/were not taking HIV medications	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I do not know whether my partner(s) was/were taking HIV medications	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
20	Have you had sex in the last 12 months? <i>This could be vaginal sex (penis in vagina) OR anal sex (penis in butt) OR oral sex.</i>					
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
21	In the last 12 months, have you experienced any incidents of sexual violence, physical abuse, or any other type of trauma from a partner?					
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
22	In the last 12 months, have you exchanged things like money or drugs for sex with a sexual partner?					
		Yes, I have a sexual partner things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes, a sexual partner gave me things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No, I have not exchanged things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 5.007. Summary of Patient Study Participants' Sexual History and Behaviors (Baseline), N=XX, Ethnicity, Study Arms**

Question Number	Question	Response	Dynamic Implementation		Routine Implementation	
			Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
14	Have you had sex in the last 6 months? <i>This could be vaginal sex (penis in vagina) OR anal sex (penis in butt) OR oral sex.</i>					
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
15	How would you describe your sexual behaviors in the last 6 months?					
		I have had vaginal sex (penis in vagina) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had vaginal sex (penis in vagina) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a bottom (penis in butt as a bottom) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a bottom (penis in butt as a bottom) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a top (penis in butt as a top) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a top (penis in butt as a top) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had oral sex (mouth, tongue, or lips on a vagina, penis, or butt) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had oral sex (mouth, tongue, or lips on a vagina, penis, or butt) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
16	How often did you use a condom when you had sex in the last 6 months?					



Question Number	Question	Response	Dynamic Implementation		Routine Implementation	
			Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
		All of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Most of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Some of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		None of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
17	In the last 6 months, how would you describe the HIV status of your sexual partner(s)?					
		I know that none of my sexual partners from the last 6 months have HIV/AIDS	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I know that at least one sexual partner from the last 6 months is living with HIV/AIDS	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I do not know my sexual partners' HIV status	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
18	As far as you know, were any of your sexual partner(s) from the last 6 months taking PrEP to prevent HIV infection? PrEP is a medication that prevents HIV.					
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
19	You mentioned that you had a least one partner in the last 6 months who is living with HIV/AIDS. As far as you know, were any of your partners taking HIV medications (antiretrovirals) to treat their HIV infection?					
		Yes, my partner(s) was/were taking HIV medications	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes, my partner(s) was/were taking HIV medications and was/were undetectable, meaning HIV tests were not finding the virus	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Dynamic Implementation		Routine Implementation	
			Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
		No, my partner(s) was/were not taking HIV medications	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I do not know whether my partner(s) was/were taking HIV medications	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
20	Have you had sex in the last 12 months? <i>This could be vaginal sex (penis in vagina) OR anal sex (penis in butt) OR oral sex.</i>					
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
21	In the last 12 months, have you experienced any incidents of sexual violence, physical abuse, or any other type of trauma from a partner?					
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
22	In the last 12 months, have you exchanged things like money or drugs for sex with a sexual partner?					
		Yes, I have a sexual partner things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes, a sexual partner gave me things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No, I have not exchanged things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 5.008. Summary of Patient Study Participants' Sexual History and Behaviors (Baseline), N=XX, Ethnicity, Total**

Question Number	Question	Response	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
14	Have you had sex in the last 6 months? <i>This could be vaginal sex (penis in vagina) OR anal sex (penis in butt) OR oral sex.</i>			
		No	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)
15	How would you describe your sexual behaviors in the last 6 months?			
		I have had vaginal sex (penis in vagina) with only 1 partner	XX (XX.X%)	XX (XX.X%)
		I have had vaginal sex (penis in vagina) with more than 1 partner	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a bottom (penis in butt as a bottom) with only 1 partner	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a bottom (penis in butt as a bottom) with more than 1 partner	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a top (penis in butt as a top) with only 1 partner	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a top (penis in butt as a top) with more than 1 partner	XX (XX.X%)	XX (XX.X%)
		I have had oral sex (mouth, tongue, or lips on a vagina, penis, or butt) with only 1 partner	XX (XX.X%)	XX (XX.X%)
		I have had oral sex (mouth, tongue, or lips on a vagina, penis, or butt) with more than 1 partner	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)
16	How often did you use a condom when you had sex in the last 6 months?			
		All of the time	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
		Most of the time	XX (XX.X%)	XX (XX.X%)
		Some of the time	XX (XX.X%)	XX (XX.X%)
		A little of the time	XX (XX.X%)	XX (XX.X%)
		None of the time	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)
17	In the last 6 months, how would you describe the HIV status of your sexual partner(s)?			
		I know that none of my sexual partners from the last 6 months have HIV/AIDS	XX (XX.X%)	XX (XX.X%)
		I know that at least one sexual partner from the last 6 months is living with HIV/AIDS	XX (XX.X%)	XX (XX.X%)
		I do not know my sexual partners' HIV status	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)
18	As far as you know, were any of your sexual partner(s) from the last 6 months taking PrEP to prevent HIV infection? PrEP is a medication that prevents HIV.			
		No	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)
19	You mentioned that you had a least one partner in the last 6 months who is living with HIV/AIDS. As far as you know, were any of your partners taking HIV medications (antiretrovirals) to treat their HIV infection?			
		Yes, my partner(s) was/were taking HIV medications	XX (XX.X%)	XX (XX.X%)
		Yes, my partner(s) was/were taking HIV medications and was/were undetectable, meaning HIV tests were not finding the virus	XX (XX.X%)	XX (XX.X%)
		No, my partner(s) was/were not taking HIV medications	XX (XX.X%)	XX (XX.X%)
		I do not know whether my partner(s) was/were taking HIV medications	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)
20	Have you had sex in the last 12 months? <i>This could be vaginal sex (penis in vagina) OR anal sex (penis in butt) OR oral sex.</i>			
		No	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)
21	In the last 12 months, have you experienced any incidents of sexual violence, physical abuse, or any other type of trauma form a partner?			
		No	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)
22	In the last 12 months, have you exchanged things like money or drugs for sex with a sexual partner?			
		Yes, I have a sexual partner things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)
		Yes, a sexual partner gave me things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)
		No, I have not exchanged things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)

**Table 5.09. Summary of Patient Study Participants' Sexual History and Behaviors (Baseline), N=XX, Gender, Total**

Question Number	Question	Response	Men who have sex with men (N = XX) n (%)	Transgender Men (N = XX) n (%)
14	Have you had sex in the last 6 months? <i>This could be vaginal sex (penis in vagina) OR anal sex (penis in butt) OR oral sex.</i>			
		No	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)
15	How would you describe your sexual behaviors in the last 6 months?			
		I have had vaginal sex (penis in vagina) with only 1 partner	XX (XX.X%)	XX (XX.X%)
		I have had vaginal sex (penis in vagina) with more than 1 partner	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a bottom (penis in butt as a bottom) with only 1 partner	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a bottom (penis in butt as a bottom) with more than 1 partner	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a top (penis in butt as a top) with only 1 partner	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a top (penis in butt as a top) with more than 1 partner	XX (XX.X%)	XX (XX.X%)
		I have had oral sex (mouth, tongue, or lips on a vagina, penis, or butt) with only 1 partner	XX (XX.X%)	XX (XX.X%)
		I have had oral sex (mouth, tongue, or lips on a vagina, penis, or butt) with more than 1 partner	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)
16	How often did you use a condom when you had sex in the last 6 months?			
		All of the time	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Men who have sex with men (N = XX) n (%)	Transgender Men (N = XX) n (%)
		Most of the time	XX (XX.X%)	XX (XX.X%)
		Some of the time	XX (XX.X%)	XX (XX.X%)
		A little of the time	XX (XX.X%)	XX (XX.X%)
		None of the time	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)
17	In the last 6 months, how would you describe the HIV status of your sexual partner(s)?			
		I know that none of my sexual partners from the last 6 months have HIV/AIDS	XX (XX.X%)	XX (XX.X%)
		I know that at least one sexual partner from the last 6 months is living with HIV/AIDS	XX (XX.X%)	XX (XX.X%)
		I do not know my sexual partners' HIV status	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)
18	As far as you know, were any of your sexual partner(s) from the last 6 months taking PrEP to prevent HIV infection? PrEP is a medication that prevents HIV.			
		No	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)
19	You mentioned that you had a least one partner in the last 6 months who is living with HIV/AIDS. As far as you know, were any of your partners taking HIV medications (antiretrovirals) to treat their HIV infection?			
		Yes, my partner(s) was/were taking HIV medications	XX (XX.X%)	XX (XX.X%)
		Yes, my partner(s) was/were taking HIV medications and was/were undetectable, meaning HIV tests were not finding the virus	XX (XX.X%)	XX (XX.X%)
		No, my partner(s) was/were not taking HIV medications	XX (XX.X%)	XX (XX.X%)
		I do not know whether my partner(s) was/were taking HIV medications	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Men who have sex with men (N = XX) n (%)	Transgender Men (N = XX) n (%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)
20	Have you had sex in the last 12 months? <i>This could be vaginal sex (penis in vagina) OR anal sex (penis in butt) OR oral sex.</i>			
		No	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)
21	In the last 12 months, have you experienced any incidents of sexual violence, physical abuse, or any other type of trauma from a partner?			
		No	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)
22	In the last 12 months, have you exchanged things like money or drugs for sex with a sexual partner?			
		Yes, I have a sexual partner things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)
		Yes, a sexual partner gave me things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)
		No, I have not exchanged things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)



Table 5.101. Summary of Patient Study Participants' HIV and PrEP Knowledge (Baseline), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
7	Do you personally know of someone living with HIV?	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
9	<b>Before enrolling in this study</b> , had you ever heard of people who do not have HIV taking <b>oral</b> PrEP pills (the medicine taken every day to reduce the risk of getting HIV)?	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
10	Do you personally <b>know</b> of a person or people who have ever taken oral PrEP?	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 5.102. Summary of Patient Study Participants' HIV and PrEP Knowledge (Baseline), N=XX, Scale Questions, Study Arms**

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
8	Please answer true or false to the following statements about HIV.				
A	A person who has HIV can look healthy.	True	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		False	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
B	There is a vaccine that can stop you from getting HIV.	True	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		False	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
C	A person will NOT get HIV if they are taking antibiotics.	True	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		False	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
D	If you only have sex once with a partner, you cannot get HIV from them.	True	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		False	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
E	People living with HIV on HIV medications cannot spread HIV.	True	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		False	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
F	Everybody who has HIV knows that they have HIV.	True	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		False	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
G	A natural (lamb skin) condom works better against HIV than a latex condom.	True	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		False	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
H	When using condoms during sex, it is safer to use water-based lubricants than oil-based lubricants.	True	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		False	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 5.103. Distributional Characteristics of Patient Study Participants' HIV and PrEP Knowledge (Baseline), N=XX, Scale Questions, Overall Score**

8. Please answer true or false to the following statements about HIV.	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean	Cronbach's $\alpha$
<b>Mean Score</b>	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	0.xx
<b>Study Arm</b>								
Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
<b>Site Volume</b>								
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
<b>Gender</b>								
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
<b>Race</b>								
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
<b>Ethnicity</b>								
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
<b>Dynamic Implementation</b>								
<b>Site Volume</b>								
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
<b>Gender</b>								
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-

8. Please answer true or false to the following statements about HIV.	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean	Cronbach's $\alpha$
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
<b>Race</b>								
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
<b>Ethnicity</b>								
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
<b>Routine Implementation</b>								
<b>Site Volume</b>								
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
<b>Gender</b>								
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
<b>Race</b>								
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
<b>Ethnicity</b>								
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—

Mean score = mean of responses to all of the items under 8 save for A and E; "Don't know" responses coded as false.

**Table 5.104. Summary of Patient Study Participants' Perception of Stigma Associated with PrEP Usage (Baseline), N=XX, Stigma, Study Arms**

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
13	To what extent do you agree with each of the following statements about PrEP?				
A	My <i>friends</i> would be supportive of me taking PrEP.	Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
B	People experience problems when they tell their sexual partner(s) they are taking PrEP.	Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
C	People experience negative judgement because they take PrEP.	Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
D	My <i>family</i> would be supportive of me taking PrEP.	Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
E	People taking PrEP receive praise for being responsible.	Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
F	I would feel ashamed to take PrEP in front of others.	Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
G	Someone taking PrEP would be seen by others as having sex with a lot of different people.	Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
H	People on PrEP are taking care of their health.	Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
I	People talking PrEP experience verbal harassment.	Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
J	I would not want others to know if I was taking PrEP.	Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
K	Someone taking PrEP should keep their pills hidden.	Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
L	I would feel proud to take PrEP every day.	Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
M	I would have sex with someone who is taking PrEP.	Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 5.105. Distributional Characteristics of Patient Study Participants' History and Perception of PrEP Usage (Baseline), N=XX, Stigma, Overall Score

13. To what extent do you agree with each of the following statements about PrEP?	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean	Cronbach's $\alpha$
<b>Mean Score</b>	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	X.XX
<b>Study Arm</b>								
Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
<b>Site Volume</b>								
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
<b>Gender</b>								
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
<b>Race</b>								
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
<b>Ethnicity</b>								
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
<b>Dynamic Implementation</b>								
<b>Site Volume</b>								
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
<b>Gender</b>								
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—

13. To what extent do you agree with each of the following statements about PrEP?	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean	Cronbach's $\alpha$
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
<b>Race</b>								
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
<b>Ethnicity</b>								
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
<b>Routine Implementation</b>								
<b>Site Volume</b>								
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
<b>Gender</b>								
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
<b>Race</b>								
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
<b>Ethnicity</b>								
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—

Mean score = mean of responses to all of the items under 13 save for J with the following items are reverse scored: A,D,E,H,L, & M. Higher total score indicates higher stigma.

Table 5.106. Summary of Patient Study Participants' Choice of APRETUDE (Baseline), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
11	Before enrolling in this study, had you heard of APRETUDE, the long acting injectable (shot) form of PrEP?	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
12	Where did you first learn about APRETUDE?				
		Healthcare provider (e.g., doctor, nurse)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Community organization	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Friend	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Family Member	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Internet (website)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Internet (social media)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Advertisement (radio, magazine, television)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
29	Why have you chosen to take (or switch to) APRETUDE?				
		I never tried PrEP before, but I want to protect myself from HIV	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I think APRETUDE is the most effective HIV prevention method available	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I will not have to worry about HIV every day	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I will be able to have sex at any moment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		and I know I am protected			
		I want to keep taking PrEP a secret	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I want a prevention option that is more convenient for my life	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		My sexual partner will not know I am taking PrEP	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		My doctor suggested I take APREUDE	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I won't have to remember to take PrEP everyday	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I often forget to take pills	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I want to try a new approach and see if it fits into my life	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer an injection to PrEP because I have difficulty swallowing pills	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I was concerned about the long-term side effects of my oral PrEP	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I do not have to worry or stress about missing a dose like oral PrEP	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I would feel more comfortable not taking pills with me when going out with people/friends	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I would feel more comfortable not taking pills with me when travelling	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I hope that injections will be easier on my stomach/digestive system	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
30	Do you have any concerns about APRETUDE?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
31	What concerns do you have about APRETUDE?				
		Pain or soreness from the injection	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other side effects from APRETUDE	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Fear of needles	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Being approved by my insurance to take it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Having to take oral PrEP first before I take APRETUDE injections	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Possible long-term effects of the injection	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		How it affects other medications I take	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Scheduling or rescheduling injection visits	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Forgetting my appointment for the injection visits	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Missing an injection visit and then getting HIV	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Missing work for the injection visits	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Making time to go to the clinic/practice for the injection visits	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Travelling to the clinic/practice for the injection visits	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Limited clinic/practice hours for injection visits	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Childcare/caregiver responsibilities during injection visits	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Lack of privacy at injection visits	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		My dignity not being respected during injection visits	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		People asking why I go to the clinic/doctor every 2 months	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		My hectic lifestyle	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		My travel or holiday schedules	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Taking medication during times when I am not having sex	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The medication not being effective at preventing HIV	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Worrying people would think I have HIV	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Worrying that people would think I have a lot of sexual partners because I am on CAB LA for PrEP	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Worrying about my privacy because I live with someone	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 5.107 Summary of Knowledge of APREUDE and Utility of Implementation Strategies (Baseline), N=XX**

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
67	Overall, how much do you know about APREUDE?				
		A lot	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Some	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Nothing	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
68	How confident are you with your current level of knowledge about APREUDE?				
		Extremely confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
69	How helpful was the information, if any, shared by the medical staff about APREUDE?				
		Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not receive any information from medical staff	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
70	How helpful has each of the following materials been in learning about APREUDE?				
A	Getting Started Brochure – the brochure that gives you an overview of how to get started with APREUDE	Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Did not use it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
B	Patient Brochure – this brochure helps you understand the process of receiving APRETUDE injections, including side effects and insurance information	Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Did not use it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
C	Let's talk about HIV & PrEP video – the video giving key facts about HIV and PrEP options (DI)	Very helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	N/A
		A little helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Not at all helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Did not use it	XX (XX.X%)	XX (XX.X%)	N/A
D	The APRETUDE Myths and Facts video – the game show video addressing common myths about APRETUDE (DI)	Very helpful	XX (XX.X%)	XX (XX.X%)	N/A

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	N/A
		A little helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Not at all helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Did not use it	XX (XX.X%)	XX (XX.X%)	N/A
E	The What to Expect video which shows you what to expect during the APREITUDE process (DI)	Very helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	N/A
		A little helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Not at all helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Did not use it	XX (XX.X%)	XX (XX.X%)	N/A
F	The ViiV Connect Video, which tells you about the ViiV Connect program and frequently asked questions (DI)	Very helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	N/A
		A little helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Not at all helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Did not use it	XX (XX.X%)	XX (XX.X%)	N/A
G	The study website where you access APRETDUE information (RI)	Very helpful	XX (XX.X%)	N/A	XX (XX.X%)
		Helpful	XX (XX.X%)	N/A	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Somewhat helpful	XX (XX.X%)	N/A	XX (XX.X%)
		A little helpful	XX (XX.X%)	N/A	XX (XX.X%)
		Not at all helpful	XX (XX.X%)	N/A	XX (XX.X%)
		Did not use it	XX (XX.X%)	N/A	XX (XX.X%)
H	The study app where you access APREUDE information (DI)	Very helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	N/A
		A little helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Not at all helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Did not use it	XX (XX.X%)	XX (XX.X%)	N/A

**Table 5.108. Attitude Regarding APREUDE and Utility of Implementation Strategies (Baseline), N=XX**

Question		Response				
75. Overall, how are you feeling about taking APREUDE?		Very positive	Somewhat positive	Neither positive nor negative	Somewhat negative	Very negative
Study Arms						
	Total (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Dynamic Implementation (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Routine Implementation (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Race, Dynamic Implementation						
	Asian (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Black or African American (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	White (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Race, Routine Implementation						
	Asian (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Black or African American (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	White (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Race, Total						

Question		Response				
	Asian (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Black or African American (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	White (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Ethnicity, Dynamic Implementation						
	Hispanic or Latino (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not Hispanic or Latino (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Ethnicity, Routine Implementation						
	Hispanic or Latino (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not Hispanic or Latino (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Ethnicity, Total						
	Hispanic or Latino (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not Hispanic or Latino (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Gender, Total						
	Men who have sex with men (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Transgender men (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 5.109. Summary of Patient Study Participant Acquisition Process (Baseline), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
71	Have you ever heard of ViiV Connect?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
72	Where did you learn about ViiV Connect?				
		My healthcare provider/healthcare clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The ViiV Connect video on the study app (DI arm only)	XX (XX.X%)	XX (XX.X%)	N/A
		ViiV Connect brochure	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A friend/family member told me	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The ViiV Connect website	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify_____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 5.110. Summary of Patient Study Participant Acquisition Process, Insurance (Baseline), N=XX**

Question		Response				
73. To what extent do you agree with each of the following statements?		Completely Agree	Agree	Neither agree nor disagree	Disagree	Completely disagree
<b>A. The staff at the clinic helped me understand the insurance approval process</b>						
Study Arms						
	Total N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Dynamic Implementation N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Routine Implementation (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Race, Dynamic Implementation						
	Asian N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Black or African American N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	White N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Race, Routine Implementation						
	Asian N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Black or African American N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	White N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Race, Total						

Question		Response				
	Asian N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Black or African American N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	White N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Ethnicity, Dynamic Implementation						
	Hispanic or Latino N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not Hispanic or Latino N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Ethnicity, Routine Implementation						
	Hispanic or Latino N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not Hispanic or Latino N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Ethnicity, Total						
	Hispanic or Latino N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not Hispanic or Latino N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Gender, Total						
	Men who have sex with men N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Transgender men N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>B. It took too long to get insurance approval for APREUDE</b>						
Study Arms						



Question		Response				
	Total N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Dynamic Implementation N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Routine Implementation N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Race, Dynamic Implementation						
	Asian N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Black or African American N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	White N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Race, Routine Implementation						
	Asian N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Black or African American N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	White N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Race, Total						
	Asian N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Black or African American N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question		Response				
	White N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Ethnicity, Dynamic Implementation						
	Hispanic or Latino N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not Hispanic or Latino N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Ethnicity, Routine Implementation						
	Hispanic or Latino N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not Hispanic or Latino N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Ethnicity, Total						
	Hispanic or Latino N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not Hispanic or Latino N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Gender, Total						
	Men who have sex with men N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Transgender men N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 5.111. Summary of Patient Study Participants' Perception of Stigma Associated with PrEP Usage (Baseline), N=XX**

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
27	Before deciding to take or switch to APRETUDE, have you ever experienced any of the following while taking oral PrEP? <i>Do not count oral Cabotegravir pills you might be taking before receiving APRETUDE.</i>				
A	Side effects	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
B	Experienced Insurance issues	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
C	The cost being too high	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
D	Problems remembering to take oral PrEP	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
E	Concerns about running out of oral PrEP	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
F	Feeling you had to hide oral PrEP from others	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
G	Thinking oral PrEP is not convenient for you	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
H	Difficulty paying for oral PrEP	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
I	Difficulty swallowing oral PrEP	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
J	Worried about potential interaction with other medicines	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
K	Not liking to take oral PrEP so frequently	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
L	Worrying that people may find out you are taking oral PrEP	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
M	Worrying that people will think you have HIV if they see you taking oral PrEP	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
N	Worrying that people would think you have a lot of sexual partners because you take oral PrEP	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
O	Worrying about your privacy because you live with someone	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
P	Worrying about your privacy because you're on you parent's health insurance plan	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Q	Other concerns (please specify _____)	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
28	What side effects have you experienced on oral PrEP?				
		Headache	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Diarrhea	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Nausea	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Vomiting	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Rash	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Loss of appetite	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Weight loss	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Stomach pain	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		New or worse kidney problems	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Bone problems	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Gas or bloating	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 5.112. Summary of Patient Study Participants' History and Perception of PrEP Usage (Baseline), N=XX, Study Arms**

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
23	Have you taken oral PrEP in the last 6 months? <i>Do not count oral cabotegravir pills you might be taking before receiving APRETUDE</i>				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
24	How would you describe your oral PrEP use in the last 6 months?				
		I take oral PrEP consistently (at least 5 or more days a week,) each week	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I take oral PrEP consistently (at least 5 or more days a week) off and on when I need to, but not every week	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I take oral PrEP for <u>less than</u> 5 days a week each week	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I take oral PrEP on demand/when I need it; this is also called PrEP 2-1-1	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
25	How many months in a row have you been taking oral PrEP?				
		Less than 2 month	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		2 to 6 months	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		7 to 12 months	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		More than 12 months	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
26	Have you ever taken oral PrEP?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 5.113. Summary of Patient Study Participants' History and Perception of PrEP Usage (Baseline), N=XX, Race, Dynamic Implementation**

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
23	Have you taken oral PrEP in the last 6 months? <i>Do not count oral cabotegravir pills you might be taking before receiving APRETUDE</i>					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
24	How would you describe your oral PrEP use in the last 6 months?					
		I take oral PrEP consistently (at least 5 or more days a week,) each week	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I take oral PrEP consistently (at least 5 or more days a week) off and on when I need to, but not every week	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I take oral PrEP for <u>less than</u> 5 days a week each week	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I take oral PrEP on demand/when I need it; this is also called PrEP 2-1-1	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
25	How many months in a row have you been taking oral PrEP?					
		Less than 2 month	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		2 to 6 months	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		7 to 12 months	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		More than 12 months	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
26	Have you ever taken oral PrEP?					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



**Table 5.114. Summary of Patient Study Participants' History and Perception of PrEP Usage (Baseline), N=XX, Race, Routine Implementation**

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
23	Have you taken oral PrEP in the last 6 months? <i>Do not count oral cabotegravir pills you might be taking before receiving APRETUDE</i>					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
24	How would you describe your oral PrEP use in the last 6 months?					
		I take oral PrEP consistently (at least 5 or more days a week,) each week	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I take oral PrEP consistently (at least 5 or more days a week) off and on when I need to, but not every week	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I take oral PrEP for <u>less than</u> 5 days a week each week	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I take oral PrEP on demand/when I need it; this is also called PrEP 2-1-1	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
25	How many months in a row have you been taking oral PrEP?					
		Less than 2 month	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		2 to 6 months	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		7 to 12 months	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		More than 12 months	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
26	Have you ever taken oral PrEP?					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 5.115. Summary of Patient Study Participants' History and Perception of PrEP Usage (Baseline), N=XX, Race, Total**

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
23	Have you taken oral PrEP in the last 6 months? <i>Do not count oral cabotegravir pills you might be taking before receiving APRETUDE</i>					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
24	How would you describe your oral PrEP use in the last 6 months?					
		I take oral PrEP consistently (at least 5 or more days a week,) each week	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I take oral PrEP consistently (at least 5 or more days a week) off and on when I need to, but not every week	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I take oral PrEP for <u>less than</u> 5 days a week each week	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I take oral PrEP on demand/when I need it; this is also called PrEP 2-1-1	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
25	How many months in a row have you been taking oral PrEP?					
		Less than 2 month	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		2 to 6 months	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		7 to 12 months	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		More than 12 months	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
26	Have you ever taken oral PrEP?					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 5.116. Summary of Patient Study Participants' History and Perception of PrEP Usage (Baseline), N=XX, Ethnicity, Study Arms**

Question Number	Question	Response	Dynamic Implementation		Routine Implementation	
			Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
23	Have you taken oral PrEP in the last 6 months? <i>Do not count oral cabotegravir pills you might be taking before receiving APREUDE</i>					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
24	How would you describe your oral PrEP use in the last 6 months?					
		I take oral PrEP consistently (at least 5 or more days a week,) each week	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I take oral PrEP consistently (at least 5 or more days a week) off and on when I need to, but not every week	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I take oral PrEP for <u>less than</u> 5 days a week each week	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I take oral PrEP on demand/when I need it; this is also called PrEP 2-1-1	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
25	How many months in a row have you been taking oral PrEP?					
		Less than 2 month	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		2 to 6 months	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Dynamic Implementation		Routine Implementation	
			Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
		7 to 12 months	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		More than 12 months	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
26	Have you ever taken oral PrEP?					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 5.117. Summary of Patient Study Participants' History and Perception of PrEP Usage (Baseline), N=XX, Ethnicity, Total**

Question Number	Question	Response	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
23	Have you taken oral PrEP in the last 6 months? <i>Do not count oral cabotegravir pills you might be taking before receiving APRETUDE</i>			
		Yes	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)
24	How would you describe your oral PrEP use in the last 6 months?			
		I take oral PrEP consistently (at least 5 or more days a week,) each week	XX (XX.X%)	XX (XX.X%)
		I take oral PrEP consistently (at least 5 or more days a week) off and on when I need to, but not every week	XX (XX.X%)	XX (XX.X%)
		I take oral PrEP for <u>less than</u> 5 days a week each week	XX (XX.X%)	XX (XX.X%)
		I take oral PrEP on demand/when I need it; this is also called PrEP 2-1-1	XX (XX.X%)	XX (XX.X%)
25	How many months in a row have you been taking oral PrEP?			
		Less than 2 month	XX (XX.X%)	XX (XX.X%)
		2 to 6 months	XX (XX.X%)	XX (XX.X%)
		7 to 12 months	XX (XX.X%)	XX (XX.X%)
		More than 12 months	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)
26	Have you ever taken oral PrEP?			

Question Number	Question	Response	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
		Yes	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)



**Table 5.118. Summary of Patient Study Participants' History and Perception of PrEP Usage (Baseline), N=XX, Gender, Total**

Question Number	Question	Response	Men who have sex with men (N = XX) n (%)	Transgender Men (N = XX) n (%)
23	Have you taken oral PrEP in the last 6 months? <i>Do not count oral cabotegravir pills you might be taking before receiving APREUDE</i>			
		Yes	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)
24	How would you describe your oral PrEP use in the last 6 months?			
		I take oral PrEP consistently (at least 5 or more days a week,) each week	XX (XX.X%)	XX (XX.X%)
		I take oral PrEP consistently (at least 5 or more days a week) off and on when I need to, but not every week	XX (XX.X%)	XX (XX.X%)
		I take oral PrEP for <u>less than</u> 5 days a week each week	XX (XX.X%)	XX (XX.X%)
		I take oral PrEP on demand/when I need it; this is also called PrEP 2-1-1	XX (XX.X%)	XX (XX.X%)
25	How many months in a row have you been taking oral PrEP?			
		Less than 2 month	XX (XX.X%)	XX (XX.X%)
		2 to 6 months	XX (XX.X%)	XX (XX.X%)
		7 to 12 months	XX (XX.X%)	XX (XX.X%)
		More than 12 months	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)
26	Have you ever taken oral PrEP?			
		Yes	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)

**Table 5.201. Distributional Characteristics of Acceptability of Intervention (AIM) (APREUDE) (PSP) (Baseline), N=XX**

32. AIM APREUDE.	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
<b>Mean Score</b>	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Study Arm</b>							
Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Gender</b>							
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Race</b>							
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Ethnicity</b>							
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Dynamic Implementation</b>							
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Gender</b>							
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)

32. AIM APREITUDE.	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Race</b>							
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Ethnicity</b>							
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Routine Implementation</b>							
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Gender</b>							
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Race</b>							
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Ethnicity</b>							
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)

**Table 5.202. Distributional Characteristics of Feasibility of Intervention (FIM) (APRETUDE) (PSP) (Baseline), N=XX**

33. FIM APRETUDE.	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
<b>Mean Score</b>	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Study Arm</b>							
Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Gender</b>							
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Race</b>							
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Ethnicity</b>							
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Dynamic Implementation</b>							
<b>Study Arm</b>							
Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)

33. FIM APREITUDE.	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Race</b>							
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Ethnicity</b>							
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Routine Implementation</b>							
<b>Study Arm</b>							
Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Race</b>							
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Ethnicity</b>							
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)

**Table 5.203. Distributional Characteristics of Accessibility of Intervention (AIM) (Telehealth) (PSP) (Baseline), N=XX**

34. AIM Telehealth.	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
<b>Mean Score</b>	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Study Arm</b>							
Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Gender</b>							
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Race</b>							
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Ethnicity</b>							
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Dynamic Implementation</b>							
<b>Study Arm</b>							
Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)

34. AIM Telehealth.	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Race</b>							
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Ethnicity</b>							
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Routine Implementation</b>							
<b>Study Arm</b>							
Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Race</b>							
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Ethnicity</b>							
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)

**Table 5.204. Distributional Characteristics of Feasibility of Intervention (FIM) (Telehealth) (PSP) (Baseline), N=XX**

35. FIM Telehealth.	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
<b>Mean Score</b>	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Study Arm</b>							
Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Gender</b>							
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Race</b>							
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Ethnicity</b>							
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Dynamic Implementation</b>							
<b>Study Arm</b>							
Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)



35. FIM Telehealth.	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Race</b>							
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Ethnicity</b>							
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Routine Implementation</b>							
<b>Study Arm</b>							
Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Race</b>							
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Ethnicity</b>							
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)

Table 5.205. Summary of Acceptability of Intervention (AIM) (APRETUDE) (PSP) (Baseline),  
N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
32	Please indicate how much you agree with each statement based on your current expectations of APRETUDE.				
	I believe APRETUDE will <b>meet my approval</b> for preventing HIV.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	APRETUDE for the prevention of HIV is <b>appealing to me.</b>	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I think I will <b>like</b> APRETUDE for the prevention of HIV.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I <b>welcome</b> APRETUDE for the prevention of HIV	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 5.206. Summary of Feasibility of Intervention (FIM) (APRETUDE) (PSP) (Baseline), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
33	Please indicate how much you agree with each statement based on your current expectations of APRETUDE.				
	Receiving APRETUDE injection every 2-months <b>seems workable</b> in my life	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Receiving APRETUDE injection every 2-months <b>seems possible</b> in my life	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Receiving APRETUDE injection every 2-months <b>seems doable</b> in my life	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Receiving APRETUDE injection every 2-months <b>seems easy</b> in my life	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 5.207. Summary of Acceptability of Intervention (AIM) (Telehealth) (PSP) (Baseline),  
N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
34	Please indicate how much you agree with each statement based on your current perceptions and experience with telehealth.				
	Using telehealth for APREUDE services <b>meets my approval.</b>	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Using telehealth for APREUDE services <b>is appealing to me.</b>	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I think I will <b>like</b> using telehealth for APREUDE services.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I <b>welcome</b> using telehealth for APREUDE services.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 5.208. Summary of Feasibility of Intervention (FIM) (Telehealth) (PSP) (Baseline), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
35	Please indicate how much you agree with each statement based on your current perceptions and experience with telehealth.				
	Using telehealth for APREITUDE services <b>seems workable</b> in my life.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Using telehealth for APREITUDE services <b>seems possible</b> in my life.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Using telehealth for APREITUDE services <b>seems doable</b> in my life.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Using telehealth for APREITUDE services <b>seems easy</b> in my life.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 5.301. Summary of Feasibility and Acceptability of Telehealth (Baseline), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
36	Do any of your healthcare providers offer any type of telehealth care, such as video or phone consultation, online appointment making, or using a portal to check documents?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
37	Have you ever used any of the telehealth care options that your healthcare provider or clinic offers?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
38	If offered via telehealth, <b>how convenient</b> do you think it would be to use the following services for APRETUDE? <i>By convenient, we mean fitting in well with your life activities and plans, with little trouble.</i>				
A	Completing relevant clinic visit forms online	Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither convenient nor inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
B	Your doctor ordering an HIV test kit and sending it to your home for you to test yourself	Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither convenient nor inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
C	Your doctor ordering an HIV test at a lab near your home where you can go to take the test	Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither convenient nor inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
D	Video chatting with your doctor	Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither convenient nor inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
E	Receiving reminders (e.g., text, email) about your scheduled injection appointment	Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither convenient nor inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
F	Scheduling your injection appointment online to go to your clinic/doctor's office for the injection	Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither convenient nor inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Somewhat inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
G	Scheduling your injection appointment online for a nurse to come to your home and to give you the injection	Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither convenient nor inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
H	Scheduling your injection appointment online to go to a pharmacy for the injection	Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither convenient nor inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
I	Sending messages to your doctor online	Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither convenient nor inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
J	Reviewing your health documents, such as test results, online	Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Neither convenient nor inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
39	How comfortable are you or would you be using telehealth to receive APRETUDE services?				
		Very comfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat comfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither comfortable nor uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 5.302. Summary of Quality of Care for Patient Study Participants (Baseline), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
74	To what extent do you agree with each of the following statements regarding your experience with your clinic/provider?				
A	My provider explained medical words that were used so that I could understand them.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
B	My provider encouraged me to ask questions.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
C	My provider really respected me.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
D	My provider gave me enough time to say what I though was important.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
E	My provider listened carefully to what I had to say.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX	XX	XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
			(XX.X%)	(XX.X%)	(XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
F	My provider explained why tests were being done.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
G	My provider made me feel comfortable talking about personal things.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
H	My privacy was respected.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
I	My provider does not judge me.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
J	The provider had a respectful attitude towards my sexual orientation.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
K	The staff at the clinic does not judge me.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
L	The staff at this clinic is kind and respectful to me.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
M	I sometimes felt insulted when the clinic staff spoke to me.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
N	I felt judged by the clinic staff for being on PrEP.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
O	I felt judged by my provider for being on PrEP.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 5.303. Summary of Quality of Care for Patient Study Participants (Baseline), N=XX, Non-Score Questions**

Question		Response			
74. To what extent do you agree with each of the following statements regarding your experience with your clinical/provider?		Completely Agree	Agree	Neither agree nor disagree	Disagree
<b>I. My provider does not judge me.</b>					
Study Arms					
	Total	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Dynamic Implementation	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Routine Implementation	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Dynamic Implementation					
	Asian	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Routine Implementation					
	Asian	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				

Question		Response			
	White	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Total					
	Asian	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Dynamic Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Routine Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Total					
	Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)

Question		Response			
	n (%)				
Gender, Total					
	Men who have sex with men	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Transgender men	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
<b>J. The provider had a respectful attitude towards my sexual orientation.</b>					
Study Arms					
	Total	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Dynamic Implementation	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Routine Implementation	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Dynamic Implementation					
	Asian	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Routine Implementation					
	Asian	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				

Question		Response			
	Black or African American	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Total					
	Asian	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Dynamic Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Routine Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Total					
	Hispanic or Latino	XX	XX	XX	XX

Question		Response			
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Gender, Total					
	Men who have sex with men	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Transgender men	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
<b>K. The staff at the clinic does not judge me.</b>					
Study Arms					
	Total	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Dynamic Implementation	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Routine Implementation	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Dynamic Implementation					
	Asian	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Routine Implementation					

Question		Response			
	Asian	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Total					
	Asian	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Dynamic Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Routine Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)

Question		Response			
	n (%)				
Ethnicity, Total					
	Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Gender, Total					
	Men who have sex with men	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Transgender men	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
<b>L. The staff at this clinic is kind and respectful to me.</b>					
Study Arms					
	Total	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Dynamic Implementation	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Routine Implementation	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Dynamic Implementation					
	Asian	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX



Question		Response			
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Routine Implementation					
	Asian	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Total					
	Asian	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Dynamic Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Routine Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)

Question		Response			
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Total					
	Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Gender, Total					
	Men who have sex with men	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Transgender men	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
M. I sometimes felt insulted when the clinic staff spoke to me.					
Study Arms					
	Total	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Dynamic Implementation	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Routine Implementation	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Dynamic Implementation					
	Asian	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX

Question		Response			
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Routine Implementation					
	Asian	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Total					
	Asian	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Dynamic Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				

Question		Response			
Ethnicity, Routine Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Total					
	Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Gender, Total					
	Men who have sex with men	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Transgender men	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
N. I felt judged by the clinic staff for being on PrEP.					
Study Arms					
	Total	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Dynamic Implementation	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Routine Implementation	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Dynamic Implementation					
	Asian	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				

Question		Response			
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Routine Implementation					
	Asian	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Total					
	Asian	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Dynamic Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				

Question		Response			
	Not Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Routine Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Total					
	Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Gender, Total					
	Men who have sex with men	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Transgender men	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
O. I felt judged by my provider for being on PrEP.					
Study Arms					
	Total	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Dynamic Implementation	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Routine Implementation	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Dynamic Implementation					
	Asian	XX	XX	XX	XX

Question		Response			
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Routine Implementation					
	Asian	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Total					
	Asian	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				

Question		Response			
Ethnicity, Dynamic Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Routine Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Total					
	Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Gender, Total					
	Men who have sex with men	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Transgender men	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				



**Table 5.304. Summary of Quality of Care for Patient Study Participants (Baseline), N=XX, Score Questions**

Question		Response			
74. To what extent do you agree with each of the following statements regarding your experience with your clinic/provider?		Completely Agree	Agree	Neither agree nor disagree	Disagree
<b>A. My provider explained medical words that were used so that I could understand them.</b>					
Study Arms					
	Total	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Dynamic Implementation	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Routine Implementation	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Dynamic Implementation					
	Asian	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Routine Implementation					
	Asian	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				

Question		Response			
	White	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Total					
	Asian	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Dynamic Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Routine Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Total					
	Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)

Question		Response			
	n (%)				
Gender, Total					
	Men who have sex with men	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Transgender men	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
<b>B. My provider encouraged me to ask questions.</b>					
Study Arms					
	Total	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Dynamic Implementation	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Routine Implementation	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Dynamic Implementation					
	Asian	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Routine Implementation					
	Asian	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				

Question		Response			
	Black or African American	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Total					
	Asian	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Dynamic Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Routine Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Total					
	Hispanic or Latino	XX	XX	XX	XX

Question		Response			
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Gender, Total					
	Men who have sex with men	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Transgender men	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
C. My provider really respected me.					
Study Arms					
	Total	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Dynamic Implementation	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Routine Implementation	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Dynamic Implementation					
	Asian	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Routine Implementation					

Question		Response			
	Asian	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Total					
	Asian	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Dynamic Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Routine Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)

Question		Response			
	n (%)				
Ethnicity, Total					
	Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Gender, Total					
	Men who have sex with men	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Transgender men	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
D. My provider gave me enough time to say what I thought was important.					
Study Arms					
	Total	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Dynamic Implementation	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Routine Implementation	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Dynamic Implementation					
	Asian	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX

Question		Response			
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Routine Implementation					
	Asian	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Total					
	Asian	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Dynamic Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Routine Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)



Question		Response			
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Total					
	Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Gender, Total					
	Men who have sex with men	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Transgender men	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
E. My provider listened carefully to what I had to say.					
Study Arms					
	Total	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Dynamic Implementation	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Routine Implementation	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Dynamic Implementation					
	Asian	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX

Question		Response			
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Routine Implementation					
	Asian	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Total					
	Asian	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Dynamic Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				

Question		Response			
Ethnicity, Routine Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Total					
	Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Gender, Total					
	Men who have sex with men	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Transgender men	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
F. My provider explained why tests were being done.					
Study Arms					
	Total	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Dynamic Implementation	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Routine Implementation	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Dynamic Implementation					
	Asian	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				

Question		Response			
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Routine Implementation					
	Asian	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Total					
	Asian	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Dynamic Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				

Question		Response			
	Not Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Routine Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Total					
	Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Gender, Total					
	Men who have sex with men	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Transgender men	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
<b>G. My provider made me feel comfortable talking about personal things.</b>					
Study Arms					
	Total	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Dynamic Implementation	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Routine Implementation	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Dynamic Implementation					
	Asian	XX	XX	XX	XX

Question		Response			
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Routine Implementation					
	Asian	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Total					
	Asian	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				

Question		Response			
Ethnicity, Dynamic Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Routine Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Total					
	Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Gender, Total					
	Men who have sex with men	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Transgender men	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
H. My privacy was respected.					
Study Arms					
	Total	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Dynamic Implementation	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Routine Implementation	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				

Question		Response			
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Dynamic Implementation					
	Asian	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Routine Implementation					
	Asian	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Total					
	Asian	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)



Question		Response			
	n (%)				
	Other	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Dynamic Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Routine Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Total					
	Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Gender, Total					
	Men who have sex with men	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Transgender men	XX	XX	XX	XX
	N = XX	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				

**Table 5.305. Distributional Characteristics of Quality of Care for Patient Study Participants (Baseline), N=XX, Score Questions, Overall Score**

74. To what extent do you agree with each of the following statements regarding your experience with your clinic/provider?	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean	Cronbach's $\alpha$
<b>Mean Score</b>	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)	0.xx
<b>Study Arm</b>								
Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)	-
Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)	-
<b>Site Volume</b>								
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)	-
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)	-
<b>Gender</b>								
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)	-
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)	-
<b>Race</b>								
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)	-
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)	-
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)	-
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)	-
<b>Ethnicity</b>								
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)	-
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)	-
<b>Dynamic Implementation</b>								
<b>Study Arm</b>								
Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)	-

74. To what extent do you agree with each of the following statements regarding your experience with your clinic/provider?	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean	Cronbach's $\alpha$
Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)	-
<b>Site Volume</b>								
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)	-
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)	-
<b>Race</b>								
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)	-
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)	-
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)	-
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)	-
<b>Ethnicity</b>								
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)	-
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)	-
<b>Routine Implementation</b>								
<b>Study Arm</b>								
Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)	-
Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)	-
<b>Site Volume</b>								
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)	-
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)	-
<b>Race</b>								
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)	-
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)	-

74. To what extent do you agree with each of the following statements regarding your experience with your clinic/provider?

	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean	Cronbach's $\alpha$
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)	—
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)	—
<b>Ethnicity</b>								
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)	—
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)	—

Mean score = mean of responses of items A-H. Responses were scored on a scale of 1-4 with higher scores indicating higher quality of care.

Table 5.306. Summary of Utility of Proposed Implementation Strategies (Baseline), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
56	How useful do you think each of the following will be in supporting you while taking APRETUDE?				
A	Brochures and other print materials to educate you on APRETUDE.	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not very useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Extremely useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
B	Videos to educate you on HIV, PrEP, APRETUDE	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not very useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Extremely useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
C	A digital calendar specifically made for APRETUDE to help you plan your injections	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not very useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Extremely useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
D	Text reminders about your injections	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not very useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
			(XX.X%)	(XX.X%)	(XX.X%)
		Extremely useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
E	Email reminders about your injections	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not very useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Extremely useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
F	Phone call reminders about your injections	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not very useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Extremely useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
G	Postal mail reminders about your injection	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not very useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Extremely useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
H	Having video or telephone appointments with your doctor	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not very useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
			(XX.X%)	(XX.X%)	(XX.X%)
		Extremely useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
I	Doing HIV tests at home	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not very useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Extremely useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
J	Doing HIV tests at a local lab near you	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not very useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Extremely useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
K	Having a nurse come to your home to conduct your HIV tests	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not very useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Extremely useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
L	Having a nurse come to your home to give your injection	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not very useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
			(XX.X%)	(XX.X%)	(XX.X%)
		Extremely useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
M	Receiving transportation to the clinic/doctor's office for your injection	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not very useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Extremely useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
N	Knowing that your clinic/doctor's office offers injections on specific days of the week	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not very useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Extremely useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
O	Ability to show up for your injection without an appointment	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not very useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Extremely useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
P	Appointments where you only get your injection and leave	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not very useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Extremely useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Q	Ability to schedule your injection appointments on weekends or after-hours	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not very useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Extremely useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
R	An app where you access APREUDE information	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not very useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Extremely useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
S	You and your doctor discussing the pros and cons (e.g., side effects, switching) of <u>different</u> PrEP options and <u>together</u> deciding which one is right for you	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not very useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Extremely useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 5.307. Summary of Patient Study Participants' Preferences/Acceptability of APRETUDE Information, Appointment Reminders, and Locations (Baseline), N=XX**

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
57	If you had questions about APRETUDE <b>before enrolling in the study</b> , where did you find answers?				
		I didn't find answers to my questions	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Product website	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Written materials such as the study handbook	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Speaking to a healthcare provider	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Social Media	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Internet search	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Friends	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Family	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have not had any questions so far	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
58	How did you receive reminder(s) about your first injection appointment?				
		Phone calls	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Texts/SMS messages	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Existing clinic app reminders	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Emails	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Reminder in the postal mail	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Face-to-face reminder from a healthcare provider	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Written reminder/appointment card with date and time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The study app (DI)	XX (XX.X%)	XX (XX.X%)	N/A
		I did not receive any reminders	XX	XX	XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
			(XX.X%)	(XX.X%)	(XX.X%)
59	Which type of appointment reminder(s) would you prefer?				
		Phone calls	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Texts/SMS messages	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Existing clinic app reminders	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Emails	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Reminder in the postal mail	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Face-to-face reminder from a healthcare provider	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Written reminder/appointment card with date and time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Another type of reminder (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I do not wish to receive any reminders	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
60	Where else would you consider receiving your injections?				
		Retail pharmacy clinic (e.g., Minute Clinic, CVS)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other pharmacy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Hospital outpatient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Infusion center	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Community-based organization	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		STD/STI clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Department of Health clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		PrEP clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Community health center	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Mobile van	XX	XX	XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
			(XX.X%)	(XX.X%)	(XX.X%)
		Nurse coming to your home	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 5.401. Summary of Acceptability and Feasibility of APRETUDE Injection Visits (Baseline), N=XX, Study Arms**

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
46	How long are you willing to spend in the clinic/practice for your injection visit from arrival at the clinic to when you leave?				
		Up to 20 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		21-40 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		41-60 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		61-90 minutes (1hr-1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		More than 90 minutes (more than 1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
47	How acceptable is coming to the clinic every 2 months for an injection?				
		Very acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
48	How convenient are your clinic's hours? <i>By convenient, we mean fitting well with your life activities and plans, with little trouble.</i>				
		Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
49	How easy or difficult do you think it will be getting to the clinic every 2 months for your injection?				
		Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
50	Approximately how long will it take you to get to the clinic/practice from your home to receive your injection?				
		Up to 20 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		21-40 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		41-60 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		61-90 minutes (1hr-1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		More than 90 minutes (more than 1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
51	How will you most likely get to the clinic/practice to get your injections?				
		Taxi/transportation service	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Ride-share service (e.g., Uber, Lyft)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Dropped off by someone else	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Drive a private vehicle	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Public transportation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Bicycle/scooter/skateboard/walking	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Transportation provided by clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
53	Do you think you will need to seek additional childcare/eldercare/other care to come to the clinic/practice for your injection visits.				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I am not caring for others right now (N/A)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
54	How much time do you think you will need to take off work to receive injections?				
		I am not working right now	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I will not need to take time off work for injections	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I will probably need to take a whole day off for each injection	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I will probably need to take a whole day off for some injections	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I will probably need to take a partial day off for each injection	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I will probably need to take a partial day off for some injections	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
55	Do you think your time off work for injections will be paid or unpaid?				
		Paid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Unpaid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 5.402. Summary of Acceptability and Feasibility of APRETUDE Injection Visits (Baseline), N=XX, Race, Dynamic Implementation**

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
46	How long are you willing to spend in the clinic/practice for your injection visit from arrival at the clinic to when you leave?					
		Up to 20 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		21-40 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		41-60 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		61-90 minutes (1hr-1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		More than 90 minutes (more than 1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
47	How acceptable is coming to the clinic every 2 months for an injection?					
		Very acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
48	How convenient are your clinic's hours? <i>By convenient, we mean fitting well with your life activities and plans, with little trouble.</i>					
		Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
49	How easy or difficult do you think it will be getting to the clinic every 2 months for your injection?					
		Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
50	Approximately how long will it take you to get to the clinic/practice from your home to receive your injection?					
		Up to 20 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		21-40 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		41-60 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		61-90 minutes (1hr-1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		More than 90 minutes (more than 1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
51	How will you most likely get to the clinic/practice to get your injections?					
		Taxi/transportation service	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Ride-share service (e.g., Uber, Lyft)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Dropped off by someone else	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Drive a private vehicle	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Public transportation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Bicycle/scooter/skateboard/walking	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Transportation provided by clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
53	Do you think you will need to seek additional childcare/eldercare/other care to come to the clinic/practice for your injection visits.					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I am not caring for others right now (N/A)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
54	How much time do you think you will need to take off work to receive injections?					
		I am not working right now	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I will not need to take time off work for injections	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I will probably need to take a whole day off for each injection	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I will probably need to take a whole day off for some injections	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I will probably need to take a partial day off for each injection	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I will probably need to take a partial day off for some injections	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
55	Do you think your time off work for injections will be paid or unpaid?					
		Paid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Unpaid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 5.403. Summary of Acceptability and Feasibility of APRETUDE Injection Visits (Baseline), N=XX, Race, Routine Implementation**

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
46	How long are you willing to spend in the clinic/practice for your injection visit from arrival at the clinic to when you leave?					
		Up to 20 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		21-40 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		41-60 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		61-90 minutes (1hr-1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		More than 90 minutes (more than 1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
47	How acceptable is coming to the clinic every 2 months for an injection?					
		Very acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
48	How convenient are your clinic's hours? <i>By convenient, we mean fitting well with your life activities and plans, with little trouble.</i>					
		Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
49	How easy or difficult do you think it will be getting to the clinic every 2 months for your injection?					
		Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
50	Approximately how long will it take you to get to the clinic/practice from your home to receive your injection?					
		Up to 20 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		21-40 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		41-60 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		61-90 minutes (1hr-1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		More than 90 minutes (more than 1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
51	How will you most likely get to the clinic/practice to get your injections?					
		Taxi/transportation service	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Ride-share service (e.g., Uber, Lyft)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Dropped off by someone else	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Drive a private vehicle	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Public transportation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Bicycle/scooter/skateboard/walking	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Transportation provided by clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
53	Do you think you will need to seek additional childcare/eldercare/other care to come to the clinic/practice for your injection visits.					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I am not caring for others right now (N/A)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
54	How much time do you think you will need to take off work to receive injections?					
		I am not working right now	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I will not need to take time off work for injections	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I will probably need to take a whole day off for each injection	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I will probably need to take a whole day off for some injections	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I will probably need to take a partial day off for each injection	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I will probably need to take a partial day off for some injections	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
55	Do you think your time off work for injections will be paid or unpaid?					
		Paid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Unpaid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 5.404. Summary of Acceptability and Feasibility of APRETUDE Injection Visits (Baseline), N=XX, Race, Total**

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
46	How long are you willing to spend in the clinic/practice for your injection visit from arrival at the clinic to when you leave?					
		Up to 20 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		21-40 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		41-60 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		61-90 minutes (1hr-1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		More than 90 minutes (more than 1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
47	How acceptable is coming to the clinic every 2 months for an injection?					
		Very acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
48	How convenient are your clinic's hours? <i>By convenient, we mean fitting well with your life activities and plans, with little trouble.</i>					
		Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
49	How easy or difficult do you think it will be getting to the clinic every 2 months for your injection?					
		Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
50	Approximately how long will it take you to get to the clinic/practice from your home to receive your injection?					
		Up to 20 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		21-40 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		41-60 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		61-90 minutes (1hr-1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		More than 90 minutes (more than 1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
51	How will you most likely get to the clinic/practice to get your injections?					
		Taxi/transportation service	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Ride-share service (e.g., Uber, Lyft)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Dropped off by someone else	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Drive a private vehicle	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Public transportation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Bicycle/scooter/skateboard/walking	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Transportation provided by clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
53	Do you think you will need to seek additional childcare/eldercare/other care to come to the clinic/practice for your injection visits.					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I am not caring for others right now (N/A)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
54	How much time do you think you will need to take off work to receive injections?					
		I am not working right now	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I will not need to take time off work for injections	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I will probably need to take a whole day off for each injection	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I will probably need to take a whole day off for some injections	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I will probably need to take a partial day off for each injection	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I will probably need to take a partial day off for some injections	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
55	Do you think your time off work for injections will be paid or unpaid?					
		Paid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Unpaid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



**Table 5.405. Summary of Acceptability and Feasibility of APRETUDE Injection Visits (Baseline), N=XX, Ethnicity, Study Arms**

Question Number	Question	Response	Dynamic Implementation		Routine Implementation	
			Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
46	How long are you willing to spend in the clinic/practice for your injection visit from arrival at the clinic to when you leave?					
		Up to 20 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		21-40 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		41-60 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		61-90 minutes (1hr-1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		More than 90 minutes (more than 1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
47	How acceptable is coming to the clinic every 2 months for an injection?					
		Very acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
48	How convenient are your clinic’s hours? <i>By convenient, we mean fitting well with your life activities and plans, with little trouble.</i>					
		Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
49	How easy or difficult do you think it will be getting to the clinic every 2 months for your injection?					
		Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Dynamic Implementation		Routine Implementation	
			Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
50	Approximately how long will it take you to get to the clinic/practice from your home to receive your injection?					
		Up to 20 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		21-40 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		41-60 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		61-90 minutes (1hr-1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		More than 90 minutes (more than 1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
51	How will you most likely get to the clinic/practice to get your injections?					
		Taxi/transportation service	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Ride-share service (e.g., Uber, Lyft)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Dropped off by someone else	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Drive a private vehicle	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Public transportation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Bicycle/scooter/skateboard/walking	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Transportation provided by clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
53	Do you think you will need to seek additional childcare/eldercare/other care to come to the clinic/practice for your injection visits.					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I am not caring for others right now (N/A)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Dynamic Implementation		Routine Implementation	
			Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
54	How much time do you think you will need to take off work to receive injections?					
		I am not working right now	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I will not need to take time off work for injections	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I will probably need to take a whole day off for each injection	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I will probably need to take a whole day off for some injections	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I will probably need to take a partial day off for each injection	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I will probably need to take a partial day off for some injections	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
55	Do you think your time off work for injections will be paid or unpaid?					
		Paid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Unpaid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 5.406. Summary of Acceptability and Feasibility of APRETUDE Injection Visits (Baseline), N=XX, Ethnicity, Total**

Question Number	Question	Response	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
46	How long are you willing to spend in the clinic/practice for your injection visit from arrival at the clinic to when you leave?			
		Up to 20 minutes	XX (XX.X%)	XX (XX.X%)
		21-40 minutes	XX (XX.X%)	XX (XX.X%)
		41-60 minutes	XX (XX.X%)	XX (XX.X%)
		61-90 minutes (1hr-1.5hrs)	XX (XX.X%)	XX (XX.X%)
		More than 90 minutes (more than 1.5hrs)	XX (XX.X%)	XX (XX.X%)
47	How acceptable is coming to the clinic every 2 months for an injection?			
		Very acceptable	XX (XX.X%)	XX (XX.X%)
		Acceptable	XX (XX.X%)	XX (XX.X%)
		Somewhat acceptable	XX (XX.X%)	XX (XX.X%)
		A little acceptable	XX (XX.X%)	XX (XX.X%)
		Not at all acceptable	XX (XX.X%)	XX (XX.X%)
48	How convenient are your clinic's hours? <i>By convenient, we mean fitting well with your life activities and plans, with little trouble.</i>			
		Very convenient	XX (XX.X%)	XX (XX.X%)
		Convenient	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)
		A little convenient	XX (XX.X%)	XX (XX.X%)
		Not at all convenient	XX (XX.X%)	XX (XX.X%)
49	How easy or difficult do you think it will be getting to the clinic every 2 months for your injection?			
		Very easy	XX (XX.X%)	XX (XX.X%)
		Easy	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
		Difficult	XX (XX.X%)	XX (XX.X%)
		Very difficult	XX (XX.X%)	XX (XX.X%)
50	Approximately how long will it take you to get to the clinic/practice from your home to receive your injection?			
		Up to 20 minutes	XX (XX.X%)	XX (XX.X%)
		21-40 minutes	XX (XX.X%)	XX (XX.X%)
		41-60 minutes	XX (XX.X%)	XX (XX.X%)
		61-90 minutes (1hr-1.5hrs)	XX (XX.X%)	XX (XX.X%)
		More than 90 minutes (more than 1.5hrs)	XX (XX.X%)	XX (XX.X%)
51	How will you most likely get to the clinic/practice to get your injections?			
		Taxi/transportation service	XX (XX.X%)	XX (XX.X%)
		Ride-share service (e.g., Uber, Lyft)	XX (XX.X%)	XX (XX.X%)
		Dropped off by someone else	XX (XX.X%)	XX (XX.X%)
		Drive a private vehicle	XX (XX.X%)	XX (XX.X%)
		Public transportation	XX (XX.X%)	XX (XX.X%)
		Bicycle/scooter/skateboard/walking	XX (XX.X%)	XX (XX.X%)
		Transportation provided by clinic	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)
53	Do you think you will need to seek additional childcare/eldercare/other care to come to the clinic/practice for your injection visits.			
		Yes	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)
		I am not caring for others right now (N/A)	XX (XX.X%)	XX (XX.X%)
54	How much time do you think you will need to take off work to receive injections?			
		I am not working right now	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
		I will not need to take time off work for injections	XX (XX.X%)	XX (XX.X%)
		I will probably need to take a whole day off for each injection	XX (XX.X%)	XX (XX.X%)
		I will probably need to take a whole day off for some injections	XX (XX.X%)	XX (XX.X%)
		I will probably need to take a partial day off for each injection	XX (XX.X%)	XX (XX.X%)
		I will probably need to take a partial day off for some injections	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)
55	Do you think your time off work for injections will be paid or unpaid?			
		Paid	XX (XX.X%)	XX (XX.X%)
		Unpaid	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)

**Table 5.407. Summary of Acceptability and Feasibility of APRETUDE Injection Visits (Baseline), N=XX, Gender, Total**

Question Number	Question	Response	Men who have sex with men (N = XX) n (%)	Transgender Men (N = XX) n (%)
46	How long are you willing to spend in the clinic/practice for your injection visit from arrival at the clinic to when you leave?			
		Up to 20 minutes	XX (XX.X%)	XX (XX.X%)
		21-40 minutes	XX (XX.X%)	XX (XX.X%)
		41-60 minutes	XX (XX.X%)	XX (XX.X%)
		61-90 minutes (1hr-1.5hrs)	XX (XX.X%)	XX (XX.X%)
		More than 90 minutes (more than 1.5hrs)	XX (XX.X%)	XX (XX.X%)
47	How acceptable is coming to the clinic every 2 months for an injection?			
		Very acceptable	XX (XX.X%)	XX (XX.X%)
		Acceptable	XX (XX.X%)	XX (XX.X%)
		Somewhat acceptable	XX (XX.X%)	XX (XX.X%)
		A little acceptable	XX (XX.X%)	XX (XX.X%)
		Not at all acceptable	XX (XX.X%)	XX (XX.X%)
48	How convenient are your clinic's hours? <i>By convenient, we mean fitting well with your life activities and plans, with little trouble.</i>			
		Very convenient	XX (XX.X%)	XX (XX.X%)
		Convenient	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)
		A little convenient	XX (XX.X%)	XX (XX.X%)
		Not at all convenient	XX (XX.X%)	XX (XX.X%)
49	How easy or difficult do you think it will be getting to the clinic every 2 months for your injection?			
		Very easy	XX (XX.X%)	XX (XX.X%)
		Easy	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Men who have sex with men (N = XX) n (%)	Transgender Men (N = XX) n (%)
		Difficult	XX (XX.X%)	XX (XX.X%)
		Very difficult	XX (XX.X%)	XX (XX.X%)
50	Approximately how long will it take you to get to the clinic/practice from your home to receive your injection?			
		Up to 20 minutes	XX (XX.X%)	XX (XX.X%)
		21-40 minutes	XX (XX.X%)	XX (XX.X%)
		41-60 minutes	XX (XX.X%)	XX (XX.X%)
		61-90 minutes (1hr-1.5hrs)	XX (XX.X%)	XX (XX.X%)
		More than 90 minutes (more than 1.5hrs)	XX (XX.X%)	XX (XX.X%)
51	How will you most likely get to the clinic/practice to get your injections?			
		Taxi/transportation service	XX (XX.X%)	XX (XX.X%)
		Ride-share service (e.g., Uber, Lyft)	XX (XX.X%)	XX (XX.X%)
		Dropped off by someone else	XX (XX.X%)	XX (XX.X%)
		Drive a private vehicle	XX (XX.X%)	XX (XX.X%)
		Public transportation	XX (XX.X%)	XX (XX.X%)
		Bicycle/scooter/skateboard/walking	XX (XX.X%)	XX (XX.X%)
		Transportation provided by clinic	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)
53	Do you think you will need to seek additional childcare/eldercare/other care to come to the clinic/practice for your injection visits.			
		Yes	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)
		I am not caring for others right now (N/A)	XX (XX.X%)	XX (XX.X%)
54	How much time do you think you will need to take off work to receive injections?			
		I am not working right now	XX (XX.X%)	XX (XX.X%)



Question Number	Question	Response	Men who have sex with men (N = XX) n (%)	Transgender Men (N = XX) n (%)
		I will not need to take time off work for injections	XX (XX.X%)	XX (XX.X%)
		I will probably need to take a whole day off for each injection	XX (XX.X%)	XX (XX.X%)
		I will probably need to take a whole day off for some injections	XX (XX.X%)	XX (XX.X%)
		I will probably need to take a partial day off for each injection	XX (XX.X%)	XX (XX.X%)
		I will probably need to take a partial day off for some injections	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)
55	Do you think your time off work for injections will be paid or unpaid?			
		Paid	XX (XX.X%)	XX (XX.X%)
		Unpaid	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)

**Table 5.408. Summary of Reach and Perceptions of Sexual Health Assessment Tool (Baseline), N=XX, Study Arms**

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
40	Did you complete a Sexual Health Assessment from your provider or clinic/practice before being told about this study?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
41	Did your provider or another person at the clinic/practice discuss the results of the assessment with you?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
42	Who discussed the results of the assessment with you?				
		My healthcare provider/doctor	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A social worker	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A peer educator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
43	How helpful was discussing the results with your provider or another person at the clinic/practice?				
		Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
44	Please rate your experience with the Sexual Health Assessment				

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
	It was easy to take the Sexual Health Assessment on my digital device	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I like that my doctor sent the assessment before my appointment	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I was concerned about the privacy of my answers	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I like that my doctor was assessing my sexual health	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The assessment asked the right questions to help my doctor and me determine whether PrEP was right for me	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The assessment made me feel uncomfortable	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
45	Why did you not complete the assessment?				
		I did not receive a Sexual Health Assessment from my provider or clinic/practice	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I forgot	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not know how to complete it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The link my doctor sent did not work	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I didn't have the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The assessment took too long to complete	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		The assessment included too many personal questions	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The assessment made me feel uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I was concerned about the privacy of my answers	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not want to share sexual health information with my doctor or clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not understand why my doctor or clinic was asking me to complete the assessment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 5.409. Summary of Reach and Perceptions of Sexual Health Assessment Tool (Baseline), N=XX, Race, Dynamic Implementation**

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
40	Did you complete a Sexual Health Assessment from your provider or clinic/practice before being told about this study?					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
41	Did your provider or another person at the clinic/practice discuss the results of the assessment with you?					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
42	Who discussed the results of the assessment with you?					
		My healthcare provider/doctor	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A social worker	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A peer educator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
43	How helpful was discussing the results with your provider or another person at the clinic/practice?					
		Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
44	Please rate your experience with the Sexual Health Assessment					

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
	It was easy to take the Sexual Health Assessment on my digital device	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I like that my doctor sent the assessment before my appointment	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I was concerned about the privacy of my answers	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I like that my doctor was assessing my sexual health	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The assessment asked the right questions to help my doctor and me determine whether PrEP was right for me	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The assessment made me feel uncomfortable	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
45	Why did you not complete the assessment?					
		I did not receive a Sexual Health Assessment from my provider or clinic/practice	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I forgot	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not know how to complete it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The link my doctor sent did not work	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I didn't have the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
		The assessment took too long to complete	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The assessment included too many personal questions	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The assessment made me feel uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I was concerned about the privacy of my answers	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not want to share sexual health information with my doctor or clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not understand why my doctor or clinic was asking me to complete the assessment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 5.410. Summary of Reach and Perceptions of Sexual Health Assessment Tool (Baseline), N=XX, Race, Routine Implementation**

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
40	Did you complete a Sexual Health Assessment from your provider or clinic/practice before being told about this study?					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
41	Did your provider or another person at the clinic/practice discuss the results of the assessment with you?					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
42	Who discussed the results of the assessment with you?					
		My healthcare provider/doctor	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A social worker	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A peer educator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
43	How helpful was discussing the results with your provider or another person at the clinic/practice?					
		Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
44	Please rate your experience with the Sexual Health Assessment					

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
	It was easy to take the Sexual Health Assessment on my digital device	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I like that my doctor sent the assessment before my appointment	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I was concerned about the privacy of my answers	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I like that my doctor was assessing my sexual health	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The assessment asked the right questions to help my doctor and me determine whether PrEP was right for me	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The assessment made me feel uncomfortable	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
45	Why did you not complete the assessment?					
		I did not receive a Sexual Health Assessment from my provider or clinic/practice	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I forgot	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not know how to complete it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The link my doctor sent did not work	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I didn't have the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
		The assessment took too long to complete	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The assessment included too many personal questions	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The assessment made me feel uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I was concerned about the privacy of my answers	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not want to share sexual health information with my doctor or clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not understand why my doctor or clinic was asking me to complete the assessment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 5.411. Summary of Reach and Perceptions of Sexual Health Assessment Tool (Baseline), N=XX, Race, Total**

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
40	Did you complete a Sexual Health Assessment from your provider or clinic/practice before being told about this study?					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
41	Did your provider or another person at the clinic/practice discuss the results of the assessment with you?					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
42	Who discussed the results of the assessment with you?					
		My healthcare provider/doctor	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A social worker	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A peer educator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
43	How helpful was discussing the results with your provider or another person at the clinic/practice?					
		Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
44	Please rate your experience with the Sexual Health Assessment					

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
	It was easy to take the Sexual Health Assessment on my digital device	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I like that my doctor sent the assessment before my appointment	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I was concerned about the privacy of my answers	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I like that my doctor was assessing my sexual health	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The assessment asked the right questions to help my doctor and me determine whether PrEP was right for me	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The assessment made me feel uncomfortable	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
45	Why did you not complete the assessment?					
		I did not receive a Sexual Health Assessment from my provider or clinic/practice	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I forgot	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not know how to complete it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The link my doctor sent did not work	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I didn't have the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
		The assessment took too long to complete	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The assessment included too many personal questions	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The assessment made me feel uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I was concerned about the privacy of my answers	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not want to share sexual health information with my doctor or clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not understand why my doctor or clinic was asking me to complete the assessment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 5.412. Summary of Reach and Perceptions of Sexual Health Assessment Tool (Baseline), N=XX, Ethnicity, Study Arms**

Question Number	Question	Response	Dynamic Implementation		Routine Implementation	
			Hispanic or Latino (N = XX)	Not Hispanic or Latino (N = XX)	Hispanic or Latino (N = XX)	Not Hispanic or Latino (N = XX)
			n (%)	n (%)	n (%)	n (%)
40	Did you complete a Sexual Health Assessment from your provider or clinic/practice before being told about this study?					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
41	Did your provider or another person at the clinic/practice discuss the results of the assessment with you?					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
42	Who discussed the results of the assessment with you?					
		My healthcare provider/doctor	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A social worker	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A peer educator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
43	How helpful was discussing the results with your provider or another person at the clinic/practice?					
		Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all helpful	XX (XX.X%)	XX	XX	XX

				(XX.X%)	(XX.X%)	(XX.X%)
44	Please rate your experience with the Sexual Health Assessment					
	It was easy to take the Sexual Health Assessment on my digital device	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I like that my doctor sent the assessment before my appointment	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I was concerned about the privacy of my answers	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I like that my doctor was assessing my sexual health	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The assessment asked the right questions to help my doctor and me determine whether PrEP was right for me	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The assessment made me feel uncomfortable	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
45	Why did you not complete the assessment?					
		I did not receive a Sexual Health Assessment from my provider or clinic/practice	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I forgot	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not know how to complete it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The link my doctor sent did not work	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I didn't have the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

		The assessment took too long to complete	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The assessment included too many personal questions	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The assessment made me feel uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I was concerned about the privacy of my answers	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not want to share sexual health information with my doctor or clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not understand why my doctor or clinic was asking me to complete the assessment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 5.413. Summary of Reach and Perceptions of Sexual Health Assessment Tool (Baseline), N=XX, Ethnicity, Total**

Question Number	Question	Response	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
40	Did you complete a Sexual Health Assessment from your provider or clinic/practice before being told about this study?			
		Yes	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)
41	Did your provider or another person at the clinic/practice discuss the results of the assessment with you?			
		Yes	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)
42	Who discussed the results of the assessment with you?			
		My healthcare provider/doctor	XX (XX.X%)	XX (XX.X%)
		A nurse	XX (XX.X%)	XX (XX.X%)
		A social worker	XX (XX.X%)	XX (XX.X%)
		A peer educator	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)
43	How helpful was discussing the results with your provider or another person at the clinic/practice?			
		Very helpful	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)
		Not at all helpful	XX (XX.X%)	XX (XX.X%)
44	Please rate your experience with the Sexual Health Assessment			

Question Number	Question	Response	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
	It was easy to take the Sexual Health Assessment on my digital device	Completely disagree	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)
	I like that my doctor sent the assessment before my appointment	Completely disagree	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)
	I was concerned about the privacy of my answers	Completely disagree	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)
	I like that my doctor was assessing my sexual health	Completely disagree	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
			(XX.X%)	(XX.X%)
	The assessment asked the right questions to help my doctor and me determine whether PrEP was right for me	Completely disagree	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)
	The assessment made me feel uncomfortable	Completely disagree	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)
45	Why did you not complete the assessment?			
		I did not receive a Sexual Health Assessment from my provider or clinic/practice	XX (XX.X%)	XX (XX.X%)
		I forgot	XX (XX.X%)	XX (XX.X%)
		I did not know how to complete it	XX (XX.X%)	XX (XX.X%)
		The link my doctor sent did not work	XX (XX.X%)	XX (XX.X%)
		I didn't have the time	XX (XX.X%)	XX (XX.X%)
		The assessment took too long to complete	XX (XX.X%)	XX (XX.X%)
		The assessment included too many personal questions	XX (XX.X%)	XX (XX.X%)
		The assessment made me feel uncomfortable	XX (XX.X%)	XX (XX.X%)



Question Number	Question	Response	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
		I was concerned about the privacy of my answers	XX (XX.X%)	XX (XX.X%)
		I did not want to share sexual health information with my doctor or clinic	XX (XX.X%)	XX (XX.X%)
		I did not understand why my doctor or clinic was asking me to complete the assessment	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)

**Table 5.414. Summary of Reach and Perceptions of Sexual Health Assessment Tool (Baseline), N=XX, Gender**

Question Number	Question	Response	Men who have sex with men (N = XX) n (%)	Transgender men (N = XX) n (%)
40	Did you complete a Sexual Health Assessment from your provider or clinic/practice before being told about this study?			
		Yes	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)
41	Did your provider or another person at the clinic/practice discuss the results of the assessment with you?			
		Yes	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)
42	Who discussed the results of the assessment with you?			
		My healthcare provider/doctor	XX (XX.X%)	XX (XX.X%)
		A nurse	XX (XX.X%)	XX (XX.X%)
		A social worker	XX (XX.X%)	XX (XX.X%)
		A peer educator	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)
43	How helpful was discussing the results with your provider or another person at the clinic/practice?			
		Very helpful	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)
		Not at all helpful	XX (XX.X%)	XX (XX.X%)
44	Please rate your experience with the Sexual Health Assessment			

Question Number	Question	Response	Men who have sex with men (N = XX) n (%)	Transgender men (N = XX) n (%)
	It was easy to take the Sexual Health Assessment on my digital device	Completely disagree	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)
	I like that my doctor sent the assessment before my appointment	Completely disagree	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)
	I was concerned about the privacy of my answers	Completely disagree	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)
	I like that my doctor was assessing my sexual health	Completely disagree	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Men who have sex with men (N = XX) n (%)	Transgender men (N = XX) n (%)
			(XX.X%)	(XX.X%)
	The assessment asked the right questions to help my doctor and me determine whether PrEP was right for me	Completely disagree	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)
	The assessment made me feel uncomfortable	Completely disagree	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)
45	Why did you not complete the assessment?			
		I did not receive a Sexual Health Assessment from my provider or clinic/practice	XX (XX.X%)	XX (XX.X%)
		I forgot	XX (XX.X%)	XX (XX.X%)
		I did not know how to complete it	XX (XX.X%)	XX (XX.X%)
		The link my doctor sent did not work	XX (XX.X%)	XX (XX.X%)
		I didn't have the time	XX (XX.X%)	XX (XX.X%)
		The assessment took too long to complete	XX (XX.X%)	XX (XX.X%)
		The assessment included too many personal questions	XX (XX.X%)	XX (XX.X%)
		The assessment made me feel uncomfortable	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Men who have sex with men (N = XX) n (%)	Transgender men (N = XX) n (%)
		I was concerned about the privacy of my answers	XX (XX.X%)	XX (XX.X%)
		I did not want to share sexual health information with my doctor or clinic	XX (XX.X%)	XX (XX.X%)
		I did not understand why my doctor or clinic was asking me to complete the assessment	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)

**Table 5.415. Summary of Reach and Perceptions of Sexual Health Assessment Tool (Baseline), N=XX, Site Volume**

Question Number	Question	Response	Total (N = XX) n (%)	High Volume (N = XX) n (%)	Low Volume (N = XX) n (%)
40	Did you complete a Sexual Health Assessment from your provider or clinic/practice before being told about this study?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
41	Did your provider or another person at the clinic/practice discuss the results of the assessment with you?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
42	Who discussed the results of the assessment with you?				
		My healthcare provider/doctor	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A social worker	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A peer educator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
43	How helpful was discussing the results with your provider or another person at the clinic/practice?				
		Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
44	Please rate your experience with the Sexual Health Assessment				

Question Number	Question	Response	Total (N = XX) n (%)	High Volume (N = XX) n (%)	Low Volume (N = XX) n (%)
	It was easy to take the Sexual Health Assessment on my digital device	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I like that my doctor sent the assessment before my appointment	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I was concerned about the privacy of my answers	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I like that my doctor was assessing my sexual health	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	High Volume (N = XX) n (%)	Low Volume (N = XX) n (%)
			(XX.X%)	(XX.X%)	(XX.X%)
	The assessment asked the right questions to help my doctor and me determine whether PrEP was right for me	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The assessment made me feel uncomfortable	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
45	Why did you not complete the assessment?				
		I did not receive a Sexual Health Assessment from my provider or clinic/practice	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I forgot	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not know how to complete it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The link my doctor sent did not work	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I didn't have the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The assessment took too long to complete	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The assessment included too many personal questions	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



Question Number	Question	Response	Total (N = XX) n (%)	High Volume (N = XX) n (%)	Low Volume (N = XX) n (%)
		The assessment made me feel uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I was concerned about the privacy of my answers	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not want to share sexual health information with my doctor or clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not understand why my doctor or clinic was asking me to complete the assessment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 5.416. Distributional Characteristics of Estimated Amount of Money Spent on Transportation for Each Injection Visit (Baseline), N=XX**

52. On average, how much do you think transportation will cost round trip for each injection visit?	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
Mean Score	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Study Arm</b>							
Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Race</b>							
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Ethnicity</b>							
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Gender</b>							
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)

Table 5.417 Summary of Optional Oral Lead-In vs. Direct to Injection (Baseline), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
61	Are you currently taking or did you take oral cabotegravir pills in preparation for your first APRETUDE injection? <i>This might have been called oral lead-in.</i>				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
62	Whose decision was it to use oral cabotegravir pills in preparation for your first injection?				
		It was primarily my decision	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		It was a joint decision between me and my provider	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		It was primarily my provider's decision	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
63	What were the main reasons to use oral cabotegravir pills in preparation for your first injection?				
		The doctor just started me on them	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The doctor wanted to see how I would react to APRETUDE	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have a history of allergy and reactions to medications and the doctor wanted to assess if I would react to APRETUDE	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The doctor wanted to be cautious with a new medication	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I wanted to make sure the medication was safe	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I wanted to have protection until the injection arrived after it was ordered	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The doctor wanted me to have protection until the injection arrived after it was ordered	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
64	How concerned would you have been if you had started directly with the APREUDE injections and not with the cabotegravir pills?				
		Very concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not very concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
65	Whose decision was it to start directly with the injections and not use the pills/oral lead-in?				
		It was primarily my decision	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		It was a joint decision between me and my provider	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		It was primarily my provider's decision	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
66	What were the main reasons that you started directly with the injection and did not use the pill/oral lead-in?				
		I did not know that I could start with the pills	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The doctor just started me with the injection	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I was already on PrEP and wanted to switch immediately	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I believed the medication is effective and didn't want to wait	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		My doctor recommended that start with the injection	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not think I would have any side effects	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

## Table Shells for Month 6/7 Analysis

Table 6.000. Demographic Characteristics of Patient Study Participants Completing Surveys (Month 6/7), N=XX .....	208
Table 6.001. Demographic Characteristics of Patient Study Participants (Month 6/7), N=XX .....	210
Table 6.002. Summary of Behaviors of Patient Study Participants (Month 6/7), N=XX .....	213
Table 6.003. Summary of Patient Study Participants' Sexual History and Behaviors (Month 6/7), N=XX, Study Arms .....	214
Table 6.004. Summary of Patient Study Participants' Sexual History and Behaviors (Month 6/7), N=XX, Race, Dynamic Implementation .....	217
Table 6.005. Summary of Patient Study Participants' Sexual History and Behaviors (Month 6/7), N=XX, Race, Routine Implementation .....	220
Table 6.006. Summary of Patient Study Participants' Sexual History and Behaviors (Month 6/7), N=XX, Race, Total.....	223
Table 6.007. Summary of Patient Study Participants' Sexual History and Behaviors (Month 6/7), N=XX, Ethnicity, Study Arms .....	226
Table 6.008. Summary of Patient Study Participants' Sexual History and Behaviors (Month 6/7), N=XX, Ethnicity, Total .....	229
Table 6.009. Summary of Patient Study Participants' Sexual History and Behaviors (Month 6/7), N=XX, Gender, Total .....	232
Table 6.101. Summary of Patient Study Participants' HIV and PrEP Knowledge (Month 6/7), N=XX .....	235
Table 6.102. Summary of Patient Study Participants' HIV and PrEP Knowledge (Month 6/7), N=XX, Scale Questions, Study Arms .....	236
Table 6.103. Distributional Characteristics of Patient Study Participants' HIV and PrEP Knowledge (Month 6/7), N=XX, Scale Questions, Overall Score .....	238
Table 6.104. Summary of Patient Study Participants' Perception of Stigma Associated with PrEP Usage (Month 6/7), N=XX, Stigma, Study Arms .....	240
Table 6.105. Distributional Characteristics of Patient Study Participants' Perception of Stigma Associated with PrEP Usage (Month 6/7), N=XX, Stigma, Overall Score.....	244
Table 6.106. Summary of Patient Study Participants' Choice of APREUDE (Month 6/7), N=XX .....	246
Table 6.107. Summary of Knowledge of APREUDE and Utility of Implementation Strategies (Month 6/7), N=XX .....	249
Table 6.108. Attitude Regarding APREUDE and Utility of Implementation Strategies (Month 6/7), N=XX.....	254
Table 6.109. Summary of Patient Study Participant Acquisition Process (Month 6/7), N=XX .....	256
Table 6.110. Summary of Patient Study Participant Acquisition Process, Insurance (Month 6/7), N=XX .....	257
Table 6.201. Distributional Characteristics of Acceptability of Intervention (AIM) (APREUDE) (PSP) (Month 6/7), N=XX .....	267
Table 6.202. Distributional Characteristics of Feasibility of Intervention (FIM) (APREUDE) (PSP) (Month 6/7), N=XX .....	270

Table 6.203. Distributional Characteristics of Accessibility of Intervention (AIM) (Telehealth) (PSP) (Month 6/7), N=XX .....	273
Table 6.204. Distributional Characteristics of Feasibility of Intervention (FIM) (Telehealth) (PSP) (Month 6/7), N=XX .....	276
Table 6.205. Summary of Acceptability of Intervention (AIM) (APRETUDE) (PSP) (Month 6/7), N=XX .....	279
Table 6.206. Summary of Feasibility of Intervention (FIM) (APRETUDE) (PSP) (Month 6/7), N=XX .....	280
Table 6.207. Summary of Acceptability of Intervention (AIM) (Telehealth) (PSP) (Month 6/7), N=XX.....	282
Table 6.208. Summary of Feasibility of Intervention (FIM) (Telehealth) (PSP) (Month 6/7), N=XX.....	284
Table 6.209. Changes from Baseline to Acceptability of Intervention Measure (AIM - APRETUDE) and Feasibility of Intervention Measure (FIM - APRETUDE) (Month 6/7), N=XX .....	286
Table 6.210. Mixed-effects Modeling of the Acceptability of Intervention Measure (AIM – APRETUDE) (Month 6/7), N= XX .....	287
Table 6.211. Mixed-effects Modeling of the Changes from Baseline to Month 6/7 in Acceptability of Intervention Measure (AIM – APRETUDE), N=XX .....	288
Table 6.212. Mixed-effects Modeling of the Feasibility of Intervention Measure (FIM – APRETUDE) (Month 6/7), N=XX .....	289
Table 6.213. Mixed-effects Modeling of the Changes from Baseline to Month 6/7 in Feasibility of Intervention Measure (FIM – APRETUDE), N=XX.....	290
Table 6.214. Changes from Baseline for Acceptability of Intervention Measure (AIM - Telehealth) and Feasibility of Intervention Measure (FIM - Telehealth) (Month 6/7), N=XX .....	291
Table 6.215. Mixed-effects Modeling of the Acceptability of Intervention Measure (AIM – Telehealth) (Month 6/7), N=XX .....	292
Table 6.216. Mixed-effects Modeling of the Changes from Baseline to Month 6/7 in Acceptability of Intervention Measure (AIM – Telehealth), N=XX.....	293
Table 6.217. Mixed-effects Modeling of the Feasibility of Intervention Measure (FIM – Telehealth) (Month 6/7), N=XX .....	294
Table 6.218. Mixed-effects Modeling of the Changes from Baseline to Month 6/7 in Feasibility of Intervention Measure (FIM – Telehealth), N=XX .....	295
Table 6.219. Summary of Pain/Activities After Injection (Month 6/7), N=XX.....	296
Table 6.220. Summary of Patient Study Participants' Labs and Missed Doses (Month 6/7), N=XX .....	299
Table 6.301. Summary of Feasibility and Acceptability of Telehealth (Month 6/7), N=XX .....	301
Table 6.302. Summary of Quality of Care for Patient Study Participants (Month 6/7), N=XX.....	309
Table 6.303. Summary of Quality of Care for Patient Study Participants (Month 6/7), N=XX, Non-Score Questions.....	313
Table 6.304. Summary of Quality of Care for Patient Study Participants (Month 6/7), N=XX, Score Questions .....	328
Table 6.305. Summary of Utility of Proposed Implementation Strategies (Month 6/7), N=XX .....	345
Table 6.306. Summary of Patient Study Participants' Preferences/Acceptability of APRETUDE Information, Appointment Reminders, and Locations (Month 6/7), N=XX .....	353
Table 6.307. Summary of Appointment Scheduling (Month 6/7), N=XX.....	356

Table 6.401. Summary of Acceptability and Feasibility of APRETUDE Injection Visits (Month 6/7), N=XX, Study Arms .....	358
Table 6.402. Summary of Acceptability and Feasibility of APRETUDE Injection Visits (Month 6/7), N=XX, Race, Dynamic Implementation .....	362
Table 6.403. Summary of Acceptability and Feasibility of APRETUDE Injection Visits (Month 6/7), N=XX, Race, Routine Implementation .....	366
Table 6.404. Summary of Acceptability and Feasibility of APRETUDE Injection Visits (Month 6/7), N=XX, Race, Total.....	370
Table 6.405. Summary of Acceptability and Feasibility of APRETUDE Injection Visits (Month 6/7), N=XX, Ethnicity, Study Arms .....	374
Table 6.406. Summary of Acceptability and Feasibility of APRETUDE Injection Visits (Month 6/7), N=XX, Ethnicity, Total .....	378
Table 6.407. Summary of Acceptability and Feasibility of APRETUDE Injection Visits (Month 6/7), N=XX, Gender, Total .....	382
Table 6.408. Summary of Reach and Perceptions of Sexual Health Assessment Tool (Month 6/7), N=XX, Study Arms .....	386
Table 6.409. Summary of Reach and Perceptions of Sexual Health Assessment Tool (Month 6/7), N=XX, Race, Dynamic Implementation .....	390
Table 6.410. Summary of Reach and Perceptions of Sexual Health Assessment Tool (Month 6/7), N=XX, Race, Routine Implementation .....	394
Table 6.411. Summary of Reach and Perceptions of Sexual Health Assessment Tool (Month 6/7), N=XX, Race, Total.....	398
Table 6.412. Summary of Reach and Perceptions of Sexual Health Assessment Tool (Month 6/7), N=XX, Ethnicity, Study Arms .....	402
Table 6.413. Summary of Reach and Perceptions of Sexual Health Assessment Tool (Month 6/7), N=XX, Ethnicity, Total .....	406
Table 6.414. Summary of Reach and Perceptions of Sexual Health Assessment Tool (Month 6/7), N=XX, Gender .....	410
Table 6.415. Summary of Reach and Perceptions of Sexual Health Assessment Tool (Month 6/7), N=XX, Site Volume .....	414
Table 6.416. Distributional Characteristics of Estimated Amount of Money Spent on Transportation for Each Injection Visit (Month 6/7), N=XX.....	418

**Table 6.000. Demographic Characteristics of Patient Study Participants Completing Surveys (Month 6/7), N=XX**

Question Number	Question	Response	Total (N=XX) n (%)	Dynamic Implementation (N=XX) n (%)	Routine Implementation (N=XX) n (%)
DM1	Age (years)	N	XX	XX	XX
		Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)
		Median	XX.X	XX.X	XX.X
		Q1, Q3	XX, XX	XX, XX	XX, XX
		Min-Max	XX.X, XX.X	XX.X, XX.X	XX.X, XX.X
DM2	Age (years), High Volume	N	XX	XX	XX
		Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)
		Median	XX.X	XX.X	XX.X
		Q1, Q3	XX, XX	XX, XX	XX, XX
		Min-Max	XX.X, XX.X	XX.X, XX.X	XX.X, XX.X
DM3	Age (years), Low Volume	N	XX	XX	XX
		Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)
		Median	XX.X	XX.X	XX.X
		Q1, Q3	XX, XX	XX, XX	XX, XX
		Min-Max	XX.X, XX.X	XX.X, XX.X	XX.X, XX.X
DM4	Age				
		18-25	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		26-35	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		36-49	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		50+	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
DM5	Study Arm				
		Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
DM6	Site Volume				
		High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
DM7	Gender				
		Men who have sex with men	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Transgender men	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
DM8	Race				
		Asian	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Black or African American	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		White	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Missing/Unknown	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



Question Number	Question	Response	Total (N=XX) n (%)	Dynamic Implementation (N=XX) n (%)	Routine Implementation (N=XX) n (%)
DM9	Ethnicity				
		Hispanic or Latino	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not Hispanic or Latino	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Missing/Unknown	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 6.001. Demographic Characteristics of Patient Study Participants (Month 6/7), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
1	Which of the following best describes your <u>current</u> relationship status?				
		Single, never married	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Single, widowed	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Single, separated or divorced	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Dating, but not living with a partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Dating and living with a partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Domestic partnership/civil union	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Married	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
2	How would you describe your <u>current</u> living situation?				
		I live in my own house or apartment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I live in my parent's house or apartment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I live in a family member's house or apartment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I live in a friend's house or apartment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I sleep on various friends' or relatives' couches	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I am homeless or am living in a shelter	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I live in motel(s)/hotel(s)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
3	What <u>best</u> describes your current employment status?				

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Employed for wages full-time (1 employer)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Employed for wages full-time (2 or more employers)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Employed for wages part-time (1 employer)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Employed for wages part-time (2 or more employers)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Self-employed	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A homemaker	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Student	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Retired	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not employed	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Unable to work (disabled)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
4	What type of medical insurance do you currently have?				
		My parents' insurance	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		My partner's/spouse's insurance	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Private insurance provided by my workplace	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Private insurance I purchased through an exchange (e.g., Obamacare, Affordable Care Act)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Federal insurance (e.g., VA, TRICARE)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Medicare or Medicaid	XX	XX	XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
			(XX.X%)	(XX.X%)	(XX.X%)
		Some other health care plan	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't have any health insurance currently	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 6.002. Summary of Behaviors of Patient Study Participants (Month 6/7), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
84	How often do you have a drink containing alcohol?				
		Never	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Monthly or less	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		2 to 4 times a month	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		2 to 3 times a week	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		4 or more times a week	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
85	On days when you drink alcohol, how many drinks containing alcohol do you typically have? (1 drink=1 standard bottle/ can of beer, 1 glass of wine, 1 mixed drink, or 1 shot of liquor)				
		1 or 2	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		3 to 4	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		5 to 6	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		7 to 9	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		10 or more	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
86	In the last 6 months, have you shot up or injected any drugs that were not prescribed for you by a healthcare provider, such as speedball, heroin, or crack? <i>By shooting up, we mean anytime you might have used drugs with a needle, either by mainlining, skin popping, or muscling.</i>				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
87	In the last 6 months, have you used any non-injection drugs (drugs you did not inject like pills, patches, or inhaled substances), <u>that</u> were not prescribed for you by a healthcare provider, such as marijuana, X, downers, or crack cocaine?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 6.003. Summary of Patient Study Participants' Sexual History and Behaviors (Month 6/7), N=XX, Study Arms**

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
8	Have you had sex in the last 6 months? <i>This could be vaginal sex (penis in vagina) OR anal sex (penis in butt) OR oral sex.</i>				
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
9	How would you describe your sexual behaviors in the last 6 months?				
		I have had vaginal sex (penis in vagina) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had vaginal sex (penis in vagina) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a bottom (penis in butt as a bottom) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a bottom (penis in butt as a bottom) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a top (penis in butt as a top) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a top (penis in butt as a top) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had oral sex (mouth, tongue, or lips on a vagina, penis, or butt) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had oral sex (mouth, tongue, or lips on a vagina, penis, or butt) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
10	How often did you use a condom when you had sex in the last 6 months?				
		All of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Most of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Some of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		None of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
11	In the last 6 months, how would you describe the HIV status of your sexual partner(s)?				
		I know that none of my sexual partners from the last 6 months have HIV/AIDS	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I know that at least one sexual partner from the last 6 months is living with HIV/AIDS	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I do not know my sexual partners' HIV status	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
12	As far as you know, were any of your sexual partner(s) from the last 6 months taking PrEP to prevent HIV infection? PrEP is a medication that prevents HIV.				
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
13	You mentioned that you had a least one partner in the last 6 months who is living with HIV/AIDS. As far as you know, were any of your partners taking HIV medications (antiretrovirals) to treat their HIV infection?				
		Yes, my partner(s) was/were taking HIV medications	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes, my partner(s) was/were taking HIV medications and was/were undetectable, meaning HIV tests were not finding the virus	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No, my partner(s) was/were not taking HIV medications	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I do not know whether my partner(s) was/were taking HIV medications	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
14	In the last 6 months, have you experienced any incidents of sexual violence, physical abuse, or any other type of trauma from a partner?				
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
16	In the last 6 months, have you exchanged things like money or drugs for sex with a sexual partner?				

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Yes, I have a sexual partner things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes, a sexual partner gave me things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No, I have not exchanged things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



**Table 6.004. Summary of Patient Study Participants' Sexual History and Behaviors (Month 6/7), N=XX, Race, Dynamic Implementation**

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
8	Have you had sex in the last 6 months? <i>This could be vaginal sex (penis in vagina) OR anal sex (penis in butt) OR oral sex.</i>					
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
9	How would you describe your sexual behaviors in the last 6 months?					
		I have had vaginal sex (penis in vagina) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had vaginal sex (penis in vagina) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a bottom (penis in butt as a bottom) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a bottom (penis in butt as a bottom) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a top (penis in butt as a top) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a top (penis in butt as a top) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had oral sex (mouth, tongue, or lips on a vagina, penis, or butt) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had oral sex (mouth, tongue, or lips on a vagina, penis, or butt) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
10	How often did you use a condom when you had sex in the last 6 months?					

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
		All of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Most of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Some of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		None of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
11	In the last 6 months, how would you describe the HIV status of your sexual partner(s)?					
		I know that none of my sexual partners from the last 6 months have HIV/AIDS	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I know that at least one sexual partner from the last 6 months is living with HIV/AIDS	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I do not know my sexual partners' HIV status	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
12	As far as you know, were any of your sexual partner(s) from the last 6 months taking PrEP to prevent HIV infection? PrEP is a medication that prevents HIV.					
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
13	You mentioned that you had a least one partner in the last 6 months who is living with HIV/AIDS. As far as you know, were any of your partners taking HIV medications (antiretrovirals) to treat their HIV infection?					
		Yes, my partner(s) was/were taking HIV medications	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes, my partner(s) was/were taking HIV medications and was/were undetectable,	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
		meaning HIV tests were not finding the virus				
		No, my partner(s) was/were not taking HIV medications	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I do not know whether my partner(s) was/were taking HIV medications	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
14	In the last 6 months, have you experienced any incidents of sexual violence, physical abuse, or any other type of trauma from a partner?					
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
15	In the last 6 months, have you exchanged things like money or drugs for sex with a sexual partner?					
		Yes, I have a sexual partner things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes, a sexual partner gave me things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No, I have not exchanged things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 6.005. Summary of Patient Study Participants' Sexual History and Behaviors (Month 6/7), N=XX, Race, Routine Implementation**

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
8	Have you had sex in the last 6 months? <i>This could be vaginal sex (penis in vagina) OR anal sex (penis in butt) OR oral sex.</i>					
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
9	How would you describe your sexual behaviors in the last 6 months?					
		I have had vaginal sex (penis in vagina) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had vaginal sex (penis in vagina) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a bottom (penis in butt as a bottom) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a bottom (penis in butt as a bottom) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a top (penis in butt as a top) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a top (penis in butt as a top) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had oral sex (mouth, tongue, or lips on a vagina, penis, or butt) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had oral sex (mouth, tongue, or lips on a vagina, penis, or butt) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
10	How often did you use a condom when you had sex in the last 6 months?					
		All of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Most of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Some of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		None of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
11	In the last 6 months, how would you describe the HIV status of your sexual partner(s)?					
		I know that none of my sexual partners from the last 6 months have HIV/AIDS	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I know that at least one sexual partner from the last 6 months is living with HIV/AIDS	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I do not know my sexual partners' HIV status	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
12	As far as you know, were any of your sexual partner(s) from the last 6 months taking PrEP to prevent HIV infection? PrEP is a medication that prevents HIV.					
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
13	You mentioned that you had a least one partner in the last 6 months who is living with HIV/AIDS. As far as you know, were any of your partners taking HIV medications (antiretrovirals) to treat their HIV infection?					
		Yes, my partner(s) was/were taking HIV medications	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes, my partner(s) was/were taking HIV medications and	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
		was/were undetectable, meaning HIV tests were not finding the virus				
		No, my partner(s) was/were not taking HIV medications	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I do not know whether my partner(s) was/were taking HIV medications	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
14	In the last 6 months, have you experienced any incidents of sexual violence, physical abuse, or any other type of trauma from a partner?					
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
15	In the last 6 months, have you exchanged things like money or drugs for sex with a sexual partner?					
		Yes, I have a sexual partner things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes, a sexual partner gave me things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No, I have not exchanged things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 6.006. Summary of Patient Study Participants' Sexual History and Behaviors (Month 6/7), N=XX, Race, Total**

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
8	Have you had sex in the last 6 months? <i>This could be vaginal sex (penis in vagina) OR anal sex (penis in butt) OR oral sex.</i>					
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
9	How would you describe your sexual behaviors in the last 6 months?					
		I have had vaginal sex (penis in vagina) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had vaginal sex (penis in vagina) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a bottom (penis in butt as a bottom) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a bottom (penis in butt as a bottom) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a top (penis in butt as a top) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a top (penis in butt as a top) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had oral sex (mouth, tongue, or lips on a vagina, penis, or butt) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had oral sex (mouth, tongue, or lips on a vagina, penis, or butt) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
10	How often did you use a condom when you had sex in the last 6 months?					
		All of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Most of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Some of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		None of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
11	In the last 6 months, how would you describe the HIV status of your sexual partner(s)?					
		I know that none of my sexual partners from the last 6 months have HIV/AIDS	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I know that at least one sexual partner from the last 6 months is living with HIV/AIDS	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I do not know my sexual partners' HIV status	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
12	As far as you know, were any of your sexual partner(s) from the last 6 months taking PrEP to prevent HIV infection? PrEP is a medication that prevents HIV.					
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
13	You mentioned that you had a least one partner in the last 6 months who is living with HIV/AIDS. As far as you know, were any of your partners taking HIV medications (antiretrovirals) to treat their HIV infection?					
		Yes, my partner(s) was/were taking HIV medications	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes, my partner(s) was/were taking HIV medications and	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
		was/were undetectable, meaning HIV tests were not finding the virus				
		No, my partner(s) was/were not taking HIV medications	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I do not know whether my partner(s) was/were taking HIV medications	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
14	In the last 6 months, have you experienced any incidents of sexual violence, physical abuse, or any other type of trauma from a partner?					
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
15	In the last 6 months, have you exchanged things like money or drugs for sex with a sexual partner?					
		Yes, I have a sexual partner things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes, a sexual partner gave me things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No, I have not exchanged things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 6.007. Summary of Patient Study Participants' Sexual History and Behaviors (Month 6/7), N=XX, Ethnicity, Study Arms**

Question Number	Question	Response	Dynamic Implementation		Routine Implementation	
			Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
8	Have you had sex in the last 6 months? <i>This could be vaginal sex (penis in vagina) OR anal sex (penis in butt) OR oral sex.</i>					
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
9	How would you describe your sexual behaviors in the last 6 months?					
		I have had vaginal sex (penis in vagina) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had vaginal sex (penis in vagina) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a bottom (penis in butt as a bottom) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a bottom (penis in butt as a bottom) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a top (penis in butt as a top) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a top (penis in butt as a top) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had oral sex (mouth, tongue, or lips on a vagina, penis, or butt) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had oral sex (mouth, tongue, or lips on a vagina, penis, or butt) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
10	How often did you use a condom when you had sex in the last 6 months?					

Question Number	Question	Response	Dynamic Implementation		Routine Implementation	
			Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
		All of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Most of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Some of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		None of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
11	In the last 6 months, how would you describe the HIV status of your sexual partner(s)?					
		I know that none of my sexual partners from the last 6 months have HIV/AIDS	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I know that at least one sexual partner from the last 6 months is living with HIV/AIDS	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I do not know my sexual partners' HIV status	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
12	As far as you know, were any of your sexual partner(s) from the last 6 months taking PrEP to prevent HIV infection? PrEP is a medication that prevents HIV.					
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
13	You mentioned that you had a least one partner in the last 6 months who is living with HIV/AIDS. As far as you know, were any of your partners taking HIV medications (antiretrovirals) to treat their HIV infection?					
		Yes, my partner(s) was/were taking HIV medications	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes, my partner(s) was/were taking HIV medications and was/were undetectable, meaning HIV tests were not finding the virus	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Dynamic Implementation		Routine Implementation	
			Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
		No, my partner(s) was/were not taking HIV medications	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I do not know whether my partner(s) was/were taking HIV medications	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
14	In the last 6 months, have you experienced any incidents of sexual violence, physical abuse, or any other type of trauma form a partner?					
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
15	In the last 6 months, have you exchanged things like money or drugs for sex with a sexual partner?					
		Yes, I have a sexual partner things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes, a sexual partner gave me things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No, I have not exchanged things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 6.008. Summary of Patient Study Participants' Sexual History and Behaviors (Month 6/7), N=XX, Ethnicity, Total**

Question Number	Question	Response	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
8	Have you had sex in the last 6 months? <i>This could be vaginal sex (penis in vagina) OR anal sex (penis in butt) OR oral sex.</i>			
		No	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)
9	How would you describe your sexual behaviors in the last 6 months?			
		I have had vaginal sex (penis in vagina) with only 1 partner	XX (XX.X%)	XX (XX.X%)
		I have had vaginal sex (penis in vagina) with more than 1 partner	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a bottom (penis in butt as a bottom) with only 1 partner	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a bottom (penis in butt as a bottom) with more than 1 partner	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a top (penis in butt as a top) with only 1 partner	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a top (penis in butt as a top) with more than 1 partner	XX (XX.X%)	XX (XX.X%)
		I have had oral sex (mouth, tongue, or lips on a vagina, penis, or butt) with only 1 partner	XX (XX.X%)	XX (XX.X%)
		I have had oral sex (mouth, tongue, or lips on a vagina, penis, or butt) with more than 1 partner	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)
10	How often did you use a condom when you had sex in the last 6 months?			
		All of the time	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
		Most of the time	XX (XX.X%)	XX (XX.X%)
		Some of the time	XX (XX.X%)	XX (XX.X%)
		A little of the time	XX (XX.X%)	XX (XX.X%)
		None of the time	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)
11	In the last 6 months, how would you describe the HIV status of your sexual partner(s)?			
		I know that none of my sexual partners from the last 6 months have HIV/AIDS	XX (XX.X%)	XX (XX.X%)
		I know that at least one sexual partner from the last 6 months is living with HIV/AIDS	XX (XX.X%)	XX (XX.X%)
		I do not know my sexual partners' HIV status	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)
12	As far as you know, were any of your sexual partner(s) from the last 6 months taking PrEP to prevent HIV infection? PrEP is a medication that prevents HIV.			
		No	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)
13	You mentioned that you had a least one partner in the last 6 months who is living with HIV/AIDS. As far as you know, were any of your partners taking HIV medications (antiretrovirals) to treat their HIV infection?			
		Yes, my partner(s) was/were taking HIV medications	XX (XX.X%)	XX (XX.X%)
		Yes, my partner(s) was/were taking HIV medications and was/were undetectable, meaning HIV tests were not finding the virus	XX (XX.X%)	XX (XX.X%)
		No, my partner(s) was/were not taking HIV medications	XX (XX.X%)	XX (XX.X%)
		I do not know whether my partner(s) was/were taking HIV medications	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)
14	In the last 6 months, have you experienced any incidents of sexual violence, physical abuse, or any other type of trauma from a partner?			
		No	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)
15	In the last 6 months, have you exchanged things like money or drugs for sex with a sexual partner?			
		Yes, I have a sexual partner things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)
		Yes, a sexual partner gave me things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)
		No, I have not exchanged things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)

**Table 6.009. Summary of Patient Study Participants' Sexual History and Behaviors (Month 6/7), N=XX, Gender, Total**

Question Number	Question	Response	Men who have sex with men (N = XX) n (%)	Transgender Men (N = XX) n (%)
8	Have you had sex in the last 6 months? <i>This could be vaginal sex (penis in vagina) OR anal sex (penis in butt) OR oral sex.</i>			
		No	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)
9	How would you describe your sexual behaviors in the last 6 months?			
		I have had vaginal sex (penis in vagina) with only 1 partner	XX (XX.X%)	XX (XX.X%)
		I have had vaginal sex (penis in vagina) with more than 1 partner	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a bottom (penis in butt as a bottom) with only 1 partner	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a bottom (penis in butt as a bottom) with more than 1 partner	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a top (penis in butt as a top) with only 1 partner	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a top (penis in butt as a top) with more than 1 partner	XX (XX.X%)	XX (XX.X%)
		I have had oral sex (mouth, tongue, or lips on a vagina, penis, or butt) with only 1 partner	XX (XX.X%)	XX (XX.X%)
		I have had oral sex (mouth, tongue, or lips on a vagina, penis, or butt) with more than 1 partner	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)
10	How often did you use a condom when you had sex in the last 6 months?			
		All of the time	XX (XX.X%)	XX (XX.X%)



Question Number	Question	Response	Men who have sex with men (N = XX) n (%)	Transgender Men (N = XX) n (%)
		Most of the time	XX (XX.X%)	XX (XX.X%)
		Some of the time	XX (XX.X%)	XX (XX.X%)
		A little of the time	XX (XX.X%)	XX (XX.X%)
		None of the time	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)
11	In the last 6 months, how would you describe the HIV status of your sexual partner(s)?			
		I know that none of my sexual partners from the last 6 months have HIV/AIDS	XX (XX.X%)	XX (XX.X%)
		I know that at least one sexual partner from the last 6 months is living with HIV/AIDS	XX (XX.X%)	XX (XX.X%)
		I do not know my sexual partners' HIV status	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)
12	As far as you know, were any of your sexual partner(s) from the last 6 months taking PrEP to prevent HIV infection? PrEP is a medication that prevents HIV.			
		No	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)
13	You mentioned that you had a least one partner in the last 6 months who is living with HIV/AIDS. As far as you know, were any of your partners taking HIV medications (antiretrovirals) to treat their HIV infection?			
		Yes, my partner(s) was/were taking HIV medications	XX (XX.X%)	XX (XX.X%)
		Yes, my partner(s) was/were taking HIV medications and was/were undetectable, meaning HIV tests were not finding the virus	XX (XX.X%)	XX (XX.X%)
		No, my partner(s) was/were not taking HIV medications	XX (XX.X%)	XX (XX.X%)
		I do not know whether my partner(s) was/were taking HIV medications	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Men who have sex with men (N = XX) n (%)	Transgender Men (N = XX) n (%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)
14	In the last 6 months, have you experienced any incidents of sexual violence, physical abuse, or any other type of trauma form a partner?			
		No	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)
15	In the last 6 months, have you exchanged things like money or drugs for sex with a sexual partner?			
		Yes, I have a sexual partner things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)
		Yes, a sexual partner gave me things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)
		No, I have not exchanged things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)

**Table 6.101. Summary of Patient Study Participants' HIV and PrEP Knowledge (Month 6/7), N=XX**

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
5	Do you personally know of someone living with HIV?	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 6.102. Summary of Patient Study Participants' HIV and PrEP Knowledge (Month 6/7), N=XX, Scale Questions, Study Arms**

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
6	Please answer true or false to the following statements about HIV.				
A	A person who has HIV can look healthy.	True	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		False	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
B	There is a vaccine that can stop you from getting HIV.	True	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		False	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
C	A person will NOT get HIV if they are taking antibiotics.	True	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		False	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
D	If you only have sex once with a partner, you cannot get HIV from them.	True	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		False	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
E	People living with HIV on HIV medications cannot spread HIV.	True	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		False	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
F	Everybody who has HIV knows that they have HIV.	True	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		False	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
G	A natural (lamb skin) condom works better against HIV than a latex condom.	True	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		False	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
H	When using condoms during sex, it is safer to use water-based lubricants than oil-based lubricants.	True	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		False	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 6.103. Distributional Characteristics of Patient Study Participants' HIV and PrEP Knowledge (Month 6/7), N=XX, Scale Questions, Overall Score**

6. Please answer true or false to the following statements about HIV.	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean	Cronbach's α
<b>Mean Score</b>	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	0.xx
<b>Study Arm</b>								
Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
<b>Site Volume</b>								
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
<b>Gender</b>								
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
<b>Race</b>								
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
<b>Ethnicity</b>								
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
<b>Dynamic Implementation</b>								
<b>Site Volume</b>								
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
<b>Gender</b>								
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-

6. Please answer true or false to the following statements about HIV.	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean	Cronbach's $\alpha$
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
<b>Race</b>								
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
<b>Ethnicity</b>								
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
<b>Routine Implementation</b>								
<b>Site Volume</b>								
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
<b>Gender</b>								
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
<b>Race</b>								
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
<b>Ethnicity</b>								
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—

Mean score = mean of correct responses to all of the items under 8 save for A and E; 'Don't know' responses coded as incorrect. Correct answers were 'False' for items B, C, D, F, and G and 'True' for item H

**Table 6.104. Summary of Patient Study Participants' Perception of Stigma Associated with PrEP Usage (Month 6/7), N=XX, Stigma, Study Arms**

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
7	To what extent do you agree with each of the following statements about PrEP?				
A	My <i>friends</i> would be supportive of me taking PrEP.	Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
B	People experience problems when they tell their sexual partner(s) they are taking PrEP.	Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
C	People experience negative judgement because they take PrEP.	Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
D	My <i>family</i> would be supportive of me taking PrEP.	Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
E	People taking PrEP receive praise for being responsible.	Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
F	I would feel ashamed to take PrEP in front of others.	Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
G	Someone taking PrEP would be seen by others as having sex with a lot of different people.	Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
H	People on PrEP are taking care of their health.	Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
I	People talking PrEP experience verbal harassment.	Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
J	I would not want others to know if I was taking PrEP.	Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
K	Someone taking PrEP should keep their pills hidden.	Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
L	I would feel proud to take PrEP every day.	Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
M	I would have sex with someone who is taking PrEP.	Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 6.105. Distributional Characteristics of Patient Study Participants' Perception of Stigma Associated with PrEP Usage (Month 6/7), N=XX, Stigma, Overall Score**

13. To what extent do you agree with each of the following statements about PrEP?	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean	Cronbach's $\alpha$
<b>Mean Score</b>	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	0.xx
<b>Study Arm</b>								
Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
<b>Site Volume</b>								
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
<b>Gender</b>								
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
<b>Race</b>								
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
<b>Ethnicity</b>								
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
<b>Dynamic Implementation</b>								
<b>Site Volume</b>								
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
<b>Gender</b>								
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-

13. To what extent do you agree with each of the following statements about PrEP?	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean	Cronbach's $\alpha$
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
<b>Race</b>								
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
<b>Ethnicity</b>								
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
<b>Routine Implementation</b>								
<b>Site Volume</b>								
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
<b>Gender</b>								
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
<b>Race</b>								
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
<b>Ethnicity</b>								
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—

Mean score = mean of responses to all of the items under 13 save for J with the following items are reverse scored: A, D, E, H, L, & M. Higher total score indicates higher stigma.

Table 6.106. Summary of Patient Study Participants' Choice of APRETUDE (Month 6/7), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
16	Do you have any concerns about APRETUDE?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
17	What concerns do you have about APRETUDE?				
		Pain or soreness from the injection	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other side effects from APRETUDE	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Fear of needles	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Change in my insurance coverage for APRETUDE	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Possible long-term effects of the injection	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		How it affects other medications I take	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Scheduling or rescheduling injection visits	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Forgetting my appointment for the injection visits	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Missing an injection visit and then getting HIV	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Missing work for the injection visits	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Making time to go to the clinic/practice for the injection every 2 months	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Travelling to the clinic/practice for the injection visits	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Limited clinic/practice hours for injection visits	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Childcare/caregiver responsibilities during injection visits	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Lack of privacy at injection visits	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		My dignity not being respected during injection visits	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		People asking why I go to the clinic/doctor every 2 months	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		My hectic lifestyle	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		My travel or holiday schedules	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Taking medication during times when I am not having sex	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The medication not being effective at preventing HIV	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Worrying people would think I have HIV	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Worrying that people would think I have a lot of sexual partners because I am on CAB LA for PrEP	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Worrying about my privacy because I live with someone	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Worrying about my privacy because I'm on my parent's health insurance	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
18	How often are you worried that people may find out that you are taking APREUDE?				
		Never	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Rarely	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Sometimes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Often	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		All the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
19	How often are you worried about forgetting your APREUDE injection visits?				
		Never	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Rarely	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Sometimes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Often	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		All the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



**Table 6.107. Summary of Knowledge of APREUDE and Utility of Implementation Strategies (Month 6/7), N=XX**

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
73	Overall, how much do you know about APREUDE?				
		A lot	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Some	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Nothing	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
74	How confident are you with your current level of knowledge about APREUDE?				
		Extremely confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
75	How helpful was the information, if any, shared by the medical staff about APREUDE?				
		Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not receive any information from medical staff	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
76	How helpful has each of the following materials been in learning about APREUDE?				
A	Getting Started Brochure – the brochure that gives you an overview of how to get started with APREUDE	Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Did not use it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
B	Patient Brochure – this brochure helps you understand the process of receiving APRETUDE injections, including side effects and insurance information	Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Did not use it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
C	Let's talk about HIV & PrEP video – the video giving key facts about HIV and PrEP options (DI)	Very helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	N/A
		A little helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Not at all helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Did not use it	XX (XX.X%)	XX (XX.X%)	N/A
D	The APRETUDE Myths and Facts video – the game show video addressing common myths about APRETUDE (DI)	Very helpful	XX (XX.X%)	XX (XX.X%)	N/A

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	N/A
		A little helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Not at all helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Did not use it	XX (XX.X%)	XX (XX.X%)	N/A
E	The What to Expect video which shows you what to expect during the APREITUDE process (DI)	Very helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	N/A
		A little helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Not at all helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Did not use it	XX (XX.X%)	XX (XX.X%)	N/A
F	The ViiV Connect Video, which tells you about the ViiV Connect program and frequently asked questions (DI)	Very helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	N/A
		A little helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Not at all helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Did not use it	XX (XX.X%)	XX (XX.X%)	N/A
G	The study website where you access APRETDUE information (RI)	Very helpful	XX (XX.X%)	N/A	XX (XX.X%)
		Helpful	XX (XX.X%)	N/A	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Somewhat helpful	XX (XX.X%)	N/A	XX (XX.X%)
		A little helpful	XX (XX.X%)	N/A	XX (XX.X%)
		Not at all helpful	XX (XX.X%)	N/A	XX (XX.X%)
		Did not use it	XX (XX.X%)	N/A	XX (XX.X%)
H	The study app/website where you access APREUDE information – the Pillar Spot (DI)	Very helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	N/A
		A little helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Not at all helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Did not use it	XX (XX.X%)	XX (XX.X%)	N/A
I	Important safety information – This document details important safety information relating to APREUDE	Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Did not use it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
J	Important facts – This document details important facts relating to APREUDE	Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Did not use it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
K	A flyer on PrEP options (DI)	Very helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	N/A
		A little helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Not at all helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Did not use it	XX (XX.X%)	XX (XX.X%)	N/A

**Table 6.108. Attitude Regarding APREUDE and Utility of Implementation Strategies (Month 6/7), N=XX**

Question		Response				
83. Overall, how are you feeling about taking APREUDE?		Very positive	Somewhat positive	Neither positive nor negative	Somewhat negative	Very negative
Study Arms						
	Total N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Dynamic Implementation N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Routine Implementation N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Race, Dynamic Implementation						
	Asian N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Black or African American N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	White N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Race, Routine Implementation						
	Asian N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Black or African American N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	White N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Race, Total						

Question		Response				
	Asian N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Black or African American N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	White N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Ethnicity, Dynamic Implementation						
	Hispanic or Latino N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not Hispanic or Latino N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Ethnicity, Routine Implementation						
	Hispanic or Latino N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not Hispanic or Latino N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Ethnicity, Total						
	Hispanic or Latino N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not Hispanic or Latino N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Gender, Total						
	Men who have sex with men N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Transgender men N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 6.109. Summary of Patient Study Participant Acquisition Process (Month 6/7), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
77	Have you ever heard of Viiv Connect?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
78	Where did you learn about Viiv Connect?				
		My healthcare provider/healthcare clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The Viiv Connect video on the study app/website (DI)	XX (XX.X%)	XX (XX.X%)	N/A
		Viiv Connect brochure	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A friend/family member told me	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The Viiv Connect website	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify_____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



**Table 6.110. Summary of Patient Study Participant Acquisition Process, Insurance (Month 6/7), N=XX**

Question		Response				
79. To what extent do you agree with each of the following statements?		Completely Agree	Agree	Neither agree nor disagree	Disagree	Completely disagree
<b>A. The staff at the clinic helped me understand the insurance approval process</b>						
Study Arms						
	Total N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Dynamic Implementation N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Routine Implementation N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Race, Dynamic Implementation						
	Asian N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Black or African American N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	White N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Race, Routine Implementation						
	Asian N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Black or African American N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	White N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Race, Total						

Question		Response				
	Asian N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Black or African American N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	White N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Ethnicity, Dynamic Implementation						
	Hispanic or Latino N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not Hispanic or Latino N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Ethnicity, Routine Implementation						
	Hispanic or Latino N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not Hispanic or Latino N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Ethnicity, Total						
	Hispanic or Latino N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not Hispanic or Latino N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Gender, Total						
	Men who have sex with men N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Transgender men N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>B. It took too long to get insurance approval for APREUDE</b>						
Study Arms						

Question		Response				
	Total N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Dynamic Implementation N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Routine Implementation N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Race, Dynamic Implementation						
	Asian N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Black or African American N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	White N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Race, Routine Implementation						
	Asian N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Black or African American N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	White N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Race, Total						
	Asian N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Black or African American N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question		Response				
	White N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Ethnicity, Dynamic Implementation						
	Hispanic or Latino N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not Hispanic or Latino N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Ethnicity, Routine Implementation						
	Hispanic or Latino N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not Hispanic or Latino N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Ethnicity, Total						
	Hispanic or Latino N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not Hispanic or Latino N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Gender, Total						
	Men who have sex with men N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Transgender men N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>C. My copy for APREUDE is acceptable</b>						
Study Arms						
	Total N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Dynamic Implementation N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question		Response				
	Routine Implementation N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Race, Dynamic Implementation						
	Asian N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Black or African American N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	White N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Race, Routine Implementation						
	Asian N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Black or African American N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	White N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Race, Total						
	Asian N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Black or African American N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	White N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Ethnicity, Dynamic Implementation						

Question		Response				
	Hispanic or Latino N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not Hispanic or Latino N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Ethnicity, Routine Implementation						
	Hispanic or Latino N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not Hispanic or Latino N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Ethnicity, Total						
	Hispanic or Latino N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not Hispanic or Latino N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Gender, Total						
	Men who have sex with men N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Transgender men N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>D. I am worried about insurance coverage long-term</b>						
Study Arms						
	Total N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Dynamic Implementation N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Routine Implementation N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Race, Dynamic Implementation						
	Asian N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question		Response				
	Black or African American N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	White N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Race, Routine Implementation						
	Asian N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Black or African American N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	White N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Race, Total						
	Asian N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Black or African American N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	White N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Ethnicity, Dynamic Implementation						
	Hispanic or Latino N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not Hispanic or Latino N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Ethnicity, Routine Implementation						

Question		Response				
	Hispanic or Latino N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not Hispanic or Latino N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Ethnicity, Total						
	Hispanic or Latino N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not Hispanic or Latino N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Gender, Total						
	Men who have sex with men N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Transgender men N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>E. The insurance approval process was simple</b>						
Study Arms						
	Total N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Dynamic Implementation N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Routine Implementation N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Race, Dynamic Implementation						
	Asian N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Black or African American N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	White N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



Question		Response				
	Other N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Race, Routine Implementation						
	Asian N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Black or African American N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	White N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Race, Total						
	Asian N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Black or African American N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	White N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Ethnicity, Dynamic Implementation						
	Hispanic or Latino N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not Hispanic or Latino N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Ethnicity, Routine Implementation						
	Hispanic or Latino N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not Hispanic or Latino N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Ethnicity, Total						

Question		Response				
	Hispanic or Latino N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not Hispanic or Latino N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Gender, Total						
	Men who have sex with men N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Transgender men N = XX n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 6.201. Distributional Characteristics of Acceptability of Intervention (AIM) (APREUDE) (PSP) (Month 6/7), N=XX**

20. AIM APREUDE.	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
<b>Mean Score</b>	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Study Arm</b>							
Dynamic Implementation	XX	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)
Routine Implementation	XX	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)
T-test Degrees of Freedom P-value	X.XXX XX 0.XXX						
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Gender</b>							
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Race</b>							
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Ethnicity</b>							
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Dynamic Implementation</b>							
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)

20. AIM APREITUDE.	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Gender</b>							
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Race</b>							
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Ethnicity</b>							
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Routine Implementation</b>							
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Gender</b>							
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Race</b>							
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Ethnicity</b>							

20. AIM APRETUDE.	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)

**Table 6.202. Distributional Characteristics of Feasibility of Intervention (FIM) (APRETUDE) (PSP) (Month 6/7), N=XX**

21. FIM APRETUDE.	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
<b>Mean Score</b>	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Study Arm</b>							
Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
T-test	X.XXX						
Degrees of Freedom	XX						
P-value	0.XXX						
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Gender</b>							
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Race</b>							
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Ethnicity</b>							
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Dynamic Implementation</b>							
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)

21. FIM APREITUDE.	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
<b>Gender</b>							
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Race</b>							
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Ethnicity</b>							
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Routine Implementation</b>							
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Gender</b>							
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Race</b>							
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Ethnicity</b>							
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)

21. FIM APRETUDE.	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)



**Table 6.203. Distributional Characteristics of Accessibility of Intervention (AIM) (Telehealth) (PSP) (Month 6/7), N=XX**

	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
<b>22. AIM TELEHEALTH.</b>							
<b>Mean Score</b>	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Study Arm</b>							
Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
T-test	X.XXX						
Degrees of Freedom	XX						
P-value	0.XXX						
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Gender</b>							
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Race</b>							
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Ethnicity</b>							
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Dynamic Implementation</b>							
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)

22. AIM TELEHEALTH.	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
<b>Gender</b>							
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Race</b>							
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Ethnicity</b>							
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Routine Implementation</b>							
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Gender</b>							
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Race</b>							
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Ethnicity</b>							
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)

	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
22. AIM TELEHEALTH.							
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)

**Table 6.204. Distributional Characteristics of Feasibility of Intervention (FIM) (Telehealth) (PSP) (Month 6/7), N=XX**

24. FIM TELEHEALTH.	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
<b>Mean Score</b>	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Study Arm</b>							
Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
T-test	X.XXX						
Degrees of Freedom	XX						
P-value	0.XXX						
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Gender</b>							
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Race</b>							
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Ethnicity</b>							
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Dynamic Implementation</b>							
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)

24. FIM TELEHEALTH.	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
<b>Gender</b>							
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Race</b>							
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Ethnicity</b>							
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Routine Implementation</b>							
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Gender</b>							
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Race</b>							
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Ethnicity</b>							
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)

24. FIM TELEHEALTH.	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)

Table 6.205. Summary of Acceptability of Intervention (AIM) (APRETUDE) (PSP) (Month 6/7), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
20	<i>Please indicate how much you agree or disagree with each statement based on your <b>experiences</b> with APRETUDE.</i>				
	APRETUDE <b>meets my approval</b> for preventing HIV.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	APRETUDE for the prevention of HIV <b>is appealing to me.</b>	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I <b>like</b> APRETUDE for the prevention of HIV.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I <b>welcome</b> APRETUDE for the prevention of HIV	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 6.206. Summary of Feasibility of Intervention (FIM) (APRETUDE) (PSP) (Month 6/7), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
21	Please indicate how much you agree with each statement based on your current expectations of APRETUDE.				
	Receiving APRETUDE injection every 2-months <b>seems workable</b> in my life	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Receiving APRETUDE injection every 2-months <b>seems possible</b> in my life	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Receiving APRETUDE injection every 2-months <b>seems doable</b> in my life	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Receiving APRETUDE injection every 2-months <b>seems easy</b> in my life	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 6.207. Summary of Acceptability of Intervention (AIM) (Telehealth) (PSP) (Month 6/7), N=XX**

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
23	Please indicate how much you agree with each statement based on your current perceptions and experience with telehealth.				
	Using telehealth for APREUDE services <b>meets my approval.</b>	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Using telehealth for APREUDE services <b>is appealing to me.</b>	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I <b>like</b> using telehealth for APREUDE services.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I <b>welcome</b> using telehealth for APREUDE services.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 6.208. Summary of Feasibility of Intervention (FIM) (Telehealth) (PSP) (Month 6/7), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
23	Please indicate how much you agree with each statement based on your current perceptions and experience with telehealth.				
	Using telehealth for APREITUDE services <b>seems workable</b> in my life.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Using telehealth for APREITUDE services <b>seems possible</b> in my life.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Using telehealth for APREITUDE services <b>seems doable</b> in my life.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Using telehealth for APREITUDE services <b>seems easy</b> in my life.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 6.209. Changes from Baseline to Acceptability of Intervention Measure (AIM - APREUDE) and Feasibility of Intervention Measure (FIM - APREUDE) (Month 6/7), N=XX**

Measure	Study Arm	n	Mean	SD	Median (Q1, Q3)	Observed Range (min, max)	Missing n (%)	95% CI for the Mean
AIM - APREUDE Baseline	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
AIM - APREUDE Month 6/7	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
AIM - APREUDE Change from Baseline to Month 6/7	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	T-test		X.XXX					
	DF		XX					
	P-Value		0.XXX					
FIM - APREUDE Baseline	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
FIM - APREUDE Month 6/7	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
FIM - APREUDE Change from Baseline to Month 6/7	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	T-test		X.XXX					
	DF		XX					
	P-Value		0.XXX					

**Table 6.210. Mixed-effects Modeling of the Acceptability of Intervention Measure (AIM – APRETUDE) (Month 6/7), N= XX**

Fixed effects					
Parameter	Estimate	Standard Error	Denominator Degrees of Freedom	T	p-Value
Intercept (RI, Low)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm (DI)	X.XX	X.XXX	XX	X.XX	0.XXXX
Volume (High)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm by Volume	X.XX	X.XXX	XX	X.XX	0.XXXX
Baseline Mean Score[1]	X.XX	X.XXX	XX	X.XX	0.XXXX
Random Effects					
Covariance Parameter	Estimate	Standard Error		Z	p-Value
Site Variance ( $\tau(0,0)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Covariance ( $\tau(0,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Baseline Variance ( $\tau(1,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Residual Variance ( $\sigma^2$ )	X.XX	X.XXX	-	X.XX	0.XXXX

Note: Null model likelihood ratio test,  $\chi^2(XX) = XXX.XX$ ,  $p = 0.XXXX$ .

[1] Baseline mean score centered by site.

**Table 6.211. Mixed-effects Modeling of the Changes from Baseline to Month 6/7 in Acceptability of Intervention Measure (AIM – APRETUDE), N=XX**

Fixed effects					
Parameter	Estimate	Standard Error	Denominator Degrees of Freedom	T	p-Value
Intercept (RI, Low)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm (DI)	X.XX	X.XXX	XX	X.XX	0.XXXX
Volume (High)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm by Volume	X.XX	X.XXX	XX	X.XX	0.XXXX
Baseline Mean Score[1]	X.XX	X.XXX	XX	X.XX	0.XXXX
Random Effects					
Covariance Parameter	Estimate	Standard Error		Z	p-Value
Site Variance ( $\tau(0,0)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Covariance ( $\tau(0,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Baseline Variance ( $\tau(1,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Residual Variance ( $\sigma^2$ )	X.XX	X.XXX	-	X.XX	0.XXXX

Note: Null model likelihood ratio test,  $\chi^2(XX) = XXX.XX$ ,  $p = 0.XXXX$ .

[1] Baseline mean score centered by site.



**Table 6.212. Mixed-effects Modeling of the Feasibility of Intervention Measure (FIM – APREUDE) (Month 6/7), N=XX**

Fixed effects					
Parameter	Estimate	Standard Error	Denominator Degrees of Freedom	T	p-Value
Intercept (RI, Low)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm (DI)	X.XX	X.XXX	XX	X.XX	0.XXXX
Volume (High)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm by Volume	X.XX	X.XXX	XX	X.XX	0.XXXX
Baseline Mean Score[1]	X.XX	X.XXX	XX	X.XX	0.XXXX
Random Effects					
Covariance Parameter	Estimate	Standard Error		Z	p-Value
Site Variance ( $\tau(0,0)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Covariance ( $\tau(0,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Baseline Variance ( $\tau(1,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Residual Variance ( $\sigma^2$ )	X.XX	X.XXX	-	X.XX	0.XXXX

Note: Null model likelihood ratio test,  $\chi^2(XX) = XXX.XX$ ,  $p = 0.XXXX$ .

[1] Baseline mean score centered by site.

**Table 6.213. Mixed-effects Modeling of the Changes from Baseline to Month 6/7 in Feasibility of Intervention Measure (FIM – APRETUDE), N=XX**

Fixed effects					
Parameter	Estimate	Standard Error	Denominator Degrees of Freedom	T	p-Value
Intercept (RI, Low)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm (DI)	X.XX	X.XXX	XX	X.XX	0.XXXX
Volume (High)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm by Volume	X.XX	X.XXX	XX	X.XX	0.XXXX
Baseline Mean Score[1]	X.XX	X.XXX	XX	X.XX	0.XXXX
Random Effects					
Covariance Parameter	Estimate	Standard Error		Z	p-Value
Site Variance ( $\tau(0,0)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Covariance ( $\tau(0,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Baseline Variance ( $\tau(1,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Residual Variance ( $\sigma^2$ )	X.XX	X.XXX	-	X.XX	0.XXXX

Note: Null model likelihood ratio test,  $\chi^2(XX) = XXX.XX$ ,  $p = 0.XXXX$ .

[1] Baseline mean score centered by site

**Table 6.214. Changes from Baseline for Acceptability of Intervention Measure (AIM - Telehealth) and Feasibility of Intervention Measure (FIM - Telehealth) (Month 6/7), N=XX**

Measure	Study Arm	n	Mean	SD	Median (Q1, Q3)	Observed Range (min, max)	Missing n (%)	95% CI for the Mean
AIM - Telehealth Baseline	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
AIM - Telehealth Month 6/7	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
AIM - Telehealth Change from Baseline to Month 6/7	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	T-test		X.XXX					
	DF		XX					
	P-Value		0.XXX					
FIM - Telehealth Baseline	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
FIM - Telehealth Month 6/7	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
FIM - Telehealth Change from Baseline to Month 6/7	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	T-test		X.XXX					
	DF		XX					
	P-Value		0.XXX					

**Table 6.215. Mixed-effects Modeling of the Acceptability of Intervention Measure (AIM – Telehealth) (Month 6/7), N=XX**

Fixed effects					
Parameter	Estimate	Standard Error	Denominator Degrees of Freedom	T	p-Value
Intercept (RI, Low)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm (DI)	X.XX	X.XXX	XX	X.XX	0.XXXX
Volume (High)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm by Volume	X.XX	X.XXX	XX	X.XX	0.XXXX
Baseline Mean Score[1]	X.XX	X.XXX	XX	X.XX	0.XXXX
Random Effects					
Covariance Parameter	Estimate	Standard Error		Z	p-Value
Site Variance ( $\tau(0,0)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Covariance ( $\tau(0,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Baseline Variance ( $\tau(1,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Residual Variance ( $\sigma^2$ )	X.XX	X.XXX	-	X.XX	0.XXXX

Note: Null model likelihood ratio test,  $\chi^2(XX) = XXX.XX$ ,  $p = 0.XXXX$ .

[1] Baseline mean score centered by site.

**Table 6.216. Mixed-effects Modeling of the Changes from Baseline to Month 6/7 in Acceptability of Intervention Measure (AIM – Telehealth), N=XX**

Fixed effects					
Parameter	Estimate	Standard Error	Denominator Degrees of Freedom	T	p-Value
Intercept (RI, Low)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm (DI)	X.XX	X.XXX	XX	X.XX	0.XXXX
Volume (High)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm by Volume	X.XX	X.XXX	XX	X.XX	0.XXXX
Baseline Mean Score[1]	X.XX	X.XXX	XX	X.XX	0.XXXX
Random Effects					
Covariance Parameter	Estimate	Standard Error		Z	p-Value
Site Variance ( $\tau(0,0)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Covariance ( $\tau(0,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Baseline Variance ( $\tau(1,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Residual Variance ( $\sigma^2$ )	X.XX	X.XXX	-	X.XX	0.XXXX

Note: Null model likelihood ratio test,  $\chi^2(XX) = XXX.XX$ ,  $p = 0.XXXX$ .

[1] Baseline mean score centered by site.

**Table 6.217. Mixed-effects Modeling of the Feasibility of Intervention Measure (FIM – Telehealth) (Month 6/7), N=XX**

Fixed effects					
Parameter	Estimate	Standard Error	Denominator Degrees of Freedom	T	p-Value
Intercept (RI, Low)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm (DI)	X.XX	X.XXX	XX	X.XX	0.XXXX
Volume (High)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm by Volume	X.XX	X.XXX	XX	X.XX	0.XXXX
Baseline Mean Score[1]	X.XX	X.XXX	XX	X.XX	0.XXXX
Random Effects					
Covariance Parameter	Estimate	Standard Error		Z	p-Value
Site Variance ( $\tau(0,0)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Covariance ( $\tau(0,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Baseline Variance ( $\tau(1,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Residual Variance ( $\sigma^2$ )	X.XX	X.XXX	-	X.XX	0.XXXX

Note: Null model likelihood ratio test,  $\chi^2(XX) = XXX.XX$ ,  $p = 0.XXXX$ .

[1] Baseline mean score centered by site.

**Table 6.218. Mixed-effects Modeling of the Changes from Baseline to Month 6/7 in Feasibility of Intervention Measure (FIM – Telehealth), N=XX**

Fixed effects					
Parameter	Estimate	Standard Error	Denominator Degrees of Freedom	T	p-Value
Intercept (RI, Low)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm (DI)	X.XX	X.XXX	XX	X.XX	0.XXXX
Volume (High)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm by Volume	X.XX	X.XXX	XX	X.XX	0.XXXX
Baseline Mean Score[1]	X.XX	X.XXX	XX	X.XX	0.XXXX
Random Effects					
Covariance Parameter	Estimate	Standard Error		Z	p-Value
Site Variance ( $\tau(0,0)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Covariance ( $\tau(0,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Baseline Variance ( $\tau(1,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Residual Variance ( $\sigma^2$ )	X.XX	X.XXX	-	X.XX	0.XXXX

Note: Null model likelihood ratio test,  $\chi^2(XX) = XXX.XX$ ,  $p = 0.XXXX$ .

[1] Baseline mean score centered by site.

Table 6.219. Summary of Pain/Activities After Injection (Month 6/7), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
65	Did you experience any local reaction(s) following an injection appointment? <i>Examples of local reactions are redness, itching, swelling, bruising.</i>				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
66	How acceptable was/were your local reaction(s)? <i>Examples of local reactions are redness, itching, swelling, bruising.</i>				
		Totally acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Moderately acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
67	How often are you able to return to your usual daily activities immediately following an injection appointment (for example, going back to work, social events, exercise, driving)?				
		Never	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Rarely	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Sometimes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Often	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Always	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
68	How bothered were you by <b>pain DURING</b> the injection?				
		Not at all	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Moderately	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Very	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Extremely	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
69	Think back to your <b>first</b> injection, please rate the amount of pain/discomfort you experienced <b>AFTER</b> receiving your <b>first</b> APRETUDE injection				
		0 (No pain)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		1	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		2	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		3	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		4	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		5	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		6	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		7	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		8	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		9	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		10 (Extreme pain)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
70	Now think about your <b>last/most recent</b> injection. Please rate the amount of pain/discomfort you experienced <b>AFTER</b> receiving your <b>most recent</b> APRETUDE injection				
		0 (No pain)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		1	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		2	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		3	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		4	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		5	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
			(XX.X%)	(XX.X%)	(XX.X%)
		6	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		7	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		8	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		9	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		10 (Extreme pain)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
71	How acceptable was your pain?				
		Totally acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Moderately acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
72	Which of the following things have you tried to reduce the pain/discomfort following your injections?				
		Took over-the-counter pain relievers	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Used a hot compress	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Used a cold compress	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Avoided sitting for long periods of time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Light stretching and exercise	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 6.220. Summary of Patient Study Participants' Labs and Missed Doses (Month 6/7), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
53	Have you missed any of your APRETUDE injection visits in the last 6 months? <i>This means not receiving an injection within your injection window.</i>				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
54	Was missing your APRETUDE injection visits planned or unplanned?				
		All the injection visits I missed were planned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Some of the injection visits I missed were planned and some were unplanned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		All the injection visits I missed were unplanned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
55	Did you start oral PrEP after missing any of your injection visits?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
56	How easy or difficult was it to start oral PrEP after a missed injection visit?				
		Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
57	How acceptable was it to start oral PrEP after a missed injection visit?				
		Very acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		A little acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 6.301. Summary of Feasibility and Acceptability of Telehealth (Month 6/7), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
22	Have you used telehealth for any APRETUDE services in the last 6 months, such as completing forms online, video chatting with your provider, getting reminders about your injection, or scheduling injection appointments online?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
25	What APRETUDE services do/did you receive via telehealth?				
A	Completing relevant clinic visit forms online	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
B	Your doctor ordering an HIV test at a lab near your home where you can go to take the test	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
C	A nurse coming to your home to give you an HIV test	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
D	Video chatting with your doctor	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
E	Receiving reminders (e.g., text, email) about your scheduled injection appointment	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
			(XX.X%)	(XX.X%)	(XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
E	Scheduling your injection appointment online to go to your clinic/doctor's office for the injection	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
F	Scheduling your injection appointment online for a nurse to come to your home and to give you the injection	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
G	A nurse coming to your home to give you the injection	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
H	Sending messages to your doctor online	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
I	Reviewing your health documents, such as test results, online	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
26	How <u>comfortable</u> is/was it to use each of the following telehealth services for APRETUDE?				
A	Completing relevant clinic visit forms online	Very comfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Somewhat comfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither comfortable nor uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not comfortable at all	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
B	Your doctor ordering an HIV test at a lab near your home where you can go to take the test	Very comfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat comfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither comfortable nor uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not comfortable at all	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
C	A nurse coming to your home to give you an HIV test	Very comfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat comfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither comfortable nor uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not comfortable at all	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
D	Video chatting with your doctor	Very comfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat comfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither comfortable nor uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not comfortable at all	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
E	Receiving reminders (e.g., text, email) about your scheduled injection appointment	Very comfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat comfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither comfortable nor uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not comfortable at all	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
F	Scheduling your injection appointment online to go to your clinic/doctor's office for the injection	Very comfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat comfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither comfortable nor uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not comfortable at all	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
G	A nurse coming to your home to give you the injection	Very comfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat comfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither comfortable nor uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not comfortable at all	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
H	Sending messages to your doctor online	Very comfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat comfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither comfortable nor uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
			(XX.X%)	(XX.X%)	(XX.X%)
		Not comfortable at all	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
I	Reviewing your health documents, such as test results, online	Very comfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat comfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither comfortable nor uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not comfortable at all	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
27	How <b>convenient</b> is/was it to use each of the telehealth services for APRETUDE? <i>By convenient, we mean fitting in well with your life activities and plans, with little trouble.</i>				
A	Completing relevant clinic visit forms online	Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither convenient nor inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
B	Your doctor ordering an HIV test at a lab near your home where you can go to take the test	Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither convenient nor inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
C	A nurse coming to your home to give you a HIV test	Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Neither convenient nor inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
D	Video chatting with your doctor	Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither convenient nor inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
E	Receiving reminders (e.g., text, email) about your scheduled injection appointment	Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither convenient nor inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
F	Scheduling your injection appointment online to go to your clinic/doctor's office for the injection	Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither convenient nor inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
G	A nurse coming to your home to give you the injection	Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither convenient nor inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
H	Sending messages to your doctor online	Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither convenient nor inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
I	Reviewing your health documents, such as test results, online	Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither convenient nor inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
28	On average, how long did you wait to connect to a doctor for video chat?				
		Up to 5 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		6 to 10 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		11 to 15 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		16 to 30 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		More than 30 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
29	I would recommend telehealth services for APRETUDE to other people.				
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 6.302. Summary of Quality of Care for Patient Study Participants (Month 6/7), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
80	To what extent do you agree with each of the following statements regarding your experience with your clinic/provider?				
A	My provider explained medical words that were used so that I could understand them.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
B	My provider encouraged me to ask questions.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
C	My provider really respected me.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
D	My provider gave me enough time to say what I though was important.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
E	My provider listened carefully to what I had to say.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
			(XX.X%)	(XX.X%)	(XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
F	My provider explained why tests were being done.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
G	My provider made me feel comfortable talking about personal things.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
H	My privacy was respected.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
I	My provider does not judge me.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
J	The provider had a respectful attitude towards my sexual orientation.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
K	The staff at the clinic does not judge me.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
L	The staff at this clinic is kind and respectful to me.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
M	I sometimes felt insulted when the clinic staff spoke to me.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
N	I felt judged by the clinic staff for being on PrEP.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
O	I felt judged by my provider for being on PrEP.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



**Table 6.303. Summary of Quality of Care for Patient Study Participants (Month 6/7), N=XX, Non-Score Questions**

Question		Response			
80. To what extent do you agree with each of the following statements regarding your experience with your clinical/provider?		Completely Agree	Agree	Neither agree nor disagree	Disagree
<b>I. My provider does not judge me.</b>					
Study Arms					
	Total	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Dynamic Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Routine Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Dynamic Implementation					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Routine Implementation					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				

Question		Response			
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Total					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Dynamic Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Routine Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Total					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)

Question		Response			
	n (%)				
Gender, Total					
	Men who have sex with men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Transgender men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
<b>J. The provider had a respectful attitude towards my sexual orientation.</b>					
Study Arms					
	Total	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Dynamic Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Routine Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Dynamic Implementation					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Routine Implementation					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				

Question		Response			
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Total					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Dynamic Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Routine Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Total					
	Hispanic or Latino	XX	XX	XX	XX

Question		Response			
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Gender, Total					
	Men who have sex with men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Transgender men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
<b>K. The staff at the clinic does not judge me.</b>					
Study Arms					
	Total	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Dynamic Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Routine Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Dynamic Implementation					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Routine Implementation					

Question		Response			
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Total					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Dynamic Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Routine Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)

Question		Response			
	n (%)				
Ethnicity, Total					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Gender, Total					
	Men who have sex with men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Transgender men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
<b>L. The staff at this clinic is kind and respectful to me.</b>					
Study Arms					
	Total	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Dynamic Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Routine Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Dynamic Implementation					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX

Question		Response			
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Routine Implementation					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Total					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Dynamic Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Routine Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)



Question		Response			
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Total					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Gender, Total					
	Men who have sex with men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Transgender men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
M. I sometimes felt insulted when the clinic staff spoke to me.					
Study Arms					
	Total	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Dynamic Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Routine Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Dynamic Implementation					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX

Question		Response			
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Routine Implementation					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Total					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Dynamic Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				

Question		Response			
Ethnicity, Routine Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Total					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Gender, Total					
	Men who have sex with men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Transgender men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
N. I felt judged by the clinic staff for being on PrEP.					
Study Arms					
	Total	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Dynamic Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Routine Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Dynamic Implementation					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				

Question		Response			
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Routine Implementation					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Total					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Dynamic Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				

Question		Response			
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Routine Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Total					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Gender, Total					
	Men who have sex with men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Transgender men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
O. I felt judged by my provider for being on PrEP.					
Study Arms					
	Total	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Dynamic Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Routine Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Dynamic Implementation					
	Asian	XX	XX	XX	XX

Question		Response			
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Routine Implementation					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Total					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				

Question		Response			
Ethnicity, Dynamic Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Routine Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Total					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Gender, Total					
	Men who have sex with men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Transgender men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				

**Table 6.304. Summary of Quality of Care for Patient Study Participants (Month 6/7), N=XX, Score Questions**

Question		Response			
80. To what extent do you agree with each of the following statements regarding your experience with your clinic/provider?		Completely Agree	Agree	Neither agree nor disagree	Disagree
<b>A. My provider explained medical words that were used so that I could understand them.</b>					
Study Arms					
	Total	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Dynamic Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Routine Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Dynamic Implementation					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Routine Implementation					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				



Question		Response			
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Total					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Dynamic Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Routine Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Total					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)

Question		Response			
	n (%)				
Gender, Total					
	Men who have sex with men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Transgender men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
B. My provider encouraged me to ask questions.					
Study Arms					
	Total	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Dynamic Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Routine Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Dynamic Implementation					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Routine Implementation					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				

Question		Response			
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Total					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Dynamic Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Routine Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Total					
	Hispanic or Latino	XX	XX	XX	XX

Question		Response			
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Gender, Total					
	Men who have sex with men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Transgender men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
C. My provider really respected me.					
Study Arms					
	Total	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Dynamic Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Routine Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Dynamic Implementation					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Routine Implementation					

Question		Response			
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Total					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Dynamic Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Routine Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)

Question		Response			
	n (%)				
Ethnicity, Total					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Gender, Total					
	Men who have sex with men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Transgender men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
D. My provider gave me enough time to say what I thought was important.					
Study Arms					
	Total	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Dynamic Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Routine Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Dynamic Implementation					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX

Question		Response			
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Routine Implementation					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Total					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Dynamic Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Routine Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)

Question		Response			
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Total					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Gender, Total					
	Men who have sex with men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Transgender men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
E. My provider listened carefully to what I had to say.					
Study Arms					
	Total	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Dynamic Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Routine Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Dynamic Implementation					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX



Question		Response			
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Routine Implementation					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Total					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Dynamic Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				

Question		Response			
Ethnicity, Routine Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Total					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Gender, Total					
	Men who have sex with men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Transgender men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
F. My provider explained why tests were being done.					
Study Arms					
	Total	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Dynamic Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Routine Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Dynamic Implementation					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				

Question		Response			
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Routine Implementation					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Total					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Dynamic Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				

Question		Response			
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Routine Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Total					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Gender, Total					
	Men who have sex with men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Transgender men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
<b>G. My provider made me feel comfortable talking about personal things.</b>					
Study Arms					
	Total	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Dynamic Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Routine Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Dynamic Implementation					
	Asian	XX	XX	XX	XX

Question		Response			
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Routine Implementation					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Total					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				

Question		Response			
Ethnicity, Dynamic Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Routine Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Total					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Gender, Total					
	Men who have sex with men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Transgender men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
H. My privacy was respected.					
Study Arms					
	Total	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Dynamic Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Routine Implementation	XX	XX	XX	XX

Question		Response			
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Dynamic Implementation					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Routine Implementation					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Total					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)

Question		Response			
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Dynamic Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Routine Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Total					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Gender, Total					
	Men who have sex with men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Transgender men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				



Table 6.305. Summary of Utility of Proposed Implementation Strategies (Month 6/7), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
49	Have you used any of the following while taking APREUDE?				
A	Brochures and other print materials to educate you on APREUDE	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
B	Videos to educate you on HIV, PrEP, APREUDE materials (DI)	Yes	XX (XX.X%)	XX (XX.X%)	N/A
		No	XX (XX.X%)	XX (XX.X%)	N/A
		Don't know	XX (XX.X%)	XX (XX.X%)	N/A
C	A digital calendar specifically made for APREUDE to help you plan your injections – found on PillarSpot (DI)	Yes	XX (XX.X%)	XX (XX.X%)	N/A
		No	XX (XX.X%)	XX (XX.X%)	N/A
		Don't know	XX (XX.X%)	XX (XX.X%)	N/A
D	Reminders about your injections	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
E	Having video or telephone appointments with your doctor	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
F	Sending chats or texts to your doctor on the Pillar Spot (DI)	Yes	XX (XX.X%)	XX (XX.X%)	N/A
		No	XX (XX.X%)	XX (XX.X%)	N/A

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Don't know	XX (XX.X%)	XX (XX.X%)	N/A
G	Having a nurse come to your home to conduct your HIV tests (DI)	Yes	XX (XX.X%)	XX (XX.X%)	N/A
		No	XX (XX.X%)	XX (XX.X%)	N/A
		Don't know	XX (XX.X%)	XX (XX.X%)	N/A
H	Having a nurse come to your home to give your injection (DI)	Yes	XX (XX.X%)	XX (XX.X%)	N/A
		No	XX (XX.X%)	XX (XX.X%)	N/A
		Don't know	XX (XX.X%)	XX (XX.X%)	N/A
I	Receiving transportation to the clinic/doctor's office for your injection (DI)	Yes	XX (XX.X%)	XX (XX.X%)	N/A
		No	XX (XX.X%)	XX (XX.X%)	N/A
		Don't know	XX (XX.X%)	XX (XX.X%)	N/A
J	A website/app where you access APRETUDE information – the Pillar Spot (DI)	Yes	XX (XX.X%)	XX (XX.X%)	N/A
		No	XX (XX.X%)	XX (XX.X%)	N/A
		Don't know	XX (XX.X%)	XX (XX.X%)	N/A
K	The website where you access APRETUDE information (RI)	Yes	XX (XX.X%)	N/A	XX (XX.X%)
		No	XX (XX.X%)	N/A	XX (XX.X%)
		Don't know	XX (XX.X%)	N/A	XX (XX.X%)
50	How useful has each of these been in supporting you while taking APRETUDE?				
A	Brochures and other print materials to educate you on APRETUDE	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not very useful	XX	XX	XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
			(XX.X%)	(XX.X%)	(XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Extremely useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
B	Videos to educate you on HIV, PrEP, APREUDE materials (DI)	Not at all useful	XX (XX.X%)	XX (XX.X%)	N/A
		Not very useful	XX (XX.X%)	XX (XX.X%)	N/A
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	N/A
		Useful	XX (XX.X%)	XX (XX.X%)	N/A
		Extremely useful	XX (XX.X%)	XX (XX.X%)	N/A
C	A digital calendar specifically made for APREUDE to help you plan your injections – found on PillarSpot (DI)	Not at all useful	XX (XX.X%)	XX (XX.X%)	N/A
		Not very useful	XX (XX.X%)	XX (XX.X%)	N/A
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	N/A
		Useful	XX (XX.X%)	XX (XX.X%)	N/A
		Extremely useful	XX (XX.X%)	XX (XX.X%)	N/A
D	Reminders about your injections	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not very useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Extremely useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
E	Having video or telephone appointments with your doctor	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not very useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Extremely useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
F	Sending chats or texts to your doctor on the Pillar Spot (DI)	Not at all useful	XX (XX.X%)	XX (XX.X%)	N/A
		Not very useful	XX (XX.X%)	XX (XX.X%)	N/A
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	N/A
		Useful	XX (XX.X%)	XX (XX.X%)	N/A
		Extremely useful	XX (XX.X%)	XX (XX.X%)	N/A
G	Having a nurse come to your home to conduct your HIV test (DI)	Not at all useful	XX (XX.X%)	XX (XX.X%)	N/A
		Not very useful	XX (XX.X%)	XX (XX.X%)	N/A
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	N/A
		Useful	XX (XX.X%)	XX (XX.X%)	N/A
		Extremely useful	XX (XX.X%)	XX (XX.X%)	N/A
H	Having a nurse come to your home to give your injection (DI)	Not at all useful	XX (XX.X%)	XX (XX.X%)	N/A
		Not very useful	XX (XX.X%)	XX (XX.X%)	N/A
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	N/A
		Useful	XX (XX.X%)	XX (XX.X%)	N/A

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Extremely useful	XX (XX.X%)	XX (XX.X%)	N/A
I	Receiving transportation to the clinic/doctor's office for your injection (DI)	Not at all useful	XX (XX.X%)	XX (XX.X%)	N/A
		Not very useful	XX (XX.X%)	XX (XX.X%)	N/A
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	N/A
		Useful	XX (XX.X%)	XX (XX.X%)	N/A
		Extremely useful	XX (XX.X%)	XX (XX.X%)	N/A
J	A website/app where you access APRETUDE information – the Pillar Spot (DI)	Not at all useful	XX (XX.X%)	XX (XX.X%)	N/A
		Not very useful	XX (XX.X%)	XX (XX.X%)	N/A
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	N/A
		Useful	XX (XX.X%)	XX (XX.X%)	N/A
		Extremely useful	XX (XX.X%)	XX (XX.X%)	N/A
K	The website where you access APRETUDE information (RI)	Not at all useful	XX (XX.X%)	N/A	XX (XX.X%)
		Not very useful	XX (XX.X%)	N/A	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	N/A	XX (XX.X%)
		Useful	XX (XX.X%)	N/A	XX (XX.X%)
		Extremely useful	XX (XX.X%)	N/A	XX (XX.X%)
51	Did your clinic or doctor offer the following for APRETUDE visits?				
A	Injections on specific days of the week	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't know	XX	XX	XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
			(XX.X%)	(XX.X%)	(XX.X%)
B	Ability to show up for your injection without an appointment	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
C	Appointments where you only get your injection and leave	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
D	Schedule out your injection appointments for 6 months or more	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
E	You and your doctor discussing the pros and cons (e.g., side effects, switching) of <u>different PrEP options</u> and <u>together</u> deciding which one is right for you.	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
52	How useful has each of these been in supporting you while taking APRETUDE?				
A	Injections on specific days of the week	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not very useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Extremely useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
B	Ability to show up for your injection without an appointment	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not very useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Extremely useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
C	Appointments where you only get your injection and leave	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not very useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Extremely useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
D	Schedule out your injection appointments for 6 months or more	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not very useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Extremely useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
E	You and your doctor discussing the pros and cons (e.g., side effects, switching) of <u>different PrEP options</u> and <u>together</u> deciding which one is right for you.	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not very useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Extremely useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



**Table 6.306. Summary of Patient Study Participants' Preferences/Acceptability of APRETUDE Information, Appointment Reminders, and Locations (Month 6/7), N=XX**

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
61	If you have questions about APRETUDE, where do you find information?				
		Product website	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Written materials such as the study handbook from my healthcare provider	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Speaking to a healthcare provider	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Social Media	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Internet search	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Friends	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Family	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The study app/website	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have not had any questions so far	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not find answers to my questions	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
62	How did you receive reminders about your injection appointments?				
		Phone calls	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Texts/SMS	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Existing clinic app reminder	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		E-mails	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Reminder in the postal mail	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Face-to-face reminder from a healthcare provider	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Written reminder/appointment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		card with date and time			
		The study app/website	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Another type of reminder (please specify) _____	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have not received any reminders	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
63	Which type(s) of appointment reminders are most helpful in keeping your appointment?				
		Phone calls	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Texts/SMS	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Existing clinic app reminder	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		E-mails	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Reminder in the postal mail	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Face-to-face reminder from a healthcare provider	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Written reminder/appointment card with date and time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The study app/website (DI)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Another type of reminder (please specify) _____	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I do not think any of the reminders are helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
64	Where else would you consider receiving your injections?				
		Retail pharmacy clinic (e.g., Minute Clinic, CVS)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other pharmacy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Hospital outpatient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Infusion center	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Community-based organization	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		STD/STI clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Department of Health clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		PrEP clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Community health center	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Mobile van	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Nurse coming to your home	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 6.307. Summary of Appointment Scheduling (Month 6/7), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
58	How easy or difficult is it to schedule appointments at the clinic/practice for your injections?				
		Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have not scheduled any appointments at the clinic/practice	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
59	How easy or difficult is it to reschedule appointments at the clinic/practice for your injections?				
		Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have not needed to reschedule any appointments	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
60	How did you <u>reschedule</u> your appointment?				
		I called the clinic/doctor's office	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I emailed the clinic/doctor's office	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I texted the clinic/doctor's office	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I scheduled the appointment online	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I sent a message on the online portal of the clinic/doctor's office	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		I went to the clinic/doctor's office	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 6.401. Summary of Acceptability and Feasibility of APRETUDE Injection Visits (Month 6/7), N=XX, Study Arms**

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
36	On average, how long have you spent at the clinic/practice for your injection visit from arrival at the clinic to when you leave?				
		Up to 20 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		21-40 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		41-60 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		61-90 minutes (1hr-1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		More than 90 minutes (more than 1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have not gotten any of my injections at a clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
37	How acceptable is coming to the clinic every 2 months for an injection?				
		Very acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
38	How convenient are your clinic's hours? <i>By convenient, we mean fitting well with your life activities and plans, with little trouble.</i>				
		Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
39	How easy or difficult has it been to get to the clinic every 2 months for your injection?				

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
40	Approximately how long has it taken you to get to the clinic/practice from your home to receive your injection?				
		Up to 20 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		21-40 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		41-60 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		61-90 minutes (1hr-1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		More than 90 minutes (more than 1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
41	How did you get to the clinic/practice for your injections?				
		Taxi/transportation service	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Ride-share service (e.g., Uber, Lyft)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Dropped off by someone else	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Drove a private vehicle	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Public transportation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Bicycle/scooter/skateboard/walking	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Transportation provided by clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
43	How convenient is the transportation provided by your clinic/practice for your injection visit every 2 months? <i>By convenient, we mean fitting in well with your life activities and plans, with little trouble.</i>				

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
44	Please provide your opinion of the transportation provided by the clinic				
	The transportation helped me keep my appointments.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The transportation service was easy to use.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
45	Have you needed to seek additional childcare/eldercare/other care to come to the clinic/practice for your injection visits?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I am not caring for others right now (N/A)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
46	Have you taken any time off from work to receive injections?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I am not working right now	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
47	How much time did you take off work to receive your injections?				
		I needed to take a whole day off work for each injection	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I needed to take a whole day off work for some injections	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I needed to take a partial day off work for each injection	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I needed to take a partial day off work for some injections	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
48	Was your time off work for injections generally paid or unpaid?				
		Paid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Unpaid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 6.402. Summary of Acceptability and Feasibility of APRETUDE Injection Visits (Month 6/7), N=XX, Race, Dynamic Implementation**

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
36	On average, how long have you spent at the clinic/practice for your injection visit from arrival at the clinic to when you leave?					
		Up to 20 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		21-40 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		41-60 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		61-90 minutes (1hr-1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		More than 90 minutes (more than 1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have not gotten any of my injections at a clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
37	How acceptable is coming to the clinic every 2 months for an injection?					
		Very acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
38	How convenient are your clinic's hours? <i>By convenient, we mean fitting well with your life activities and plans, with little trouble.</i>					
		Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
39	How easy or difficult has it been to get to the clinic every 2 months for your injection?					
		Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
		Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
40	Approximately how long has it taken you to get to the clinic/practice from your home to receive your injection?					
		Up to 20 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		21-40 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		41-60 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		61-90 minutes (1hr-1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		More than 90 minutes (more than 1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
41	How did you get to the clinic/practice for your injections?					
		Taxi/transportation service	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Ride-share service (e.g., Uber, Lyft)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Dropped off by someone else	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Drove a private vehicle	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Public transportation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Bicycle/scooter/skateboard/walking	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Transportation provided by clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
43	How convenient is the transportation provided by your clinic/practice for your injection visit every 2 months? <i>By convenient, we mean fitting in well with your life activities and plans, with little trouble.</i>					
		Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
44	Please provide your opinion of the transportation provided by the clinic					
	The transportation helped me keep my appointments.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The transportation service was easy to use.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
45	Have you needed to seek additional childcare/eldercare/other care to come to the clinic/practice for your injection visits?					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I am not caring for others right now (N/A)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
46	Have you taken any time off from work to receive injections?					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I am not working right now	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
47	How much time did you take off work to receive your injections?					
		I needed to take a whole day off work for each injection	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I needed to take a whole day off work for some injections	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I needed to take a partial day off work for each injection	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I needed to take a partial day off work for some injections	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
48	Was your time off work for injections generally paid or unpaid?					
		Paid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Unpaid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 6.403. Summary of Acceptability and Feasibility of APRETUDE Injection Visits (Month 6/7), N=XX, Race, Routine Implementation**

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
36	On average, how long have you spent at the clinic/practice for your injection visit from arrival at the clinic to when you leave?					
		Up to 20 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		21-40 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		41-60 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		61-90 minutes (1hr-1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		More than 90 minutes (more than 1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have not gotten any of my injections at a clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
37	How acceptable is coming to the clinic every 2 months for an injection?					
		Very acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
38	How convenient are your clinic's hours? <i>By convenient, we mean fitting well with your life activities and plans, with little trouble.</i>					
		Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
39	How easy or difficult has it been to get to the clinic every 2 months for your injection?					
		Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
		Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
40	Approximately how long has it taken you to get to the clinic/practice from your home to receive your injection?					
		Up to 20 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		21-40 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		41-60 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		61-90 minutes (1hr-1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		More than 90 minutes (more than 1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
41	How did you get to the clinic/practice for your injections?					
		Taxi/transportation service	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Ride-share service (e.g., Uber, Lyft)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Dropped off by someone else	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Drove a private vehicle	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Public transportation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Bicycle/scooter/skateboard/walking	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Transportation provided by clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
43	How convenient is the transportation provided by your clinic/practice for your injection visit every 2 months? <i>By convenient, we mean fitting in well with your life activities and plans, with little trouble.</i>					
		Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
44	Please provide your opinion of the transportation provided by the clinic					
	The transportation helped me keep my appointments.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The transportation service was easy to use.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
45	Have you needed to seek additional childcare/eldercare/other care to come to the clinic/practice for your injection visits?					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I am not caring for others right now (N/A)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
46	Have you taken any time off from work to receive injections?					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I am not working right now	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
47	How much time did you take off work to receive your injections?					
		I needed to take a whole day off work for each injection	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I needed to take a whole day off work for some injections	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I needed to take a partial day off work for each injection	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I needed to take a partial day off work for some injections	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
48	Was your time off work for injections generally paid or unpaid?					
		Paid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Unpaid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 6.404. Summary of Acceptability and Feasibility of APRETUDE Injection Visits (Month 6/7), N=XX, Race, Total**

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
36	On average, how long have you spent at the clinic/practice for your injection visit from arrival at the clinic to when you leave?					
		Up to 20 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		21-40 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		41-60 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		61-90 minutes (1hr-1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		More than 90 minutes (more than 1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have not gotten any of my injections at a clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
37	How acceptable is coming to the clinic every 2 months for an injection?					
		Very acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
38	How convenient are your clinic's hours? <i>By convenient, we mean fitting well with your life activities and plans, with little trouble.</i>					
		Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
39	How easy or difficult has it been to get to the clinic every 2 months for your injection?					
		Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
		Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
40	Approximately how long has it taken you to get to the clinic/practice from your home to receive your injection?					
		Up to 20 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		21-40 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		41-60 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		61-90 minutes (1hr-1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		More than 90 minutes (more than 1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
41	How did you get to the clinic/practice for your injections?					
		Taxi/transportation service	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Ride-share service (e.g., Uber, Lyft)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Dropped off by someone else	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Drove a private vehicle	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Public transportation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Bicycle/scooter/skateboard/walking	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Transportation provided by clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
43	How convenient is the transportation provided by your clinic/practice for your injection visit every 2 months? <i>By convenient, we mean fitting in well with your life activities and plans, with little trouble.</i>					
		Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
44	Please provide your opinion of the transportation provided by the clinic					
	The transportation helped me keep my appointments.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The transportation service was easy to use.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
45	Have you needed to seek additional childcare/eldercare/other care to come to the clinic/practice for your injection visits?					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I am not caring for others right now (N/A)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
46	Have you taken any time off from work to receive injections?					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I am not working right now	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
47	How much time did you take off work to receive your injections?					
		I needed to take a whole day off work for each injection	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I needed to take a whole day off work for some injections	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I needed to take a partial day off work for each injection	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I needed to take a partial day off work for some injections	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
48	Was your time off work for injections generally paid or unpaid?					
		Paid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Unpaid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 6.405. Summary of Acceptability and Feasibility of APRETUDE Injection Visits (Month 6/7), N=XX, Ethnicity, Study Arms**

Question Number	Question	Response	Dynamic Implementation		Routine Implementation	
			Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
36	On average, how long have you spent at the clinic/practice for your injection visit from arrival at the clinic to when you leave?					
		Up to 20 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		21-40 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		41-60 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		61-90 minutes (1hr-1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		More than 90 minutes (more than 1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have not gotten any of my injections at a clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
37	How acceptable is coming to the clinic every 2 months for an injection?					
		Very acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
38	How convenient are your clinic’s hours? <i>By convenient, we mean fitting well with your life activities and plans, with little trouble.</i>					
		Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
39	How easy or difficult has it been to get to the clinic every 2 months for your injection?					

Question Number	Question	Response	Dynamic Implementation		Routine Implementation	
			Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
		Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
40	Approximately how long has it taken you to get to the clinic/practice from your home to receive your injection?					
		Up to 20 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		21-40 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		41-60 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		61-90 minutes (1hr-1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		More than 90 minutes (more than 1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
41	How did you get to the clinic/practice for your injections?					
		Taxi/transportation service	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Ride-share service (e.g., Uber, Lyft)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Dropped off by someone else	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Drove a private vehicle	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Public transportation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Bicycle/scooter/skateboard/walking	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Transportation provided by clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
43	How convenient is the transportation provided by your clinic/practice for your injection visit every 2 months? <i>By convenient, we mean fitting in well with your life activities and plans, with little trouble.</i>					

Question Number	Question	Response	Dynamic Implementation		Routine Implementation	
			Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
		Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
44	Please provide your opinion of the transportation provided by the clinic					
	The transportation helped me keep my appointments.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The transportation service was easy to use.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
45	Have you needed to seek additional childcare/eldercare/other care to come to the clinic/practice for your injection visits?					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



Question Number	Question	Response	Dynamic Implementation		Routine Implementation	
			Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
		I am not caring for others right now (N/A)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
46	Have you taken any time off from work to receive injections?					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I am not working right now	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
47	How much time did you take off work to receive your injections?					
		I needed to take a whole day off work for each injection	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I needed to take a whole day off work for some injections	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I needed to take a partial day off work for each injection	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I needed to take a partial day off work for some injections	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
48	Was your time off work for injections generally paid or unpaid?					
		Paid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Unpaid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 6.406. Summary of Acceptability and Feasibility of APRETUDE Injection Visits (Month 6/7), N=XX, Ethnicity, Total**

Question Number	Question	Response	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
36	On average, how long have you spent at the clinic/practice for your injection visit from arrival at the clinic to when you leave?			
		Up to 20 minutes	XX (XX.X%)	XX (XX.X%)
		21-40 minutes	XX (XX.X%)	XX (XX.X%)
		41-60 minutes	XX (XX.X%)	XX (XX.X%)
		61-90 minutes (1hr-1.5hrs)	XX (XX.X%)	XX (XX.X%)
		More than 90 minutes (more than 1.5hrs)	XX (XX.X%)	XX (XX.X%)
		I have not gotten any of my injections at a clinic	XX (XX.X%)	XX (XX.X%)
37	How acceptable is coming to the clinic every 2 months for an injection?			
		Very acceptable	XX (XX.X%)	XX (XX.X%)
		Acceptable	XX (XX.X%)	XX (XX.X%)
		Somewhat acceptable	XX (XX.X%)	XX (XX.X%)
		A little acceptable	XX (XX.X%)	XX (XX.X%)
		Not at all acceptable	XX (XX.X%)	XX (XX.X%)
38	How convenient are your clinic's hours? <i>By convenient, we mean fitting well with your life activities and plans, with little trouble.</i>			
		Very convenient	XX (XX.X%)	XX (XX.X%)
		Convenient	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)
		A little convenient	XX (XX.X%)	XX (XX.X%)
		Not at all convenient	XX (XX.X%)	XX (XX.X%)
39	How easy or difficult has it been to get to the clinic every 2 months for your injection?			
		Very easy	XX (XX.X%)	XX (XX.X%)
		Easy	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)
		Difficult	XX (XX.X%)	XX (XX.X%)
		Very difficult	XX (XX.X%)	XX (XX.X%)
40	Approximately how long has it taken you to get to the clinic/practice from your home to receive your injection?			
		Up to 20 minutes	XX (XX.X%)	XX (XX.X%)
		21-40 minutes	XX (XX.X%)	XX (XX.X%)
		41-60 minutes	XX (XX.X%)	XX (XX.X%)
		61-90 minutes (1hr-1.5hrs)	XX (XX.X%)	XX (XX.X%)
		More than 90 minutes (more than 1.5hrs)	XX (XX.X%)	XX (XX.X%)
41	How did you get to the clinic/practice for your injections?			
		Taxi/transportation service	XX (XX.X%)	XX (XX.X%)
		Ride-share service (e.g., Uber, Lyft)	XX (XX.X%)	XX (XX.X%)
		Dropped off by someone else	XX (XX.X%)	XX (XX.X%)
		Drove a private vehicle	XX (XX.X%)	XX (XX.X%)
		Public transportation	XX (XX.X%)	XX (XX.X%)
		Bicycle/scooter/skateboard/walking	XX (XX.X%)	XX (XX.X%)
		Transportation provided by clinic	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)
43	How convenient is the transportation provided by your clinic/practice for your injection visit every 2 months? <i>By convenient, we mean fitting in well with your life activities and plans, with little trouble.</i>			
		Very convenient	XX (XX.X%)	XX (XX.X%)
		Convenient	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
		A little convenient	XX (XX.X%)	XX (XX.X%)
		Not at all convenient	XX (XX.X%)	XX (XX.X%)
44	Please provide your opinion of the transportation provided by the clinic			
	The transportation helped me keep my appointments.	Completely disagree	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)
	The transportation service was easy to use.	Completely disagree	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)
45	Have you needed to seek additional childcare/eldercare/other care to come to the clinic/practice for your injection visits?			
		Yes	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)
		I am not caring for others right now (N/A)	XX (XX.X%)	XX (XX.X%)
46	Have you taken any time off from work to receive injections?			
		Yes	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)
		I am not working right now	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
47	How much time did you take off work to receive your injections?			
		I needed to take a whole day off work for each injection	XX (XX.X%)	XX (XX.X%)
		I needed to take a whole day off work for some injections	XX (XX.X%)	XX (XX.X%)
		I needed to take a partial day off work for each injection	XX (XX.X%)	XX (XX.X%)
		I needed to take a partial day off work for some injections	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)
48	Was your time off work for injections generally paid or unpaid?			
		Paid	XX (XX.X%)	XX (XX.X%)
		Unpaid	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)

**Table 6.407. Summary of Acceptability and Feasibility of APRETUDE Injection Visits (Month 6/7), N=XX, Gender, Total**

Question Number	Question	Response	Dynamic Implementation		Routine Implementation	
			Men who have sex with men (N = XX) n (%)	Transgender Men (N = XX) n (%)	Men who have sex with men (N = XX) n (%)	Transgender Men (N = XX) n (%)
36	On average, how long have you spent at the clinic/practice for your injection visit from arrival at the clinic to when you leave?					
		Up to 20 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		21-40 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		41-60 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		61-90 minutes (1hr-1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		More than 90 minutes (more than 1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have not gotten any of my injections at a clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
37	How acceptable is coming to the clinic every 2 months for an injection?					
		Very acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
38	How convenient are your clinic’s hours? <i>By convenient, we mean fitting well with your life activities and plans, with little trouble.</i>					
		Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
39	How easy or difficult has it been to get to the clinic every 2 months for your injection?					

Question Number	Question	Response	Dynamic Implementation		Routine Implementation	
			Men who have sex with men (N = XX) n (%)	Transgender Men (N = XX) n (%)	Men who have sex with men (N = XX) n (%)	Transgender Men (N = XX) n (%)
		Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
40	Approximately how long has it taken you to get to the clinic/practice from your home to receive your injection?					
		Up to 20 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		21-40 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		41-60 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		61-90 minutes (1hr-1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		More than 90 minutes (more than 1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
41	How did you get to the clinic/practice for your injections?					
		Taxi/transportation service	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Ride-share service (e.g., Uber, Lyft)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Dropped off by someone else	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Drove a private vehicle	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Public transportation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Bicycle/scooter/skateboard/walking	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Transportation provided by clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
43	How convenient is the transportation provided by your clinic/practice for your injection visit every 2 months? <i>By convenient, we mean fitting in well with your life activities and plans, with little trouble.</i>					

Question Number	Question	Response	Dynamic Implementation		Routine Implementation	
			Men who have sex with men (N = XX) n (%)	Transgender Men (N = XX) n (%)	Men who have sex with men (N = XX) n (%)	Transgender Men (N = XX) n (%)
		Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
44	Please provide your opinion of the transportation provided by the clinic					
	The transportation helped me keep my appointments.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The transportation service was easy to use.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
45	Have you needed to seek additional childcare/eldercare/other care to come to the clinic/practice for your injection visits?					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



Question Number	Question	Response	Dynamic Implementation		Routine Implementation	
			Men who have sex with men (N = XX) n (%)	Transgender Men (N = XX) n (%)	Men who have sex with men (N = XX) n (%)	Transgender Men (N = XX) n (%)
		I am not caring for others right now (N/A)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
46	Have you taken any time off from work to receive injections?					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I am not working right now	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
47	How much time did you take off work to receive your injections?					
		I needed to take a whole day off work for each injection	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I needed to take a whole day off work for some injections	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I needed to take a partial day off work for each injection	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I needed to take a partial day off work for some injections	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
48	Was your time off work for injections generally paid or unpaid?					
		Paid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Unpaid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 6.408. Summary of Reach and Perceptions of Sexual Health Assessment Tool (Month 6/7), N=XX, Study Arms**

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
30	Did you complete a Sexual Health Assessment from your provider or clinic/practice in the last 6 months?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
31	Did your provider or another person at the clinic/practice discuss the results of the assessment with you?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't remember	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
32	Who discussed the results of the assessment with you?				
		My healthcare provider/doctor	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A social worker	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A peer educator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
33	How helpful was discussing the results with your provider or another person at the clinic/practice?				
		Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
34	Please rate your experience with the Sexual Health Assessment				

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
	It was easy to take the Sexual Health Assessment on my digital device.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I like that my doctor sent the assessment before my appointment.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I was concerned about the privacy of my answers.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I like that my doctor was assessing my sexual health.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The assessment asked the right questions to help my doctor and me determine whether PrEP was right for me.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The assessment made me feel uncomfortable.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
35	Why did you not complete the assessment?				
		I did not receive a Sexual Health Assessment from my provider or clinic/practice	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I forgot	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not know how to complete it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The link my doctor sent did not work	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I didn't have the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The assessment took too long to complete	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		The assessment included too many personal questions	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The assessment made me feel uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I was concerned about the privacy of my answers	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not want to share sexual health information with my doctor or clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not understand why my doctor or clinic was asking me to complete the assessment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 6.409. Summary of Reach and Perceptions of Sexual Health Assessment Tool (Month 6/7), N=XX, Race, Dynamic Implementation**

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
30	Did you complete a Sexual Health Assessment from your provider or clinic/practice in the last 6 months?					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
31	Did your provider or another person at the clinic/practice discuss the results of the assessment with you?					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't remember	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
32	Who discussed the results of the assessment with you?					
		My healthcare provider/doctor	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A social worker	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A peer educator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
33	How helpful was discussing the results with your provider or another person at the clinic/practice?					
		Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
34	Please rate your experience with the Sexual Health Assessment					

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
	It was easy to take the Sexual Health Assessment on my digital device.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I like that my doctor sent the assessment before my appointment.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I was concerned about the privacy of my answers.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I like that my doctor was assessing my sexual health.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The assessment asked the right questions to help my doctor and me determine whether PrEP was right for me.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The assessment made me feel uncomfortable.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
35	Why did you not complete the assessment?					
		I did not receive a Sexual Health Assessment from my provider or clinic/practice	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I forgot	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not know how to complete it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The link my doctor sent did not work	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I didn't have the time	XX	XX	XX	XX



Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
			(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
		The assessment took too long to complete	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The assessment included too many personal questions	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The assessment made me feel uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I was concerned about the privacy of my answers	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not want to share sexual health information with my doctor or clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not understand why my doctor or clinic was asking me to complete the assessment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 6.410. Summary of Reach and Perceptions of Sexual Health Assessment Tool (Month 6/7), N=XX, Race, Routine Implementation**

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
30	Did you complete a Sexual Health Assessment from your provider or clinic/practice in the last 6 months?					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
31	Did your provider or another person at the clinic/practice discuss the results of the assessment with you?					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't remember	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
32	Who discussed the results of the assessment with you?					
		My healthcare provider/doctor	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A social worker	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A peer educator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
33	How helpful was discussing the results with your provider or another person at the clinic/practice?					
		Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
34	Please rate your experience with the Sexual Health Assessment					
	It was easy to take the Sexual Health Assessment on my digital device.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I like that my doctor sent the assessment before my appointment.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I was concerned about the privacy of my answers.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I like that my doctor was assessing my sexual health.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The assessment asked the right questions to help my doctor and me determine whether PrEP was right for me.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The assessment made me feel uncomfortable.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
35	Why did you not complete the assessment?					
		I did not receive a Sexual Health Assessment from my provider or clinic/practice	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I forgot	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not know how to complete it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
		The link my doctor sent did not work	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I didn't have the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The assessment took too long to complete	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The assessment included too many personal questions	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The assessment made me feel uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I was concerned about the privacy of my answers	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not want to share sexual health information with my doctor or clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not understand why my doctor or clinic was asking me to complete the assessment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 6.411. Summary of Reach and Perceptions of Sexual Health Assessment Tool (Month 6/7), N=XX, Race, Total**

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
30	Did you complete a Sexual Health Assessment from your provider or clinic/practice in the last 6 months?					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
31	Did your provider or another person at the clinic/practice discuss the results of the assessment with you?					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't remember	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
32	Who discussed the results of the assessment with you?					
		My healthcare provider/doctor	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A social worker	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A peer educator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
33	How helpful was discussing the results with your provider or another person at the clinic/practice?					
		Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
34	Please rate your experience with the Sexual Health Assessment					

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
	It was easy to take the Sexual Health Assessment on my digital device.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I like that my doctor sent the assessment before my appointment.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I was concerned about the privacy of my answers.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I like that my doctor was assessing my sexual health.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The assessment asked the right questions to help my doctor and me determine whether PrEP was right for me.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The assessment made me feel uncomfortable.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
35	Why did you not complete the assessment?					
		I did not receive a Sexual Health Assessment from my provider or clinic/practice	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I forgot	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not know how to complete it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The link my doctor sent did not work	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I didn't have the time	XX	XX	XX	XX



Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
			(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
		The assessment took too long to complete	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The assessment included too many personal questions	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The assessment made me feel uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I was concerned about the privacy of my answers	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not want to share sexual health information with my doctor or clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not understand why my doctor or clinic was asking me to complete the assessment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 6.412. Summary of Reach and Perceptions of Sexual Health Assessment Tool (Month 6/7), N=XX, Ethnicity, Study Arms**

Question Number	Question	Response	Dynamic Implementation		Routine Implementation	
			Hispanic or Latino (N = XX)	Not Hispanic or Latino (N = XX)	Hispanic or Latino (N = XX)	Not Hispanic or Latino (N = XX)
			n (%)	n (%)	n (%)	n (%)
30	Did you complete a Sexual Health Assessment from your provider or clinic/practice in the last 6 months?					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
31	Did your provider or another person at the clinic/practice discuss the results of the assessment with you?					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't remember	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
32	Who discussed the results of the assessment with you?					
		My healthcare provider/doctor	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A social worker	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A peer educator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
33	How helpful was discussing the results with your provider or another person at the clinic/practice?					
		Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all helpful	XX (XX.X%)	XX	XX	XX

Question Number	Question	Response	Dynamic Implementation		Routine Implementation	
			Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
				(XX.X%)	(XX.X%)	(XX.X%)
34	Please rate your experience with the Sexual Health Assessment					
	It was easy to take the Sexual Health Assessment on my digital device.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I like that my doctor sent the assessment before my appointment.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I was concerned about the privacy of my answers.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I like that my doctor was assessing my sexual health.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Dynamic Implementation		Routine Implementation	
			Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The assessment asked the right questions to help my doctor and me determine whether PrEP was right for me.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The assessment made me feel uncomfortable.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
35	Why did you not complete the assessment?					
		I did not receive a Sexual Health Assessment from my provider or clinic/practice	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Dynamic Implementation		Routine Implementation	
			Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
		I forgot	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not know how to complete it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The link my doctor sent did not work	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I didn't have the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The assessment took too long to complete	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The assessment included too many personal questions	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The assessment made me feel uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I was concerned about the privacy of my answers	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not want to share sexual health information with my doctor or clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not understand why my doctor or clinic was asking me to complete the assessment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 6.413. Summary of Reach and Perceptions of Sexual Health Assessment Tool (Month 6/7), N=XX, Ethnicity, Total**

Question Number	Question	Response	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
30	Did you complete a Sexual Health Assessment from your provider or clinic/practice in the last 6 months?			
		Yes	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)
31	Did your provider or another person at the clinic/practice discuss the results of the assessment with you?			
		Yes	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)
		I don't remember	XX (XX.X%)	XX (XX.X%)
32	Who discussed the results of the assessment with you?			
		My healthcare provider/doctor	XX (XX.X%)	XX (XX.X%)
		A nurse	XX (XX.X%)	XX (XX.X%)
		A social worker	XX (XX.X%)	XX (XX.X%)
		A peer educator	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)
33	How helpful was discussing the results with your provider or another person at the clinic/practice?			
		Very helpful	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)
		Not at all helpful	XX (XX.X%)	XX (XX.X%)
34	Please rate your experience with the Sexual Health Assessment			

Question Number	Question	Response	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
	It was easy to take the Sexual Health Assessment on my digital device.	Completely disagree	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)
	I like that my doctor sent the assessment before my appointment.	Completely disagree	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)
	I was concerned about the privacy of my answers.	Completely disagree	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)
	I like that my doctor was assessing my sexual health.	Completely disagree	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
			(XX.X%)	(XX.X%)
	The assessment asked the right questions to help my doctor and me determine whether PrEP was right for me.	Completely disagree	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)
	The assessment made me feel uncomfortable.	Completely disagree	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)
35	Why did you not complete the assessment?			
		I did not receive a Sexual Health Assessment from my provider or clinic/practice	XX (XX.X%)	XX (XX.X%)
		I forgot	XX (XX.X%)	XX (XX.X%)
		I did not know how to complete it	XX (XX.X%)	XX (XX.X%)
		The link my doctor sent did not work	XX (XX.X%)	XX (XX.X%)
		I didn't have the time	XX (XX.X%)	XX (XX.X%)
		The assessment took too long to complete	XX (XX.X%)	XX (XX.X%)
		The assessment included too many personal questions	XX (XX.X%)	XX (XX.X%)
		The assessment made me feel uncomfortable	XX (XX.X%)	XX (XX.X%)



Question Number	Question	Response	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
		I was concerned about the privacy of my answers	XX (XX.X%)	XX (XX.X%)
		I did not want to share sexual health information with my doctor or clinic	XX (XX.X%)	XX (XX.X%)
		I did not understand why my doctor or clinic was asking me to complete the assessment	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)

**Table 6.414. Summary of Reach and Perceptions of Sexual Health Assessment Tool (Month 6/7), N=XX, Gender**

Question Number	Question	Response	Men who have sex with men (N = XX) n (%)	Transgender men (N = XX) n (%)
30	Did you complete a Sexual Health Assessment from your provider or clinic/practice in the last 6 months?			
		Yes	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)
31	Did your provider or another person at the clinic/practice discuss the results of the assessment with you?			
		Yes	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)
		I don't remember	XX (XX.X%)	XX (XX.X%)
32	Who discussed the results of the assessment with you?			
		My healthcare provider/doctor	XX (XX.X%)	XX (XX.X%)
		A nurse	XX (XX.X%)	XX (XX.X%)
		A social worker	XX (XX.X%)	XX (XX.X%)
		A peer educator	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)
33	How helpful was discussing the results with your provider or another person at the clinic/practice?			
		Very helpful	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)
		Not at all helpful	XX (XX.X%)	XX (XX.X%)
34	Please rate your experience with the Sexual Health Assessment			

Question Number	Question	Response	Men who have sex with men (N = XX) n (%)	Transgender men (N = XX) n (%)
	It was easy to take the Sexual Health Assessment on my digital device.	Completely disagree	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)
	I like that my doctor sent the assessment before my appointment.	Completely disagree	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)
	I was concerned about the privacy of my answers.	Completely disagree	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)
	I like that my doctor was assessing my sexual health.	Completely disagree	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Men who have sex with men (N = XX) n (%)	Transgender men (N = XX) n (%)
			(XX.X%)	(XX.X%)
	The assessment asked the right questions to help my doctor and me determine whether PrEP was right for me.	Completely disagree	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)
	The assessment made me feel uncomfortable.	Completely disagree	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)
35	Why did you not complete the assessment?			
		I did not receive a Sexual Health Assessment from my provider or clinic/practice	XX (XX.X%)	XX (XX.X%)
		I forgot	XX (XX.X%)	XX (XX.X%)
		I did not know how to complete it	XX (XX.X%)	XX (XX.X%)
		The link my doctor sent did not work	XX (XX.X%)	XX (XX.X%)
		I didn't have the time	XX (XX.X%)	XX (XX.X%)
		The assessment took too long to complete	XX (XX.X%)	XX (XX.X%)
		The assessment included too many personal questions	XX (XX.X%)	XX (XX.X%)
		The assessment made me feel uncomfortable	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Men who have sex with men (N = XX) n (%)	Transgender men (N = XX) n (%)
		I was concerned about the privacy of my answers	XX (XX.X%)	XX (XX.X%)
		I did not want to share sexual health information with my doctor or clinic	XX (XX.X%)	XX (XX.X%)
		I did not understand why my doctor or clinic was asking me to complete the assessment	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)

**Table 6.415. Summary of Reach and Perceptions of Sexual Health Assessment Tool (Month 6/7), N=XX, Site Volume**

Question Number	Question	Response	Total (N = XX) n (%)	High Volume (N = XX) n (%)	Low Volume (N = XX) n (%)
30	Did you complete a Sexual Health Assessment from your provider or clinic/practice in the last 6 months?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
31	Did your provider or another person at the clinic/practice discuss the results of the assessment with you?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't remember	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
32	Who discussed the results of the assessment with you?				
		My healthcare provider/doctor	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A social worker	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A peer educator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
33	How helpful was discussing the results with your provider or another person at the clinic/practice?				
		Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
34	Please rate your experience with the Sexual Health Assessment				

Question Number	Question	Response	Total (N = XX) n (%)	High Volume (N = XX) n (%)	Low Volume (N = XX) n (%)
	It was easy to take the Sexual Health Assessment on my digital device.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I like that my doctor sent the assessment before my appointment.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I was concerned about the privacy of my answers.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I like that my doctor was assessing my sexual health.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	High Volume (N = XX) n (%)	Low Volume (N = XX) n (%)
			(XX.X%)	(XX.X%)	(XX.X%)
	The assessment asked the right questions to help my doctor and me determine whether PrEP was right for me.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The assessment made me feel uncomfortable.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
35	Why did you not complete the assessment?				
		I did not receive a Sexual Health Assessment from my provider or clinic/practice	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I forgot	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not know how to complete it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The link my doctor sent did not work	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I didn't have the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The assessment took too long to complete	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The assessment included too many personal questions	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



Question Number	Question	Response	Total (N = XX) n (%)	High Volume (N = XX) n (%)	Low Volume (N = XX) n (%)
		The assessment made me feel uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I was concerned about the privacy of my answers	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not want to share sexual health information with my doctor or clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not understand why my doctor or clinic was asking me to complete the assessment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 6.416. Distributional Characteristics of Estimated Amount of Money Spent on Transportation for Each Injection Visit (Month 6/7), N=XX**

42. On average, how much did transportation cost round trip for each injection visit?	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
<b>Mean Score</b>	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Study Arm</b>							
Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Gender</b>							
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Race</b>							
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Ethnicity</b>							
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Dynamic Implementation</b>							
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Gender</b>							
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)

42. On average, how much did transportation cost round trip for each injection visit?	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Race</b>							
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Ethnicity</b>							
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Routine Implementation</b>							
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Gender</b>							
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Race</b>							
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Ethnicity</b>							
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)

## Table Shells for Month 12/13 Analysis

Table 7.000. Demographic Characteristics of Patient Study Participants Completing Surveys (Month 12/13), N=XX .....	424
Table 7.001. Summary of Demographic Characteristics of Patient Study Participants (Month 12/13), N=XX.....	426
Table 7.002. Summary of Behaviors of Patient Study Participants (Month 12/13), N=XX .....	429
Table 7.003. Summary of Patient Study Participants' Sexual History and Behaviors (Month 12/13), N=XX, Study Arms .....	431
Table 7.004. Summary of Patient Study Participants' Sexual History and Behaviors (Month 12/13), N=XX, Race, Dynamic Implementation .....	434
Table 7.005. Summary of Patient Study Participants' Sexual History and Behaviors (Month 12/13), N=XX, Race, Routine Implementation .....	437
Table 7.006. Summary of Patient Study Participants' Sexual History and Behaviors (Month 12/13), N=XX, Race, Total.....	440
Table 7.007. Summary of Patient Study Participants' Sexual History and Behaviors (Month 12/13), N=XX, Ethnicity, Study Arms .....	443
Table 7.008. Summary of Patient Study Participants' Sexual History and Behaviors (Month 12/13), N=XX, Ethnicity, Total .....	446
Table 7.009. Summary of Patient Study Participants' Sexual History and Behaviors (Month 12/13), N=XX, Gender, Total .....	449
Table 7.010. Summary of How Patient Study Participants Learned About PILLAR (Month 12/13), N=XX.	452
Table 7.101. Summary of Patient Study Participants' HIV and PrEP Knowledge (Month 12/13), N=XX....	453
Table 7.102. Summary of Patient Study Participants' HIV and PrEP Knowledge (Month 12/13), N=XX, Scale Questions, Study Arms .....	454
Table 7.103. Distributional Characteristics of Patient Study Participants' HIV and PrEP Knowledge (Month 12/13), N=XX, Scale Questions, Overall Score .....	456
Table 7.104. Summary of Patient Study Participants' Perception of Stigma Associated with PrEP Usage (Month 12/13), N=XX, Stigma, Study Arms.....	459
Table 7.105. Distributional Characteristics of Patient Study Participants' Perception of Stigma Associated with PrEP Usage (Month 12/13), N=XX, Stigma, Overall Score.....	463
Table 7.106. Summary of Patient Study Participants' Choice of APRETUDE (Month 12/13), N=XX .....	466
Table 7.107. Summary of Knowledge of APRETUDE and Utility of Implementation Strategies (Month 12/13), N=XX .....	469
Table 7.108. Attitude Regarding APRETUDE and Utility of Implementation Strategies (Month 12/13), N=XX.....	474
Table 7.109. Summary of Patient Study Participant Acquisition Process (Month 12/13), N=XX .....	476
Table 7.110. Summary of Patient Study Participant Acquisition Process, Insurance (Month 12/13), N=XX.....	477
Table 7.201. Distributional Characteristics of Acceptability of Intervention (AIM) (APRETUDE) (PSP) (Month 12/13), N=XX .....	487

Table 7.202. Distributional Characteristics of Feasibility of Intervention (FIM) (APREUDE) (PSP) (Month 12/13), N=XX .....	490
Table 7.203. Distributional Characteristics of Accessibility of Intervention (AIM) (Telehealth) (PSP) (Month 12/13), N=XX .....	493
Table 7.204. Distributional Characteristics of Feasibility of Intervention (FIM) (Telehealth) (PSP) (Month 12/13), N=XX .....	496
Table 7.205. Summary of Acceptability of Intervention (AIM) (APREUDE) (PSP) (Month 6/7), N=XX .....	499
Table 7.206. Summary of Feasibility of Intervention (FIM) (APREUDE) (PSP) (Month 6/7), N=XX .....	501
Table 7.207. Summary of Acceptability of Intervention (AIM) (Telehealth) (PSP) (Month 6/7), N=XX.....	503
Table 7.208. Summary of Feasibility of Intervention (FIM) (Telehealth) (PSP) (Month 6/7), N=XX.....	505
Table 7.209. Changes from Baseline for Acceptability of Intervention Measure (AIM - APREUDE) and Feasibility of Intervention Measure (FIM - APREUDE) (Month 12/13), N=XX .....	507
Table 7.210. Mixed-effects Modeling of the Acceptability of Intervention Measure (AIM – APREUDE) (Month 12/13), N=XX .....	508
Table 7.211. Mixed-effects Modeling of the Changes from Baseline to Month 12/13 in Acceptability of Intervention Measure (AIM – APREUDE), N=XX .....	509
Table 7.212. Mixed-effects Modeling of the Feasibility of Intervention Measure (FIM – APREUDE) (Month 12/13), N=XX .....	510
Table 7.213. Mixed-effects Modeling of the Changes from Baseline to Month 12/13 in Feasibility of Intervention Measure (FIM – APREUDE), N=XX.....	511
Table 7.214. Changes from Baseline for Acceptability of Intervention Measure (AIM - Telehealth) and Feasibility of Intervention Measure (FIM - Telehealth) (Month 12/13), N=XX .....	512
Table 7.215. Mixed-effects Modeling of the Acceptability of Intervention Measure (AIM – Telehealth) (Month 12/13), N=XX .....	513
Table 7.216. Mixed-effects Modeling of the Changes from Baseline to Month 12/13 in Acceptability of Intervention Measure (AIM – Telehealth), N=XX.....	514
Table 7.217. Mixed-effects Modeling of the Feasibility of Intervention Measure (FIM – Telehealth) (Month 12/13), N=XX .....	515
Table 7.218. Mixed-effects Modeling of the Changes from Baseline to Month 12/13 in Feasibility of Intervention Measure (FIM – Telehealth), N=XX .....	516
Table 7.219. Summary of Pain/Activities After Injection (Month 12/13), N=XX.....	517
Table 7.220. Summary of Patient Study Participants' Labs and Missed Doses (Month 12/13), N=XX .....	520
Table 7.301. Summary of Feasibility and Acceptability of Telehealth (Month 12/13), N=XX.....	522
Table 7.302. Summary of Quality of Care for Patient Study Participants (Month 12/13), N=XX.....	530
Table 7.303. Summary of Quality of Care for Patient Study Participants (Month 12/13), N=XX, Non- Score Questions.....	534
Table 7.304. Summary of Quality of Care for Patient Study Participants (Month 12/13), N=XX, Score Questions .....	549
Table 7.305. Distributional Characteristics of Quality of Care for Patient Study Participants (Month 12/13), N=XX, Score Questions, Overall Score.....	566
Table 7.306. Summary of Utility of Proposed Implementation Strategies (Month 12/13), N=XX .....	569

Table 7.307. Summary of Patient Study Participants' Preferences/Acceptability of APRETUDE Information, Appointment Reminders, and Locations (Month 12/13), N=XX .....	577
Table 7.308. Summary of Appointment Scheduling (Month 12/13), N=XX.....	581
Table 7.401. Summary of Acceptability and Feasibility of APRETUDE Injection Visits (Month 12/13), N=XX, Study Arms .....	583
Table 7.402. Summary of Acceptability and Feasibility of APRETUDE Injection Visits (Month 6/7), N=XX, Race, Dynamic Implementation .....	587
Table 7.403. Summary of Acceptability and Feasibility of APRETUDE Injection Visits (Month 6/7), N=XX, Race, Routine Implementation .....	591
Table 7.404. Summary of Acceptability and Feasibility of APRETUDE Injection Visits (Month 6/7), N=XX, Race, Total.....	595
Table 7.405. Summary of Acceptability and Feasibility of APRETUDE Injection Visits (Month 6/7), N=XX, Ethnicity, Study Arms .....	599
Table 7.406. Summary of Acceptability and Feasibility of APRETUDE Injection Visits (Month 6/7), N=XX, Ethnicity, Total .....	603
Table 7.407. Summary of Acceptability and Feasibility of APRETUDE Injection Visits (Month 6/7), N=XX, Gender, Total .....	607
Table 7.408. Summary of Reach and Perceptions of Sexual Health Assessment Tool (Month 12/13), N=XX, Study Arms .....	611
Table 7.409. Summary of Reach and Perceptions of Sexual Health Assessment Tool (Month 12/13), N=XX, Race, Dynamic Implementation .....	615
Table 7.410. Summary of Reach and Perceptions of Sexual Health Assessment Tool (Month 12/13), N=XX, Race, Routine Implementation .....	619
Table 7.411. Summary of Reach and Perceptions of Sexual Health Assessment Tool (Month 12/13), N=XX, Race, Total.....	623
Table 7.412. Summary of Reach and Perceptions of Sexual Health Assessment Tool (Month 12/13), N=XX, Ethnicity, Study Arms .....	627
Table 7.413. Summary of Reach and Perceptions of Sexual Health Assessment Tool (Month 12/13), N=XX, Ethnicity, Total .....	631
Table 7.414. Summary of Reach and Perceptions of Sexual Health Assessment Tool (Month 12/13), N=XX, Gender .....	635
Table 7.415. Summary of Reach and Perceptions of Sexual Health Assessment Tool (Month 12/13), N=XX, Site Volume .....	639
Table 7.416. Proportion of PSP Taking the Sexual Health Assessment through Month 13 .....	643
Table 7.417. Distributional Characteristics of Estimated Amount of Money Spent on Transportation for Each Injection Visit (Month 12/13), N=XX.....	644
Table 7.501. Test for Differences of Implementation Arm by Site Volume on Feasibility of Intervention Measure, APRETUDE (Month 12/13), N=XX.....	646
Table 7.502. Test for Differences of Implementation Arm by Site Volume on Feasibility of Intervention Measure, Telehealth (Month 12/13), N=XX.....	646

Table 7.503. Test for Differences of Implementation Arm by Site Volume on Acceptability of  
Intervention Measure, APRETUDE (Month 12/13), N=XX..... 646

Table 7.504. Test for Differences of Implementation Arm by Site Volume on Acceptability of  
Intervention Measure, Telehealth (Month 12/13), N=XX..... 646

**Table 7.000. Demographic Characteristics of Patient Study Participants Completing Surveys (Month 12/13), N=XX**

Question Number	Question	Response	Total (N=XX) n (%)	Dynamic Implementation (N=XX) n (%)	Routine Implementation (N=XX) n (%)
DM1	Age (years)	N	XX	XX	XX
		Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)
		Median	XX.X	XX.X	XX.X
		Q1, Q3	XX, XX	XX, XX	XX, XX
		Min-Max	XX.X, XX.X	XX.X, XX.X	XX.X, XX.X
DM2	Age (years), High Volume	N	XX	XX	XX
		Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)
		Median	XX.X	XX.X	XX.X
		Q1, Q3	XX, XX	XX, XX	XX, XX
		Min-Max	XX.X, XX.X	XX.X, XX.X	XX.X, XX.X
DM3	Age (years), Low Volume	N	XX	XX	XX
		Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)
		Median	XX.X	XX.X	XX.X
		Q1, Q3	XX, XX	XX, XX	XX, XX
		Min-Max	XX.X, XX.X	XX.X, XX.X	XX.X, XX.X
DM4	Age				
		18-25	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		26-35	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		36-49	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		50+	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
DM5	Study Arm				
		Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
DM6	Site Volume				
		High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
DM7	Gender				
		Men who have sex with men	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Transgender men	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
DM8	Race				
		Asian	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Black or African American	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		White	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Missing/Unknown	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



Question Number	Question	Response	Total (N=XX) n (%)	Dynamic Implementation (N=XX) n (%)	Routine Implementation (N=XX) n (%)
DM9	Ethnicity				
		Hispanic or Latino	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not Hispanic or Latino	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Missing/Unknown	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 7.001. Summary of Demographic Characteristics of Patient Study Participants (Month 12/13), N=XX**

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
1	Which of the following best describes your <u>current</u> relationship status?				
		Single, never married	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Single, widowed	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Single, separated or divorced	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Dating, but not living with a partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Dating and living with a partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Domestic partnership/civil union	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Married	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
2	How would you describe your <u>current</u> living situation?				
		I live in my own house or apartment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I live in my parent's house or apartment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I live in a family member's house or apartment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I live in a friend's house or apartment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I sleep on various friends' or relatives' couches	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I am homeless or am living in a shelter	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I live in motel(s)/hotel(s)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
3	What <u>best</u> describes your current employment status?				

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Employed for wages full-time (1 employer)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Employed for wages full-time (2 or more employers)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Employed for wages part-time (1 employer)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Employed for wages part-time (2 or more employers)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Self-employed	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A homemaker	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Student	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Retired	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not employed	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Unable to work (disabled)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
4	What type of medical insurance do you currently have?				
		My parents' insurance	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		My partner's/spouse's insurance	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Private insurance provided by my workplace	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Private insurance I purchased through an exchange (e.g., Obamacare, Affordable Care Act)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Federal insurance (e.g., VA, TRICARE)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Medicare or Medicaid	XX	XX	XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
			(XX.X%)	(XX.X%)	(XX.X%)
		Some other health care plan	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't have any health insurance currently	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 7.002. Summary of Behaviors of Patient Study Participants (Month 12/13), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
87	How often do you have a drink containing alcohol?				
		Never	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Monthly or less	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		2 to 4 times a month	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		2 to 3 times a week	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		4 or more times a week	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
88	On days when you drink alcohol, how many drinks containing alcohol do you typically have? (1 drink=1 standard bottle/ can of beer, 1 glass of wine, 1 mixed drink, or 1 shot of liquor)				
		1 or 2	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		3 to 4	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		5 to 6	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		7 to 9	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		10 or more	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
89	In the last 6 months, have you shot up or injected any drugs that were not prescribed for you by a healthcare provider, such as speedball, heroin, or crack? <i>By shooting up, we mean anytime you might have used drugs with a needle, either by mainlining, skin popping, or muscling.</i>				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
90	In the last 6 months, have you used any non-injection drugs (drugs you did not inject like pills, patches, or inhaled substances), <u>that</u> were not prescribed for you by a healthcare provider, such as marijuana, X, downers, or crack cocaine?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX	XX	XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
			(XX.X%)	(XX.X%)	(XX.X%)

**Table 7.003. Summary of Patient Study Participants' Sexual History and Behaviors (Month 12/13), N=XX, Study Arms**

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
8	Have you had sex in the last 6 months? <i>This could be vaginal sex (penis in vagina) OR anal sex (penis in butt) OR oral sex.</i>				
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
9	How would you describe your sexual behaviors in the last 6 months?				
		I have had vaginal sex (penis in vagina) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had vaginal sex (penis in vagina) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a bottom (penis in butt as a bottom) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a bottom (penis in butt as a bottom) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a top (penis in butt as a top) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a top (penis in butt as a top) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had oral sex (mouth, tongue, or lips on a vagina, penis, or butt) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had oral sex (mouth, tongue, or lips on a vagina, penis, or butt) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
10	How often did you use a condom when you had sex in the last 6 months?				
		All of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Most of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Some of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		None of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
11	In the last 6 months, how would you describe the HIV status of your sexual partner(s)?				
		I know that none of my sexual partners from the last 6 months have HIV/AIDS	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I know that at least one sexual partner from the last 6 months is living with HIV/AIDS	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I do not know my sexual partners' HIV status	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
12	As far as you know, were any of your sexual partner(s) from the last 6 months taking PrEP to prevent HIV infection? PrEP is a medication that prevents HIV.				
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
13	You mentioned that you had a least one partner in the last 6 months who is living with HIV/AIDS. As far as you know, were any of your partners taking HIV medications (antiretrovirals) to treat their HIV infection?				
		Yes, my partner(s) was/were taking HIV medications	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes, my partner(s) was/were taking HIV medications and was/were undetectable, meaning HIV tests were not finding the virus	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No, my partner(s) was/were not taking HIV medications	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I do not know whether my partner(s) was/were taking HIV medications	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
14	In the last 6 months, have you experienced any incidents of sexual violence, physical abuse, or any other type of trauma form a partner?				
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
15	In the last 6 months, have you exchanged things like money or drugs for sex with a sexual partner?				



Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Yes, I have a sexual partner things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes, a sexual partner gave me things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No, I have not exchanged things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 7.004. Summary of Patient Study Participants' Sexual History and Behaviors (Month 12/13), N=XX, Race, Dynamic Implementation**

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
8	Have you had sex in the last 6 months? <i>This could be vaginal sex (penis in vagina) OR anal sex (penis in butt) OR oral sex.</i>					
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
9	How would you describe your sexual behaviors in the last 6 months?					
		I have had vaginal sex (penis in vagina) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had vaginal sex (penis in vagina) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a bottom (penis in butt as a bottom) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a bottom (penis in butt as a bottom) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a top (penis in butt as a top) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a top (penis in butt as a top) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had oral sex (mouth, tongue, or lips on a vagina, penis, or butt) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had oral sex (mouth, tongue, or lips on a vagina, penis, or butt) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
10	How often did you use a condom when you had sex in the last 6 months?					

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
		All of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Most of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Some of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		None of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
11	In the last 6 months, how would you describe the HIV status of your sexual partner(s)?					
		I know that none of my sexual partners from the last 6 months have HIV/AIDS	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I know that at least one sexual partner from the last 6 months is living with HIV/AIDS	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I do not know my sexual partners' HIV status	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
12	As far as you know, were any of your sexual partner(s) from the last 6 months taking PrEP to prevent HIV infection? PrEP is a medication that prevents HIV.					
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
13	You mentioned that you had a least one partner in the last 6 months who is living with HIV/AIDS. As far as you know, were any of your partners taking HIV medications (antiretrovirals) to treat their HIV infection?					
		Yes, my partner(s) was/were taking HIV medications	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes, my partner(s) was/were taking HIV medications and was/were undetectable,	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
		meaning HIV tests were not finding the virus				
		No, my partner(s) was/were not taking HIV medications	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I do not know whether my partner(s) was/were taking HIV medications	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
14	In the last 6 months, have you experienced any incidents of sexual violence, physical abuse, or any other type of trauma form a partner?					
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
15	In the last 6 months, have you exchanged things like money or drugs for sex with a sexual partner?					
		Yes, I have a sexual partner things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes, a sexual partner gave me things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No, I have not exchanged things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 7.005. Summary of Patient Study Participants' Sexual History and Behaviors (Month 12/13), N=XX, Race, Routine Implementation**

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
8	Have you had sex in the last 6 months? <i>This could be vaginal sex (penis in vagina) OR anal sex (penis in butt) OR oral sex.</i>					
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
9	How would you describe your sexual behaviors in the last 6 months?					
		I have had vaginal sex (penis in vagina) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had vaginal sex (penis in vagina) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a bottom (penis in butt as a bottom) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a bottom (penis in butt as a bottom) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a top (penis in butt as a top) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a top (penis in butt as a top) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had oral sex (mouth, tongue, or lips on a vagina, penis, or butt) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had oral sex (mouth, tongue, or lips on a vagina, penis, or butt) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
10	How often did you use a condom when you had sex in the last 6 months?					
		All of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Most of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Some of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		None of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
11	In the last 6 months, how would you describe the HIV status of your sexual partner(s)?					
		I know that none of my sexual partners from the last 6 months have HIV/AIDS	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I know that at least one sexual partner from the last 6 months is living with HIV/AIDS	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I do not know my sexual partners' HIV status	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
12	As far as you know, were any of your sexual partner(s) from the last 6 months taking PrEP to prevent HIV infection? PrEP is a medication that prevents HIV.					
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
13	You mentioned that you had a least one partner in the last 6 months who is living with HIV/AIDS. As far as you know, were any of your partners taking HIV medications (antiretrovirals) to treat their HIV infection?					
		Yes, my partner(s) was/were taking HIV medications	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes, my partner(s) was/were taking HIV medications and	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
		was/were undetectable, meaning HIV tests were not finding the virus				
		No, my partner(s) was/were not taking HIV medications	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I do not know whether my partner(s) was/were taking HIV medications	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
14	In the last 6 months, have you experienced any incidents of sexual violence, physical abuse, or any other type of trauma from a partner?					
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
15	In the last 6 months, have you exchanged things like money or drugs for sex with a sexual partner?					
		Yes, I have a sexual partner things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes, a sexual partner gave me things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No, I have not exchanged things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 7.006. Summary of Patient Study Participants' Sexual History and Behaviors (Month 12/13), N=XX, Race, Total**

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
8	Have you had sex in the last 6 months? <i>This could be vaginal sex (penis in vagina) OR anal sex (penis in butt) OR oral sex.</i>					
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
9	How would you describe your sexual behaviors in the last 6 months?					
		I have had vaginal sex (penis in vagina) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had vaginal sex (penis in vagina) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a bottom (penis in butt as a bottom) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a bottom (penis in butt as a bottom) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a top (penis in butt as a top) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a top (penis in butt as a top) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had oral sex (mouth, tongue, or lips on a vagina, penis, or butt) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had oral sex (mouth, tongue, or lips on a vagina, penis, or butt) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
10	How often did you use a condom when you had sex in the last 6 months?					
		All of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Most of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Some of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		None of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
11	In the last 6 months, how would you describe the HIV status of your sexual partner(s)?					
		I know that none of my sexual partners from the last 6 months have HIV/AIDS	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I know that at least one sexual partner from the last 6 months is living with HIV/AIDS	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I do not know my sexual partners' HIV status	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
12	As far as you know, were any of your sexual partner(s) from the last 6 months taking PrEP to prevent HIV infection? PrEP is a medication that prevents HIV.					
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
13	You mentioned that you had a least one partner in the last 6 months who is living with HIV/AIDS. As far as you know, were any of your partners taking HIV medications (antiretrovirals) to treat their HIV infection?					
		Yes, my partner(s) was/were taking HIV medications	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes, my partner(s) was/were taking HIV medications and	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
		was/were undetectable, meaning HIV tests were not finding the virus				
		No, my partner(s) was/were not taking HIV medications	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I do not know whether my partner(s) was/were taking HIV medications	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
14	In the last 6 months, have you experienced any incidents of sexual violence, physical abuse, or any other type of trauma form a partner?					
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
15	In the last 6 months, have you exchanged things like money or drugs for sex with a sexual partner?					
		Yes, I have a sexual partner things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes, a sexual partner gave me things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No, I have not exchanged things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 7.007. Summary of Patient Study Participants' Sexual History and Behaviors (Month 12/13), N=XX, Ethnicity, Study Arms**

Question Number	Question	Response	Dynamic Implementation		Routine Implementation	
			Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
8	Have you had sex in the last 6 months? <i>This could be vaginal sex (penis in vagina) OR anal sex (penis in butt) OR oral sex.</i>					
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
9	How would you describe your sexual behaviors in the last 6 months?					
		I have had vaginal sex (penis in vagina) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had vaginal sex (penis in vagina) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a bottom (penis in butt as a bottom) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a bottom (penis in butt as a bottom) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a top (penis in butt as a top) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a top (penis in butt as a top) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had oral sex (mouth, tongue, or lips on a vagina, penis, or butt) with only 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have had oral sex (mouth, tongue, or lips on a vagina, penis, or butt) with more than 1 partner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
10	How often did you use a condom when you had sex in the last 6 months?					

Question Number	Question	Response	Dynamic Implementation		Routine Implementation	
			Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
		All of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Most of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Some of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		None of the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
11	In the last 6 months, how would you describe the HIV status of your sexual partner(s)?					
		I know that none of my sexual partners from the last 6 months have HIV/AIDS	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I know that at least one sexual partner from the last 6 months is living with HIV/AIDS	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I do not know my sexual partners' HIV status	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
12	As far as you know, were any of your sexual partner(s) from the last 6 months taking PrEP to prevent HIV infection? PrEP is a medication that prevents HIV.					
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
13	You mentioned that you had a least one partner in the last 6 months who is living with HIV/AIDS. As far as you know, were any of your partners taking HIV medications (antiretrovirals) to treat their HIV infection?					
		Yes, my partner(s) was/were taking HIV medications	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes, my partner(s) was/were taking HIV medications and was/were undetectable, meaning HIV tests were not finding the virus	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Dynamic Implementation		Routine Implementation	
			Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
		No, my partner(s) was/were not taking HIV medications	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I do not know whether my partner(s) was/were taking HIV medications	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
14	In the last 6 months, have you experienced any incidents of sexual violence, physical abuse, or any other type of trauma from a partner?					
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
15	In the last 6 months, have you exchanged things like money or drugs for sex with a sexual partner?					
		Yes, I have a sexual partner things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes, a sexual partner gave me things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No, I have not exchanged things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 7.008. Summary of Patient Study Participants' Sexual History and Behaviors (Month 12/13), N=XX, Ethnicity, Total**

Question Number	Question	Response	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
8	Have you had sex in the last 6 months? <i>This could be vaginal sex (penis in vagina) OR anal sex (penis in butt) OR oral sex.</i>			
		No	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)
9	How would you describe your sexual behaviors in the last 6 months?			
		I have had vaginal sex (penis in vagina) with only 1 partner	XX (XX.X%)	XX (XX.X%)
		I have had vaginal sex (penis in vagina) with more than 1 partner	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a bottom (penis in butt as a bottom) with only 1 partner	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a bottom (penis in butt as a bottom) with more than 1 partner	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a top (penis in butt as a top) with only 1 partner	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a top (penis in butt as a top) with more than 1 partner	XX (XX.X%)	XX (XX.X%)
		I have had oral sex (mouth, tongue, or lips on a vagina, penis, or butt) with only 1 partner	XX (XX.X%)	XX (XX.X%)
		I have had oral sex (mouth, tongue, or lips on a vagina, penis, or butt) with more than 1 partner	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)
10	How often did you use a condom when you had sex in the last 6 months?			
		All of the time	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
		Most of the time	XX (XX.X%)	XX (XX.X%)
		Some of the time	XX (XX.X%)	XX (XX.X%)
		A little of the time	XX (XX.X%)	XX (XX.X%)
		None of the time	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)
11	In the last 6 months, how would you describe the HIV status of your sexual partner(s)?			
		I know that none of my sexual partners from the last 6 months have HIV/AIDS	XX (XX.X%)	XX (XX.X%)
		I know that at least one sexual partner from the last 6 months is living with HIV/AIDS	XX (XX.X%)	XX (XX.X%)
		I do not know my sexual partners' HIV status	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)
12	As far as you know, were any of your sexual partner(s) from the last 6 months taking PrEP to prevent HIV infection? PrEP is a medication that prevents HIV.			
		No	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)
13	You mentioned that you had a least one partner in the last 6 months who is living with HIV/AIDS. As far as you know, were any of your partners taking HIV medications (antiretrovirals) to treat their HIV infection?			
		Yes, my partner(s) was/were taking HIV medications	XX (XX.X%)	XX (XX.X%)
		Yes, my partner(s) was/were taking HIV medications and was/were undetectable, meaning HIV tests were not finding the virus	XX (XX.X%)	XX (XX.X%)
		No, my partner(s) was/were not taking HIV medications	XX (XX.X%)	XX (XX.X%)
		I do not know whether my partner(s) was/were taking HIV medications	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)
14	In the last 6 months, have you experienced any incidents of sexual violence, physical abuse, or any other type of trauma from a partner?			
		No	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)
15	In the last 6 months, have you exchanged things like money or drugs for sex with a sexual partner?			
		Yes, I have a sexual partner things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)
		Yes, a sexual partner gave me things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)
		No, I have not exchanged things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)



**Table 7.009. Summary of Patient Study Participants' Sexual History and Behaviors (Month 12/13), N=XX, Gender, Total**

Question Number	Question	Response	Men who have sex with men (N = XX) n (%)	Transgender Men (N = XX) n (%)
8	Have you had sex in the last 6 months? <i>This could be vaginal sex (penis in vagina) OR anal sex (penis in butt) OR oral sex.</i>			
		No	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)
9	How would you describe your sexual behaviors in the last 6 months?			
		I have had vaginal sex (penis in vagina) with only 1 partner	XX (XX.X%)	XX (XX.X%)
		I have had vaginal sex (penis in vagina) with more than 1 partner	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a bottom (penis in butt as a bottom) with only 1 partner	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a bottom (penis in butt as a bottom) with more than 1 partner	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a top (penis in butt as a top) with only 1 partner	XX (XX.X%)	XX (XX.X%)
		I have had anal sex as a top (penis in butt as a top) with more than 1 partner	XX (XX.X%)	XX (XX.X%)
		I have had oral sex (mouth, tongue, or lips on a vagina, penis, or butt) with only 1 partner	XX (XX.X%)	XX (XX.X%)
		I have had oral sex (mouth, tongue, or lips on a vagina, penis, or butt) with more than 1 partner	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)
10	How often did you use a condom when you had sex in the last 6 months?			
		All of the time	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Men who have sex with men (N = XX) n (%)	Transgender Men (N = XX) n (%)
		Most of the time	XX (XX.X%)	XX (XX.X%)
		Some of the time	XX (XX.X%)	XX (XX.X%)
		A little of the time	XX (XX.X%)	XX (XX.X%)
		None of the time	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)
11	In the last 6 months, how would you describe the HIV status of your sexual partner(s)?			
		I know that none of my sexual partners from the last 6 months have HIV/AIDS	XX (XX.X%)	XX (XX.X%)
		I know that at least one sexual partner from the last 6 months is living with HIV/AIDS	XX (XX.X%)	XX (XX.X%)
		I do not know my sexual partners' HIV status	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)
12	As far as you know, were any of your sexual partner(s) from the last 6 months taking PrEP to prevent HIV infection? PrEP is a medication that prevents HIV.			
		No	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)
13	You mentioned that you had a least one partner in the last 6 months who is living with HIV/AIDS. As far as you know, were any of your partners taking HIV medications (antiretrovirals) to treat their HIV infection?			
		Yes, my partner(s) was/were taking HIV medications	XX (XX.X%)	XX (XX.X%)
		Yes, my partner(s) was/were taking HIV medications and was/were undetectable, meaning HIV tests were not finding the virus	XX (XX.X%)	XX (XX.X%)
		No, my partner(s) was/were not taking HIV medications	XX (XX.X%)	XX (XX.X%)
		I do not know whether my partner(s) was/were taking HIV medications	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Men who have sex with men (N = XX) n (%)	Transgender Men (N = XX) n (%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)
14	In the last 6 months, have you experienced any incidents of sexual violence, physical abuse, or any other type of trauma from a partner?			
		No	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)
15	In the last 6 months, have you exchanged things like money or drugs for sex with a sexual partner?			
		Yes, I have a sexual partner things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)
		Yes, a sexual partner gave me things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)
		No, I have not exchanged things like drugs or money for sex	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)

**Table 7.010. Summary of How Patient Study Participants Learned About PILLAR (Month 12/13), N=XX**

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
91	How did you learn about the PILLAR study?				
		A discussion with my healthcare provider	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A flyer or poster in my clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A friend/family told me	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Social media	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		An event in my community	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify)_____	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 7.101. Summary of Patient Study Participants' HIV and PrEP Knowledge (Month 12/13), N=XX**

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
5	Do you personally know of someone living with HIV?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 7.102. Summary of Patient Study Participants' HIV and PrEP Knowledge (Month 12/13), N=XX, Scale Questions, Study Arms**

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
6	Please answer true or false to the following statements about HIV.				
A	A person who has HIV can look healthy.	True	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		False	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
B	There is a vaccine that can stop you from getting HIV.	True	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		False	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
C	A person will NOT get HIV if they are taking antibiotics.	True	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		False	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
D	If you only have sex once with a partner, you cannot get HIV from them.	True	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		False	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
E	People living with HIV on HIV medications cannot spread HIV.	True	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		False	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
F	Everybody who has HIV knows that they have HIV.	True	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		False	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
G	A natural (lamb skin) condom works better against HIV than a latex condom.	True	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		False	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
H	When using condoms during sex, it is safer to use water-based lubricants than oil-based lubricants.	True	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		False	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 7.103. Distributional Characteristics of Patient Study Participants' HIV and PrEP Knowledge (Month 12/13), N=XX, Scale Questions, Overall Score**

6. Please answer true or false to the following statements about HIV.	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean	Cronbach's $\alpha$
<b>Mean Score</b>	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	0.xx
<b>Study Arm</b>								
Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
<b>Site Volume</b>								
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
<b>Gender</b>								
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
<b>Race</b>								
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
<b>Ethnicity</b>								
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
<b>Dynamic Implementation</b>								
<b>Site Volume</b>								
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
<b>Gender</b>								



6. Please answer true or false to the following statements about HIV.	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean	Cronbach's $\alpha$
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
<b>Race</b>								
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
<b>Ethnicity</b>								
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
<b>Routine Implementation</b>								
<b>Site Volume</b>								
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
<b>Gender</b>								
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
<b>Race</b>								
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
<b>Ethnicity</b>								
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—

6. Please answer true or false to the following statements about HIV.	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean	Cronbach's $\alpha$
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—

Mean score = mean of correct responses to all of the items under 8 save for A and E; 'Don't know' responses coded as incorrect. Correct answers were 'False' for items B, C, D, F, and G and 'True' for item H.

**Table 7.104. Summary of Patient Study Participants' Perception of Stigma Associated with PrEP Usage (Month 12/13), N=XX, Stigma, Study Arms**

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
7	To what extent do you agree with each of the following statements about PrEP?				
A	My <i>friends</i> would be supportive of me taking PrEP.	Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
B	People experience problems when they tell their sexual partner(s) they are taking PrEP.	Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
C	People experience negative judgement because they take PrEP.	Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
D	My <i>family</i> would be supportive of me taking PrEP.	Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
E	People taking PrEP receive praise for being responsible.	Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
F	I would feel ashamed to take PrEP in front of others.	Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
G	Someone taking PrEP would be seen by others as having sex with a lot of different people.	Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
H	People on PrEP are taking care of their health.	Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
I	People talking PrEP experience verbal harassment.	Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
J	I would not want others to know if I was taking PrEP.	Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
K	Someone taking PrEP should keep their pills hidden.	Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
L	I would feel proud to take PrEP every day.	Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
M	I would have sex with someone who is taking PrEP.	Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 7.105. Distributional Characteristics of Patient Study Participants' Perception of Stigma Associated with PrEP Usage (Month 12/13), N=XX, Stigma, Overall Score**

7. To what extent do you agree with each of the following statements about PrEP?	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean	Cronbach's α
<b>Mean Score</b>	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	0.xx
<b>Study Arm</b>								
Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
<b>Site Volume</b>								
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
<b>Gender</b>								
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
<b>Race</b>								
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
<b>Ethnicity</b>								
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
<b>Dynamic Implementation</b>								
<b>Site Volume</b>								
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
<b>Gender</b>								

7. To what extent do you agree with each of the following statements about PrEP?	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean	Cronbach's $\alpha$
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
<b>Race</b>								
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
<b>Ethnicity</b>								
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
<b>Routine Implementation</b>								
<b>Site Volume</b>								
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
<b>Gender</b>								
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
<b>Race</b>								
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
<b>Ethnicity</b>								
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—



7. To what extent do you agree with each of the following statements about PrEP?	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean	Cronbach's $\alpha$
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—

Mean score = mean of responses to all of the items under 13 save for J with the following items are reverse scored: A, D, E, H, L, & M. Higher total score indicates higher stigma.

Table 7.106. Summary of Patient Study Participants' Choice of APRETUDE (Month 12/13), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
16	Do you have any concerns about APRETUDE?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
17	What concerns do you have about APRETUDE?				
		Pain or soreness from the injection	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other side effects from APRETUDE	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Fear of needles	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Change in my insurance coverage for APRETUDE	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Possible long-term effects of the injection	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		How it affects other medications I take	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Scheduling or rescheduling injection visits	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Forgetting my appointment for the injection visits	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Missing an injection visit and then getting HIV	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Missing work for the injection visits	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Making time to go to the clinic/practice for the injection every 2 months	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Travelling to the clinic/practice for the injection visits	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Limited clinic/practice hours for injection visits	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Childcare/caregiver responsibilities during injection visits	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Lack of privacy at injection visits	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		My dignity not being respected during injection visits	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		People asking why I go to the clinic/doctor every 2 months	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		My hectic lifestyle	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		My travel or holiday schedules	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Taking medication during times when I am not having sex	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The medication not being effective at preventing HIV	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Worrying people would think I have HIV	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Worrying that people would think I have a lot of sexual partners because I am on CAB LA for PrEP	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Worrying about my privacy because I live with someone	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Worrying about my privacy because I'm on my parent's health insurance	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
18	How often are you worried that people may find out that you are taking APREUDE?				
		Never	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Rarely	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Sometimes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Often	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		All the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
19	How often are you worried about forgetting your APREUDE injection visits?				
		Never	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Rarely	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Sometimes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Often	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		All the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 7.107. Summary of Knowledge of APRETUDE and Utility of Implementation Strategies (Month 12/13), N=XX**

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
75	Overall, how much do you know about APRETUDE?				
		A lot	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Some	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Nothing	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
76	How confident are you with your current level of knowledge about APRETUDE?				
		Extremely confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
77	How helpful is the information, if any, shared by the medical staff about APRETUDE?				
		Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not receive any information from medical staff	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
78	How helpful has each of the following materials been in learning about APRETUDE?				
A	Getting Started Brochure – the brochure that gives you an overview of how to get started with APRETUDE	Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Did not receive/Did not use it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
B	Patient Brochure – this brochure helps you understand the process of receiving APRETUDE injections, including side effects and insurance information	Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Did not receive/Did not use it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
C	Let's talk about HIV & PrEP video – the video giving key facts about HIV and PrEP options (DI)	Very helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	N/A
		A little helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Not at all helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Did not receive/Did not use it	XX (XX.X%)	XX (XX.X%)	N/A
D	The APRETUDE Myths and Facts video – the game	Very helpful	XX	XX	N/A

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
	show video addressing common myths about APREITUDE (DI)		(XX.X%)	(XX.X%)	
		Helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	N/A
		A little helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Not at all helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Did not receive/Did not use it	XX (XX.X%)	XX (XX.X%)	N/A
E	The What to Expect video which shows you what to expect during the APREITUDE process (DI)	Very helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	N/A
		A little helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Not at all helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Did not receive/Did not use it	XX (XX.X%)	XX (XX.X%)	N/A
F	The ViiV Connect Video, which tells you about the ViiV Connect program and frequently asked questions (DI)	Very helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	N/A
		A little helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Not at all helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Did not receive/Did not use it	XX (XX.X%)	XX (XX.X%)	N/A

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
G	The study website where you access APRETDUE information (RI)	Very helpful	XX (XX.X%)	N/A	XX (XX.X%)
		Helpful	XX (XX.X%)	N/A	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	N/A	XX (XX.X%)
		A little helpful	XX (XX.X%)	N/A	XX (XX.X%)
		Not at all helpful	XX (XX.X%)	N/A	XX (XX.X%)
		Did not receive/Did not use it	XX (XX.X%)	N/A	XX (XX.X%)
H	The study app/website where you access APRETDUE information – the Pillar Spot (DI)	Very helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	N/A
		A little helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Not at all helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Did not receive/Did not use it	XX (XX.X%)	XX (XX.X%)	N/A
I	Important safety information – This document details important safety information relating to APRETDUE	Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Did not receive/Did not use it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
J	Important facts – This document details important facts relating to APRETUDE	Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Did not receive/Did not use it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
K	A flyer on PrEP options (DI)	Very helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	N/A
		A little helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Not at all helpful	XX (XX.X%)	XX (XX.X%)	N/A
		Did not receive/Did not use it	XX (XX.X%)	XX (XX.X%)	N/A

**Table 7.108. Attitude Regarding APREUDE and Utility of Implementation Strategies (Month 12/13), N=XX**

Question		Response				
86. Overall, how are you feeling about taking APREUDE?		Very positive	Somewhat positive	Neither positive nor negative	Somewhat negative	Very negative
Study Arms						
	Total (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Dynamic Implementation (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Routine Implementation (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Race, Dynamic Implementation						
	Asian (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Black or African American (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	White (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Race, Routine Implementation						
	Asian (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Black or African American (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	White (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Race, Total						

Question		Response				
	Asian (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Black or African American (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	White (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Ethnicity, Dynamic Implementation						
	Hispanic or Latino (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not Hispanic or Latino (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Ethnicity, Routine Implementation						
	Hispanic or Latino (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not Hispanic or Latino (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Ethnicity, Total						
	Hispanic or Latino (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not Hispanic or Latino (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Gender, Total						
	Men who have sex with men (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Transgender men (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 7.109. Summary of Patient Study Participant Acquisition Process (Month 12/13), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
79	Have you ever heard of ViiV Connect?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
80	Where did you learn about ViiV Connect?				
		My healthcare provider/healthcare clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The ViiV Connect video on the study app/website (DI)	XX (XX.X%)	XX (XX.X%)	N/A
		ViiV Connect brochure	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A friend/family member told me	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The ViiV Connect website	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify_____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 7.110. Summary of Patient Study Participant Acquisition Process, Insurance (Month 12/13), N=XX**

Question		Response				
81. To what extent do you agree with each of the following statements?		Completely Agree	Agree	Neither agree nor disagree	Disagree	Completely disagree
<b>A. The staff at the clinic helped me understand the insurance approval process</b>						
Study Arms						
	Total (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Dynamic Implementation (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Routine Implementation (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Race, Dynamic Implementation						
	Asian (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Black or African American (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	White (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Race, Routine Implementation						
	Asian (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Black or African American (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	White (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Race, Total						

Question		Response				
	Asian (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Black or African American (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	White (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Ethnicity, Dynamic Implementation						
	Hispanic or Latino (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not Hispanic or Latino (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Ethnicity, Routine Implementation						
	Hispanic or Latino (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not Hispanic or Latino (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Ethnicity, Total						
	Hispanic or Latino (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not Hispanic or Latino (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Gender, Total						
	Men who have sex with men (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Transgender men (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>B. It took too long to get insurance approval for APREUDE</b>						
Study Arms						

Question		Response				
	Total (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Dynamic Implementation (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Routine Implementation (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Race, Dynamic Implementation						
	Asian (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Black or African American (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	White (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Race, Routine Implementation						
	Asian (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Black or African American (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	White (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Race, Total						
	Asian (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Black or African American (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question		Response				
	White (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Ethnicity, Dynamic Implementation						
	Hispanic or Latino (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not Hispanic or Latino (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Ethnicity, Routine Implementation						
	Hispanic or Latino (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not Hispanic or Latino (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Ethnicity, Total						
	Hispanic or Latino (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not Hispanic or Latino (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Gender, Total						
	Men who have sex with men (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Transgender men (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>C. My copay for APRETUDE is acceptable</b>						
Study Arms						
	Total (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Dynamic Implementation (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



Question		Response				
	Routine Implementation (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Race, Dynamic Implementation						
	Asian (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Black or African American (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	White (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Race, Routine Implementation						
	Asian (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Black or African American (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	White (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Race, Total						
	Asian (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Black or African American (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	White (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Ethnicity, Dynamic Implementation						

Question		Response				
	Hispanic or Latino (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not Hispanic or Latino (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Ethnicity, Routine Implementation						
	Hispanic or Latino (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not Hispanic or Latino (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Ethnicity, Total						
	Hispanic or Latino (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not Hispanic or Latino (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Gender, Total						
	Men who have sex with men (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Transgender men (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>D. I am worried about insurance coverage long-term</b>						
Study Arms						
	Total (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Dynamic Implementation (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Routine Implementation (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Race, Dynamic Implementation						
	Asian (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question		Response				
	Black or African American (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	White (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Race, Routine Implementation						
	Asian (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Black or African American (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	White (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Race, Total						
	Asian (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Black or African American (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	White (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Ethnicity, Dynamic Implementation						
	Hispanic or Latino (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not Hispanic or Latino (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Ethnicity, Routine Implementation						

Question		Response				
	Hispanic or Latino (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not Hispanic or Latino (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Ethnicity, Total						
	Hispanic or Latino (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not Hispanic or Latino (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Gender, Total						
	Men who have sex with men (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Transgender men (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>E. The insurance approval process was simple</b>						
Study Arms						
	Total (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Dynamic Implementation (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Routine Implementation (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Race, Dynamic Implementation						
	Asian (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Black or African American (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	White (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question		Response				
	Other (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Race, Routine Implementation						
	Asian (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Black or African American (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	White (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Race, Total						
	Asian (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Black or African American (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	White (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Ethnicity, Dynamic Implementation						
	Hispanic or Latino (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not Hispanic or Latino (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Ethnicity, Routine Implementation						
	Hispanic or Latino (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not Hispanic or Latino (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Ethnicity, Total						

Question		Response				
	Hispanic or Latino (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not Hispanic or Latino (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Gender, Total						
	Men who have sex with men (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Transgender men (N = XX) n (%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 7.201. Distributional Characteristics of Acceptability of Intervention (AIM) (APREUDE) (PSP) (Month 12/13), N=XX**

20. AIM APREUDE.	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
<b>Mean Score</b>	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Study Arm</b>							
Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
T-test	X.XXX						
Degrees of Freedom	XX						
P-value	0.XXX						
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Gender</b>							
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Race</b>							
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Ethnicity</b>							
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Dynamic Implementation</b>							
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)

20. AIM APREITUDE.	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
<b>Gender</b>							
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Race</b>							
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Ethnicity</b>							
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Routine Implementation</b>							
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Gender</b>							
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Race</b>							
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Ethnicity</b>							
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)



20. AIM APREITUDE.	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)

**Table 7.202. Distributional Characteristics of Feasibility of Intervention (FIM) (APRETUDE) (PSP) (Month 12/13), N=XX**

21. FIM APRETUDE.	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
<b>Mean Score</b>	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Study Arm</b>							
Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
T-test	X.XXX						
Degrees of Freedom	XX						
P-value	0.XXX						
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Gender</b>							
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Race</b>							
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Ethnicity</b>							
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Dynamic Implementation</b>							
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)

21. FIM APREITUDE.	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
<b>Gender</b>							
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Race</b>							
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Ethnicity</b>							
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Routine Implementation</b>							
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Gender</b>							
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Race</b>							
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Ethnicity</b>							
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)

21. FIM APRETUDE.	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)

**Table 7.203. Distributional Characteristics of Accessibility of Intervention (AIM) (Telehealth) (PSP) (Month 12/13), N=XX**

	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
<b>23. AIM TELEHEALTH.</b>							
<b>Mean Score</b>	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Study Arm</b>							
Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
T-test	X.XXX						
Degrees of Freedom	XX						
P-value	0.XXX						
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Gender</b>							
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Race</b>							
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Ethnicity</b>							
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Dynamic Implementation</b>							
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)

23. AIM TELEHEALTH.	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
<b>Gender</b>							
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Race</b>							
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Ethnicity</b>							
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Routine Implementation</b>							
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Gender</b>							
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Race</b>							
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Ethnicity</b>							
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)

23. AIM TELEHEALTH.	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)

**Table 7.204. Distributional Characteristics of Feasibility of Intervention (FIM) (Telehealth) (PSP) (Month 12/13), N=XX**

	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
<b>24. FIM TELEHEALTH.</b>							
<b>Mean Score</b>	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Study Arm</b>							
Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
T-test	X.XXX						
Degrees of Freedom	XX						
P-value	0.XXX						
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Gender</b>							
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Race</b>							
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Ethnicity</b>							
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Dynamic Implementation</b>							
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)



24. FIM TELEHEALTH.	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
<b>Gender</b>							
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Race</b>							
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Ethnicity</b>							
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Routine Implementation</b>							
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Gender</b>							
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Race</b>							
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Ethnicity</b>							
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)

24. FIM TELEHEALTH.	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)

Table 7.205. Summary of Acceptability of Intervention (AIM) (APRETUDE) (PSP) (Month 6/7), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
20	Please indicate how much you agree with each statement based on your current expectations of APRETUDE.				
	APRETUDE <b>meets my approval</b> for preventing HIV.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	APRETUDE for the prevention of HIV <b>is appealing to me.</b>	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I <b>like</b> APRETUDE for the prevention of HIV.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I <b>welcome</b> APRETUDE for the prevention of HIV	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 7.206. Summary of Feasibility of Intervention (FIM) (APRETUDE) (PSP) (Month 6/7), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
21	Please indicate how much you agree with each statement based on your experiences with APRETUDE.				
	Receiving APRETUDE injection every 2-months <b>seems workable</b> in my life	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Receiving APRETUDE injection every 2-months <b>seems possible</b> in my life	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Receiving APRETUDE injection every 2-months <b>seems doable</b> in my life	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Receiving APRETUDE injection every 2-months <b>seems easy</b> in my life	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 7.207. Summary of Acceptability of Intervention (AIM) (Telehealth) (PSP) (Month 6/7), N=XX**

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
23	Please indicate how much you agree with each statement based on your current perceptions and experience with telehealth.				
	Using telehealth for APREUDE services <b>meets my approval.</b>	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Using telehealth for APREUDE services <b>is appealing to me.</b>	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I <b>like</b> using telehealth for APREUDE services.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I <b>welcome</b> using telehealth for APREUDE services.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



Table 7.208. Summary of Feasibility of Intervention (FIM) (Telehealth) (PSP) (Month 6/7), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
24	Please indicate how much you agree with each statement based on your current perceptions and experience with telehealth.				
	Using telehealth for APREITUDE services <b>seems workable</b> in my life.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Using telehealth for APREITUDE services <b>seems possible</b> in my life.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Using telehealth for APREITUDE services <b>seems doable</b> in my life.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Using telehealth for APREITUDE services <b>seems easy</b> in my life.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 7.209. Changes from Baseline for Acceptability of Intervention Measure (AIM - APRETUDE) and Feasibility of Intervention Measure (FIM - APRETUDE) (Month 12/13), N=XX**

Measure	Study Arm	n	Mean	SD	Median (Q1, Q3)	Observed Range (min, max)	Missing n (%)	95% CI for the Mean
AIM - APRETUDE Baseline	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
AIM - APRETUDE Month 12/13	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
AIM - APRETUDE Change from Baseline to Month 12/13	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	T-test		X.XXX					
	DF		XX					
	P-Value		0.XXX					
FIM - APRETUDE Baseline	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
FIM - APRETUDE Month 12/13	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
FIM - APRETUDE Change from Baseline to Month 12/13	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	T-test		X.XXX					
	DF		XX					
	P-Value		0.XXX					

**Table 7.210. Mixed-effects Modeling of the Acceptability of Intervention Measure (AIM – APREUDE) (Month 12/13), N=XX**

Fixed effects					
Parameter	Estimate	Standard Error	Denominator Degrees of Freedom	T	p-Value
Intercept (RI, Low)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm (DI)	X.XX	X.XXX	XX	X.XX	0.XXXX
Volume (High)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm by Volume	X.XX	X.XXX	XX	X.XX	0.XXXX
Baseline Mean Score[1]	X.XX	X.XXX	XX	X.XX	0.XXXX
Random Effects					
Covariance Parameter	Estimate	Standard Error		Z	p-Value
Site Variance ( $\tau(0,0)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Covariance ( $\tau(0,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Baseline Variance ( $\tau(1,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Residual Variance ( $\sigma^2$ )	X.XX	X.XXX	-	X.XX	0.XXXX

Note: Null model likelihood ratio test,  $\chi^2(XX) = XXX.XX$ ,  $p = 0.XXXX$ .

[1] Baseline mean score centered by site.

**Table 7.211. Mixed-effects Modeling of the Changes from Baseline to Month 12/13 in Acceptability of Intervention Measure (AIM – APRETUDE), N=XX**

Fixed effects					
Parameter	Estimate	Standard Error	Denominator Degrees of Freedom	T	p-Value
Intercept (RI, Low)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm (DI)	X.XX	X.XXX	XX	X.XX	0.XXXX
Volume (High)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm by Volume	X.XX	X.XXX	XX	X.XX	0.XXXX
Baseline Mean Score[1]	X.XX	X.XXX	XX	X.XX	0.XXXX
Random Effects					
Covariance Parameter	Estimate	Standard Error		Z	p-Value
Site Variance ( $\tau(0,0)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Covariance ( $\tau(0,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Baseline Variance ( $\tau(1,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Residual Variance ( $\sigma^2$ )	X.XX	X.XXX	-	X.XX	0.XXXX

Note: Null model likelihood ratio test,  $\chi^2(XX) = XXX.XX$ ,  $p = 0.XXXX$ .

[1] Baseline mean score centered by site.

**Table 7.212. Mixed-effects Modeling of the Feasibility of Intervention Measure (FIM – APREUDE) (Month 12/13), N=XX**

Fixed effects					
Parameter	Estimate	Standard Error	Denominator Degrees of Freedom	T	p-Value
Intercept (RI, Low)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm (DI)	X.XX	X.XXX	XX	X.XX	0.XXXX
Volume (High)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm by Volume	X.XX	X.XXX	XX	X.XX	0.XXXX
Baseline Mean Score[1]	X.XX	X.XXX	XX	X.XX	0.XXXX
Random Effects					
Covariance Parameter	Estimate	Standard Error		Z	p-Value
Site Variance ( $\tau(0,0)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Covariance ( $\tau(0,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Baseline Variance ( $\tau(1,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Residual Variance ( $\sigma^2$ )	X.XX	X.XXX	-	X.XX	0.XXXX

Note: Null model likelihood ratio test,  $\chi^2(XX) = XXX.XX$ ,  $p = 0.XXXX$ .

[1] Baseline mean score centered by site.

**Table 7.213. Mixed-effects Modeling of the Changes from Baseline to Month 12/13 in Feasibility of Intervention Measure (FIM – APRETUDE), N=XX**

Fixed effects					
Parameter	Estimate	Standard Error	Denominator Degrees of Freedom	T	p-Value
Intercept (RI, Low)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm (DI)	X.XX	X.XXX	XX	X.XX	0.XXXX
Volume (High)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm by Volume	X.XX	X.XXX	XX	X.XX	0.XXXX
Baseline Mean Score[1]	X.XX	X.XXX	XX	X.XX	0.XXXX
Random Effects					
Covariance Parameter	Estimate	Standard Error		Z	p-Value
Site Variance ( $\tau(0,0)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Covariance ( $\tau(0,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Baseline Variance ( $\tau(1,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Residual Variance ( $\sigma^2$ )	X.XX	X.XXX	-	X.XX	0.XXXX

Note: Null model likelihood ratio test,  $\chi^2(XX) = XXX.XX$ ,  $p = 0.XXXX$ .

[1] Baseline mean score centered by site.

**Table 7.214. Changes from Baseline for Acceptability of Intervention Measure (AIM - Telehealth) and Feasibility of Intervention Measure (FIM - Telehealth) (Month 12/13), N=XX**

Measure	Study Arm	n	Mean	SD	Median (Q1, Q3)	Observed Range (min, max)	Missing n (%)	95% CI for the Mean
AIM - Telehealth Baseline	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
AIM - Telehealth Month 12/13	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
AIM - Telehealth Change from Baseline to Month 12/13	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	T-test		X.XXX					
	DF		XX					
	P-Value		0.XXX					
FIM - Telehealth Baseline	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
FIM - Telehealth Month 12/13	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
FIM - Telehealth Change from Baseline to Month 12/13	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	T-test		X.XXX					
	DF		XX					
	P-Value		0.XXX					



**Table 7.215. Mixed-effects Modeling of the Acceptability of Intervention Measure (AIM – Telehealth) (Month 12/13), N=XX**

Fixed effects					
Parameter	Estimate	Standard Error	Denominator Degrees of Freedom	T	p-Value
Intercept (RI, Low)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm (DI)	X.XX	X.XXX	XX	X.XX	0.XXXX
Volume (High)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm by Volume	X.XX	X.XXX	XX	X.XX	0.XXXX
Baseline Mean Score[1]	X.XX	X.XXX	XX	X.XX	0.XXXX
Random Effects					
Covariance Parameter	Estimate	Standard Error		Z	p-Value
Site Variance ( $\tau(0,0)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Covariance ( $\tau(0,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Baseline Variance ( $\tau(1,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Residual Variance ( $\sigma^2$ )	X.XX	X.XXX	-	X.XX	0.XXXX

Note: Null model likelihood ratio test,  $\chi^2(XX) = XXX.XX$ ,  $p = 0.XXXX$ .

[1] Baseline mean score centered by site.

**Table 7.216. Mixed-effects Modeling of the Changes from Baseline to Month 12/13 in Acceptability of Intervention Measure (AIM – Telehealth), N=XX**

Fixed effects					
Parameter	Estimate	Standard Error	Denominator Degrees of Freedom	T	p-Value
Intercept (RI, Low)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm (DI)	X.XX	X.XXX	XX	X.XX	0.XXXX
Volume (High)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm by Volume	X.XX	X.XXX	XX	X.XX	0.XXXX
Baseline Mean Score[1]	X.XX	X.XXX	XX	X.XX	0.XXXX
Random Effects					
Covariance Parameter	Estimate	Standard Error		Z	p-Value
Site Variance ( $\tau(0,0)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Covariance ( $\tau(0,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Baseline Variance ( $\tau(1,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Residual Variance ( $\sigma^2$ )	X.XX	X.XXX	-	X.XX	0.XXXX

Note: Null model likelihood ratio test,  $\chi^2(XX) = XXX.XX$ ,  $p = 0.XXXX$ .

[1] Baseline mean score centered by site.

**Table 7.217. Mixed-effects Modeling of the Feasibility of Intervention Measure (FIM – Telehealth) (Month 12/13), N=XX**

Fixed effects					
Parameter	Estimate	Standard Error	Denominator Degrees of Freedom	T	p-Value
Intercept (RI, Low)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm (DI)	X.XX	X.XXX	XX	X.XX	0.XXXX
Volume (High)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm by Volume	X.XX	X.XXX	XX	X.XX	0.XXXX
Baseline Mean Score[1]	X.XX	X.XXX	XX	X.XX	0.XXXX
Random Effects					
Covariance Parameter	Estimate	Standard Error		Z	p-Value
Site Variance ( $\tau(0,0)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Covariance ( $\tau(0,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Baseline Variance ( $\tau(1,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Residual Variance ( $\sigma^2$ )	X.XX	X.XXX	-	X.XX	0.XXXX

Note: Null model likelihood ratio test,  $\chi^2(XX) = XXX.XX$ ,  $p = 0.XXXX$ .

[1] Baseline mean score centered by site.

**Table 7.218. Mixed-effects Modeling of the Changes from Baseline to Month 12/13 in Feasibility of Intervention Measure (FIM – Telehealth), N=XX**

Fixed effects					
Parameter	Estimate	Standard Error	Denominator Degrees of Freedom	T	p-Value
Intercept (RI, Low)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm (DI)	X.XX	X.XXX	XX	X.XX	0.XXXX
Volume (High)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm by Volume	X.XX	X.XXX	XX	X.XX	0.XXXX
Baseline Mean Score[1]	X.XX	X.XXX	XX	X.XX	0.XXXX
Random Effects					
Covariance Parameter	Estimate	Standard Error		Z	p-Value
Site Variance ( $\tau(0,0)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Covariance ( $\tau(0,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Baseline Variance ( $\tau(1,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Residual Variance ( $\sigma^2$ )	X.XX	X.XXX	-	X.XX	0.XXXX

Note: Null model likelihood ratio test,  $\chi^2(XX) = XXX.XX$ ,  $p = 0.XXXX$ .

[1] Baseline mean score centered by site.

Table 7.219. Summary of Pain/Activities After Injection (Month 12/13), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
67	Did you experience any local reaction(s) following an injection appointment? <i>Examples of local reactions are redness, itching, swelling, bruising.</i>				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
68	How acceptable was/were your local reaction(s)? <i>Examples of local reactions are redness, itching, swelling, bruising.</i>				
		Totally acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Moderately acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
69	How often are you able to return to your usual daily activities immediately following an injection appointment (for example, going back to work, social events, exercise, driving)?				
		Never	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Rarely	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Sometimes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Often	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Always	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
70	How bothered were you by pain <u>DURING</u> the injection?				
		Not at all	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Moderately	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Very	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Extremely	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
71	Think back to your <b>first</b> injection, please rate the amount of pain/discomfort you experienced <b>AFTER</b> receiving your <b>first</b> APRETUDE injection				
		0 (No pain)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		1	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		2	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		3	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		4	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		5	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		6	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		7	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		8	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		9	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		10 (Extreme pain)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
72	Now think about your <b>last/most recent</b> injection. Please rate the amount of pain/discomfort you experienced <b>AFTER</b> receiving your <b>most recent</b> APRETUDE injection				
		0 (No pain)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		1	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		2	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		3	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		4	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		5	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
			(XX.X%)	(XX.X%)	(XX.X%)
		6	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		7	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		8	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		9	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		10 (Extreme pain)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
73	How acceptable was your pain?				
		Totally acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Moderately acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
74	Which of the following things have you tried to reduce the pain/discomfort following your injections?				
		Took over-the-counter pain relievers	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Used a hot compress	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Used a cold compress	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Avoided sitting for long periods of time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Light stretching and exercise	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 7.220. Summary of Patient Study Participants' Labs and Missed Doses (Month 12/13), N=XX**

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
53	Have you missed any of your APRETUDE injection visits in the last 6 months? <i>This means not receiving an injection within your injection window.</i>				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
54	Was missing your APRETUDE injection visits planned or unplanned?				
		All the injection visits I missed were planned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Some of the injection visits I missed were planned and some were unplanned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		All the injection visits I missed were unplanned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
55	Did you start oral PrEP after missing any of your injection visits?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
56	How easy or difficult was it to start oral PrEP after a missed injection visit?				
		Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
57	How acceptable was it to start oral PrEP after a missed injection visit?				
		Very acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Somewhat acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 7.301. Summary of Feasibility and Acceptability of Telehealth (Month 12/13), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
22	Have you used telehealth for any APRETUDE services in the last 6 months, such as completing forms online, video chatting with your provider, getting reminders about your injection, or scheduling injection appointments online?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
25	What APRETUDE services do/did you receive via telehealth?				
A	Completing relevant clinic visit forms online	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
B	Your doctor ordering an HIV test at a lab near your home where you can go to take the test	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
C	A nurse coming to your home to give you an HIV test	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
D	Video chatting with your doctor	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
E	Receiving reminders (e.g., text, email) about your scheduled injection appointment	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
			(XX.X%)	(XX.X%)	(XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
F	Scheduling your injection appointment online to go to your clinic/doctor's office for the injection	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
G	A nurse coming to your home to give you the injection	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
H	Sending messages to your doctor online	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
I	Reviewing your health documents, such as test results, online	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
J	A nurse coming to your home to conduct your labs (e.g., STI tests)	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
26	How <u>comfortable</u> is/was it to use each of the following telehealth services for APREITUDE?				
A	Completing relevant clinic visit forms online	Very comfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat comfortable	XX	XX	XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
			(XX.X%)	(XX.X%)	(XX.X%)
		Neither comfortable nor uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not comfortable at all	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
B	Your doctor ordering an HIV test at a lab near your home where you can go to take the test	Very comfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat comfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither comfortable nor uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not comfortable at all	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
C	A nurse coming to your home to give you an HIV test	Very comfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat comfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither comfortable nor uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not comfortable at all	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
D	Video chatting with your doctor	Very comfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat comfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither comfortable nor uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not comfortable at all	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
E	Receiving reminders (e.g., text, email) about your	Very comfortable	XX	XX	XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
	scheduled injection appointment		(XX.X%)	(XX.X%)	(XX.X%)
		Somewhat comfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither comfortable nor uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not comfortable at all	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
F	Scheduling your injection appointment online to go to your clinic/doctor's office for the injection	Very comfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat comfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither comfortable nor uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not comfortable at all	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
G	A nurse coming to your home to give you the injection	Very comfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat comfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither comfortable nor uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not comfortable at all	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
H	Sending messages to your doctor online	Very comfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat comfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither comfortable nor uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not comfortable at all	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
			(XX.X%)	(XX.X%)	(XX.X%)
I	Reviewing your health documents, such as test results, online	Very comfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat comfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither comfortable nor uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not comfortable at all	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
J	A nurse coming to your home to conduct your labs (e.g., STI tests)	Very comfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat comfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither comfortable nor uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not comfortable at all	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
27	How <u>convenient</u> is/was it to use each of the telehealth services for APREUDE? <i>By convenient, we mean fitting in well with your life activities and plans, with little trouble.</i>				
A	Completing relevant clinic visit forms online	Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither convenient nor inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
B	Your doctor ordering an HIV test at a lab near your home where you can go to take the test	Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither convenient nor inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Somewhat inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
C	A nurse coming to your home to give you an HIV test	Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither convenient nor inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
D	Video chatting with your doctor	Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither convenient nor inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
E	Receiving reminders (e.g., text, email) about your scheduled injection appointment	Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither convenient nor inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
F	Scheduling your injection appointment online to go to your clinic/doctor's office for the injection	Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
			(XX.X%)	(XX.X%)	(XX.X%)
		Neither convenient nor inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
G	A nurse coming to your home to give you the injection	Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither convenient nor inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
H	Sending messages to your doctor online	Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither convenient nor inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
I	Reviewing your health documents, such as test results, online	Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither convenient nor inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
J	A nurse coming to your home to conduct your labs (e.g., STI tests)	Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither convenient nor inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very inconvenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
28	On average, how long did you wait to connect to a doctor for video chat?				
		Up to 5 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		6 to 10 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		11 to 15 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		16 to 30 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		More than 30 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
29	I would recommend telehealth services for APRETUDE to other people.				
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 7.302. Summary of Quality of Care for Patient Study Participants (Month 12/13), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
82	To what extent do you agree with each of the following statements regarding your experience with your clinic/provider?				
A	My provider explained medical words that were used so that I could understand them.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
B	My provider encouraged me to ask questions.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
C	My provider really respected me.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
D	My provider gave me enough time to say what I though was important.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
E	My provider listened carefully to what I had to say.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
			(XX.X%)	(XX.X%)	(XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
F	My provider explained why tests were being done.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
G	My provider made me feel comfortable talking about personal things.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
H	My privacy was respected.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
I	My provider does not judge me.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
J	The provider had a respectful attitude towards my sexual orientation.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
K	The staff at the clinic does not judge me.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
L	The staff at this clinic is kind and respectful to me.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
M	I sometimes felt insulted when the clinic staff spoke to me.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
N	I felt judged by the clinic staff for being on PrEP.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
O	I felt judged by my provider for being on PrEP.	Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 7.303. Summary of Quality of Care for Patient Study Participants (Month 12/13), N=XX, Non-Score Questions**

Question		Response			
82. To what extent do you agree with each of the following statements regarding your experience with your clinical/provider?		Completely Agree	Agree	Neither agree nor disagree	Disagree
<b>I. My provider does not judge me.</b>					
Study Arms					
	Total	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Dynamic Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Routine Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Dynamic Implementation					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Routine Implementation					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				

Question		Response			
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Total					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Dynamic Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Routine Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Total					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)

Question		Response			
	n (%)				
Gender, Total					
	Men who have sex with men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Transgender men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
<b>J. The provider had a respectful attitude towards my sexual orientation.</b>					
Study Arms					
	Total	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Dynamic Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Routine Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Dynamic Implementation					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Routine Implementation					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				



Question		Response			
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Total					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Dynamic Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Routine Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Total					
	Hispanic or Latino	XX	XX	XX	XX

Question		Response			
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Gender, Total					
	Men who have sex with men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Transgender men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
<b>K. The staff at the clinic does not judge me.</b>					
Study Arms					
	Total	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Dynamic Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Routine Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Dynamic Implementation					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Routine Implementation					

Question		Response			
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Total					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Dynamic Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Routine Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)

Question		Response			
	n (%)				
Ethnicity, Total					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Gender, Total					
	Men who have sex with men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Transgender men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
<b>L. The staff at this clinic is kind and respectful to me.</b>					
Study Arms					
	Total	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Dynamic Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Routine Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Dynamic Implementation					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX

Question		Response			
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Routine Implementation					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Total					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Dynamic Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Routine Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)

Question		Response			
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Total					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Gender, Total					
	Men who have sex with men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Transgender men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
<b>M. I sometimes felt insulted when the clinic staff spoke to me.</b>					
Study Arms					
	Total	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Dynamic Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Routine Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Dynamic Implementation					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX

Question		Response			
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Routine Implementation					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Total					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Dynamic Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				

Question		Response			
Ethnicity, Routine Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Total					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Gender, Total					
	Men who have sex with men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Transgender men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
N. I felt judged by the clinic staff for being on PrEP.					
Study Arms					
	Total	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Dynamic Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Routine Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Dynamic Implementation					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX



Question		Response			
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Routine Implementation					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Total					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Dynamic Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				

Question		Response			
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Routine Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Total					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Gender, Total					
	Men who have sex with men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Transgender men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
O. I felt judged by my provider for being on PrEP.					
Study Arms					
	Total	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Dynamic Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Routine Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Dynamic Implementation					
	Asian	XX	XX	XX	XX

Question		Response			
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Routine Implementation					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Total					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				

Question		Response			
Ethnicity, Dynamic Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Routine Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Total					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Gender, Total					
	Men who have sex with men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Transgender men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				

**Table 7.304. Summary of Quality of Care for Patient Study Participants (Month 12/13), N=XX, Score Questions**

Question		Response			
82. To what extent do you agree with each of the following statements regarding your experience with your clinic/provider?		Completely Agree	Agree	Disagree	Completely Disagree
<b>A. My provider explained medical words that were used so that I could understand them.</b>					
Study Arms					
	Total	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Dynamic Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Routine Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Dynamic Implementation					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Routine Implementation					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				

Question		Response			
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Total					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Dynamic Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Routine Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Total					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)

Question		Response			
	n (%)				
Gender, Total					
	Men who have sex with men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Transgender men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
<b>B. My provider encouraged me to ask questions.</b>					
Study Arms					
	Total	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Dynamic Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Routine Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Dynamic Implementation					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Routine Implementation					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				

Question		Response			
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Total					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Dynamic Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Routine Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Total					
	Hispanic or Latino	XX	XX	XX	XX



Question		Response			
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Gender, Total					
	Men who have sex with men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Transgender men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
C. My provider really respected me.					
Study Arms					
	Total	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Dynamic Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Routine Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Dynamic Implementation					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Routine Implementation					

Question		Response			
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Total					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Dynamic Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Routine Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)

Question		Response			
	n (%)				
Ethnicity, Total					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Gender, Total					
	Men who have sex with men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Transgender men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
D. My provider gave me enough time to say what I thought was important.					
Study Arms					
	Total	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Dynamic Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Routine Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Dynamic Implementation					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX

Question		Response			
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Routine Implementation					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Total					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Dynamic Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Routine Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)

Question		Response			
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Total					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Gender, Total					
	Men who have sex with men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Transgender men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
E. My provider listened carefully to what I had to say.					
Study Arms					
	Total	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Dynamic Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Routine Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Dynamic Implementation					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX

Question		Response			
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Routine Implementation					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Total					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Dynamic Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				

Question		Response			
Ethnicity, Routine Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Total					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Gender, Total					
	Men who have sex with men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Transgender men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
F. My provider explained why tests were being done.					
Study Arms					
	Total	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Dynamic Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Routine Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Dynamic Implementation					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				

Question		Response			
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Routine Implementation					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Total					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Dynamic Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				



Question		Response			
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Routine Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Total					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Gender, Total					
	Men who have sex with men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Transgender men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
<b>G. My provider made me feel comfortable talking about personal things.</b>					
Study Arms					
	Total	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Dynamic Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Routine Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Dynamic Implementation					
	Asian	XX	XX	XX	XX

Question		Response			
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Routine Implementation					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Total					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				

Question		Response			
Ethnicity, Dynamic Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Routine Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Total					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Gender, Total					
	Men who have sex with men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Transgender men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
H. My privacy was respected.					
Study Arms					
	Total	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Dynamic Implementation	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Routine Implementation	XX	XX	XX	XX

Question		Response			
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Dynamic Implementation					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Routine Implementation					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Race, Total					
	Asian	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Black or African American	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	White	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)

Question		Response			
	n (%)				
	Other	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Dynamic Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Routine Implementation					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Ethnicity, Total					
	Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Not Hispanic or Latino	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
Gender, Total					
	Men who have sex with men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				
	Transgender men	XX	XX	XX	XX
	(N = XX)	(XX.X%)	(XX.X%)	(XX.X%)	(XX.X%)
	n (%)				

**Table 7.305. Distributional Characteristics of Quality of Care for Patient Study Participants (Month 12/13), N=XX, Score Questions, Overall Score**

82. To what extent do you agree with each of the following statements regarding your experience with your clinic/provider?	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean	Cronbach's $\alpha$
<b>Mean Score</b>	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	0.xx
<b>Study Arm</b>								
Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
<b>Site Volume</b>								
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
<b>Gender</b>								
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
<b>Race</b>								
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
<b>Ethnicity</b>								
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
<b>Dynamic Implementation</b>								
<b>Site Volume</b>								
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	-

82. To what extent do you agree with each of the following statements regarding your experience with your clinic/provider?	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean	Cronbach's $\alpha$
<b>Gender</b>								
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
<b>Race</b>								
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
<b>Ethnicity</b>								
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
<b>Routine Implementation</b>								
<b>Site Volume</b>								
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
<b>Gender</b>								
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
<b>Race</b>								
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—

82. To what extent do you agree with each of the following statements regarding your experience with your clinic/provider?

	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean	Cronbach's $\alpha$
<b>Ethnicity</b>								
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)	—

Mean score = mean of responses of items A-H. Responses were scored on a scale of 1-4 with higher scores indicating higher quality of care.



Table 7.306. Summary of Utility of Proposed Implementation Strategies (Month 12/13), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
49	Have you used any of the following while taking APREUDE?				
A	Brochures and other print materials to educate you on APREUDE	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
B	Videos to educate you on HIV, PrEP, APREUDE materials (DI)	Yes	XX (XX.X%)	XX (XX.X%)	N/A
		No	XX (XX.X%)	XX (XX.X%)	N/A
		Don't know	XX (XX.X%)	XX (XX.X%)	N/A
C	A digital calendar specifically made for APREUDE to help you plan your injections – found on PillarSpot (DI)	Yes	XX (XX.X%)	XX (XX.X%)	N/A
		No	XX (XX.X%)	XX (XX.X%)	N/A
		Don't know	XX (XX.X%)	XX (XX.X%)	N/A
D	Reminders about your injections	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
E	Having video or telephone appointments with your doctor	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
F	Sending chats or texts to your doctor on the Pillar Spot (DI)	Yes	XX (XX.X%)	XX (XX.X%)	N/A
		No	XX (XX.X%)	XX (XX.X%)	N/A

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Don't know	XX (XX.X%)	XX (XX.X%)	N/A
G	Having a nurse come to your home to conduct your HIV tests (DI)	Yes	XX (XX.X%)	XX (XX.X%)	N/A
		No	XX (XX.X%)	XX (XX.X%)	N/A
		Don't know	XX (XX.X%)	XX (XX.X%)	N/A
H	Having a nurse come to your home to give your injection (DI)	Yes	XX (XX.X%)	XX (XX.X%)	N/A
		No	XX (XX.X%)	XX (XX.X%)	N/A
		Don't know	XX (XX.X%)	XX (XX.X%)	N/A
I	Receiving transportation to the clinic/doctor's office for your injection (DI)	Yes	XX (XX.X%)	XX (XX.X%)	N/A
		No	XX (XX.X%)	XX (XX.X%)	N/A
		Don't know	XX (XX.X%)	XX (XX.X%)	N/A
J	A website/app where you access APRETUDE information – the Pillar Spot (DI)	Yes	XX (XX.X%)	XX (XX.X%)	N/A
		No	XX (XX.X%)	XX (XX.X%)	N/A
		Don't know	XX (XX.X%)	XX (XX.X%)	N/A
K	The website where you access APRETUDE information (RI)	Yes	XX (XX.X%)	N/A	XX (XX.X%)
		No	XX (XX.X%)	N/A	XX (XX.X%)
		Don't know	XX (XX.X%)	N/A	XX (XX.X%)
50	How useful has each of these been in supporting you while taking APRETUDE?				
A	Brochures and other print materials to educate you on APRETUDE	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not very useful	XX	XX	XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
			(XX.X%)	(XX.X%)	(XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Extremely useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
B	Videos to educate you on HIV, PrEP, APREUDE (DI)	Not at all useful	XX (XX.X%)	XX (XX.X%)	N/A
		Not very useful	XX (XX.X%)	XX (XX.X%)	N/A
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	N/A
		Useful	XX (XX.X%)	XX (XX.X%)	N/A
		Extremely useful	XX (XX.X%)	XX (XX.X%)	N/A
C	A digital calendar specifically made for APREUDE to help you plan your injections – found on PillarSpot (DI)	Not at all useful	XX (XX.X%)	XX (XX.X%)	N/A
		Not very useful	XX (XX.X%)	XX (XX.X%)	N/A
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	N/A
		Useful	XX (XX.X%)	XX (XX.X%)	N/A
		Extremely useful	XX (XX.X%)	XX (XX.X%)	N/A
D	Reminders about your injections	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not very useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Extremely useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
E	Having video or telephone appointments with your doctor	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not very useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Extremely useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
F	Sending chats or texts to your doctor on the Pillar Spot (DI)	Not at all useful	XX (XX.X%)	XX (XX.X%)	N/A
		Not very useful	XX (XX.X%)	XX (XX.X%)	N/A
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	N/A
		Useful	XX (XX.X%)	XX (XX.X%)	N/A
		Extremely useful	XX (XX.X%)	XX (XX.X%)	N/A
G	Having a nurse come to your home to conduct your HIV tests (DI)	Not at all useful	XX (XX.X%)	XX (XX.X%)	N/A
		Not very useful	XX (XX.X%)	XX (XX.X%)	N/A
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	N/A
		Useful	XX (XX.X%)	XX (XX.X%)	N/A
		Extremely useful	XX (XX.X%)	XX (XX.X%)	N/A
H	Having a nurse come to your home to give your injection (DI)	Not at all useful	XX (XX.X%)	XX (XX.X%)	N/A
		Not very useful	XX (XX.X%)	XX (XX.X%)	N/A
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	N/A
		Useful	XX (XX.X%)	XX (XX.X%)	N/A

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Extremely useful	XX (XX.X%)	XX (XX.X%)	N/A
I	Receiving transportation to the clinic/doctor's office for your injection (DI)	Not at all useful	XX (XX.X%)	XX (XX.X%)	N/A
		Not very useful	XX (XX.X%)	XX (XX.X%)	N/A
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	N/A
		Useful	XX (XX.X%)	XX (XX.X%)	N/A
		Extremely useful	XX (XX.X%)	XX (XX.X%)	N/A
J	A website/app where you access APRETUDE information – the Pillar Spot (DI)	Not at all useful	XX (XX.X%)	XX (XX.X%)	N/A
		Not very useful	XX (XX.X%)	XX (XX.X%)	N/A
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	N/A
		Useful	XX (XX.X%)	XX (XX.X%)	N/A
		Extremely useful	XX (XX.X%)	XX (XX.X%)	N/A
K	The website where you access APRETUDE information (RI)	Not at all useful	XX (XX.X%)	N/A	XX (XX.X%)
		Not very useful	XX (XX.X%)	N/A	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	N/A	XX (XX.X%)
		Useful	XX (XX.X%)	N/A	XX (XX.X%)
		Extremely useful	XX (XX.X%)	N/A	XX (XX.X%)
51	Did your clinic or doctor offer the following for APRETUDE visits?				
A	Injections on specific days of the week	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't know	XX	XX	XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
			(XX.X%)	(XX.X%)	(XX.X%)
B	Ability to show up for your injection without an appointment	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
C	Appointments where you only get your injection and leave	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
D	Schedule out your injection appointments for 6 months or more	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
E	You and your doctor discussing the pros and cons (e.g., side effects, switching) of <u>different PrEP options</u> and <u>together</u> deciding which one is right for you	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
52	How useful has each of these been in supporting you while taking APREUDE?				
A	Injections on specific days of the week	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not very useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Extremely useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
B	Ability to show up for your injection without an appointment	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not very useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Extremely useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
C	Appointments where you only get your injection and leave	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not very useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Extremely useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
D	Schedule out your injection appointments for 6 months or more	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not very useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Extremely useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
E	You and your doctor discussing the pros and cons (e.g., side effects, switching) of <u>different PrEP options</u> and <u>together</u> deciding which one is right for you	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not very useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Extremely useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
85	I am happy I switched from oral PrEP to APRETUDE.				
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not use oral PrEP before receiving APRETUDE	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
84	I would recommend APRETUDE to other people who could benefit from it.				
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



**Table 7.307. Summary of Patient Study Participants' Preferences/Acceptability of APRETUDE Information, Appointment Reminders, and Locations (Month 12/13), N=XX**

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
61	If you have questions about APRETUDE, where do you find information?				
		I did not find answers to my questions	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Product website	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Written materials such as the study handbook	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Speaking to a healthcare provider	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Social Media	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Internet search	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Friends	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Family	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The study app/website	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have not had any questions so far	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
62	How did you receive reminders about your injection appointments?				
		Phone calls	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Texts/SMS	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Existing clinic app reminder	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		E-mails	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Reminder in the postal mail	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Face-to-face reminder from a healthcare provider	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Written reminder/appointment	XX	XX	XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		card with date and time	(XX.X%)	(XX.X%)	(XX.X%)
		The study app/website	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Another type of reminder (please specify) _____	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have not received any reminders	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
63	Which type(s) of appointment reminders are most helpful in keeping your appointment?				
		Phone calls	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Texts/SMS	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Existing clinic app reminder	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		E-mails	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Reminder in the postal mail	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Face-to-face reminder from a healthcare provider	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Written reminder/appointment card with date and time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The study app/website	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Another type of reminder (please specify) _____	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I do not think any of the reminders are helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
64	Have you received APREUDE injections at any locations other than your clinic in the past 12 months?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
65	Which of the following locations have you received APREUDE injections in the past 12 months?				
		Nurse coming to your home	XX	XX	XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
			(XX.X%)	(XX.X%)	(XX.X%)
		Infusion center	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Retail pharmacy clinic (e.g., Minute Clinic, CVS)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other pharmacy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Hospital outpatient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Community-based organization	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		STD/STI clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Department of Health clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		PrEP clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Community health center	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Mobile van	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify) _____	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
66	Where else would you consider receiving your injections?				
		Retail pharmacy clinic (e.g., Minute Clinic, CVS)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other pharmacy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Hospital outpatient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Infusion center	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Community-based organization	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		STD/STI clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Department of Health clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		PrEP clinic	XX	XX	XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
			(XX.X%)	(XX.X%)	(XX.X%)
		Community health center	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Mobile van	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Nurse coming to your home	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 7.308. Summary of Appointment Scheduling (Month 12/13), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX)	Routine Implementation (N = XX)
58	How easy or difficult is it to schedule appointments at the clinic/practice for your injections?				
		Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have not scheduled any appointments at the clinic/practice	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
59	How easy or difficult is it to reschedule appointments at the clinic/practice for your injections?				
		Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have not needed to reschedule any appointments	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
60	How did you <u>reschedule</u> your appointment?				
		I called the clinic/doctor's office	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I emailed the clinic/doctor's office	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I texted the clinic/doctor's office	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I scheduled the appointment online	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I sent a message on the online portal of the clinic/doctor's office	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX)	Routine Implementation (N = XX)
		I went to the clinic/doctor's office	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 7.401. Summary of Acceptability and Feasibility of APRETUDE Injection Visits (Month 12/13), N=XX, Study Arms**

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
36	On average, how long have you spent at the clinic/practice for your injection visit from arrival at the clinic to when you leave?				
		Up to 20 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		21-40 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		41-60 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		61-90 minutes (1hr-1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		More than 90 minutes (more than 1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have not gotten any of my injections at a clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
37	How acceptable is coming to the clinic every 2 months for an injection?				
		Very acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
38	How convenient are your clinic's hours? <i>By convenient, we mean fitting well with your life activities and plans, with little trouble.</i>				
		Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
39	How easy or difficult has it been to get to the clinic every 2 months for your injection?				

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
40	Approximately how long has it taken you to get to the clinic/practice from your home to receive your injection?				
		Up to 20 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		21-40 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		41-60 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		61-90 minutes (1hr-1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		More than 90 minutes (more than 1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
41	How did you get to the clinic/practice for your injections?				
		Taxi/transportation service	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Ride-share service (e.g., Uber, Lyft)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Dropped off by someone else	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Drove a private vehicle	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Public transportation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Bicycle/scooter/skateboard/walking	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Transportation provided by clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
43	How convenient is the transportation provided by your clinic/practice for your injection visit every 2 months? <i>By convenient, we mean fitting in well with your life activities and plans, with little trouble.</i>				
		Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
44	Please provide your opinion of the transportation provided by the clinic				
	The transportation helped me keep my appointments.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The transportation service was easy to use.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
45	Have you needed to seek additional childcare/eldercare/other care to come to the clinic/practice for your injection visits?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I am not caring for others right now (N/A)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
46	Have you taken any time off from work to receive injections?				
		Yes	XX	XX	XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
			(XX.X%)	(XX.X%)	(XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I am not working right now	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
47	How much time did you take off work to receive your injections?				
		I needed to take a whole day off work for each injection	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I needed to take a whole day off work for some injections	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I needed to take a partial day off work for each injection	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I needed to take a partial day off work for some injections	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
48	Was your time off work for injections generally paid or unpaid?				
		Paid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Unpaid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 7.402. Summary of Acceptability and Feasibility of APRETUDE Injection Visits (Month 6/7), N=XX, Race, Dynamic Implementation**

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
36	On average, how long have you spent at the clinic/practice for your injection visit from arrival at the clinic to when you leave?					
		Up to 20 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		21-40 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		41-60 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		61-90 minutes (1hr-1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		More than 90 minutes (more than 1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have not gotten any of my injections at a clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
37	How acceptable is coming to the clinic every 2 months for an injection?					
		Very acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
38	How convenient are your clinic's hours? <i>By convenient, we mean fitting well with your life activities and plans, with little trouble.</i>					
		Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
39	How easy or difficult has it been to get to the clinic every 2 months for your injection?					
		Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
		Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
40	Approximately how long has it taken you to get to the clinic/practice from your home to receive your injection?					
		Up to 20 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		21-40 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		41-60 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		61-90 minutes (1hr-1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		More than 90 minutes (more than 1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
41	How did you get to the clinic/practice for your injections?					
		Taxi/transportation service	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Ride-share service (e.g., Uber, Lyft)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Dropped off by someone else	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Drove a private vehicle	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Public transportation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Bicycle/scooter/skateboard/walking	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Transportation provided by clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
43	How convenient is the transportation provided by your clinic/practice for your injection visit every 2 months? <i>By convenient, we mean fitting in well with your life activities and plans, with little trouble.</i>					
		Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
44	Please provide your opinion of the transportation provided by the clinic					
	The transportation helped me keep my appointments.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The transportation service was easy to use.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
45	Have you needed to seek additional childcare/eldercare/other care to come to the clinic/practice for your injection visits?					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I am not caring for others right now (N/A)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
46	Have you taken any time off from work to receive injections?					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I am not working right now	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
47	How much time did you take off work to receive your injections?					
		I needed to take a whole day off work for each injection	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I needed to take a whole day off work for some injections	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I needed to take a partial day off work for each injection	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I needed to take a partial day off work for some injections	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
48	Was your time off work for injections generally paid or unpaid?					
		Paid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Unpaid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 7.403. Summary of Acceptability and Feasibility of APRETUDE Injection Visits (Month 6/7), N=XX, Race, Routine Implementation**

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
36	On average, how long have you spent at the clinic/practice for your injection visit from arrival at the clinic to when you leave?					
		Up to 20 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		21-40 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		41-60 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		61-90 minutes (1hr-1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		More than 90 minutes (more than 1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have not gotten any of my injections at a clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
37	How acceptable is coming to the clinic every 2 months for an injection?					
		Very acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
38	How convenient are your clinic's hours? <i>By convenient, we mean fitting well with your life activities and plans, with little trouble.</i>					
		Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
39	How easy or difficult has it been to get to the clinic every 2 months for your injection?					
		Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
		Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
40	Approximately how long has it taken you to get to the clinic/practice from your home to receive your injection?					
		Up to 20 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		21-40 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		41-60 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		61-90 minutes (1hr-1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		More than 90 minutes (more than 1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
41	How did you get to the clinic/practice for your injections?					
		Taxi/transportation service	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Ride-share service (e.g., Uber, Lyft)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Dropped off by someone else	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Drove a private vehicle	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Public transportation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Bicycle/scooter/skateboard/walking	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Transportation provided by clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
43	How convenient is the transportation provided by your clinic/practice for your injection visit every 2 months? <i>By convenient, we mean fitting in well with your life activities and plans, with little trouble.</i>					
		Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
44	Please provide your opinion of the transportation provided by the clinic					
	The transportation helped me keep my appointments.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The transportation service was easy to use.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
45	Have you needed to seek additional childcare/eldercare/other care to come to the clinic/practice for your injection visits?					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I am not caring for others right now (N/A)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
46	Have you taken any time off from work to receive injections?					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I am not working right now	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
47	How much time did you take off work to receive your injections?					
		I needed to take a whole day off work for each injection	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I needed to take a whole day off work for some injections	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I needed to take a partial day off work for each injection	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I needed to take a partial day off work for some injections	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
48	Was your time off work for injections generally paid or unpaid?					
		Paid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Unpaid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 7.404. Summary of Acceptability and Feasibility of APRETUDE Injection Visits (Month 6/7), N=XX, Race, Total**

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
36	On average, how long have you spent at the clinic/practice for your injection visit from arrival at the clinic to when you leave?					
		Up to 20 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		21-40 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		41-60 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		61-90 minutes (1hr-1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		More than 90 minutes (more than 1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have not gotten any of my injections at a clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
37	How acceptable is coming to the clinic every 2 months for an injection?					
		Very acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
38	How convenient are your clinic's hours? <i>By convenient, we mean fitting well with your life activities and plans, with little trouble.</i>					
		Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
39	How easy or difficult has it been to get to the clinic every 2 months for your injection?					
		Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
		Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
40	Approximately how long has it taken you to get to the clinic/practice from your home to receive your injection?					
		Up to 20 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		21-40 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		41-60 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		61-90 minutes (1hr-1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		More than 90 minutes (more than 1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
41	How did you get to the clinic/practice for your injections?					
		Taxi/transportation service	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Ride-share service (e.g., Uber, Lyft)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Dropped off by someone else	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Drove a private vehicle	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Public transportation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Bicycle/scooter/skateboard/walking	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Transportation provided by clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
43	How convenient is the transportation provided by your clinic/practice for your injection visit every 2 months? <i>By convenient, we mean fitting in well with your life activities and plans, with little trouble.</i>					
		Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
44	Please provide your opinion of the transportation provided by the clinic					
	The transportation helped me keep my appointments.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The transportation service was easy to use.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
45	Have you needed to seek additional childcare/eldercare/other care to come to the clinic/practice for your injection visits?					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I am not caring for others right now (N/A)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
46	Have you taken any time off from work to receive injections?					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I am not working right now	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
47	How much time did you take off work to receive your injections?					
		I needed to take a whole day off work for each injection	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I needed to take a whole day off work for some injections	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I needed to take a partial day off work for each injection	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I needed to take a partial day off work for some injections	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
48	Was your time off work for injections generally paid or unpaid?					
		Paid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Unpaid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 7.405. Summary of Acceptability and Feasibility of APRETUDE Injection Visits (Month 6/7), N=XX, Ethnicity, Study Arms**

Question Number	Question	Response	Dynamic Implementation		Routine Implementation	
			Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
36	On average, how long have you spent at the clinic/practice for your injection visit from arrival at the clinic to when you leave?					
		Up to 20 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		21-40 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		41-60 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		61-90 minutes (1hr-1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		More than 90 minutes (more than 1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have not gotten any of my injections at a clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
37	How acceptable is coming to the clinic every 2 months for an injection?					
		Very acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
38	How convenient are your clinic’s hours? <i>By convenient, we mean fitting well with your life activities and plans, with little trouble.</i>					
		Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
39	How easy or difficult has it been to get to the clinic every 2 months for your injection?					

Question Number	Question	Response	Dynamic Implementation		Routine Implementation	
			Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
		Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
40	Approximately how long has it taken you to get to the clinic/practice from your home to receive your injection?					
		Up to 20 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		21-40 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		41-60 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		61-90 minutes (1hr-1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		More than 90 minutes (more than 1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
41	How did you get to the clinic/practice for your injections?					
		Taxi/transportation service	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Ride-share service (e.g., Uber, Lyft)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Dropped off by someone else	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Drove a private vehicle	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Public transportation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Bicycle/scooter/skateboard/walking	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Transportation provided by clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
43	How convenient is the transportation provided by your clinic/practice for your injection visit every 2 months? <i>By convenient, we mean fitting in well with your life activities and plans, with little trouble.</i>					



Question Number	Question	Response	Dynamic Implementation		Routine Implementation	
			Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
		Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
44	Please provide your opinion of the transportation provided by the clinic					
	The transportation helped me keep my appointments.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The transportation service was easy to use.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
45	Have you needed to seek additional childcare/eldercare/other care to come to the clinic/practice for your injection visits?					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Dynamic Implementation		Routine Implementation	
			Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
		I am not caring for others right now (N/A)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
46	Have you taken any time off from work to receive injections?					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I am not working right now	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
47	How much time did you take off work to receive your injections?					
		I needed to take a whole day off work for each injection	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I needed to take a whole day off work for some injections	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I needed to take a partial day off work for each injection	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I needed to take a partial day off work for some injections	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
48	Was your time off work for injections generally paid or unpaid?					
		Paid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Unpaid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 7.406. Summary of Acceptability and Feasibility of APRETUDE Injection Visits (Month 6/7), N=XX, Ethnicity, Total**

Question Number	Question	Response	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
36	On average, how long have you spent at the clinic/practice for your injection visit from arrival at the clinic to when you leave?			
		Up to 20 minutes	XX (XX.X%)	XX (XX.X%)
		21-40 minutes	XX (XX.X%)	XX (XX.X%)
		41-60 minutes	XX (XX.X%)	XX (XX.X%)
		61-90 minutes (1hr-1.5hrs)	XX (XX.X%)	XX (XX.X%)
		More than 90 minutes (more than 1.5hrs)	XX (XX.X%)	XX (XX.X%)
		I have not gotten any of my injections at a clinic	XX (XX.X%)	XX (XX.X%)
37	How acceptable is coming to the clinic every 2 months for an injection?			
		Very acceptable	XX (XX.X%)	XX (XX.X%)
		Acceptable	XX (XX.X%)	XX (XX.X%)
		Somewhat acceptable	XX (XX.X%)	XX (XX.X%)
		A little acceptable	XX (XX.X%)	XX (XX.X%)
		Not at all acceptable	XX (XX.X%)	XX (XX.X%)
38	How convenient are your clinic's hours? <i>By convenient, we mean fitting well with your life activities and plans, with little trouble.</i>			
		Very convenient	XX (XX.X%)	XX (XX.X%)
		Convenient	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)
		A little convenient	XX (XX.X%)	XX (XX.X%)
		Not at all convenient	XX (XX.X%)	XX (XX.X%)
39	How easy or difficult has it been to get to the clinic every 2 months for your injection?			
		Very easy	XX (XX.X%)	XX (XX.X%)
		Easy	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)
		Difficult	XX (XX.X%)	XX (XX.X%)
		Very difficult	XX (XX.X%)	XX (XX.X%)
40	Approximately how long has it taken you to get to the clinic/practice from your home to receive your injection?			
		Up to 20 minutes	XX (XX.X%)	XX (XX.X%)
		21-40 minutes	XX (XX.X%)	XX (XX.X%)
		41-60 minutes	XX (XX.X%)	XX (XX.X%)
		61-90 minutes (1hr-1.5hrs)	XX (XX.X%)	XX (XX.X%)
		More than 90 minutes (more than 1.5hrs)	XX (XX.X%)	XX (XX.X%)
41	How did you get to the clinic/practice for your injections?			
		Taxi/transportation service	XX (XX.X%)	XX (XX.X%)
		Ride-share service (e.g., Uber, Lyft)	XX (XX.X%)	XX (XX.X%)
		Dropped off by someone else	XX (XX.X%)	XX (XX.X%)
		Drove a private vehicle	XX (XX.X%)	XX (XX.X%)
		Public transportation	XX (XX.X%)	XX (XX.X%)
		Bicycle/scooter/skateboard/walking	XX (XX.X%)	XX (XX.X%)
		Transportation provided by clinic	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)
43	How convenient is the transportation provided by your clinic/practice for your injection visit every 2 months? <i>By convenient, we mean fitting in well with your life activities and plans, with little trouble.</i>			
		Very convenient	XX (XX.X%)	XX (XX.X%)
		Convenient	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
		A little convenient	XX (XX.X%)	XX (XX.X%)
		Not at all convenient	XX (XX.X%)	XX (XX.X%)
44	Please provide your opinion of the transportation provided by the clinic			
	The transportation helped me keep my appointments.	Completely disagree	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)
	The transportation service was easy to use.	Completely disagree	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)
45	Have you needed to seek additional childcare/eldercare/other care to come to the clinic/practice for your injection visits?			
		Yes	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)
		I am not caring for others right now (N/A)	XX (XX.X%)	XX (XX.X%)
46	Have you taken any time off from work to receive injections?			
		Yes	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)
		I am not working right now	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
47	How much time did you take off work to receive your injections?			
		I needed to take a whole day off work for each injection	XX (XX.X%)	XX (XX.X%)
		I needed to take a whole day off work for some injections	XX (XX.X%)	XX (XX.X%)
		I needed to take a partial day off work for each injection	XX (XX.X%)	XX (XX.X%)
		I needed to take a partial day off work for some injections	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)
48	Was your time off work for injections generally paid or unpaid?			
		Paid	XX (XX.X%)	XX (XX.X%)
		Unpaid	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)

**Table 7.407. Summary of Acceptability and Feasibility of APRETUDE Injection Visits (Month 6/7), N=XX, Gender, Total**

Question Number	Question	Response	Dynamic Implementation		Routine Implementation	
			Men who have sex with men (N = XX) n (%)	Transgender Men (N = XX) n (%)	Men who have sex with men (N = XX) n (%)	Transgender Men (N = XX) n (%)
36	On average, how long have you spent at the clinic/practice for your injection visit from arrival at the clinic to when you leave?					
		Up to 20 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		21-40 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		41-60 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		61-90 minutes (1hr-1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		More than 90 minutes (more than 1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have not gotten any of my injections at a clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
37	How acceptable is coming to the clinic every 2 months for an injection?					
		Very acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
38	How convenient are your clinic’s hours? <i>By convenient, we mean fitting well with your life activities and plans, with little trouble.</i>					
		Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
39	How easy or difficult has it been to get to the clinic every 2 months for your injection?					

Question Number	Question	Response	Dynamic Implementation		Routine Implementation	
			Men who have sex with men (N = XX) n (%)	Transgender Men (N = XX) n (%)	Men who have sex with men (N = XX) n (%)	Transgender Men (N = XX) n (%)
		Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
40	Approximately how long has it taken you to get to the clinic/practice from your home to receive your injection?					
		Up to 20 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		21-40 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		41-60 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		61-90 minutes (1hr-1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		More than 90 minutes (more than 1.5hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
41	How did you get to the clinic/practice for your injections?					
		Taxi/transportation service	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Ride-share service (e.g., Uber, Lyft)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Dropped off by someone else	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Drove a private vehicle	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Public transportation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Bicycle/scooter/skateboard/walking	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Transportation provided by clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify _____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
43	How convenient is the transportation provided by your clinic/practice for your injection visit every 2 months? <i>By convenient, we mean fitting in well with your life activities and plans, with little trouble.</i>					



Question Number	Question	Response	Dynamic Implementation		Routine Implementation	
			Men who have sex with men (N = XX) n (%)	Transgender Men (N = XX) n (%)	Men who have sex with men (N = XX) n (%)	Transgender Men (N = XX) n (%)
		Very convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all convenient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
44	Please provide your opinion of the transportation provided by the clinic					
	The transportation helped me keep my appointments.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The transportation service was easy to use.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
45	Have you needed to seek additional childcare/eldercare/other care to come to the clinic/practice for your injection visits?					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Dynamic Implementation		Routine Implementation	
			Men who have sex with men (N = XX) n (%)	Transgender Men (N = XX) n (%)	Men who have sex with men (N = XX) n (%)	Transgender Men (N = XX) n (%)
		I am not caring for others right now (N/A)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
46	Have you taken any time off from work to receive injections?					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I am not working right now	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
47	How much time did you take off work to receive your injections?					
		I needed to take a whole day off work for each injection	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I needed to take a whole day off work for some injections	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I needed to take a partial day off work for each injection	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I needed to take a partial day off work for some injections	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
48	Was your time off work for injections generally paid or unpaid?					
		Paid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Unpaid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 7.408. Summary of Reach and Perceptions of Sexual Health Assessment Tool (Month 12/13), N=XX, Study Arms**

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
30	Did you complete a Sexual Health Assessment from your provider or clinic/practice in the last 6 months?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
31	Did your provider or another person at the clinic/practice discuss the results of the assessment with you?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't remember	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
32	Who discussed the results of the assessment with you?				
		My healthcare provider/doctor	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A social worker	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A peer educator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
33	How helpful was discussing the results with your provider or another person at the clinic/practice?				
		Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
34	Please rate your experience with the Sexual Health Assessment				

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
	It was easy to take the Sexual Health Assessment on my digital device.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I like that my doctor sent the assessment before my appointment.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I was concerned about the privacy of my answers.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I like that my doctor was assessing my sexual health	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The assessment asked the right questions to help my doctor and me determine whether PrEP was right for me.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The assessment made me feel uncomfortable.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
35	Why did you not complete the assessment?				
		I did not receive a Sexual Health Assessment from my provider or clinic/practice	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I forgot	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not know how to complete it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The link my doctor sent did not work	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I didn't have the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The assessment took too long to complete	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		The assessment included too many personal questions	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The assessment made me feel uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I was concerned about the privacy of my answers	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not want to share sexual health information with my doctor or clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not understand why my doctor or clinic was asking me to complete the assessment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 7.409. Summary of Reach and Perceptions of Sexual Health Assessment Tool (Month 12/13), N=XX, Race, Dynamic Implementation**

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
30	Did you complete a Sexual Health Assessment from your provider or clinic/practice in the last 6 months?					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
31	Did your provider or another person at the clinic/practice discuss the results of the assessment with you?					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't remember	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
32	Who discussed the results of the assessment with you?					
		My healthcare provider/doctor	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A social worker	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A peer educator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
33	How helpful was discussing the results with your provider or another person at the clinic/practice?					
		Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
34	Please rate your experience with the Sexual Health Assessment					

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
	It was easy to take the Sexual Health Assessment on my digital device.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I like that my doctor sent the assessment before my appointment.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I was concerned about the privacy of my answers.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I like that my doctor was assessing my sexual health	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The assessment asked the right questions to help my doctor and me determine whether PrEP was right for me.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The assessment made me feel uncomfortable.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
35	Why did you not complete the assessment?					
		I did not receive a Sexual Health Assessment from my provider or clinic/practice	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I forgot	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not know how to complete it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
		The link my doctor sent did not work	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I didn't have the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The assessment took too long to complete	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The assessment included too many personal questions	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The assessment made me feel uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I was concerned about the privacy of my answers	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not want to share sexual health information with my doctor or clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not understand why my doctor or clinic was asking me to complete the assessment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 7.410. Summary of Reach and Perceptions of Sexual Health Assessment Tool (Month 12/13), N=XX, Race, Routine Implementation**

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
30	Did you complete a Sexual Health Assessment from your provider or clinic/practice in the last 6 months?					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
31	Did your provider or another person at the clinic/practice discuss the results of the assessment with you?					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't remember	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
32	Who discussed the results of the assessment with you?					
		My healthcare provider/doctor	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A social worker	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A peer educator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
33	How helpful was discussing the results with your provider or another person at the clinic/practice?					
		Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
34	Please rate your experience with the Sexual Health Assessment					

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
	It was easy to take the Sexual Health Assessment on my digital device.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I like that my doctor sent the assessment before my appointment.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I was concerned about the privacy of my answers.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I like that my doctor was assessing my sexual health	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The assessment asked the right questions to help my doctor and me determine whether PrEP was right for me.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The assessment made me feel uncomfortable.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
35	Why did you not complete the assessment?					
		I did not receive a Sexual Health Assessment from my provider or clinic/practice	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I forgot	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not know how to complete it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
		The link my doctor sent did not work	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I didn't have the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The assessment took too long to complete	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The assessment included too many personal questions	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The assessment made me feel uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I was concerned about the privacy of my answers	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not want to share sexual health information with my doctor or clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not understand why my doctor or clinic was asking me to complete the assessment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 7.411. Summary of Reach and Perceptions of Sexual Health Assessment Tool (Month 12/13), N=XX, Race, Total**

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
30	Did you complete a Sexual Health Assessment from your provider or clinic/practice in the last 6 months?					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
31	Did your provider or another person at the clinic/practice discuss the results of the assessment with you?					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't remember	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
32	Who discussed the results of the assessment with you?					
		My healthcare provider/doctor	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A social worker	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A peer educator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
33	How helpful was discussing the results with your provider or another person at the clinic/practice?					
		Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
34	Please rate your experience with the Sexual Health Assessment					

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
	It was easy to take the Sexual Health Assessment on my digital device.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I like that my doctor sent the assessment before my appointment.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I was concerned about the privacy of my answers.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I like that my doctor was assessing my sexual health	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The assessment asked the right questions to help my doctor and me determine whether PrEP was right for me.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The assessment made me feel uncomfortable.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
35	Why did you not complete the assessment?					
		I did not receive a Sexual Health Assessment from my provider or clinic/practice	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I forgot	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not know how to complete it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Asian (N = XX) n (%)	Black or African American (N = XX) n (%)	White (N = XX) n (%)	Other (N = XX) n (%)
		The link my doctor sent did not work	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I didn't have the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The assessment took too long to complete	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The assessment included too many personal questions	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The assessment made me feel uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I was concerned about the privacy of my answers	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not want to share sexual health information with my doctor or clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not understand why my doctor or clinic was asking me to complete the assessment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 7.412. Summary of Reach and Perceptions of Sexual Health Assessment Tool (Month 12/13), N=XX, Ethnicity, Study Arms**

Question Number	Question	Response	Dynamic Implementation		Routine Implementation	
			Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
30	Did you complete a Sexual Health Assessment from your provider or clinic/practice in the last 6 months?					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
31	Did your provider or another person at the clinic/practice discuss the results of the assessment with you?					
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't remember	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
32	Who discussed the results of the assessment with you?					
		My healthcare provider/doctor	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A social worker	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A peer educator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
33	How helpful was discussing the results with your provider or another person at the clinic/practice?					
		Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all helpful	XX (XX.X%)	XX	XX	XX

Question Number	Question	Response	Dynamic Implementation		Routine Implementation	
			Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
				(XX.X%)	(XX.X%)	(XX.X%)
34	Please rate your experience with the Sexual Health Assessment					
	It was easy to take the Sexual Health Assessment on my digital device.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I like that my doctor sent the assessment before my appointment.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I was concerned about the privacy of my answers.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I like that my doctor was assessing my sexual health.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Dynamic Implementation		Routine Implementation	
			Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The assessment asked the right questions to help my doctor and me determine whether PrEP was right for me.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The assessment made me feel uncomfortable.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
35	Why did you not complete the assessment?					
		I did not receive a Sexual Health Assessment from my provider or clinic/practice	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Dynamic Implementation		Routine Implementation	
			Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
		I forgot	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not know how to complete it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The link my doctor sent did not work	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I didn't have the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The assessment took too long to complete	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The assessment included too many personal questions	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The assessment made me feel uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I was concerned about the privacy of my answers	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not want to share sexual health information with my doctor or clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not understand why my doctor or clinic was asking me to complete the assessment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 7.413. Summary of Reach and Perceptions of Sexual Health Assessment Tool (Month 12/13), N=XX, Ethnicity, Total**

Question Number	Question	Response	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
30	Did you complete a Sexual Health Assessment from your provider or clinic/practice in the last 6 months?			
		Yes	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)
31	Did your provider or another person at the clinic/practice discuss the results of the assessment with you?			
		Yes	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)
		I don't remember	XX (XX.X%)	XX (XX.X%)
32	Who discussed the results of the assessment with you?			
		My healthcare provider/doctor	XX (XX.X%)	XX (XX.X%)
		A nurse	XX (XX.X%)	XX (XX.X%)
		A social worker	XX (XX.X%)	XX (XX.X%)
		A peer educator	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)
33	How helpful was discussing the results with your provider or another person at the clinic/practice?			
		Very helpful	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)
		Not at all helpful	XX (XX.X%)	XX (XX.X%)
34	Please rate your experience with the Sexual Health Assessment			

Question Number	Question	Response	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
	It was easy to take the Sexual Health Assessment on my digital device.	Completely disagree	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)
	I like that my doctor sent the assessment before my appointment.	Completely disagree	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)
	I was concerned about the privacy of my answers.	Completely disagree	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)
	I like that my doctor was assessing my sexual health.	Completely disagree	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)



Question Number	Question	Response	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
			(XX.X%)	(XX.X%)
	The assessment asked the right questions to help my doctor and me determine whether PrEP was right for me.	Completely disagree	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)
	The assessment made me feel uncomfortable.	Completely disagree	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)
35	Why did you not complete the assessment?			
		I did not receive a Sexual Health Assessment from my provider or clinic/practice	XX (XX.X%)	XX (XX.X%)
		I forgot	XX (XX.X%)	XX (XX.X%)
		I did not know how to complete it	XX (XX.X%)	XX (XX.X%)
		The link my doctor sent did not work	XX (XX.X%)	XX (XX.X%)
		I didn't have the time	XX (XX.X%)	XX (XX.X%)
		The assessment took too long to complete	XX (XX.X%)	XX (XX.X%)
		The assessment included too many personal questions	XX (XX.X%)	XX (XX.X%)
		The assessment made me feel uncomfortable	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Hispanic or Latino (N = XX) n (%)	Not Hispanic or Latino (N = XX) n (%)
		I was concerned about the privacy of my answers	XX (XX.X%)	XX (XX.X%)
		I did not want to share sexual health information with my doctor or clinic	XX (XX.X%)	XX (XX.X%)
		I did not understand why my doctor or clinic was asking me to complete the assessment	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)

**Table 7.414. Summary of Reach and Perceptions of Sexual Health Assessment Tool (Month 12/13), N=XX, Gender**

Question Number	Question	Response	Men who have sex with men (N = XX) n (%)	Transgender men (N = XX) n (%)
30	Did you complete a Sexual Health Assessment from your provider or clinic/practice in the last 6 months?			
		Yes	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)
31	Did your provider or another person at the clinic/practice discuss the results of the assessment with you?			
		Yes	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)
		I don't remember	XX (XX.X%)	XX (XX.X%)
32	Who discussed the results of the assessment with you?			
		My healthcare provider/doctor	XX (XX.X%)	XX (XX.X%)
		A nurse	XX (XX.X%)	XX (XX.X%)
		A social worker	XX (XX.X%)	XX (XX.X%)
		A peer educator	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)
33	How helpful was discussing the results with your provider or another person at the clinic/practice?			
		Very helpful	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)
		Not at all helpful	XX (XX.X%)	XX (XX.X%)
34	Please rate your experience with the Sexual Health Assessment			

Question Number	Question	Response	Men who have sex with men (N = XX) n (%)	Transgender men (N = XX) n (%)
	It was easy to take the Sexual Health Assessment on my digital device.	Completely disagree	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)
	I like that my doctor sent the assessment before my appointment.	Completely disagree	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)
	I was concerned about the privacy of my answers.	Completely disagree	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)
	I like that my doctor was assessing my sexual health.	Completely disagree	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Men who have sex with men (N = XX) n (%)	Transgender men (N = XX) n (%)
			(XX.X%)	(XX.X%)
	The assessment asked the right questions to help my doctor and me determine whether PrEP was right for me.	Completely disagree	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)
	The assessment made me feel uncomfortable.	Completely disagree	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)
35	Why did you not complete the assessment?			
		I did not receive a Sexual Health Assessment from my provider or clinic/practice	XX (XX.X%)	XX (XX.X%)
		I forgot	XX (XX.X%)	XX (XX.X%)
		I did not know how to complete it	XX (XX.X%)	XX (XX.X%)
		The link my doctor sent did not work	XX (XX.X%)	XX (XX.X%)
		I didn't have the time	XX (XX.X%)	XX (XX.X%)
		The assessment took too long to complete	XX (XX.X%)	XX (XX.X%)
		The assessment included too many personal questions	XX (XX.X%)	XX (XX.X%)
		The assessment made me feel uncomfortable	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Men who have sex with men (N = XX) n (%)	Transgender men (N = XX) n (%)
		I was concerned about the privacy of my answers	XX (XX.X%)	XX (XX.X%)
		I did not want to share sexual health information with my doctor or clinic	XX (XX.X%)	XX (XX.X%)
		I did not understand why my doctor or clinic was asking me to complete the assessment	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)

**Table 7.415. Summary of Reach and Perceptions of Sexual Health Assessment Tool (Month 12/13), N=XX, Site Volume**

Question Number	Question	Response	Total (N = XX) n (%)	High Volume (N = XX) n (%)	Low Volume (N = XX) n (%)
30	Did you complete a Sexual Health Assessment from your provider or clinic/practice in the last 6 months?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
31	Did your provider or another person at the clinic/practice discuss the results of the assessment with you?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't remember	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
32	Who discussed the results of the assessment with you?				
		My healthcare provider/doctor	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A social worker	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A peer educator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
33	How helpful was discussing the results with your provider or another person at the clinic/practice?				
		Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
34	Please rate your experience with the Sexual Health Assessment				

Question Number	Question	Response	Total (N = XX) n (%)	High Volume (N = XX) n (%)	Low Volume (N = XX) n (%)
	It was easy to take the Sexual Health Assessment on my digital device.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I like that my doctor sent the assessment before my appointment.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I was concerned about the privacy of my answers.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I like that my doctor was assessing my sexual health.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



Question Number	Question	Response	Total (N = XX) n (%)	High Volume (N = XX) n (%)	Low Volume (N = XX) n (%)
			(XX.X%)	(XX.X%)	(XX.X%)
	The assessment asked the right questions to help my doctor and me determine whether PrEP was right for me.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The assessment made me feel uncomfortable.	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
35	Why did you not complete the assessment?				
		I did not receive a Sexual Health Assessment from my provider or clinic/practice	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I forgot	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not know how to complete it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The link my doctor sent did not work	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I didn't have the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The assessment took too long to complete	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The assessment included too many personal questions	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	High Volume (N = XX) n (%)	Low Volume (N = XX) n (%)
		The assessment made me feel uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I was concerned about the privacy of my answers	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not want to share sexual health information with my doctor or clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I did not understand why my doctor or clinic was asking me to complete the assessment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other (please specify ____)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 7.416. Proportion of PSP Taking the Sexual Health Assessment through Month 13

Proportion Taking the Sexual Health Assessment through Month 13	N=XX n	%
<b>Study Arm</b>		
Dynamic Implementation	XX	X.XX%
Routine Implementation	XX	X.XX%
<b>Site Volume</b>		
High	XX	X.XX%
Low	XX	X.XX%
<b>Gender</b>		
Men who have sex with men	XX	X.XX
Transgender Men	XX	X.XX%
<b>Race</b>		
Asian	XX	X.XX%
Black or African American	XX	X.XX%
White	XX	X.XX%
Other	XX	X.XX%
<b>Ethnicity</b>		
Hispanic or Latino	XX	X.XX%
Not Hispanic or Latino	XX	X.XX%
<b>Setting of administration</b>		
Face-to-face	XX	X.XX%
Telehealth	XX	X.XX%
<b>Dynamic Implementation</b>		
<b>Race</b>		
Asian	XX	X.XX%
Black or African American	XX	X.XX%
White	XX	X.XX%
Other	XX	X.XX%
<b>Ethnicity</b>		
Hispanic or Latino	XX	X.XX%
Not Hispanic or Latino	XX	X.XX%
<b>Routine Implementation</b>		
<b>Race</b>		
Asian	XX	X.XX%
Black or African American	XX	X.XX%
White	XX	X.XX%
Other	XX	X.XX%
<b>Ethnicity</b>		
Hispanic or Latino	XX	X.XX%
Not Hispanic or Latino	XX	X.XX%

**Table 7.417. Distributional Characteristics of Estimated Amount of Money Spent on Transportation for Each Injection Visit (Month 12/13), N=XX**

42. On average, how much did transportation cost round trip for each injection visit?	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
<b>Mean Score</b>	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Study Arm</b>							
Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Gender</b>							
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Race</b>							
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Ethnicity</b>							
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Dynamic Implementation</b>							
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Gender</b>							
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)

42. On average, how much did transportation cost round trip for each injection visit?	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Race</b>							
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Ethnicity</b>							
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Routine Implementation</b>							
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Gender</b>							
Men who have sex with men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Transgender Men	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Race</b>							
Asian	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Black or African American	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
White	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
<b>Ethnicity</b>							
Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
Not Hispanic or Latino	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)

**Table 7.501. Test for Differences of Implementation Arm by Site Volume on Feasibility of Intervention Measure, APRETUDE (Month 12/13), N=XX**

Source	DF	MS	F	p
Study Arm (DI vs. RI)	X.XX	X.XXX	XX	0.XXXX
Volume (High vs. Low)	X.XX	X.XXX	XX	0.XXXX
Interaction, Arm by Volume	X.XX	X.XXX	XX	0.XXXX
Error	X.XX	X.XXX	-	-

**Table 7.502. Test for Differences of Implementation Arm by Site Volume on Feasibility of Intervention Measure, Telehealth (Month 12/13), N=XX**

Source	DF	MS	F	p
Study Arm (DI vs. RI)	X.XX	X.XXX	XX	0.XXXX
Volume (High vs. Low)	X.XX	X.XXX	XX	0.XXXX
Interaction, Arm by Volume	X.XX	X.XXX	XX	0.XXXX
Error	X.XX	X.XXX	-	-

**Table 7.503. Test for Differences of Implementation Arm by Site Volume on Acceptability of Intervention Measure, APRETUDE (Month 12/13), N=XX**

Source	DF	MS	F	p
Study Arm (DI vs. RI)	X.XX	X.XXX	XX	0.XXXX
Volume (High vs. Low)	X.XX	X.XXX	XX	0.XXXX
Interaction, Arm by Volume	X.XX	X.XXX	XX	0.XXXX
Error	X.XX	X.XXX	-	-

**Table 7.504. Test for Differences of Implementation Arm by Site Volume on Acceptability of Intervention Measure, Telehealth (Month 12/13), N=XX**

Source	DF	MS	F	p
Study Arm (DI vs. RI)	X.XX	X.XXX	XX	0.XXXX
Volume (High vs. Low)	X.XX	X.XXX	XX	0.XXXX
Interaction, Arm by Volume	X.XX	X.XXX	XX	0.XXXX
Error	X.XX	X.XXX	-	-

# A Phase 4, Randomized, Open-label, Two-arm Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low- and High-volume Pre-exposure Prophylaxis (PrEP) Sites in the US for HIV Uninfected MSM and Transgender Men ≥18: 217710 PILLAR

## Statistical Analysis Plan: Staff Study Participants Questionnaire

EVA-32399 | October 4, 2024 | Version 2.0

Prepared For:

PPD | Study Delivery Lead—Respiratory & Specialty, GSK

PPD, PhD, MPH | PPD, Global Implementation Science, ViiV Healthcare



Prepared By:

PPD, MA | Senior Research Scientist, Patient Centered Research | PPD

PPD, MPH | Research Scientist, Patient Centered Research | PPD

PPD, MSc | Lead Data Analyst, Patient Centered Research | PPD

PPD, MPH | Research Associate III, Patient Centered Research | PPD

Project Contact:

PPD, MS, PMP | Tel: PPD



# Table of Contents

<b>1</b>	<b>INTRODUCTION.....</b>	<b>1</b>
<b>2</b>	<b>PILLAR STUDY DESIGN .....</b>	<b>1</b>
2.1	Feasibility of Intervention Measure .....	3
2.2	Acceptability of Intervention Measure .....	4
2.3	SSP Additional Questionnaire Items .....	4
2.4	Summary of Feasibility.....	4
2.5	Analysis Population.....	5
2.6	Missing Data Handling Scheme.....	5
2.7	Significance Levels and Multiplicity .....	5
<b>3</b>	<b>STATISTICAL METHODS .....</b>	<b>5</b>
3.1	Cross-sectional Distributional Characteristics of Study Variables and Features of Score Distributions .....	6
3.2	Feasibility and Acceptability of APRETUDE, Implementation Support, and Telehealth .....	6
3.2.1	Cross-sectional Descriptive Statistics by Visits .....	6
3.2.2	Assessment of Variability Within vs. Between Clusters.....	Error! Bookmark not defined.
3.2.3	Mixed-effects Models at M4/5 and M12/13 .....	6
3.2.4	Change from Baseline Mixed Models.....	7
3.3	SSP Perception of Facilitators and Barriers to Feasibility and Acceptability of APRETUDE .....	7
3.4	Acceptability and Utility of DI Compared with RI for APRETUDE Administration .....	8
3.5	Fidelity and Reach of Client Sexual Health Assessment .....	8
3.5.1	SSP Perceptions of Sexual Health Assessment .....	8
3.5.2	Fidelity and Reach of Client Sexual Health Assessment .....	8
3.6	Feasibility of Implementation of APRETUDE.....	8
3.7	Summaries of Site-level Characteristics.....	8
3.8	Differences by Implementation Arm and Site Volume, FIM APRETUDE, FIM Implementation Support, and FIM Telehealth .....	9
<b>4</b>	<b>REFERENCES.....</b>	<b>10</b>
<b>5</b>	<b>TABLE SHELLS FOR BASELINE ANALYSIS.....</b>	<b>11</b>
<b>6</b>	<b>TABLES FOR MONTH 4/5 ANALYSIS.....</b>	<b>104</b>
<b>7</b>	<b>TABLES FOR MONTH 12/13 ANALYSIS .....</b>	<b>262</b>
<b>8</b>	<b>MULTIPLE TIMEPOINT TABLES .....</b>	<b>439</b>



## List of Abbreviations

Abbreviation	Definition
AIM	Acceptability of Intervention Measure
CAB	Cabotegravir
FIM	Feasibility of Intervention Measure
DTI	Direct to injection
LA	Long-acting
ISQ	Implementation science questionnaire
MSM	Men who have sex with men
PrEP	Pre-exposure prophylaxis
PSP	Patient Study Participant
RE-AIM	Reach, Efficacy, Adoption, Implementation, Maintenance
OLI	Oral lead-in
REML	Residual maximum likelihood
SAP	Statistical analysis plan
RI	Routine implementation
SD	Standard deviation
SSP	Staff Study Participant
SSI	Semi-structured interviews
TGM	Transgender Men

# 1 Introduction

---

The study is conducted following the FDA approval and commercial availability of cabotegravir long-acting for pre-exposure prophylaxis (CAB LA for PrEP) in the U.S. This is an open-label, phase 4, two-arm (dynamic implementation and routine implementation) study of the delivery of CAB LA for PrEP in low and high-volume sites in the U.S. for men who have sex with men (MSM) and transgender (TGM) men greater than or equal to 18 years of age. About eighteen clinics (~9 high and ~9 low volume) have been randomized 2:1 to either dynamic implementation (DI) or routine implementation (RI) (protocol # 217710/ Amendment 1.0).

This statistical analysis plan (SAP) describes the analysis of the Staff Study Participant (SSP) questionnaire, which includes the analyses assessing the study personnel's responses to questions regarding acceptability and feasibility of implementing cabotegravir (CAB, GKS1265744) long-acting (CAB LA, APRETUDE), as well as their assessments of the process of delivering APRETUDE to Patient Study Participants (PSPs).

# 2 Pillar Study Design

---

The phase 4 study is designed to evaluate dynamic implementation (DI) versus routine implementation (RI) strategies on the feasibility of delivering APRETUDE within a variety of study sites—e.g., high versus low volume PrEP centers—over 12 months. The patient population includes MSM and TGM, but the focus of the current SAP is on the study staff at the PrEP sites. Approximately 18 sites were randomized 2:1 in the DI or RI implementation arms with approximately five staff members designated at each of these sites as SSPs. The key comparison of interest is the DI vs RI comparison, and since the randomization is at the site level, SSPs are nested within the randomization, i.e., the study is cluster-randomized. This may affect the interpretation of certain outcomes as the independence of responses may not hold. The implementation outcomes for this phase of data analysis will be assessed from the perspective of the SSPs.<sup>1</sup>

Objectives/endpoints relevant to the current SAP are listed in [Table A](#).

Table A. Study objectives for SSP data

Objective Type	Objectives	Endpoints
Primary	To evaluate feasibility of dynamic implementation (DI) compared to routine implementation (RI) for APRETUDE administration.	Staff study participants' (SSPs) mean Feasibility of Intervention Measure (FIM) score at M13. <sup>1</sup>
Secondary	To evaluate change in feasibility of RI and DI for APRETUDE administration	Change from baseline in SSPs' FIM score at M5 and M13.
	To evaluate change in feasibility of RI and DI for APRETUDE administration	SSPs perceptions of facilitators and barriers to RI and DI and overall implementation of PrEP into routine care assessed through M13.
	To evaluate feasibility and acceptability of telehealth delivery for APRETUDE administration by clinical staff.	SSPs' mean FIM and AIM scores as well as ISQ responses for telehealth delivery at BL, M5 and M13.
	To evaluate feasibility and acceptability of telehealth delivery for APRETUDE administration by clinical staff.	Change from baseline in SSPs' FIM and AIM score as well as ISQ responses for telehealth delivery at M5 and M13.
	To evaluate feasibility and acceptability of telehealth delivery for APRETUDE administration by clinical staff.	SSPs perception of facilitators and barriers to feasibility and acceptability of telehealth use through M13.
	To evaluate acceptability and utility of DI compared to RI for APRETUDE administration	SSPs' mean AIM score and ISQ responses at BL, M5 and M13.
	To evaluate acceptability and utility of DI compared to RI for APRETUDE administration	Change from baseline in SSPs' AIM score and ISQ responses at M5 and M13.
	To evaluate acceptability and utility of DI compared to RI for APRETUDE administration	Proportion of SSPs that respond in agreement on relevant items on the ISQ that each implementation strategy is fit for use through M13.
	To evaluate acceptability and utility of DI compared to RI for APRETUDE administration	SSPs perceptions of utility of implementation strategies and facilitators and barriers to acceptability of RI and DI through M13.
	To evaluate fidelity to injection and dosing window	SSPs perception of barriers and facilitators to fidelity to injections through M13.
	To evaluate fidelity and reach of client Sexual Health Assessment	Proportion of site staff who administer Sexual Health Assessment through M13.
	To evaluate fidelity and reach of client Sexual Health Assessment	SSPs perceptions of Sexual Health Assessment through M13.
	To evaluate adaptations to any implementation strategies used in clinics to include but not limited to modifications to toolkits, RI and DI to support APRETUDE implementation	SSPs perceptions of adaptations to implementation strategies through M13.
	To evaluate perceptions, barriers and facilitators with SSPs	SSPs perception of barriers and facilitators through M13.
Tertiary	CCI	

Objective Type	Objectives	Endpoints
	CCI	

<sup>1</sup>If the site has only DTI patients, endpoints will be a month prior for SSPs

## 2.1 Feasibility of Intervention Measure

The Feasibility of Intervention Measure (FIM) is employed to evaluate the extent to which an intervention can be carried out. This four-item measure assesses perceived intervention feasibility by employing a standard item stem to various aspects of feasibility. The items are measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The FIM has been validated with other implementation outcome measures.<sup>2</sup> Higher scores for FIM indicate greater feasibility. There are no reverse-scored items on the FIM and the mean score for feasibility of the intervention is calculated by averaging the responses from four items. The FIM has been adapted to measure SSPs' assessments of implementation of APRETUDE, implementation support, and telehealth. Mean scores for the FIM are derived by averaging the four items at each administration where at least two of four item responses are available. This mechanism for handling scoring in the presence of missing item-level responses has been used widely in patient- and clinician-reported outcomes.<sup>3</sup>

## 2.2 Acceptability of Intervention Measure

The Acceptability of Intervention Measure (AIM) is employed to evaluate the perception that a given intervention or treatment is satisfactory. It is similar to the FIM as it is a four-item measure, but it assesses perceived intervention acceptability instead of feasibility. The items are measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The AIM was validated with a suite of implementation outcome measures.<sup>2</sup> Higher scores for AIM indicate greater acceptability. As with the FIM, there are no reverse-scored items on the AIM, and the mean score for acceptability of the intervention is calculated by averaging the responses from four items, provided at least two of the four items have viable responses.<sup>3</sup> The AIM has been adapted to measure SSPs' assessments of the implementation of: APRETUDE, implementation support, and telehealth.

## 2.3 SSP Additional Questionnaire Items

The tailored SSP questionnaire was developed specifically for this study and contains items regarding the SSP's role at the study site, as well as their attitudes, concerns, and anticipated/implemented procedures regarding the use of APRETUDE. The baseline SSP questionnaire has 78 items plus subitems including the FIM and AIM. The Month 4/5 and Month 12/13 questionnaires have 98 and 103 items including the FIM and AIM, respectively, plus subitems that employ several different response options.

## 2.4 Summary of Feasibility

Feasibility will be systematically evaluated and summarized using the RE-AIM Framework (Reach, Efficacy, Adoption, Implementation, Maintenance). This is adapted from Brant (2020).<sup>4</sup> Feasibility will be summarized across different data streams. Assessment will entail summarizing the following:

- Reach: 1) number of PrEP seeking individuals taken from the Clinic Demographic Questionnaires administered quarterly; 2) number of SSP administered sexual health assessments; 3) number of PSPs who receive sexual health assessments
- Effectiveness: 1) percent of initiated oral PrEP vs. APRETUDE taken from Clinic Demographic Questionnaires administered quarterly; 2) percent of individuals on APRETUDE taken from the Clinic Demographic Questionnaires administered quarterly; 3) SSP skill level with PrEP
- Adoption: Data from the implementation science questionnaire on perceptions of barriers and facilitators
- Implementation: Summary for FRAME-IS results and pre-screening or screening records.
- Maintenance: SSP satisfaction and assessment of APRETUDE implementation from implementation science question

SSP-supplied data to support the RE-AIM Framework include data listed above that come from the quarterly Clinic Demographic Questionnaire and the SSP-administered implementation science questionnaire.

## 2.5 Analysis Population

The study population in this analysis will be all the respondents who complete any item on the SSP questionnaire at any time point.

## 2.6 Missing Data Handling Scheme

Missing data at the item level are anticipated to be rare. However, in some cases, the SSP may terminate before completing the survey in its entirety. The scoring algorithm and handling the missing values for FIM and AIM are described in Sections 2.1, 2.2, and 3.2.1. If a participant decides to withdraw from the study, the data will be handled according to the protocol: “If the SSP is changing roles, the individual assuming the role will be enrolled in the study. An SSP will be considered lost to follow-up only if that SSP role in the clinic is eliminated. Otherwise, an SSP who leaves their role will be replaced with the SSP who assumes the role to complete subsequent assessments.” SSPs will be analyzed according to the data given, no data imputation will be implemented. Replacement SSPs will be included in any cross-sectional analyses. Although it is not anticipated that any replacement SSPs will have baseline data and thus will not be included in change from baseline analyses, should a replacement SSP have baseline data, those individuals would be included in change from baseline analyses.

## 2.7 Significance Levels and Multiplicity

Any statistical significance tests will be two-tailed and will be conducted with Type I error probability fixed at 0.05. Statistical significance, then, will be determined if the p-value is less than 0.05. No multiplicity adjustment will be performed. The general null and alternative hypotheses for statistical tests will be for a given parameter ( $\theta$ )—e.g., mean:

$$H_0: \theta = 0$$

Versus

$$H_A: \theta \neq 0$$

# 3 Statistical Methods

Continuous and interval-like variables will be summarized using descriptive statistics (e.g., n, mean, standard deviation [SD], minimum, first quartile, median, third quartile, and maximum). Means and quartiles will be summarized to one decimal place beyond the data values, SD will be reported to two decimal places more than the source data, and minima and maxima will be reported to the same precision level as the source data. Categorical variables will be reported as frequency counts as whole numbers and percentages with one decimal (e.g., 10.1%), the percentage of SSPs in corresponding categories. Continuous outcomes will be evaluated depending on the number of group comparisons being made. Grouping variables with two levels will be compared with t-tests. Grouping variables with three or more categories will be evaluated with F-tests and pairwise comparisons will be calculated to aid in interpretation of main effects. Categorical variables will be analyzed with Cochran-Mantel-Haenszel tests or Fisher’s Exact Test depending on data availability per category, i.e., if any cell of a given contingency table has a cell with incidence of five or less. Summaries by clinic/practice type will be stratified by the following groupings based on Question 1 from the Site Questionnaire:

University/Academia/Research; Federally Qualified Health Center /Department of Health; Nonprofit; Private.

### **3.1 Cross-sectional Distributional Characteristics of Study Variables and Features of Score Distributions**

For questions with ordinal responses, a univariate distribution of every item will be tabulated. Standard distributional statistics will be tabulated for interval-like (ordinal) variables, including mean, SD, median, percentage missing, minimum, and maximum of responses, percentage of the sample at the ceiling and floor, first and third quartiles, and 95% confidence intervals. For questions with categorical responses, a frequency distribution of all responses will be presented with the number and percentage of a given response.

### **3.2 Feasibility and Acceptability of APRETUDE, Implementation Support, and Telehealth**

#### **3.2.1 Cross-sectional Descriptive Statistics by Visits**

SSPs' mean FIM and AIM scores focusing on APRETUDE, Implementation Support, and telehealth at baseline, M4/M5, and M12/M13 will be evaluated by the study arms by both descriptive statistics and using the mixed-effects modeling approaches described below. Descriptive statistics of scores and coded item response will include those listed in Section 3.1 for continuous variables. Additionally, item response frequencies and percentages will be produced for individual items to further assess the distribution of responses.

#### **3.2.2 Mixed-effects Models at M4/5 and M12/13**

Cross-sectional mixed-effects models will be fit to the FIM and AIM mean scores at M4/5 and M12/13. These mixed-effects models will be fit using residual maximum likelihood (REML) and will assume data are missing at random. All data will be included regardless of early cessation from the implementation arm. The dependent variables will be the FIM and AIM mean scores, respectively. In the model, implementation arm (DI versus RI), site volume (high versus low) and the implementation arm by site volume interaction will be fitted as fixed terms, with separate random intercepts fitted to allow for clustering within sites, and for variability within the sites. Site volume was categorized as high versus low according to the reported estimate of PrEP patient seen monthly. These data were split at the median of 50; values above 50 were considered high and those below 50 were considered low. The baseline scores centered around their site mean will be fitted as both fixed and random covariates. An unstructured covariance structure will be fitted to account for the dependence of the residuals within the provider. Should the unstructured covariance structure cause model fitting problems (e.g., nonconvergence), heterogenous compound symmetry will be considered followed by homogenous compound symmetry. Should model fitting problems persist, the random effect on centered mean baseline score will be removed and models will be fit according to the same order of covariance structures (unstructured, then heterogenous compound symmetry, then homogenous compound symmetry).

The corresponding multilevel model for the FIM and AIM scores,  $Y_{ij}$ , for the  $i^{th}$  individual at the  $j^{th}$  site is expressed as:

$$Y_{ij} = \beta_{00} + \beta_{01}I_j + \beta_{02}V_j + \beta_{03}I_jV_j + \beta_{10}(B_{ij} - \bar{B}_j) + u_{0j} + u_{1j}(B_{ij} - \bar{B}_j) + e_{ij}$$

$$e_{ij} \sim N(0, \sigma^2)$$

$$\begin{pmatrix} u_{0j} \\ u_{1j} \end{pmatrix} \sim N \left[ \begin{pmatrix} 0 \\ 0 \end{pmatrix}, \begin{pmatrix} \tau_{00} & \tau_{01} \\ \tau_{10} & \tau_{11} \end{pmatrix} \right]$$

With fixed effects for baseline score ( $B_{ij} - \bar{B}_j$ ), implementation arm ( $I_j$ ), site volume ( $V_j$ ), and the arm by volume interaction. The parameter  $\beta_{00}$  is the fixed mean for the RI arm with low volume. The parameters  $\beta_{01}$ ,  $\beta_{02}$ ,  $\beta_{03}$ , and  $\beta_{10}$  are regression weights for the fixed effects of DI arm, high volume, arm by volume, and baseline score, respectively. Random effects for sites ( $u_{0j}$ ), baseline scores across sites ( $u_{1j}$ ), and the residual error ( $e_{ij}$ ) are also included. All random effects and the error term are assumed to be independent. Coding of the mixed-effects models will be done as suggested by Singer (1998).<sup>5</sup> It is worth noting that there is likely a range restriction on both FIM and AIM endpoints given that the measures are fairly discrete (i.e., on a 1-5 scale with 0.25 increments) and so adjustment of the mixed-effects models may be necessary if the model fits are determined to be affected by this range restriction. The study implementation arms and specific timepoint contrasts will be calculated within the mixed-effects modeling framework.

### 3.2.3 Change from Baseline Mixed Models

Change from baseline in SSPs' AIM and FIM scores at M4/5, and M12/M13 will be modeled similarly to those described in Section 3.2.2. The dependent variables in this case, however, will be the change from baseline in FIM and AIM mean scores, respectively.

The corresponding multilevel model for the changes from baseline in FIM and AIM scores,  $(Y_{ij} - B_{ij})$ , for the  $i^{th}$  individual at the  $j^{th}$  site is expressed as:

$$(Y_{ij} - B_{ij}) = \beta_{00} + \beta_{01}I_j + \beta_{02}V_j + \beta_{03}I_jV_j + \beta_{10}(B_{ij} - \bar{B}_j) + u_{0j} + u_{1j}(B_{ij} - \bar{B}_j) + e_{ij}$$

$$e_{ij} \sim N(0, \sigma^2)$$

$$\begin{pmatrix} u_{0j} \\ u_{1j} \end{pmatrix} \sim N \left[ \begin{pmatrix} 0 \\ 0 \end{pmatrix}, \begin{pmatrix} \tau_{00} & \tau_{01} \\ \tau_{10} & \tau_{11} \end{pmatrix} \right]$$

Similar to the model in Section 3.2.2, we include the same fixed and random effects. All random effects and the error term are assumed to be independent and random effects will be fit with an unstructured covariance matrix at the outset. Model fitting will be attempted until an adequately fitting model is found according to the hierarchy of covariance structures and model specifications described in section 3.2.2. REML will be used to estimate the model's parameters.

## 3.3 SSP Perception of Facilitators and Barriers to Feasibility and Acceptability of APRETUDE

The SSP perception of facilitators and barriers to feasibility and acceptability of APRETUDE will be tabulated by implementation arm and site volume. Descriptive analyses of the facilitators and barriers will



be conducted at all time points. Additionally, post-baseline—i.e., at M4/5 and M12/M13—Cochran–Mantel–Haenszel tests of these categorical outcomes by arm and subgroup will be completed with a p-value less than 0.05 considered to be statistically significant. Also, Fisher’s Exact test may be used if any cell in the cross-tabulation of categorical variables is five or less.

### **3.4 Acceptability and Utility of DI Compared with RI for APRETUDE Administration**

Proportion of SSPs responded in agreement on relevant items that each implementation strategy is fit for use, e.g., if a strategy is used and whether that strategy was found to be useful, at M12/M13 will be estimated. It will be compared between the two study arms, site volume, and SSP type as a stratification factor using a Cochran–Mantel–Haenszel test. Baseline responses will be summarized descriptively.

### **3.5 Fidelity and Reach of Client Sexual Health Assessment**

#### **3.5.1 SSP Perceptions of Sexual Health Assessment**

SSP perceptions of Sexual Health Assessment through M4/5 and M12/M13 will be tabulated by implementation arm and site volume. Cochran–Mantel–Haenszel tests will be computed comparing implementation arms at M12/13. A p-value of less than 0.05 will be considered statistically significant.

#### **3.5.2 Fidelity and Reach of Client Sexual Health Assessment**

Proportions of the site staff who administer the Sexual Health Assessment through M12/M13 and by clinic characteristics and their 95% confidence interval will be estimated. The difference between the proportions by clinic characteristics will be assessed using a two-sided 95% confidence intervals, and a Cochran–Mantel–Haenszel statistic will be provided.

### **3.6 Feasibility of Implementation of APRETUDE**

SSP evaluations of feasibility measured as reach, effectiveness, adoption, implementation, and maintenance through M13 will be tabulated by study arm and clinic characteristics, and a Cochran–Mantel–Haenszel test of these categorical outcomes of the subgroups will be completed. A p-value less than 0.05 will be considered statistically significant. The subgroups will include study arm and clinic characteristics. The analysis will be completed at M4/5 and M12/M13.

### **3.7 Summaries of Site-level Characteristics**

Responses by the site designee for the 17-item overall site-level questionnaire will be summarized at baseline.

### **3.8 Differences by Implementation Arm and Site Volume, AIM/FIM APRETUDE, AIM/FIM Implementation Support, and AIM/FIM Telehealth**

Difference for AIM/FIM means scores in SSP by implementation arm (RI, DI), site volume (high, low), and the interaction of these variables will be tested using a 2 x 2 between-subjects analysis of variance. The AIM/FIM for APRETUDE, implementation support and telehealth will be tested, separately, in all analyses all factors will be fixed. Significant interactions will be followed up with appropriate simple effects.

## 4 References

---

1. A Phase 4, randomized, open-label, two-arm study evaluating implementation strategies for the delivery of Cabotegravir in low and high-volume pre-exposure prophylaxis (PrEP) sites in the U.S. for HIV uninfected MSM and transgender men  $\geq 18$ . Study protocol 217710/Amendment 1.0. ViiV Healthcare Company, Research Triangle Park, NC.
2. Weiner BJ, Lewis CC, Stanick C, et al. Psychometric assessment of three newly developed implementation outcome measures. *Implement Sci.* 2017;12(1):108.
3. Cella D. *Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System—Version 4*. Evanston, IL: Center on Outcomes, Research & Education (CORE), Evanston Northwestern Healthcare and Northwestern University; 1997.
4. Brant AR, Dhillon P, Hull S, et al. Integrating HIV Pre-Exposure Prophylaxis into Family Planning Care: A RE-AIM Framework Evaluation. *AIDS Patient Care STDS.* 2020;34(6):259-266.
5. Singer JD. Using SAS PROC MIXED to fit multilevel models, hierarchical models, and individual growth models. *J Educational Behavioral Stat.* 1998;24(4):323-355.

## 5 Table shells for Baseline Analysis

Table 1.001	Demographic Characteristics of Staff Study Participants (Month 1), N=XX .....	13
Table 1.002	Characteristics of Staff Study Participants (Month 1), N=XX .....	15
Table 1.003	Summary of Confidence with Skills (Month 1), N=XX .....	17
Table 1.004	Summary of Staff Study Participants' Perceptions Regarding APRETUDE (Month 1), N=XX...	19
Table 1.005	Summary of Experiences with the Acquisition Process (Month 1), N=XX.....	23
Table 1.101	Summary of Acceptability of Intervention Measure (AIM - APRETUDE) and Feasibility of Intervention Measure (FIM - APRETUDE ) Items (Month 1), N=XX.....	30
Table 1.102	Distributional Characteristics of the Acceptability of Intervention Measure (AIM – APRETUDE) (Month 1), N=XX.....	31
Table 1.103	Distributional Characteristics of the Feasibility of Intervention Measure (FIM - APRETUDE) (Month 1), N=XX.....	33
Table 1.201	Summary of Acceptability of Intervention Measure (AIM - IMPLEMENTATION SUPPORT) and Feasibility of Intervention Measure (FIM - IMPLEMENTATION SUPPORT) Items (Month 1), N=XX .....	35
Table 1.202	Distributional Characteristics of the Acceptability of Intervention Measure (AIM – IMPLEMENTATION SUPPORT) (Month 1), N=XX.....	36
Table 1.203	Distributional Characteristics of the Feasibility of Intervention Measure (FIM - IMPLEMENTATION SUPPORT) (Month 1), N=XX.....	38
Table 1.301	Summary of Acceptability of Intervention Measure (AIM - TELEHEALTH) and Feasibility of Intervention Measure (FIM - TELEHEALTH) Items (Month 1), N=XX .....	40
Table 1.302	Distributional Characteristics of the Acceptability of Intervention Measure (AIM – TELEHEALTH) (Month 1), N=XX.....	41
Table 1.303	Distributional Characteristics of the Feasibility of Intervention Measure (FIM - TELEHEALTH) (Month 1), N=XX.....	43
Table 1.304	Summary of Feasibility and Acceptability of Telehealth (Month 1), N=XX .....	45
Table 1.401	Summary of Utility of Proposed Implementation Strategies (Month 1), N=XX .....	50
Table 1.501	Summary of Perceived Barriers to Delivering APRETUDE to Patients (Month 1), N=XX .....	54
Table 1.502	Summary of Perceptions of Administering APRETUDE (Month 1), N=XX .....	57
Table 1.503	Summary of Perceived Barriers to Managing Delivery of APRETUDE (Month 1), N=XX .....	59
Table 1.504	Summary of Perceived Resourcing Barriers to Support Delivery of APRETUDE (Month 1), N=XX.....	62
Table 1.505	Summary of Perceptions of Clinic/Practice Culture and Environment .....	65
Table 1.506	Summary of Barriers to PrEP Provisioning (Month 1), N=XX .....	67
Table 1.601	Summary of the Sexual Health Assessment Tool (Month 1), N=XX .....	69
Table 1.602	Summary of the PrEP Communication Tool (Month 1), N=XX .....	72
Table 1.701	Summary of the Optional Oral Lead-in Phase of APRETUDE (Month 1), N=XX.....	74
Table 1.702	Summary of Study Staff Participants' Injectable Cabotegrevir Experience (Month 1), N=XX.....	76

Table 1.801	Summary of Perceived Number of APRETUDE Patients Clinic/Practice Can Manage Per Week on an Ongoing Basis (Month 1), N=XX.....	80
Table 1.802	Distributional Characteristics of Reported Number of People in Clinic Trained and Prepared to Give APRETUDE Injections (Month 1), N=XX.....	81
Table 1.803	Distributional Characteristics of Estimated Number of Staff Needed Per Week to Incorporate APRETUDE into Clinic/Practice for Approximately 25 People (Month 1), N=XX.....	82
Table 1.804	Summary of Estimated Percentage of Staff Time/Full-Time Equivalent Hours Needed Per Week to Incorporate APRETUDE into Clinic/Practice for Approximately 25 People (Month 1), N=XX.....	83
Table 1.805	Summary of Plans to Create New Roles/Positions in Clinic to Coordinate the APRETUDE Program (Month 1), N=XX.....	84
Table 1.806	Summary of Number of New Roles/Positions in Clinic to Coordinate the APRETUDE Program (Month 1), N=XX.....	85
Table 1.807	Summary of How Clinic/Practice Plans to Track Patients on APRETUDE (Month 1), N=XX.....	86
Table 1.808	Summary of How Clinic/Practice Responds to Patients who Do Not Show for a Regularly Scheduled Appointment (Month 1), N=XX.....	87
Table 1.809	Summary Characteristics of Whether Clinic/Practice has Specific Person in Charge of Following Up on No-Shows (Month 1), N=XX.....	88
Table 1.810	Summary of Type of Systems Clinic has in Place to Remind Patients of Upcoming Appointments (Month 1), N=XX.....	89
Table 1.811	Summary of Type of Systems Clinic has in Place to Offer Upcoming Appointments (Month 1), N=XX.....	90
Table 1.812	Summary of Implementing APRETUDE in Practice (Month 1), N=XX.....	91
Table 1.901	Distributional Characteristics of Select Study Site Characteristics (Month 1), N=XX.....	93
Table 1.902	Summary of Selected Study Site Characteristics (Month 1), N=XX.....	102

Table 1.001 Demographic Characteristics of Staff Study Participants (Month 1), N=XX

Question Number		Total (N=XX)	Study Arm	
			Dynamic Implementation (N=XX)	Routine Implementation (N=XX)
		n (%)	n (%)	n (%)
69	<b>Gender</b>			
	Cisgender Male	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Cisgender Female	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Transgender Man	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Transgender Woman	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Nonbinary	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Gender Queer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other Gender	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
70	<b>Age (years)</b>			
	N	XX	XX	XX
	Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)
	Median	XX.X	XX.X	XX.X
	Q1, Q3	XX, XX	XX, XX	XX, XX
	Min-Max	XX.X, XX.X	XX.X, XX.X	XX.X, XX.X
	Missing	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
70	<b>Age (years), High Volume</b>			
	N	XX	XX	XX
	Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)
	Median	XX.X	XX.X	XX.X
	Q1, Q3	XX, XX	XX, XX	XX, XX
	Min-Max	XX.X, XX.X	XX.X, XX.X	XX.X, XX.X
	Missing	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
70	<b>Age (years), Low Volume</b>			
	N	XX	XX	XX
	Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)
	Median	XX.X	XX.X	XX.X
	Q1, Q3	XX, XX	XX, XX	XX, XX
	Min-Max	XX.X, XX.X	XX.X, XX.X	XX.X, XX.X
	Missing	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
70	<b>Age</b>			
	18-25	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	26-35	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	66-49	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number		Study Arm		
		Total (N=XX)	Dynamic Implementation (N=XX)	Routine Implementation (N=XX)
		n (%)	n (%)	n (%)
	50+	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>71</b>	<b>Race</b>			
	White/Caucasian	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Black	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Asian	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Native American	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Pacific Islander	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Mixed Race	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other Race	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I Prefer not to Answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>72</b>	<b>Ethnicity</b>			
	Hispanic/Latinx	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Non-Hispanic/Latinx	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 1.002 Characteristics of Staff Study Participants (Month 1), N=XX

Question Number	Characteristic	Study Arm		
		Total (N=XX)	Dynamic Implementation (N=XX)	Routine Implementation (N=XX)
		n (%)	n (%)	n (%)
<b>1</b>	<b>Provider Type</b>			
	Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Nurse Practitioner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Physician Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Social worker/case manager	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Office administrator/clinic administrator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Laboratory staff/technician/phlebotomist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Front desk staff/ Scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>2</b>	<b>Personally Administer Injections</b>			
	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>3</b>	<b>Prescribe Medications as part of role</b>			
	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>4</b>	<b>Currently Prescribing Oral PrEP[2]</b>			
	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>5</b>	<b>Currently Provide PrEP Counseling</b>			
	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>73</b>	<b>Specialty[2][3]</b>			
	Infectious disease specialist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Internal medicine/ primary care/general doctor/ family practitioner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	HIC Specialist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Immunologist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Women's health/obstetricians and gynecologists	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Endocrinologist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other[4]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



Question Number	Characteristic	Study Arm		
<b>74</b>	<b>Length of Time practicing Medicine</b>			
	<1 year	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	1–5 years	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	6–10 years	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	11-15 years	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	16-20 years	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	>21 years	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

[1] Other responses include: xxx

[2] Only SSPs who responded 'Yes' to 'Do you prescribe medications as part of your role?'

[3] Not mutually exclusive

[4] Other responses include: xxx

Table 1.003 Summary of Confidence with Skills (Month 1), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Study Arm	
				Dynamic Implementation (N = XX) n (%)	Routine Implementation ( N = XX) n (%)
6	Please rate your level of confidence for each skill listed:				
	Talking to Patient About Sexual History	Somewhat Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Extremely Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not Applicable To My Role	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Screening Patient to Determine CAND PrEP	Not At All Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A Little Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Extremely Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not Applicable To My Role	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Answering Patient's Questions About PrEP	A Little Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Extremely Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not Applicable To My Role	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Suggesting PrEP to a Patient	Not At All Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A Little Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Extremely Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Study Arm	
				Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Not Applicable To My Role	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Monitoring a Patient on PrEP	Not At All Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A Little Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Extremely Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not Applicable To My Role	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 1.004 Summary of Staff Study Participants' Perceptions Regarding APRETUDE (Month 1), N=XX**

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
7	In your opinion, APRETUDE is appropriate for which individuals?				
		Are Sexually Active	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Have Been Sexually Active With 1 Or More Partners In The Last 6 Months	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Are Currently Adherent On Daily Oral Prep	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Are Non-Adherent On Daily Oral Prep	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Use Prep On Demand (I.E., Event-Based Prep, Prep 2-1-1)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Could Benefit From Prep But Do Not Want To Use Daily Prep	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Have Previously Used And Discontinued Daily Prep	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Feel Stigmatized About Taking Oral Prep	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Request APRETUDE Spontaneously	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Have Sex Without A Condom	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Engage In Anal Sex	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Have A Sexual Partner Living With HIV	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Live In Areas With High HIV Prevalence	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Currently Have Or Recently (Within The Past 6 Months) Have Had An Sti Other Than HIV	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Are In Monogamous Relationships	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Inject Drugs	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Have Sex With A Person/People Who Inject Drugs	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Experience Stigma Around Using HIV Prevention	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Are Concerned About Taking Pills Every Day	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Experience Stress Or Anxiety Over Adherence Of A Daily Pill Regimen	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Have More Chaotic Lifestyles (E.G., Variable Work Schedules, Frequent Travel, Balancing Work And School)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Have More Structured Lifestyles (E.G., Regular Work Hours, Little To No Unplanned Travels)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Have Difficulty Planning Or Organizing	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Have Stable Income And Stable Housing	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Experience Homelessness Or Are Unstably Housed	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Have Psychiatric Comorbidities	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Have Sex With Someone Who Has Recently Been In Jail/Prison	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Are Incarcerated, Temporarily Incarcerated, Or Recently Released From Incarcerated	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
8	Are individuals with specific demographics more appropriate for APREITUDE?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
9	In your opinion, what are the demographics of the individuals who are appropriate for APREITUDE?				
		Patients <35 Years Old	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Patients 35-50 Years Old	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Patients >50 Years Old	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Black Transgender Men	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Black Transgender Women	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Black Cisgender Women	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Black Cisgender Men	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Black Non-Binary Individuals	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Black Men Who Have Sex With Men	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		White Transgender Men	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		White Transgender Women	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		White Cisgender Women	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		White Cisgender Men	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		White Non-Binary Individuals	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		White Men Who Have Sex With Men	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Latinx Transgender Men	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Latinx Transgender Women	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Latinx Cisgender Women	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Latinx Cisgender Men	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Latinx Non-Binary Individuals	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Latinx Men Who Have Sex With Men	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other Transgender Men Of Color	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other Transgender Women Of Color	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other Cisgender Women Of Color	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other Cisgender Men Of Color	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other Non-Binary Individuals Of Color	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other Men Who Have Sex With Men	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
10	Has any of the patients at this clinic/practice asked for (or about) APRETUDE?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
11	Are you or this clinic/practice proactively informing patients about APREUDE?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
12	How are you or this clinic/practice informing patients about APREUDE?				
		Provision Of Educational Materials	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		During Consultation With Patient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Through Peer Educators	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Referring Patients To Prep Providers	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Posters In The Clinic/Practice	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Flyers In The Clinic/Practice	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Mentions On The Clinic/Practice's Website	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Mentions On Social Media	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 1.005 Summary of Experiences with the Acquisition Process (Month 1), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
34	Are you or will you be involved in any part of acquisition process for APRETUDE, such as completing enrollment forms, prior authorization, claims, sending documents to insurance companies, and purchasing APRETUDE?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
35	How will your providers or clinic/practice acquire APRETUDE?				
		Buy-And-Bill - Purchases Apretude From A Wholesaler Or Specialty Distributor And Bills The Primary Third-Party Payer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		White Bagging - Submits Prescription To A Specialty Pharmacy Within Viiv's Specialty Pharmacy Network And The Specialty Pharmacy Processes The Claim And Ships Apretude For Administration	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Clear Bagging - Internal Pharmacy Maintains Inventory Of The Medication, Processes The Claim, And Delivers The Medication	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
36	Who in your clinic/practice is responsible for completing the insurance benefits verification process for specialty medications for patients?				
		Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Nurse Practitioner/Physician Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Specialty Pharmacy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Social Worker/Case Manager	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Front Desk Staff/Scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Dedicated Administrator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Apretude Coordinator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
37	Have you or your clinic/practice used ViiV Connect previously?				
		Yes, I Have Personally Used It	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes, The Clinic/Practice Has Used It But I Have Not Personally Used It	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
38	For each item, please indicate how concerned you would be about each of the following based on your current expectations, understanding and knowledge of ViiV Connect.				
	Authorization Wait Times	Extremely Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Moderately Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Slightly Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not At All Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Understanding Status of Authorization	Extremely Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Moderately Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Slightly Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Not At All Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Extremely Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Moderately Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Slightly Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not At All Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Amount of paperwork	Extremely Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Moderately Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Slightly Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not At All Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Clarity on Coverage Approval	Extremely Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Moderately Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Slightly Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not At All Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Ensuring Medication Comes to Right Place	Extremely Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Moderately Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Slightly Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not At All Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Potential Loss of Enthusiasm of APREUDE	Extremely Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Moderately Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Slightly Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not At All Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Patient Dissatisfy With Clinic Staff	Extremely Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Moderately Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Slightly Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not At All Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Staff Dissatisfy With Acquisition Proc	Extremely Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Moderately Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Slightly Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not At All Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Potential Disruption of Clinic Flow	Extremely Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Moderately Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Slightly Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not At All Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Time-consuming Process	Extremely Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Moderately Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Slightly Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Somewhat Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not At All Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Inequitable Access for Eligible Patients	Extremely Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Moderately Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Slightly Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not At All Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
39	“I would recommend ViiV Connect to other providers and clinics/practices to aid in the acquisition of ViiV medications.”				
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither Agree Or Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
40	How helpful or unhelpful do you think each type of support would be to your clinic/practice in using ViiV Connect?				
	ViiV Connect Services and Support Info	Not At All Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A Little Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Acquisition Guides	Not At All Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A Little Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Billing, Coding and Reimbursement Info	Not At All Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A Little Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Benefits Verification	Not At All Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A Little Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Live Support	Not At All Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A Little Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Video for Patients on What Viiv Connect	Not At All Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A Little Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
	Video for Provider Describe ViiV Connect	Not At All Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A Little Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Payer/Insurer List Cover Med & Coverage	Not At All Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A Little Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Patient Info Abt ViiV Connect & Acq Proc	Not At All Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A Little Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	ViiV Connect Tracker	Not At All Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A Little Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 1.101 Summary of Acceptability of Intervention Measure (AIM - APRETUDE) and Feasibility of Intervention Measure (FIM - APRETUDE ) Items (Month 1), N=XX**

Measure	Item	Total Sample n (%)	1 Completely Disagree n (%)	2 Disagree n (%)	3 Neither Agree nor Disagree n (%)	4 Agree n (%)	5 Completely Agree n (%)
AIM	1. The idea of APRETUDE in our clinic/practice meets my approval.	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
	2. The idea of APRETUDE in our clinic/practice is appealing to me.	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
	3. I like the idea of APRETUDE in our clinic/practice.	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
	4. I welcome APRETUDE in our clinic/practice.	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
FIM	1. APRETUDE seems implementable in our clinic/practice	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
	2. APRETUDE seems possible in our clinic/practice	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
	3. APRETUDE seems doable in our clinic/practice	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
	4. APRETUDE seems easy to use in our clinic/practice	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)

**Table 1.102 Distributional Characteristics of the Acceptability of Intervention Measure (AIM – APREUDE) (Month 1), N=XX**

AIM – APREUDE	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
Mean Score	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
<b>Study Arm</b>							
Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
<b>Clinic Type</b>							
University/Academia/Research	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
FQHC/Department of Health	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Nonprofit	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Private	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
<b>Provider Type</b>							
Physician	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Mid-level providers[1]	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Nurse	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Medical Assistant	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Pharmacist	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Social worker/case manager/PrEP educator/PrEP navigator	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Office administrator /clinic administrator/front desk staff/scheduler	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Laboratory staff/technician/phlebotomist/other	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)



AIM – APRETUDE	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
<b>Items</b>							
1. The idea of APRETUDE in our clinic/practice meets my approval.	XX	X.X	X.XX	X.XX (X.XX,X.XX)	X.X (X, X)	XX (XX.X)	(X.XX, X.XX)
2. The idea of APRETUDE in our clinic/practice is appealing to me.	XX	X.X	X.XX	X.XX (X.XX,X.XX)	X.X (X, X)	XX (XX.X)	(X.XX, X.XX)
3. I like the idea of APRETUDE in our clinic/practice.	XX	X.X	X.XX	X.XX (X.XX,X.XX)	X.X (X, X)	XX (XX.X)	(X.XX, X.XX)
4. I welcome APRETUDE in our clinic/practice.	XX	X.X	X.XX	X.XX (X.XX,X.XX)	X.X (X, X)	XX (XX.X)	(X.XX, X.XX)

[1] Mid-level providers include nurse practitioners and physician assistants.

**Table 1.103 Distributional Characteristics of the Feasibility of Intervention Measure (FIM - APREUDE) (Month 1), N=XX**

FIM - APREUDE	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
Mean Score	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
<b>Study Arm</b>							
Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
<b>Clinic Type</b>							
University/Academia/Research	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
FQHC/Department of Health	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Nonprofit	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Private	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
<b>Provider Type</b>							
Physician	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Mid-level providers[1]	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Nurse	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Medical Assistant	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Pharmacist	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Social worker/case manager/PrEP educator/PrEP navigator	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Office administrator /clinic administrator/front desk staff/scheduler	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Laboratory staff/technician/phlebotomist/other	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)

FIM - APRETUDE	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
<b>Items</b>							
1. APRETUDE seems implementable in our clinic/practice	XX	X.X	X.XX	X.XX (X.XX,X.XX)	X.X (X, X)	XX (XX.X)	(X.XX, X.XX)
2. APRETUDE seems possible in our clinic/practice	XX	X.X	X.XX	X.XX (X.XX,X.XX)	X.X (X, X)	XX (XX.X)	(X.XX, X.XX)
3. APRETUDE seems doable in our clinic/practice	XX	X.X	X.XX	X.XX (X.XX,X.XX)	X.X (X, X)	XX (XX.X)	(X.XX, X.XX)
4. APRETUDE seems easy to use in our clinic/practice	XX	X.X	X.XX	X.XX (X.XX,X.XX)	X.X (X, X)	XX (XX.X)	(X.XX, X.XX)

[1] Mid-level providers include nurse practitioners and physician assistants.

**Table 1.201 Summary of Acceptability of Intervention Measure (AIM - IMPLEMENTATION SUPPORT) and Feasibility of Intervention Measure (FIM - IMPLEMENTATION SUPPORT) Items (Month 1), N=XX**

Measure	Item	Total Sample	1 Completely Disagree	2 Disagree	3 Neither Agree nor Disagree	4 Agree	5 Completely Agree
		n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
AIM	1. The implementation support has met my approval.	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
	2. The implementation support was appealing to me.	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
	3. I like the implementation support I have received.	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
	4. I welcome the implementation support I have received.	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
FIM	1. The implementation support seems implementable in our clinic/practice	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
	2. The implementation support seems possible in our clinic/practice	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
	3. The implementation support seems doable in our clinic/practice	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
	4. The implementation support seems easy to use in our clinic/practice	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)

**Table 1.202    Distributional Characteristics of the Acceptability of Intervention Measure (AIM – IMPLEMENTATION SUPPORT) (Month 1), N=XX**

AIM – IMPLEMENTATION SUPPORT	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
Mean Score	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
<b>Study Arm</b>							
Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
<b>Clinic Type</b>							
University/Academia/Research	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
FQHC/Department of Health	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Nonprofit	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Private	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
<b>Provider Type</b>							
Physician	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Mid-level providers[1]	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Nurse	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Medical Assistant	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Pharmacist	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Social worker/case manager/PrEP educator/PrEP navigator	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Office administrator /clinic administrator/front desk staff/scheduler	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Laboratory staff/technician/phlebotomist/other	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)

AIM – IMPLEMENTATION SUPPORT	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
<b>Items</b>							
1. The implementation support has met my approval.	XX	X.X	X.XX	X.XX (X.XX,X.XX)	X.X (X, X)	XX (XX.X)	(X.XX, X.XX)
2. The implementation support was appealing to me.	XX	X.X	X.XX	X.XX (X.XX,X.XX)	X.X (X, X)	XX (XX.X)	(X.XX, X.XX)
3. I like the implementation support I have received	XX	X.X	X.XX	X.XX (X.XX,X.XX)	X.X (X, X)	XX (XX.X)	(X.XX, X.XX)
4. I welcome the implementation support I have received.	XX	X.X	X.XX	X.XX (X.XX,X.XX)	X.X (X, X)	XX (XX.X)	(X.XX, X.XX)

[1] Mid-level providers include nurse practitioners and physician assistants.

**Table 1.203    Distributional Characteristics of the Feasibility of Intervention Measure (FIM - IMPLEMENTATION SUPPORT) (Month 1), N=XX**

FIM - IMPLEMENTATION SUPPORT	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
Mean Score	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
<b>Study Arm</b>							
Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
<b>Clinic Type</b>							
University/Academia/Research	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
FQHC/Department of Health	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Nonprofit	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Private	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
<b>Provider Type</b>							
Physician	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Mid-level providers[1]	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Nurse	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Medical Assistant	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Pharmacist	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Social worker/case manager/PrEP educator/PrEP navigator	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Office administrator /clinic administrator/front desk staff/scheduler	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Laboratory staff/technician/phlebotomist/other	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)

FIM - IMPLEMENTATION SUPPORT	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
<b>Items</b>							
1. The implementation support seems implementable in our clinic/practice	XX	X.X	X.XX	X.XX (X.XX,X.XX)	X.X (X, X)	XX (XX.X)	(X.XX, X.XX)
2. The implementation support seems possible in our clinic/practice	XX	X.X	X.XX	X.XX (X.XX,X.XX)	X.X (X, X)	XX (XX.X)	(X.XX, X.XX)
3. The implementation support seems doable in our clinic/practice	XX	X.X	X.XX	X.XX (X.XX,X.XX)	X.X (X, X)	XX (XX.X)	(X.XX, X.XX)
4. The implementation support seems easy to use in our clinic/practice	XX	X.X	X.XX	X.XX (X.XX,X.XX)	X.X (X, X)	XX (XX.X)	(X.XX, X.XX)

[1] Mid-level providers include nurse practitioners and physician assistants.



**Table 1.301 Summary of Acceptability of Intervention Measure (AIM - TELEHEALTH) and Feasibility of Intervention Measure (FIM - TELEHEALTH) Items (Month 1), N=XX**

Measure	Item	Total Sample n (%)	1 Completely Disagree n (%)	2 Disagree n (%)	3 Neither Agree nor Disagree n (%)	4 Agree n (%)	5 Completely Agree n (%)
AIM	1. The idea of telehealth for APRETUDE in our clinic/practice meets my approval.	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
	2. The idea of telehealth for APRETUDE in our clinic/practice is appealing to me.	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
	3. I like the idea of telehealth for APRETUDE in our clinic/practice.	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
	4. I welcome telehealth for APRETUDE in our clinic/practice.	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
FIM	1. Telehealth for APRETUDE seems implementable in our clinic/practice	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
	2. Telehealth for APRETUDE seems possible in our clinic/practice	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
	3. Telehealth for APRETUDE seems doable in our clinic/practice	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
	4. Telehealth for APRETUDE seems easy to use in our clinic/practice	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)

**Table 1.302 Distributional Characteristics of the Acceptability of Intervention Measure (AIM – TELEHEALTH) (Month 1), N=XX**

AIM – TELEHEALTH	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
Mean Score	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Study Arm							
Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Site Volume							
High	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Clinic Type							
University/Academia/Research	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
FQHC/Department of Health	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Nonprofit	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Private	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Provider Type							
Physician	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Mid-level providers[1]	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Nurse	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Medical Assistant	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Pharmacist	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Social worker/case manager/PrEP educator/PrEP navigator	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Office administrator /clinic administrator/front desk staff/scheduler	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Laboratory staff/technician/phlebotomist/other	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)

AIM – TELEHEALTH	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
Items							
1. The idea of telehealth for APREITUDE in our clinic/practice meets my approval.	XX	X.X	X.XX	X.XX (X.XX,X.XX)	X.X (X, X)	XX (XX.X)	(X.XX, X.XX)
2. The idea of telehealth for APREITUDE in our clinic/practice is appealing to me.	XX	X.X	X.XX	X.XX (X.XX,X.XX)	X.X (X, X)	XX (XX.X)	(X.XX, X.XX)
3. I like the idea of telehealth for APREITUDE in our clinic/practice.	XX	X.X	X.XX	X.XX (X.XX,X.XX)	X.X (X, X)	XX (XX.X)	(X.XX, X.XX)
4. I welcome telehealth for APREITUDE in our clinic/practice.	XX	X.X	X.XX	X.XX (X.XX,X.XX)	X.X (X, X)	XX (XX.X)	(X.XX, X.XX)

[1] Mid-level providers include nurse practitioners and physician assistants.

**Table 1.303    Distributional Characteristics of the Feasibility of Intervention Measure (FIM - TELEHEALTH) (Month 1), N=XX**

FIM - TELEHEALTH	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
Mean Score	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
<b>Study Arm</b>							
Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
<b>Clinic Type</b>							
University/Academia/Research	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
FQHC/Department of Health	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Nonprofit	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Private	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
<b>Provider Type</b>							
Physician	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Mid-level providers[1]	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Nurse	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Medical Assistant	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Pharmacist	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Social worker/case manager/PrEP educator/PrEP navigator	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Office administrator /clinic administrator/front desk staff/scheduler	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Laboratory staff/technician/phlebotomist/o ther	XX	X.XX	X.XXX	X.XX (X.XX,X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)

FIM - TELEHEALTH	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
<b>Items</b>							
1. Telehealth for APREITUDE seems implementable in our clinic/practice	XX	X.X	X.XX	X.XX (X.XX,X.XX)	X.X (X, X)	XX (XX.X)	(X.XX, X.XX)
2. Telehealth for APREITUDE seems possible in our clinic/practice	XX	X.X	X.XX	X.XX (X.XX,X.XX)	X.X (X, X)	XX (XX.X)	(X.XX, X.XX)
3. Telehealth for APREITUDE seems doable in our clinic/practice	XX	X.X	X.XX	X.XX (X.XX,X.XX)	X.X (X, X)	XX (XX.X)	(X.XX, X.XX)
4. Telehealth for APREITUDE seems easy to use in our clinic/practice	XX	X.X	X.XX	X.XX (X.XX,X.XX)	X.X (X, X)	XX (XX.X)	(X.XX, X.XX)

[1] Mid-level providers include nurse practitioners and physician assistants.

Table 1.304 Summary of Feasibility and Acceptability of Telehealth (Month 1), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
19	Does your clinic/practice use any form of telehealth (i.e., use of electronic information and telecommunication technologies)?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
20	What are the current telehealth services and capabilities of your clinic/practice?				
		Video Consultation: Using Videoconferencing Technology To Facilitate A Patient Visit With Both Physician And Patient Present At The Same Time.	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Telephone Consultation And Visits	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Remote Monitoring Of Patient Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Online Appointment Scheduling: Ability For Patients To Make Appointments Without Interacting With Staff	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Patient Portal Conversations: Ability For Patients To Send Messages In An Online Portal	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		At-Home Testing Services: Providers Order Tests And Send To Patient's Home To Complete			
		Sending And Receiving Patient Reported Outcomes Questionnaires (E.G., Quality Of Life, Health Behaviors), Via An Online System	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Online Prescription Refill Requests	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Online Portal For Patients To Access Medical Documents, Such As Visit Summaries And Test Results	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Text Messaging With Patients About Care	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Email Reminders To Patients About Upcoming Visits	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Text Reminders	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Automated Phone Call Reminder	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Staff Phone Call Reminder	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Sending Motivational Reminders To Adhere To Care	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
21	Overall, how comfortable are you using telehealth systems to care for patients?				
		Very Comfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Comfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither Comfortable Nor Uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Uncomfortable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Using The Telehealth Systems Is Not Part Of My Role	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
22	Why is telehealth not used by your clinic/practice?				
		Do Not Know How To Use Telehealth	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Telehealth Is Too Expensive	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Telehealth Is Too Impersonal	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Telehealth Does Not Allow Staff To Do The Necessary Physical Exams	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Concerns About Telehealth Privacy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Lack Of Patient Access To Computers And/Or The Internet	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
23	How easy or difficult do you think it would be for your clinic/practice to implement the following modules via telehealth to provide APREITUDE services?				
	Digital Assmt to Patients Before Appt	Very Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither Easy Nor Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Online Schedule/Reschedule Cons/Inj Appt	Very Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Somewhat Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither Easy Nor Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	HIV Test Service: At Home Testing Kit	Very Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither Easy Nor Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	HIV Test Service: Lab Testing	Very Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither Easy Nor Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	HIV Test Service: Clinic Appt for Test	Very Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither Easy Nor Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Video/VR Consult. for Initial/FU Visits	Very Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither Easy Nor Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Insurance/Benefits Verifications	Very Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Neither Easy Nor Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Send Oral Lead-in to Patient's Home	Very Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither Easy Nor Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Home Health Nurse to Administer Inj	Very Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither Easy Nor Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Clinic Appt to Receive Only Injection	Very Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither Easy Nor Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Alt Inj Site for Inj Administration	Very Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither Easy Nor Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Inj Appt Reminders: Text, Digital, Email	Very Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Neither Easy Nor Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Motiv Rem to Patient Persist on APRETUDE	Very Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither Easy Nor Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 1.401 Summary of Utility of Proposed Implementation Strategies (Month 1), N=XX

24. How useful will the following be in the implementation of APRETUDE into your practice/clinic?	Total Sample n (%)	Not at all useful n (%)	A little useful n (%)	Somewhat useful n (%)	Useful n (%)	Very useful n (%)
A. Sexual Health Assessment tool: short assessment sent digitally to patients before their appointment <sup>1</sup>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
B. Frequently Asked Questions Brochure – designed to answer questions providers may have when implementing APRETUDE in their practice	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
C. Readiness Consideration – checklist that helps providers assess readiness to prescribe APRETUDE in the practice	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
D. Getting Started Overview - guide that provides initiation and administration guidance for the APRETUDE injections, along with some additional helpful resources, including information on the acquisition process	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

24. How useful will the following be in the implementation of APRETUDE into your practice/clinic?	Total Sample n (%)	Not at all useful n (%)	A little useful n (%)	Somewhat useful n (%)	Useful n (%)	Very useful n (%)
E. Injection Education Video – walks through the process of administering APRETUDE injection	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
F. Provider Website – location where all materials and videos on APRETUDE for the study are located <sup>2</sup>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
G. Patient materials (e.g., welcome brochure)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
H. Implementation Guidance Video – guidance on how to implement APRETUDE into the clinic/practice	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
I. Appointment scheduler – planner to help schedule patient's appointment accounting for target injection date	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

24. How useful will the following be in the implementation of APRETUDE into your practice/clinic?	Total Sample n (%)	Not at all useful n (%)	A little useful n (%)	Somewhat useful n (%)	Useful n (%)	Very useful n (%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
J. Pre-scheduled appointment Guidance – document on how to preschedule appointments <sup>1</sup>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
K. Designated injection days Guidance – document on how to use designated injections day(s)/specific days for patients to receive injections <sup>1</sup>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
L. Drop-in Injection Visits Guidance – document on how to provide injection only/drop-in visits <sup>1</sup>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
M. Providing transportation support to patients to appointments <sup>1</sup>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
N. One-on-one monthly implementation facilitation calls to help problem solve issues during implementation <sup>1</sup>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
O. Group implementation facilitation calls to help problem	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

24. How useful will the following be in the implementation of APREUDE into your practice/clinic?	Total Sample n (%)	Not at all useful n (%)	A little useful n (%)	Somewhat useful n (%)	Useful n (%)	Very useful n (%)
solve issues during implementation with other clinics/practices						
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
P. Document on how to discuss sexual health <sup>1</sup>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Q. PrEP Options Communication tool – infographic to help discuss the pros and cons of PrEP options with patients to help patients decide on a PrEP option <sup>1</sup>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
R. Information on transgender-friendly care [1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

[1] Only SSPs in the Dynamic Implementation were asked this question

**Table 1.501 Summary of Perceived Barriers to Delivering APRETUDE to Patients (Month 1), N=XX**

41. Please indicate how concerned you would be about each of the following being a barrier or challenge to delivering APRETUDE to patients based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
<b>A. Patients' ability to keep appointments</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>B. Patients' injection-related pain/soreness</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>C. Risk of drug resistance for patients not adherent to injections</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>D. Cost of APRETUDE</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

41. Please indicate how concerned you would be about each of the following being a barrier or challenge to delivering APRETUDE to patients based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
<b>E. Keeping a patient engaged and motivated to continue APRETUDE</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>F. Identifying eligible individuals for APRETUDE</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>G. Worried that a patient will feel stigmatized if offered APRETUDE</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>H. Patients' willingness to travel every 2 months for an injection appointment</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>I. Patient lack of belief in the efficacy of APRETUDE</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



41. Please indicate how concerned you would be about each of the following being a barrier or challenge to delivering APRETUDE to patients based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 1.502 Summary of Perceptions of Administering APRETUDE (Month 1), N=XX

42. Please indicate how concerned you would be about each of the following being a barrier or challenge to APRETUDE administration based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
<b>A. Difficulty of giving the gluteal medial injection</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>B. Understanding how to manage patients who miss an injection dose</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>C. How to transition patients off of APRETUDE who want to stop taking it (e.g., should other PrEP be offered)</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>D. Understanding how to use oral PrEP medication for a <u>planned</u> missed injection visit</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

42. Please indicate how concerned you would be about each of the following being a barrier or challenge to APRETUDE administration based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>E. Understanding how to restart APRETUDE after a missed injection</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>F. Managing the oral lead-in phase of APRETUDE before starting injections if needed</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>G. Ability to provide adherence counseling and support, when injection dosing visits are missed</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 1.503 Summary of Perceived Barriers to Managing Delivery of APRETUDE (Month 1), N=XX**

43. Please indicate how concerned you would be about each of the following being a barrier or challenge to APRETUDE delivery based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
<b>A. Management of scheduling injection appointments every 2 months during correct injection (i.e., dosing) windows</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>B. Management of rescheduling appointments during correct injection (i.e., dosing) windows</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>C. Ability to schedule/reschedule patients who missed APRETUDE visits within correct injection (i.e., dosing) windows</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>D. Ability to identify and flag missed injection visits to providers (in a timely manner)</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

43. Please indicate how concerned you would be about each of the following being a barrier or challenge to APRETUDE delivery based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>E. Ability to manage patients presenting to APRETUDE injection appointments with other care needs that need to be addressed</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>F. Persistence to follow up with patient on missed appointments</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>G. Provider time to discuss HIV prevention with all eligible patients</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>H. Ability to provide HIV screening as indicated at each injection visit and</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

43. Please indicate how concerned you would be about each of the following being a barrier or challenge to APRETUDE delivery based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
<b>provide rapid intervention/follow-up based on results status</b>						
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>I. HIV monitoring requirements associated with APRETUDE</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 1.504 Summary of Perceived Resourcing Barriers to Support Delivery of APREUDE (Month 1), N=XX**

44. Please indicate how concerned you would be about each of the following potentially being a barrier or challenge to APREUDE delivery based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
<b>A. Staff resourcing to ensure appropriate clinic flow</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>B. Number of exam rooms for injections</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>C. Clinic staff to administer injections</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

44. Please indicate how concerned you would be about each of the following potentially being a barrier or challenge to APRETUDE delivery based on your current expectations and knowledge.						
	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
<b>D. Staff preparation (i.e., education, training, in-services) to implement APRETUDE</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>E. Staff time to provide counseling and support to patients, such as answering questioning between visit, keeping patients motivated</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>F. Staff belief in the efficacy of APRETUDE</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



44. Please indicate how concerned you would be about each of the following potentially being a barrier or challenge to APREUDE delivery based on your current expectations and knowledge.	<div> <div></div> <div></div> <div></div> <div></div> <div></div> <div></div> </div>					
	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 1.505 Summary of Perceptions of Clinic/Practice Culture and Environment

45. How much do you agree or disagree with the following statements about your clinic/practice?	Total Sample n (%)	Completely Disagree n (%)	Disagree n (%)	Neither agree nor disagree n (%)	Agree n (%)	Completely Agree n (%)
<b>A. People at all levels openly talk about what is and isn't working</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>B. Most people in this clinic are willing to change how they do things in response to feedback from others</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>C. It is hard to get things to change in our clinic</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>D. People in this clinic operate as a real team</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation						
<b>Site Volume</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low						
<b>E. Staff members often show signs of stress and strain</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						

45. How much do you agree or disagree with the following statements about your clinic/practice?	Total Sample n (%)	Completely Disagree n (%)	Disagree n (%)	Neither agree nor disagree n (%)	Agree n (%)	Completely Agree n (%)
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>F. We regularly take time to consider ways to improve how we do things</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>G. Leadership strongly supports clinic change efforts</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 1.506 Summary of Barriers to PrEP Provisioning (Month 1), N=XX

68. Indicate your level of agreement with the following statements:	Total Sample n (%)	Completely Disagree n (%)	Disagree n (%)	Neither agree nor disagree n (%)	Agree n (%)	Completely Agree n (%)
<b>A. The use of PrEP will cause patients to engage in riskier behaviors</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>B. Providing PrEP endorses the risk behaviors of users</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>C. Only people who engage in risky behavior need PrEP</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>D. Only people with many sexual partners need PrEP</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation						
<b>Site Volume</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low						
<b>E. All sexually active people can benefit from PrEP</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

68. Indicate your level of agreement with the following statements:	Total Sample n (%)	Completely Disagree n (%)	Disagree n (%)	Neither agree nor disagree n (%)	Agree n (%)	Completely Agree n (%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>F. Providing PrEP will result in an increase in sexually transmitted diseases among patients</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>G. People do not need PrEP if they act responsibly</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 1.601 Summary of the Sexual Health Assessment Tool (Month 1), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
25	Has your clinic/practice started to use the Sexual Health Assessment Tool?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
26	Who in your clinic/practice is or will be responsible for distributing the Sexual Health Assessment tool to patients?				
		Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Nurse Practitioner/Physician Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Social Worker/Case Manager	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Front Desk Staff/Scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Peer Educator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
27	Who in your clinic/practice is or will be responsible for reviewing and discussing the results of the Sexual Health Assessment tool with patients?				
		Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Nurse Practitioner/Physician Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Social Worker/Case Manager	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Front Desk Staff/Scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Peer Educator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The Results Are Or Will Not Be Discussed With Patients	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
28	How often is your clinic/practice planning to use the Sexual Health Assessment tool with each patient?				
		Annually With Each Patient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		As Needed Based On Patient Behaviors	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		As Needed Based On Patient Demographics	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Before Every Visit With Each Patient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
29	"Please indicate your level of agreement with the following statements about the Sexual Health Tool."				
	The Sexual Health Assessment Tool is/will be easy to implement in my clinic/practice	Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither Agree Nor Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The Sexual Health Assessment Tool is/will be an easy way to identify individuals interested in PrEP	Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither Agree Nor Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
	The Sexual Health Assessment Tool helps/will help to facilitate conversations about PrEP with patients	Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither Agree Nor Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



Table 1.602 Summary of the PrEP Communication Tool (Month 1), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
30	Has your clinic/practice started to use PrEP Options Communication Tool?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
31	Who in your clinic/practice is or will be responsible for using the PrEP Options Communication Tool with patients?				
		Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Nurse Practitioner/Physician Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Social Worker/Case Manager	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Front Desk Staff/Scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Peer Educator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
32	How often is your clinic/practice planning to use PrEP Options Communication Tool with each patient?				
		Annually With Each Patient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Before Every Visit With Each Patient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		As Needed Based On Patient Demographics	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		As Needed Based On Patient Behaviors	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
33	“Please indicate your level of agreement with the following statements about the PrEP Options Communication Tool”				
	The PrEP Options Communication Tool will be easy to implement in my clinic/practice	Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither Agree Nor Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The PrEP Options Communication Tool will help to facilitate conversations about PrEP with patients	Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither Agree Nor Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 1.701 Summary of the Optional Oral Lead-in Phase of APRETUDE (Month 1), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
62	What sources of information will you draw upon in assessing whether an oral lead-in is needed or not?				
		Scientific Literature	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Independent Medical Education	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Data From Viiv/Gsk	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Scientific Conferences	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Clinic Rounds	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Cdc Guidelines	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other Medical Colleagues	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A Little Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
63	What are the main factors that will drive your decision to use oral lead-in?				
		The Ability To Assess The Safety/Tolerability Of Apretude In All Patients	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The Ability To Assess The Safety/Tolerability Of Apretude In Patients With A History Of Allergy/Drug Intolerance	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The Availability Of More Data From Clinical Trials Using An Oral Lead-In Phase	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The Ability To Increase Drug Concentration Before Starting The Injections	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Being Cautious With A New Medication	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Providing Patient With Protection Against HIV Until The Injection Arrives	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Patient Request	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
64	How influential would you say the patient's preferences will be in the decision of whether or not to use an oral lead-in phase?				
		Very Influential	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Influential	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Influential	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not Very Influential	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not At All Influential	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
65	Are you prescribing or planning to prescribe optional oral lead-in for APRETUDE prior to the first injection?				
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes, For All Patients	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes, For Some Patients	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not Sure	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
66	For patients who plan to miss an injection, what protection do you offer or plan on offering them until they receive their next injection?				
		Cabotegravir Oral Tablets	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Tdf/Ftc	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Taf/Ftc	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Provision Of Condoms	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Risk Reduction Education	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		None	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 1.702 Summary of Study Staff Participants' Injectable Cabotegrevir Experience (Month 1), N=XX**

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
60	Does your clinic/practice currently administer CABENUVA, the long acting injectable treatment for people living with HIV?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
61	How easy or difficult has it been to implement CABENUVA in your clinic/practice?				
		Very Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither Easy Nor Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
67	"Please rate how appropriate you believe each setting would be for administering the APRETUDE."				
	HIV-Specialty Clinic	Very Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A Little Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not At All Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Primary Care Clinic/Private Practice	Very Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A Little Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Not At All Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Women's Health Practice/Center	Very Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A Little Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not At All Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Community Health Center	Very Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A Little Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not At All Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Hospital Outpatient	Very Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A Little Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not At All Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Retail Pharmacy	Very Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A Little Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not At All Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other Pharmacy	Very Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A Little Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not At All Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	At Home/Home-based Bare	Very Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A Little Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not At All Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Community Based Organization	Very Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A Little Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not At All Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Infusion Center	Very Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A Little Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not At All Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	STD/STI Clinic	Very Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		A Little Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not At All Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	PrEP Clinic	Very Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A Little Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not At All Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Department of Health Clinic	Very Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A Little Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not At All Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other(s), please specify	Very Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A Little Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not At All Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



**Table 1.801 Summary of Perceived Number of APRETUDE Patients Clinic/Practice Can Manage Per Week on an Ongoing Basis (Month 1), N=XX**

46. How many APRETUDE patients do you think your clinic/practice can manage per week on an ongoing basis?	Total Sample n (%)	0-10 Patients n (%)	11-25 Patients n (%)	26-50 Patients n (%)	51-100 Patients n (%)	101-200 Patients n (%)	>200 Patients n (%)	I don't know n=xx (%)
<b>Total Sample</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>								
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>								
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 1.802    Distributional Characteristics of Reported Number of People in Clinic Trained and Prepared to Give APRETUDE Injections (Month 1), N=XX**

47. Approximately how many people in your clinic are trained and prepared to give APRETUDE injections?	Total Sample n (%)	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum and Maximum)	Missing n (%)	95% CI for the Mean	I don't know n (%)
<b>Total Sample</b>	XX (XX.X)	X.X	X.XX	X.X (X.X,X.X)	XX (XX, XX)	XX (XX.X%)	(X.XX, X.XX)	XX (XX.X%)
<b>Study Arm</b>								
Dynamic Implementation	XX (XX.X)	X.X	X.XX	X.X (X.X,X.X)	XX (XX, XX)	XX (XX.X%)	(X.XX, X.XX)	XX (XX.X%)
Routine Implementation	XX (XX.X)	X.X	X.XX	X.X (X.X,X.X)	XX (XX, XX)	XX (XX.X%)	(X.XX, X.XX)	XX (XX.X%)
<b>Site Volume</b>								
High	XX (XX.X)	X.X	X.XX	X.X (X.X,X.X)	XX (XX, XX)	XX (XX.X%)	(X.XX, X.XX)	XX (XX.X%)
Low	XX (XX.X)	X.X	X.XX	X.X (X.X,X.X)	XX (XX, XX)	XX (XX.X%)	(X.XX, X.XX)	XX (XX.X%)

**Table 1.803**    Distributional Characteristics of Estimated Number of Staff Needed Per Week to Incorporate APRETUDE into Clinic/Practice for Approximately 25 People (Month 1), N=XX

48. How much staff in total do you estimate will be needed per week to incorporate APRETUDE into your clinic/practice for approximately 25 people?	Total Sample n (%)	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum and Maximum)	Percent Missing	95% CI for the Mean	I don't know n (%)
<b>Total Sample</b>	XX (XX.X)	XX (XX.X)	X.XX	X.XXX	X.XX (X.XX, X.XX)	XX.X (XX.X, XX.X)	XX (XX.X%)	(X.XXX, X.XXX)	XX (XX.X%)
<b>Study Arm</b>									
Dynamic Implementation	XX (XX.X)	XX (XX.X)	X.XX	X.XXX	X.XX (X.XX, X.XX)	XX.X (XX.X, XX.X)	XX (XX.X%)	(X.XXX, X.XXX)	XX (XX.X%)
Routine Implementation	XX (XX.X)	XX (XX.X)	X.XX	X.XXX	X.XX (X.XX, X.XX)	XX.X (XX.X, XX.X)	XX (XX.X%)	(X.XXX, X.XXX)	XX (XX.X%)
<b>Site Volume</b>									
High	XX (XX.X)	XX (XX.X)	X.XX	X.XXX	X.XX (X.XX, X.XX)	XX.X (XX.X, XX.X)	XX (XX.X%)	(X.XXX, X.XXX)	XX (XX.X%)
Low	XX (XX.X)	XX (XX.X)	X.XX	X.XXX	X.XX (X.XX, X.XX)	XX.X (XX.X, XX.X)	XX (XX.X%)	(X.XXX, X.XXX)	XX (XX.X%)

**Table 1.804 Summary of Estimated Percentage of Staff Time/Full-Time Equivalent Hours Needed Per Week to Incorporate APRETUDE into Clinic/Practice for Approximately 25 People (Month 1), N=XX**

49. How much staff time/full-time equivalent hours (FTE) do you estimate will be needed per week to incorporate APRETUDE into your clinic/practice for approximately 25 people?	Total Sample n (%)	1-20% FTE or 0.4 - 8hrs of staff time n (%)	21-40% FTE or 8.4 - 16hrs of staff time n (%)	41-60% FTE or 16.4 - 24 hrs of staff time n (%)	61-80% FTE or 24.4 - 32hrs of staff time n (%)	81-100% FTE or 32.4 - 40hrs of staff time n (%)	I don't know n (%)
<b>Total Sample</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>							
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>							
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 1.805 Summary of Plans to Create New Roles/Positions in Clinic to Coordinate the APRETUDE Program (Month 1), N=XX**

50. Do you plan to create new role(s)/new position(s) in your clinic to coordinate the APRETUDE program?	Total Sample n (%)	Yes n (%)	No n (%)	Maybe n (%)	I don't know n (%)
<b>Total Sample</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>					
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>					
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 1.806 Summary of Number of New Roles/Positions in Clinic to Coordinate the APREUDE Program (Month 1), N=XX**

51. How many new role(s)/new position(s) are you planning to create in your clinic to coordinate the APREUDE program? [1]	Total Sample n (%)	1 n (%)	2 n (%)	3 n (%)	4 n (%)	5 n (%)	More than 5 n (%)	I don't know n (%)
<b>Total Sample</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>								
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>								
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

[1] Only includes SSPs who responded 'yes' or 'maybe' to 'Do you plan to create new role(s)/new position(s) in your clinic to coordinate the APREUDE program?'

**Table 1.807 Summary of How Clinic/Practice Plans to Track Patients on APREUDE (Month 1), N=XX**

52. How does your clinic/practice plan to track patients on APREUDE?	Total Sample n (%)	Use a spreadsheet such as MS Excel n (%)	Assign specific staff to track patients n (%)	Have providers track their own patients n (%)	Create alerts in electronic medical records (EMRs) n (%)	Other [1] n (%)	I don't know n (%)
<b>Total Sample</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>							
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>							
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

[1] Other responses include: xxxxx

**Table 1.808 Summary of How Clinic/Practice Responds to Patients who Do Not Show for a Regularly Scheduled Appointment (Month 1), N=XX**

53. What does your clinic/practice do if a patient does not show for a regularly scheduled appointment?	Total Sample n (%)	Phone the patient to reschedule n (%)	Text the patient to reschedule n (%)	Email the patient to reschedule n (%)	Send the patient a postal letter to reschedule n (%)	Wait until the patient contacts the clinic/practice to reschedule n (%)	Charge the patient a fee for not showing up n (%)	I don't know/not applicable to role n (%)	Other [1] n (%)
<b>Total Sample</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>									
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>									
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

[1] Other responses include: xxxxx



**Table 1.809 Summary Characteristics of Whether Clinic/Practice has Specific Person in Charge of Following Up on No-Shows (Month 1), N=XX**

54. Is there a specific person in charge of following up on no-shows?	Total Sample n (%)	Yes n (%)	No n (%)	I don't know n (%)
<b>Total Sample</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>				
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>				
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 1.810 Summary of Type of Systems Clinic has in Place to Remind Patients of Upcoming Appointments (Month 1), N=XX**

55. What type of systems does your clinic have in place to remind patients of an upcoming appointment?[1]	Total Sample n (%)	Phone Call from Staff n (%)	Automated Phone call n (%)	Text Message n (%)	Email n (%)	Postal Mail n (%)	Phone App Notification n (%)	Other [2] n (%)
<b>Total Sample</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>								
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>								
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

[1] Responses are not mutually exclusive; participants can select all that apply

[2] Other responses included: xxxxx

**Table 1.811 Summary of Type of Systems Clinic has in Place to Offer Upcoming Appointments (Month 1), N=XX**

56. How do you plan to offer appointments for APRETUDE injections? [1]	Total Sample	Study Arm		Site Volume	
		Dynamic Implementation	Routine Implementation	High	Low
	n (%)	n (%)	n (%)	n (%)	n (%)
Appointments each day of the week	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Appointments only on certain days of the week	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Appointments spread out over the month	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Injection only appointments	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Allow patients to drop-in for injections on any day without an appointment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Allow patients to drop-in with little advanced notice (e.g., 24 hour notice)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Allow patients to drop-in on a specific injection day without an appointment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
After hours appointments	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Appointments each day of the week	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Before hours appointment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Weekend appointments	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Home nursing appointments	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mobile clinic option	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Alternate site appointments	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Depends on the schedule of the injection nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Depends on the schedule of the APRETUDE provider	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 1.812 Summary of Implementing APRETUDE in Practice (Month 1), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
57	Does your clinic/practice currently offer the following types of appointments to patients for any of your services?				
	After Hours	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Before Hours	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Weekend Hours	No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Home Nursing	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Mobile Clinic	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Drop-in visits without prior appointment	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Drop-in visits with little advance scheduling	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
58	How do you feel about implementing APRETUDE at your clinic/practice?	Extremely Positive	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Positive	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Positive	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A Little Positive	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not At All Positive	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
59	How easy or difficult will it be to implement APRETUDE into your current workflow?	Very Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Somewhat Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither Easy Nor Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 1.901 Distributional Characteristics of Select Study Site Characteristics (Month 1), N=XX

Question Number	Question	Response	Statistics	Total (N = XX)	Dynamic Implementation (N = XX)	Routine Implementation (N = XX)
2	Please estimate the percentage of your patients with the following types of insurance/health coverage.					
		% of Medicare	n Mean SD Minimum Q1 Median Q3 Maximum	XX XX.X XX.XX XX.X XX.X XX.X XX.X XX.X	XX XX.X XX.XX XX.X XX.X XX.X XX.X XX.X	XX XX.X XX.XX XX.X XX.X XX.X XX.X XX.X
		% of Medicaid	n Mean SD Minimum Q1 Median Q3 Maximum	XX XX.X XX.XX XX.X XX.X XX.X XX.X XX.X	XX XX.X XX.XX XX.X XX.X XX.X XX.X XX.X	XX XX.X XX.XX XX.X XX.X XX.X XX.X XX.X
		% of Federal (VA, TRICARE, IHS)	n Mean SD Minimum Q1 Median Q3 Maximum	XX XX.X XX.XX XX.X XX.X XX.X XX.X XX.X	XX XX.X XX.XX XX.X XX.X XX.X XX.X XX.X	XX XX.X XX.XX XX.X XX.X XX.X XX.X XX.X
		% of Private/Commercial Insurance	n Mean SD Minimum Q1 Median	XX XX.X XX.XX XX.X XX.X XX.X	XX XX.X XX.XX XX.X XX.X XX.X	XX XX.X XX.XX XX.X XX.X XX.X

Question Number	Question	Response	Statistics	Total (N = XX)	Dynamic Implementation (N = XX)	Routine Implementation (N = XX)
			Q3 Maximum	XX.X XX.X	XX.X XX.X	XX.X XX.X
		% of Self-pay	n Mean SD Minimum Q1 Median Q3 Maximum	XX XX.X XX.XX XX.X XX.X XX.X XX.X	XX XX.X XX.XX XX.X XX.X XX.X XX.X	XX XX.X XX.XX XX.X XX.X XX.X XX.X
		% of Uninsured	n Mean SD Minimum Q1 Median Q3 Maximum	XX XX.X XX.XX XX.X XX.X XX.X XX.X	XX XX.X XX.XX XX.X XX.X XX.X XX.X	XX XX.X XX.XX XX.X XX.X XX.X XX.X
		% of Other	n Mean SD Minimum Q1 Median Q3 Maximum	XX XX.X XX.XX XX.X XX.X XX.X XX.X	XX XX.X XX.XX XX.X XX.X XX.X XX.X	XX XX.X XX.XX XX.X XX.X XX.X XX.X
4	How many health care providers (e.g., MD/DO, NP, PA) does the clinic/practice have (including both full-time and part-time)?					
		Insert number	n Mean SD Minimum Q1	XX XX.X XX.XX XX.X XX.X	XX XX.X XX.XX XX.X XX.X	XX XX.X XX.XX XX.X XX.X

Question Number	Question	Response	Statistics	Total (N = XX)	Dynamic Implementation (N = XX)	Routine Implementation (N = XX)
			Median	XX.X	XX.X	XX.X
			Q3	XX.X	XX.X	XX.X
			Maximum			
6	Please estimate the total patient population at this clinic/practice					
		Total Pt Population at Clinic/Practice	n	XX	XX	XX
			Mean	XX.X	XX.X	XX.X
			SD	XX.XX	XX.XX	XX.XX
			Minimum	XX.X	XX.X	XX.X
			Q1	XX.X	XX.X	XX.X
			Median	XX.X	XX.X	XX.X
			Q3	XX.X	XX.X	XX.X
			Maximum	XX.X	XX.X	XX.X
7	Please estimate the percentage of the clinic/practice's patient population who are:					
		% of Patients <35 Years Old	n	XX	XX	XX
			Mean	XX.X	XX.X	XX.X
			SD	XX.XX	XX.XX	XX.XX
			Minimum	XX.X	XX.X	XX.X
			Q1	XX.X	XX.X	XX.X
			Median	XX.X	XX.X	XX.X
			Q3	XX.X	XX.X	XX.X
			Maximum	XX.X	XX.X	XX.X
		% of Patients 35-50 Years Old	n	XX	XX	XX
			Mean	XX.X	XX.X	XX.X
			SD	XX.XX	XX.XX	XX.XX
			Minimum	XX.X	XX.X	XX.X
			Q1	XX.X	XX.X	XX.X
			Median	XX.X	XX.X	XX.X
			Q3	XX.X	XX.X	XX.X
			Maximum	XX.X	XX.X	XX.X
		% of Patients >50 Years Old	n	XX	XX	XX
			Mean	XX.X	XX.X	XX.X
				XX.XX	XX.XX	XX.XX



Question Number	Question	Response	Statistics	Total (N = XX)	Dynamic Implementation (N = XX)	Routine Implementation (N = XX)
			SD	XX.X	XX.X	XX.X
			Minimum	XX.X	XX.X	XX.X
			Q1	XX.X	XX.X	XX.X
			Median	XX.X	XX.X	XX.X
			Q3	XX.X	XX.X	XX.X
			Maximum			
8	Please estimate the percentage of the clinic/practice's patient population who are:					
		% of Transgender Women	n	XX	XX	XX
			Mean	XX.X	XX.X	XX.X
			SD	XX.XX	XX.XX	XX.XX
			Minimum	XX.X	XX.X	XX.X
			Q1	XX.X	XX.X	XX.X
			Median	XX.X	XX.X	XX.X
			Q3	XX.X	XX.X	XX.X
			Maximum	XX.X	XX.X	XX.X
		% of Transgender Men	n	XX	XX	XX
			Mean	XX.X	XX.X	XX.X
			SD	XX.XX	XX.XX	XX.XX
			Minimum	XX.X	XX.X	XX.X
			Q1	XX.X	XX.X	XX.X
			Median	XX.X	XX.X	XX.X
			Q3	XX.X	XX.X	XX.X
			Maximum	XX.X	XX.X	XX.X
		% of Cisgender Heterosexual Men	n	XX	XX	XX
			Mean	XX.X	XX.X	XX.X
			SD	XX.XX	XX.XX	XX.XX
			Minimum	XX.X	XX.X	XX.X
			Q1	XX.X	XX.X	XX.X
			Median	XX.X	XX.X	XX.X
			Q3	XX.X	XX.X	XX.X
			Maximum	XX.X	XX.X	XX.X
		% of Cisgender Heterosexual Women	n	XX	XX	XX
			Mean	XX.X	XX.X	XX.X

Question Number	Question	Response	Statistics	Total (N = XX)	Dynamic Implementation (N = XX)	Routine Implementation (N = XX)
			SD	XX.XX	XX.XX	XX.XX
			Minimum	XX.X	XX.X	XX.X
			Q1	XX.X	XX.X	XX.X
			Median	XX.X	XX.X	XX.X
			Q3	XX.X	XX.X	XX.X
			Maximum	XX.X	XX.X	XX.X
		% of Cisgender Men Who Have Sex With Men	n	XX	XX	XX
			Mean	XX.X	XX.X	XX.X
			SD	XX.XX	XX.XX	XX.XX
			Minimum	XX.X	XX.X	XX.X
			Q1	XX.X	XX.X	XX.X
			Median	XX.X	XX.X	XX.X
			Q3	XX.X	XX.X	XX.X
			Maximum	XX.X	XX.X	XX.X
		% of Non-binary	n	XX	XX	XX
			Mean	XX.X	XX.X	XX.X
			SD	XX.XX	XX.XX	XX.XX
			Minimum	XX.X	XX.X	XX.X
			Q1	XX.X	XX.X	XX.X
			Median	XX.X	XX.X	XX.X
			Q3	XX.X	XX.X	XX.X
			Maximum	XX.X	XX.X	XX.X
9	Among patients who are transgender men, please estimate the percentage who are:					
		% of Black/African American,Non-Hispanic	n	XX	XX	XX
			Mean	XX.X	XX.X	XX.X
			SD	XX.XX	XX.XX	XX.XX
			Minimum	XX.X	XX.X	XX.X
			Q1	XX.X	XX.X	XX.X
			Median	XX.X	XX.X	XX.X
			Q3	XX.X	XX.X	XX.X
			Maximum	XX.X	XX.X	XX.X

Question Number	Question	Response	Statistics	Total (N = XX)	Dynamic Implementation (N = XX)	Routine Implementation (N = XX)
		% of White, Non-Hispanic	n Mean SD Minimum Q1 Median Q3 Maximum	XX XX.X XX.XX XX.X XX.X XX.X XX.X XX.X	XX XX.X XX.XX XX.X XX.X XX.X XX.X XX.X	XX XX.X XX.XX XX.X XX.X XX.X XX.X XX.X
		% of Latinx/Latino	n Mean SD Minimum Q1 Median Q3 Maximum	XX XX.X XX.XX XX.X XX.X XX.X XX.X XX.X	XX XX.X XX.XX XX.X XX.X XX.X XX.X XX.X	XX XX.X XX.XX XX.X XX.X XX.X XX.X XX.X
		% of Other Race/Ethnicity, Non-Hispanic	n Mean SD Minimum Q1 Median Q3 Maximum	XX XX.X XX.XX XX.X XX.X XX.X XX.X XX.X	XX XX.X XX.XX XX.X XX.X XX.X XX.X XX.X	XX XX.X XX.XX XX.X XX.X XX.X XX.X XX.X
10	Among patients who are men who have sex with men, please estimate the percentage who are:					
		% of Black/African American, Non-Hispanic	n Mean SD Minimum Q1 Median Q3	XX XX.X XX.XX XX.X XX.X XX.X XX.X	XX XX.X XX.XX XX.X XX.X XX.X XX.X	XX XX.X XX.XX XX.X XX.X XX.X XX.X

Question Number	Question	Response	Statistics	Total (N = XX)	Dynamic Implementation (N = XX)	Routine Implementation (N = XX)
			Maximum			
		% of White, Non-Hispanic	n	XX	XX	XX
			Mean	XX.X	XX.X	XX.X
			SD	XX.XX	XX.XX	XX.XX
			Minimum	XX.X	XX.X	XX.X
			Q1	XX.X	XX.X	XX.X
			Median	XX.X	XX.X	XX.X
			Q3	XX.X	XX.X	XX.X
			Maximum	XX.X	XX.X	XX.X
		% of Latinx/Latino	n	XX	XX	XX
			Mean	XX.X	XX.X	XX.X
			SD	XX.XX	XX.XX	XX.XX
			Minimum	XX.X	XX.X	XX.X
			Q1	XX.X	XX.X	XX.X
			Median	XX.X	XX.X	XX.X
			Q3	XX.X	XX.X	XX.X
			Maximum	XX.X	XX.X	XX.X
		% of Other Race/Ethnicity, Non-Hispanic	n	XX	XX	XX
			Mean	XX.X	XX.X	XX.X
			SD	XX.XX	XX.XX	XX.XX
			Minimum	XX.X	XX.X	XX.X
			Q1	XX.X	XX.X	XX.X
			Median	XX.X	XX.X	XX.X
			Q3	XX.X	XX.X	XX.X
			Maximum	XX.X	XX.X	XX.X
11	In the last year, what was the estimated number of HIV-negative patients seen at your clinic/practice?					
		Estimated HIV-negative Pt seen at Clinic	n	XX	XX	XX
			Mean	XX.X	XX.X	XX.X
			SD	XX.XX	XX.XX	XX.XX
			Minimum	XX.X	XX.X	XX.X
			Q1	XX.X	XX.X	XX.X
			Median	XX.X	XX.X	XX.X

Question Number	Question	Response	Statistics	Total (N = XX)	Dynamic Implementation (N = XX)	Routine Implementation (N = XX)
			Q3	XX.X	XX.X	XX.X
			Maximum	XX.X	XX.X	XX.X
12	How many patients would you estimate received oral PrEP at the clinic/practice in the last year? Please provide for entire clinic/practice					
		HIV PrEP Seeking Persons Clinic See	n	XX	XX	XX
			Mean	XX.X	XX.X	XX.X
			SD	XX.XX	XX.XX	XX.XX
			Minimum	XX.X	XX.X	XX.X
			Q1	XX.X	XX.X	XX.X
			Median	XX.X	XX.X	XX.X
			Q3	XX.X	XX.X	XX.X
			Maximum	XX.X	XX.X	XX.X
13	How many patients would you estimate received APRETUDE at the clinic/practice in the last year? Please provide estimate for entire clinic/practice. Do not include patients who received APRETUDE in clinical trials.					
		Estimate Pt Initiated Any PrEP Oral/Inj	n	XX	XX	XX
			Mean	XX.X	XX.X	XX.X
			SD	XX.XX	XX.XX	XX.XX
			Minimum	XX.X	XX.X	XX.X
			Q1	XX.X	XX.X	XX.X
			Median	XX.X	XX.X	XX.X
			Q3	XX.X	XX.X	XX.X
			Maximum	XX.X	XX.X	XX.X
14	How many HIV PrEP seeking persons did the clinic/practice see in the last 3 months? Please provide for the entire clinic/practice					
		Estimate Pt Initiated Any PrEP Oral/Inj	n	XX	XX	XX
			Mean	XX.X	XX.X	XX.X
			SD	XX.XX	XX.XX	XX.XX
			Minimum	XX.X	XX.X	XX.X
			Q1	XX.X	XX.X	XX.X
			Median	XX.X	XX.X	XX.X
			Q3	XX.X	XX.X	XX.X
			Maximum	XX.X	XX.X	XX.X
15	How many patients would you estimate initiated any type of PrEP – oral or injectable – at the clinic/practice in the last 3 months? Please provide for the entire clinic/practice					

Question Number	Question	Response	Statistics	Total (N = XX)	Dynamic Implementation (N = XX)	Routine Implementation (N = XX)
		Estimate Pt Initiated Any PrEP Oral/Inj	n Mean SD Minimum Q1 Median Q3 Maximum	XX XX.X XX.XX XX.X XX.X XX.X XX.X XX.X	XX XX.X XX.XX XX.X XX.X XX.X XX.X XX.X	XX XX.X XX.XX XX.X XX.X XX.X XX.X XX.X
16	How many patients would you estimate initiated APRETUDE in the last 3 months at the clinic/practice? Please provide for the entire clinic/practice					
		Estimate Pt Initiated APRETUDE at Clinic	n Mean SD Minimum Q1 Median Q3 Maximum	XX XX.X XX.XX XX.X XX.X XX.X XX.X XX.X	XX XX.X XX.XX XX.X XX.X XX.X XX.X XX.X	XX XX.X XX.XX XX.X XX.X XX.X XX.X XX.X
17	Of all patients who have been prescribed PrEP at your clinic/practice, how many would you estimate have completed the Sexual Health Assessment? Please provide for entire clinic/practice					
		Est. Pt prescribe PrEP/Complete Sex Asmt	n Mean SD Minimum Q1 Median Q3 Maximum	XX XX.X XX.XX XX.X XX.X XX.X XX.X XX.X	XX XX.X XX.XX XX.X XX.X XX.X XX.X XX.X	XX XX.X XX.XX XX.X XX.X XX.X XX.X XX.X

Table 1.902 Summary of Selected Study Site Characteristics (Month 1), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
1	Which of the following best describes the practice setting or affiliation?				
		AIDS HEALTHCARE FOUNDATION (AHF)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		COMMUNITY BASED-ORGANIZATION/PROVIDER	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		FEDERALLY QUALIFIED HEALTH CENTER (FQHC)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HOSPITAL - GENERAL, COMMUNITY, DISTRICT GENERAL	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		NON-PROFIT/NOT-FOR-PROFIT ORGANIZATION	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		PRIVATE PRACTICE - HIV SPECIALIST (SUCH AS INFECTIOUS DISEASE OR PRIMARY CARE PHYSICIAN W/ SUB-SPECIALTY IN HIV)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		PRIVATE PRACTICE INTERNAL MEDICINE AND HIV SPECIALIST	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		RESEARCH INSTITUTION - NOT UNIVERSITY-BASED	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		UNIVERSITY OR MEDICAL SCHOOL BASED HOSPITAL/ UNIVERSITY ACADEMIC SETTING	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
3	Is the practice/clinic located in an Ending the Epidemic (ETE) County?				
		NO	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		YES	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
5	What types of clinical staff are at the clinic/practice?				
		CRC, PATIENT CARE COORDINATOR	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		FRONT DESK STAFF/ SCHEDULER	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		LABORATORY STAFF/TECHNICIAN/PHLEBOTOMIST	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		MEDICAL ASSISTANT	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		MENTAL HEALTH THERAPIST	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		MOBILE TESTING/WELLNESS CLINIC/MOBILE CLINIC	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		NURSE	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		NURSE PRACTITIONER/ PHYSICIAN ASSISTANT	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		OFFICE ADMINISTRATOR /CLINIC ADMINISTRATOR	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		PHARMACIST	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		PHYSICIAN	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		PREP EDUCATOR/PREP NAVIGATOR	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		SOCIAL WORKER/CASE MANAGER	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



## 6 Tables for Month 4/5 Analysis

Table 2.001	Demographic Characteristics of New Staff Study Participants (Month 4/5), N=XX .....	107
Table 2.002	Demographic Characteristics of Longitudinal* Staff Study Participants (Month 4/5), N=XX .....	109
Table 2.003	Characteristics of New Staff Study Participants (Month 4/5), N=XX.....	111
Table 2.004	Characteristics of Longitudinal* Staff Study Participants (Month 4/5), N=XX .....	113
Table 2.005	Summary of Confidence with Skills (Month 4/5), N=XX.....	115
Table 2.006	Summary of Staff Study Participants' Perceptions Regarding APRETUDE (Month 4/5), N=XX .....	117
Table 2.007	Summary of Experiences with the Acquisition Process (Month 4/5), N=XX .....	119
Table 2.101	Summary of Acceptability of Intervention Measure (AIM - APRETUDE) and Feasibility of Intervention Measure (FIM - APRETUDE ) Items (Month 4/5), N=XX .....	128
Table 2.102	Distributional Characteristics of the Acceptability of Intervention Measure (AIM – APRETUDE) (Month 4/5), N=XX .....	130
Table 2.103	Distributional Characteristics of the Feasibility of Intervention Measure (FIM - APRETUDE) (Month 4/5), N=XX .....	132
Table 2.104	Changes from Baseline to Acceptability of Intervention Measure (AIM - APRETUDE) and Feasibility of Intervention Measure (FIM - APRETUDE) (Month 4/5), N=XX .... <b>Error! Bookmark not defined.</b>	
Table 2.105	Mixed-effects Modeling of the Acceptability of Intervention Measure (AIM – APRETUDE) (Month 4/5), N=XX .....	135
Table 2.106	Mixed-effects Modeling of the Changes from Baseline to Month 4/5 in Acceptability of Intervention Measure (AIM – APRETUDE), N=XX .....	136
Table 2.107	Mixed-effects Modeling of the Feasibility of Intervention Measure (FIM – APRETUDE) (Month 4/5), N=XX .....	137
Table 2.108	Mixed-effects Modeling of the Changes from Baseline to Month 4/5 in Feasibility of Intervention Measure (FIM – APRETUDE), N=XX.....	138
Table 2.201	Summary of Acceptability of Intervention Measure (AIM - Implementation Support) and Feasibility of Intervention Measure (FIM - Implementation Support) Items (Month 4/5), N=XX .....	139
Table 2.202	Distributional Characteristics of the Acceptability of Intervention Measure (AIM – Implementation Support) (Month 4/5), N=XX.....	141
Table 2.203	Distributional Characteristics of the Feasibility of Intervention Measure (FIM - Implementation Support) (Month 4/5), N=XX.....	143
Table 2.204	Changes from Baseline for Acceptability of Intervention Measure (AIM - Implementation Support) and Feasibility of Intervention Measure (FIM - Implementation Support) (Month 4/5), N=XX.....	145
Table 2.205	Mixed-effects Modeling of the Acceptability of Intervention Measure (AIM – Implementation Support) (Month 4/5), N=XX.....	146

Table 2.206	Mixed-effects Modeling of the Changes from Baseline to Month 4/5 in Acceptability of Intervention Measure (AIM – Implementation Support), N=XX .....	147
Table 2.207	Mixed-effects Modeling of the Feasibility of Intervention Measure (FIM – Implementation Support) (Month 4/5), N=XX .....	148
Table 2.208	Mixed-effects Modeling of the Changes from Baseline to Month 4/5 in Feasibility of Intervention Measure (FIM – Implementation Support), N=XX .....	149
Table 2.301	Summary of Acceptability of Intervention Measure (AIM - Telehealth) and Feasibility of Intervention Measure (FIM - Telehealth ) Items (Month 4/5), N=XX .....	150
Table 2.302	Distributional Characteristics of the Acceptability of Intervention Measure (AIM – Telehealth) (Month 4/5), N=XX .....	152
Table 2.303	Distributional Characteristics of the Feasibility of Intervention Measure (FIM - Telehealth) (Month 4/5), N=XX .....	154
Table 2.304	Changes from Baseline for Acceptability of Intervention Measure (AIM - Telehealth) and Feasibility of Intervention Measure (FIM - Telehealth ) (Month 4/5), N=XX .....	156
Table 2.305	Mixed-effects Modeling of the Acceptability of Intervention Measure (AIM – Telehealth) (Month 4/5), N=XX .....	157
Table 2.306	Mixed-effects Modeling of the Changes from Baseline to Month 4/5 in Acceptability of Intervention Measure (AIM – Telehealth), N=XX .....	158
Table 2.307	Mixed-effects Modeling of the Feasibility of Intervention Measure (FIM – Telehealth) (Month 4/5), N=XX .....	159
Table 2.308	Mixed-effects Modeling of the Changes from Baseline to Month 4/5 in Feasibility of Intervention Measure (FIM – Telehealth), N=XX .....	160
Table 2.309	Summary of Feasibility and Acceptability of Telehealth (Month 4/5), N=XX .....	161
Table 2.310	Summary of Telehealth Services/Systems Used (Month 4/5), N=XX .....	167
Table 2.311	Summary of Ease of Use of Telehealth Services/Systems Used (Month 4/5), N=XX .....	171
Table 2.312	Summary of Helpfulness of Services/Systems Used (Month 4/5), N=XX .....	176
Table 2.313	Summary of Satisfaction of Services/Systems Used (Month 4/5), N=XX .....	181
Table 2.401	Summary of Utility of Proposed Implementation Strategies (Month 4/5), N=XX .....	186
Table 2.501	Summary of Perceived Barriers to Delivering APRETUDE to Patients (Month 4/5), N=XX ....	193
Table 2.502	Summary of Perceptions of Administering APRETUDE (Month 4/5), N=XX .....	202
Table 2.503	Summary of Perceived Barriers to Managing Delivery of APRETUDE (Month 4/5), N=XX ....	209
Table 2.504	Summary of Perceived Resourcing Barriers to Support Delivery of APRETUDE (Month 4/5), N=XX .....	218
Table 2.505	Summary of Perceptions of Clinic/Practice Culture and Environment (Month 4/5), N=XX ..	224
Table 2.506	Summary of Barriers to PrEP Provisioning (Month 4/5), N=XX .....	226
Table 2.507	Distributional Characteristics of Barriers to PrEP Provisioning (Month 4/5), N=XX .....	228
Table 2.508	Shift from Baseline to Month 4/5 in Summary of Perceived Barriers to Delivering APRETUDE to Patients (Month 4/5), N=XX .....	230
Table 2.509	Shift from Baseline to Month 4/5 in Summary of Perceptions of Administering APRETUDE (Month 4/5), N=XX .....	231

Table 2.510	Shift from Baseline to Month 4/5 in Summary of Perceived Barriers to Managing Delivery of APRETUDE (Month 4/5), N=XX .....	232
Table 2.511	Shift from Baseline to Month 4/5 in Summary of Perceived Resourcing Barriers to Support Delivery of APRETUDE (Month 4/5), N=XX.....	232
Table 2.512	Shift from Baseline to Month 4/5 in Summary of Perceptions of Clinic/Practice Culture and Environment (Month 4/5), N=XX.....	232
Table 2.513	Shift from Baseline to Month 4/5 in Summary of Barriers to PrEP Provisioning (Month 4/5), N=XX .....	233
Table 2.601	Summary of the Sexual Health Assessment Tool (Month 4/5), N=XX.....	234
Table 2.602	Summary of the PrEP Communication Tool (Month 4/5), N=XX.....	237
Table 2.701	Summary of the Optional Oral Lead-in Phase of APRETUDE (Month 4/5), N=XX .....	240
Table 2.801	Summary of Perceived Number of APRETUDE Patients Clinic/Practice Can Manage Per Week on an Ongoing Basis (Month 4/5), N=XX .....	246
Table 2.802	Distributional Characteristics of People in Clinic Trained and Prepared to Give APRETUDE Injections (Month 4/5), N=XX.....	247
Table 2.803	Distributional Characteristics of Estimated Number of Staff Needed Per Week to Incorporate APRETUDE into Clinic/Practice for Approximately 25 People (Month 4/5), N=XX.....	248
Table 2.804	Summary of Estimated Percentage of Staff Time/Full-Time Equivalent Hours Needed Per Week to Incorporate APRETUDE into Clinic/Practice for Approximately 25 People (Month 4/5), N=XX .....	249
Table 2.805	Summary of Plans to Create New Roles/Positions in Clinic to Coordinate the APRETUDE Program (Month 4/5), N=XX.....	250
Table 2.806	Summary of Number of New Roles/Positions in Clinic to Coordinate the APRETUDE Program (Month 4/5), N=XX.....	251
Table 2.807	Summary of How Clinic/Practice Plans to Track Patients on APRETUDE (Month 4/5), N=XX.....	252
Table 2.808	Summary of How Clinic/Practice Responds to Patients who Do Not Show for a Regularly Scheduled Appointment (Month 4/5), N=XX.....	253
Table 2.809	Summary of Whether Clinic/Practice has Specific Person in Charge of Following Up on No-Shows (Month 4/5), N=XX .....	254
Table 2.810	Summary of Type of Systems Clinic has in Place to Remind Patients of Upcoming Appointments (Month 4/5), N=XX.....	255
Table 2.811	Summary of Type of Systems Clinic has in Place to Offer Upcoming Appointments (Month 4/5), N=XX .....	256
Table 2.812	Summary of Implementing APRETUDE in Practice (Month 4/5), N=XX .....	258
Table 2.901	Quarterly Site Reporting.....	260

Table 2.001 Demographic Characteristics of New Staff Study Participants (Month 4/5), N=XX

Question Number	Characteristic	Study Arm		
		Total (N=XX)	Dynamic Implementation (N=XX)	Routine Implementation (N=XX)
		n (%)	n (%)	n (%)
<b>88</b>	<b>Gender</b>			
	Cisgender Male	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Cisgender Female	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Transgender Man	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Transgender Woman	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Nonbinary	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Gender Queer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other Gender	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>89</b>	<b>Age (years)</b>			
	N	XX	XX	XX
	Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)
	Median	XX.X	XX.X	XX.X
	Q1, Q3	XX, XX	XX, XX	XX, XX
	Min-Max	XX.X, XX.X	XX.X, XX.X	XX.X, XX.X
	Missing	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>89</b>	<b>Age (years), High Volume</b>			
	N	XX	XX	XX
	Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)
	Median	XX.X	XX.X	XX.X
	Q1, Q3	XX, XX	XX, XX	XX, XX
	Min-Max	XX.X, XX.X	XX.X, XX.X	XX.X, XX.X
	Missing	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>89</b>	<b>Age (years), Low Volume</b>			
	N	XX	XX	XX
	Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)
	Median	XX.X	XX.X	XX.X
	Q1, Q3	XX, XX	XX, XX	XX, XX
	Min-Max	XX.X, XX.X	XX.X, XX.X	XX.X, XX.X
	Missing	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>89</b>	<b>Age</b>			
	18-25	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	26-35	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	66-49	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Characteristic	Study Arm		
		Total (N=XX)	Dynamic Implementation (N=XX)	Routine Implementation (N=XX)
		n (%)	n (%)	n (%)
	50+	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>90</b>	<b>Race</b>			
	White/Caucasian	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Black	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Asian	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Native American	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Pacific Islander	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Mixed Race	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other Race	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I Prefer not to Answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>91</b>	<b>Ethnicity</b>			
	Hispanic/Latinx	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Non-Hispanic/Latinx	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 2.002 Demographic Characteristics of Longitudinal\* Staff Study Participants (Month 4/5), N=XX**

Question Number	Characteristic	Study Arm		
		Total (N=XX)	Dynamic Implementation (N=XX)	Routine Implementation (N=XX)
		n (%)	n (%)	n (%)
<b>88</b>	<b>Gender</b>			
	Cisgender Male	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Cisgender Female	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Transgender Man	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Transgender Woman	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Nonbinary	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Gender Queer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other Gender	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>89</b>	<b>Age (years)</b>			
	N	XX	XX	XX
	Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)
	Median	XX.X	XX.X	XX.X
	Q1, Q3	XX, XX	XX, XX	XX, XX
	Min-Max	XX.X, XX.X	XX.X, XX.X	XX.X, XX.X
	Missing	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>89</b>	<b>Age (years), High Volume</b>			
	N	XX	XX	XX
	Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)
	Median	XX.X	XX.X	XX.X
	Q1, Q3	XX, XX	XX, XX	XX, XX
	Min-Max	XX.X, XX.X	XX.X, XX.X	XX.X, XX.X
	Missing	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>89</b>	<b>Age (years), Low Volume</b>			
	N	XX	XX	XX
	Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)
	Median	XX.X	XX.X	XX.X
	Q1, Q3	XX, XX	XX, XX	XX, XX
	Min-Max	XX.X, XX.X	XX.X, XX.X	XX.X, XX.X
	Missing	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>89</b>	<b>Age</b>			
	18-25	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	26-35	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Characteristic	Study Arm		
		Total (N=XX)	Dynamic Implementation (N=XX)	Routine Implementation (N=XX)
		n (%)	n (%)	n (%)
	66-49	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	50+	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>90</b>	<b>Race</b>			
	White/Caucasian	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Black	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Asian	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Native American	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Pacific Islander	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Mixed Race	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other Race	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I Prefer not to Answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>91</b>	<b>Ethnicity</b>			
	Hispanic/Latinx	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Non-Hispanic/Latinx	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

\* Longitudinal = SSPs who completed any portion of any questionnaire at Baseline and at Month 4/5

Table 2.003 Characteristics of New Staff Study Participants (Month 4/5), N=XX

Question Number	Characteristic	Study Arm		
		Total (N=XX)	Dynamic Implementation (N=XX)	Routine Implementation (N=XX)
		n (%)	n (%)	n (%)
<b>1</b>	<b>Provider Type</b>			
	Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Nurse Practitioner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Physician Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Social worker/case manager	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Office administrator/clinic administrator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Laboratory staff/technician/phlebotomist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Front desk staff/ Scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>2</b>	<b>Personally Administer Injections</b>			
	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>3</b>	<b>Prescribe Medications as part of role</b>			
	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>4</b>	<b>Currently Provide PrEP Counseling</b>			
	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>92</b>	<b>Specialty</b>			
	Infectious disease specialist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Internal medicine/ primary care/general doctor/ family practitioner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	HIC Specialist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Immunologist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Women's health/obstetricians and gynecologists	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Endocrinologist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other[2]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>93</b>	<b>Length of Time practicing Medicine</b>			
	<1 year	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	1–5 years	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



Question Number	Characteristic		Study Arm	
	6–10 years	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	11-15 years	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	16-20 years	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	>21 years	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

[1] Other responses include: xxx

[2] Other responses include: xxx

Table 2.004 Characteristics of Longitudinal\* Staff Study Participants (Month 4/5), N=XX

Question Number	Characteristic	Study Arm		
		Total (N=XX)	Dynamic Implementation (N=XX)	Routine Implementation (N=XX)
		n (%)	n (%)	n (%)
<b>1</b>	<b>Provider Type</b>			
	Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Nurse Practitioner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Physician Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Social worker/case manager	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Office administrator/clinic administrator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Laboratory staff/technician/phlebotomist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Front desk staff/ Scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>2</b>	<b>Personally Administer Injections</b>			
	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>3</b>	<b>Prescribe Medications as part of role</b>			
	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>4</b>	<b>Currently Provide PrEP Counseling</b>			
	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>92</b>	<b>Specialty</b>			
	Infectious disease specialist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Internal medicine/ primary care/general doctor/ family practitioner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	HIC Specialist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Immunologist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Women's health/obstetricians and gynecologists	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Endocrinologist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other[2]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>93</b>	<b>Length of Time practicing Medicine</b>			
	<1 year	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	1–5 years	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Characteristic	Study Arm		
	6–10 years	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	11-15 years	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	16-20 years	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	>21 years	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

\* Longitudinal = SSPs who completed any portion of any questionnaire at Baseline and at Month 4/5

[1] Other responses include: xxx

[2] Other responses include: xxx

Table 2.005 Summary of Confidence with Skills (Month 4/5), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
5	“Please rate your level of confidence for each skill listed.”				
	Talking to Patient About Sexual History	Not At All Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A Little Bit Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not Applicable To My Role	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Screening a patient to determine whether they are an appropriate candidate for PrEP	Not At All Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A Little Bit Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not Applicable To My Role	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Answering Patient's Questions About PrEP	Not At All Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A Little Bit Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not Applicable To My Role	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Suggesting PrEP to a Patient	Not At All Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A Little Bit Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not Applicable To My Role	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
	Counseling a patient about using other methods of protection (e.g., condoms) while on PrEP	Not At All Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A Little Bit Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not Applicable To My Role	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Monitoring a Patient on PrEP	Not At All Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A Little Bit Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not Applicable To My Role	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 2.006 Summary of Staff Study Participants' Perceptions Regarding APRETUDE (Month 4/5), N=XX**

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
6	In your opinion, APRETUDE is appropriate for which individuals?				
		are sexually active	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		have been sexually active with 1 or more partners in the last 6 months	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		are currently adherent on daily oral PrEP	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		are non-adherent on daily oral PrEP	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		use PrEP on demand (i.e., event-based PrEP, PrEP 2-1-1)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		could benefit from PrEP but do not want to use daily PrEP	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		have previously used and discontinued daily PrEP	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		feel stigmatized about taking oral PrEP	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		request APRETUDE spontaneously	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		have sex without a condom	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		engage in anal sex	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		have a sexual partner living with HIV	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		live in areas with high HIV prevalence	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		currently have or recently (within the past 6 months) have had an STI other than HIV	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		are in monogamous relationships	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		inject drugs	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		have sex with a person/people who inject drugs	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		experience stigma around using HIV prevention	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		are concerned about taking pills every day	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		experience stress or anxiety over adherence of a daily pill regimen	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		have more chaotic lifestyles (e.g., variable work schedules, frequent travel, balancing work and school)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		have more structured lifestyles (e.g., regular work hours, little to no unplanned travels)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		have difficulty planning or organizing	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		have stable income and stable housing	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		experience homelessness or are unstably housed	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		have psychiatric comorbidities	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		have sex with someone who has recently been in jail/prison	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		are incarcerated, temporarily incarcerated, or recently released from incarcerated	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
7	Has any of the patients at this clinic/practice asked for (or about) APREUDE?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
8	Are you or this clinic/practice proactively informing patients about APREUDE?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
9	How are you or this clinic/practice informing patients about APREUDE?				
		Provision of educational materials	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		During consultation with patient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Through peer educators	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Referring patients to PrEP providers	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Posters in the clinic/practice	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Flyers in the clinic/practice	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Mentions on the clinic/practice's website	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Mentions on social media	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 2.007 Summary of Experiences with the Acquisition Process (Month 4/5), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
39	Are you involved in any of part of the benefits verification and acquisition process for APRETUDE, such as completing enrollment forms, sending documents to insurance companies, purchasing APRETUDE?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
40	Is your clinic/practice using ViiV Connect to acquire APRETUDE?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
41	Do You Personally Use ViiV Connect?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
42	How are your providers or clinic/practice acquiring APRETUDE?				
		Buy-and-Bill - purchases APRETUDE from a wholesaler or specialty distributor and bills the primary third-party payer.	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		White Bagging - submits prescription to a specialty pharmacy within ViiV's specialty pharmacy network and the specialty pharmacy processes the claim and ships APRETUDE for administration.	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Clear Bagging - internal pharmacy maintains inventory of the medication, processes the claim, and delivers the medication.	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
43	Who in your clinic/practice is primarily responsible for completing the insurance benefits verification process for APRETUDE?				
		Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Nurse practitioner/physician assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Specialty pharmacy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Medical assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Social worker/case manager	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Dedicated administrator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		APREUDE coordinator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
44	On average, how long does it take to complete the APREUDE enrollment form?				
		1-5 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		6-10 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		11-15 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		16-20 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		21-25 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		26-30 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		31+ minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I have not completed this form	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
45	On average, how long has it taken to receive confirmation of benefits verification for APREUDE?				
		1-2 days	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		3-4 days	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		5-6 days	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		7-8 days	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		9-10 days	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		11-15 days	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		16-20 days	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		20+ days	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
46	On average, how long has it taken for patients to receive APREUDE from the point of benefits verification?				
		1-2 days	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		3-4 days	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		5-6 days	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		7-8 days	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		9-10 days	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		11-15 days	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		16-20 days	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		20+ days	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
47	“For each item, please indicate how concerned you are about each of the following based on your current expectations, understanding and knowledge of ViiV Connect.”				
	Authorization wait times	Extremely concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Moderately concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Slightly concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Understanding status of authorization	Extremely concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Moderately concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Slightly concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Understanding how to seek assistance	Extremely concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Moderately concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Slightly concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Amount of paperwork	Extremely concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Moderately concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Slightly concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Clarity on coverage approval	Extremely concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Moderately concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Slightly concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Ensuring medication comes to the right place (e.g., clinic/practice, pharmacy)	Extremely concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Moderately concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Slightly concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Potential loss of enthusiasm for APREITUDE by patients	Extremely concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Moderately concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Somewhat concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Slightly concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Potential patient dissatisfaction with clinic staff	Extremely concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Moderately concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Slightly concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Staff dissatisfaction with the acquisition process	Extremely concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Moderately concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Slightly concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Potential disruption of clinic flow	Extremely concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Moderately concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Slightly concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Time-consuming process	Extremely concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Moderately concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Slightly concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Inequitable access for eligible patients	Extremely concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Moderately concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Slightly concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
48	"Please indicate how much you agree or disagree with each of the following statements."				
	I understand how to use Viiv Connect (skip applicable if Q41=yes)	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I understand how to complete the APREUDE forms in Viiv Connect (skip applicable if Q41=yes)	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Completing the benefits enrollment forms is easy	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The live support for Viiv Connect is helpful	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I am knowledgeable about the patient savings card for APREUDE for patients	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The benefits verification process of Viiv Connect is time consuming (RC) (skip applicable if Q41=yes)	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I am satisfied with the benefits verification process	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	It has been easy to acquire APREUDE for patients	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I know what to do if I am having trouble acquiring APREUDE for patients	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I am knowledgeable about the patient assistance program for APREUDE	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
49	How helpful or unhelpful has each type of support been to your clinic/practice in using Viiv Connect?"				
	Viiv Connect Services and Support information (e.g., Viiv Connect Brochure, Provider Portal Brochure)	Not at all helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Did not use it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Viiv Connect Enrollment information (annotated enrollment forms, enrollment form)	Not at all helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Did not use it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Acquisition Guides (e.g., ordering guide, buy and bill checklist, specialty pharmacy checklist)	Not at all helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Did not use it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Billing, Coding and reimbursement information (e.g., prior authorization checklist, reimbursement guide)	Not at all helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Did not use it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Benefits Verification – understanding summary of benefits (illustrated form highlights patient benefit summary and how to read it)	Not at all helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Did not use it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Live support (e.g., access coordinators)	Not at all helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Did not use it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Video for patients on what is ViV Connect (DI)	Not at all helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Did not use it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	A video for providers describing what is ViiV Connect (DI)	Not at all helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Did not use it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Patient informational material about ViiV Connect and the acquisition process	Not at all helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Did not use it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Medication Acquisition Tracker – web-based tool to track patients’ benefits acquisition journey from enrollment to medication receipt at the clinic/practice (DI)	Not at all helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Did not use it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	APREUDE Payer Information found on the PILLAR Spot: spreadsheet updated on a weekly basis and gives providers information on which payers are covering APREUDE and under what type of benefit	Not at all helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Did not use it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
50	How helpful or unhelpful has receiving the list of payers/insurers who cover the medication and when coverage began has been to your clinic/practice?				
		Not at all helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Did not use it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
51	I would recommend ViiV Connect to other providers and clinics/practices to aid in the acquisition of ViiV medications.				
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



**Table 2.101 Summary of Acceptability of Intervention Measure (AIM - APREUDE) and Feasibility of Intervention Measure (FIM - APREUDE ) Items (Month 4/5), N=XX**

Measure	Item	Study Arm	Total Sample n (%)	1 Completely Disagree n (%)	2 Disagree n (%)	3 Neither Agree nor Disagree n (%)	4 Agree n (%)	5 Completely Agree n (%)
AIM	1. APREUDE in our clinic/practice meets my approval.	Overall	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Dynamic Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Routine Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
	2. APREUDE in our clinic/practice is appealing to me.	Overall	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Dynamic Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Routine Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
	3. I like APREUDE in our clinic/practice.	Overall	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Dynamic Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Routine Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
FIM	4. I welcome APREUDE in our clinic/practice.	Overall	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Dynamic Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Routine Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
	1. APREUDE seems implementable in our clinic/practice.	Overall	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Dynamic Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Routine Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
	2. APREUDE seems possible in our clinic/practice.	Overall	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Dynamic Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Routine Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)

Measure	Item	Study Arm	Total Sample n (%)	1 Completely Disagree n (%)	2 Disagree n (%)	3 Neither Agree nor Disagree n (%)	4 Agree n (%)	5 Completely Agree n (%)
		Implementation						
		Routine Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
	3. APREITUDE seems doable in our clinic/practice.	Overall	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Dynamic Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Routine Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
	4. APREITUDE seems easy to use in our clinic/practice	Overall	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Dynamic Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Routine Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)

**Table 2.102 Distributional Characteristics of the Acceptability of Intervention Measure (AIM – APREUDE) (Month 4/5), N=XX**

AIM – APREUDE	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
Mean Score	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
<b>Study Arm</b>							
Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
T-test		X.XXX					
Degrees of Freedom		XX					
P-Value		0.XXX					
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
T-test		X.XXX					
Degrees of Freedom		XX					
P-Value		0.XXX					
<b>Clinic Type</b>							
University/Academia/Research	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
FQHC/Department of Health	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Nonprofit	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Private	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
<b>Provider Type</b>							
Physician	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Mid-level providers[1]	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Nurse	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Medical Assistant	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Pharmacist	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Social worker/case manager/PrEP educator/PrEP navigator	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)

AIM – APREITUDE	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
Office administrator /clinic administrator/front desk staff/scheduler	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.XX (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
Laboratory staff/technician/phlebotomist/other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.XX (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
<b>Items</b>							
1. APREITUDE in our clinic/practice meets my approval.	XX	X.X	X.XX	X.X (X.X, X.X)	X (X, X)	XX (XX.X)	(X.XX, X.XX)
2. APREITUDE in our clinic/practice is appealing to me.	XX	X.X	X.XX	X.X (X.X, X.X)	X (X, X)	XX (XX.X)	(X.XX, X.XX)
3. I like APREITUDE in our clinic/practice.	XX	X.X	X.XX	X.X (X.X, X.X)	X (X, X)	XX (XX.X)	(X.XX, X.XX)
4. I welcome APREITUDE in our clinic/practice.	XX	X.X	X.XX	X.X (X.X, X.X)	X (X, X)	XX (XX.X)	(X.XX, X.XX)

[1] Mid-level providers include nurse practitioners and physician assistants.

**Table 2.103 Distributional Characteristics of the Feasibility of Intervention Measure (FIM - APREUDE) (Month 4/5), N=XX**

FIM - APREUDE	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
Mean Score	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
<b>Study Arm</b>							
Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
T-test		X.XXX					
Degrees of Freedom		XX					
P-Value		0.XXX					
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
T-test		X.XXX					
Degrees of Freedom		XX					
P-Value		0.XXX					
<b>Clinic Type</b>							
University/Academia/Research	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
FQHC/Department of Health	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Nonprofit	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Private	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
<b>Provider Type</b>							
Physician	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Mid-level providers[1]	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Nurse	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Medical Assistant	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Pharmacist	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Social worker/case manager/PrEP educator/PrEP navigator	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)

FIM - APREUDE	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
Office administrator /clinic administrator/front desk staff/scheduler	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Laboratory staff/technician/phlebotomist/other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
<b>Items</b>							
1. APREUDE seems implementable in our clinic/practice.	XX	X.X	X.XX	X.X (X.X, X.X)	X (X, X)	XX (XX.X)	(X.XX, X.XX)
2. APREUDE seems possible in our clinic/practice.	XX	X.X	X.XX	X.X (X.X, X.X)	X (X, X)	XX (XX.X)	(X.XX, X.XX)
3. APREUDE seems doable in our clinic/practice.	XX	X.X	X.XX	X.X (X.X, X.X)	X (X, X)	XX (XX.X)	(X.XX, X.XX)
4. APREUDE seems easy to use in our clinic/practice	XX	X.X	X.XX	X.X (X.X, X.X)	X (X, X)	XX (XX.X)	(X.XX, X.XX)

[1] Mid-level providers include nurse practitioners and physician assistants.

**Table 2.104 Changes from Baseline to Acceptability of Intervention Measure (AIM - APRETUDE) and Feasibility of Intervention Measure (FIM - APRETUDE) (Month 4/5), N=XX**

Measure	Study Arm	n	Mean	SD	Median (Q1, Q3)	Observed Range (min, max)	Missing n (%)	95% CI for the Mean
AIM - APRETUDE Baseline	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
AIM - APRETUDE Month 4/5	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
AIM - APRETUDE Change from Baseline to Month 4/5	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	T-test		X.XXX					
	DF		XX					
	P-Value		0.XXX					
FIM - APRETUDE Baseline	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
FIM - APRETUDE Month 4/5	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
FIM - APRETUDE Change from Baseline to Month 4/5	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	T-test		X.XXX					
	DF		XX					
	P-Value		0.XXX					

**Table 2.105 Mixed-effects Modeling of the Acceptability of Intervention Measure (AIM – APREUDE) (Month 4/5), N=XX**

Fixed effects					
Parameter	Estimate	Standard Error	Denominator Degrees of Freedom	T	p-Value
Intercept (RI, Low)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm (DI)	X.XX	X.XXX	XX	X.XX	0.XXXX
Volume (High)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm by Volume	X.XX	X.XXX	XX	X.XX	0.XXXX
Baseline Mean Score[1]	X.XX	X.XXX	XX	X.XX	0.XXXX
Random Effects					
Covariance Parameter	Estimate	Standard Error		Z	p-Value
Site Variance ( $\tau(0,0)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Covariance ( $\tau(0,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Baseline Variance ( $\tau(1,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Residual Variance ( $\sigma^2$ )	X.XX	X.XXX	-	X.XX	0.XXXX

Note: Null model likelihood ratio test,  $\chi^2(XX) = XXX.XX$ ,  $p = 0.XXXX$ .

[1] Baseline mean score centered by site.



**Table 2.106 Mixed-effects Modeling of the Changes from Baseline to Month 4/5 in Acceptability of Intervention Measure (AIM – APRETUDE), N=XX**

Fixed effects					
Parameter	Estimate	Standard Error	Denominator Degrees of Freedom	T	p-Value
Intercept (RI, Low)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm (DI)	X.XX	X.XXX	XX	X.XX	0.XXXX
Volume (High)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm by Volume	X.XX	X.XXX	XX	X.XX	0.XXXX
Baseline Mean Score[1]	X.XX	X.XXX	XX	X.XX	0.XXXX
Random Effects					
Covariance Parameter	Estimate	Standard Error		Z	p-Value
Site Variance ( $\tau(0,0)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Covariance ( $\tau(0,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Baseline Variance ( $\tau(1,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Residual Variance ( $\sigma^2$ )	X.XX	X.XXX	-	X.XX	0.XXXX

Note: Null model likelihood ratio test,  $\chi^2(XX) = XXX.XX$ ,  $p = 0.XXXX$ .

[1] Baseline mean score centered by site.

**Table 2.107 Mixed-effects Modeling of the Feasibility of Intervention Measure (FIM – APREUDE) (Month 4/5), N=XX**

Fixed effects					
Parameter	Estimate	Standard Error	Denominator Degrees of Freedom	T	p-Value
Intercept (RI, Low)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm (DI)	X.XX	X.XXX	XX	X.XX	0.XXXX
Volume (High)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm by Volume	X.XX	X.XXX	XX	X.XX	0.XXXX
Baseline Mean Score[1]	X.XX	X.XXX	XX	X.XX	0.XXXX
Random Effects					
Covariance Parameter	Estimate	Standard Error		Z	p-Value
Site Variance ( $\tau(0,0)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Covariance ( $\tau(0,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Baseline Variance ( $\tau(1,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Residual Variance ( $\sigma^2$ )	X.XX	X.XXX	-	X.XX	0.XXXX

Note: Null model likelihood ratio test,  $\chi^2(XX) = XXX.XX$ ,  $p = 0.XXXX$ .

[1] Baseline mean score centered by site.

**Table 2.108 Mixed-effects Modeling of the Changes from Baseline to Month 4/5 in Feasibility of Intervention Measure (FIM – APRETUDE), N=XX**

Fixed effects					
Parameter	Estimate	Standard Error	Denominator Degrees of Freedom	T	p-Value
Intercept (RI, Low)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm (DI)	X.XX	X.XXX	XX	X.XX	0.XXXX
Volume (High)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm by Volume	X.XX	X.XXX	XX	X.XX	0.XXXX
Baseline Mean Score[1]	X.XX	X.XXX	XX	X.XX	0.XXXX
Random Effects					
Covariance Parameter	Estimate	Standard Error		Z	p-Value
Site Variance ( $\tau(0,0)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Covariance ( $\tau(0,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Baseline Variance ( $\tau(1,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Residual Variance ( $\sigma^2$ )	X.XX	X.XXX	-	X.XX	0.XXXX

Note: Null model likelihood ratio test,  $\chi^2(XX) = XXX.XX$ ,  $p = 0.XXXX$ .

[1] Baseline mean score centered by site.

**Table 2.201 Summary of Acceptability of Intervention Measure (AIM - Implementation Support) and Feasibility of Intervention Measure (FIM - Implementation Support) Items (Month 4/5), N=XX**

Measure	Item	Study Arm	Total Sample n (%)	1 Completely Disagree n (%)	2 Disagree n (%)	3 Neither Agree nor Disagree n (%)	4 Agree n (%)	5 Completely Agree n (%)
AIM	1. The implementation support has met my approval.	Overall	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Dynamic Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Routine Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
	2. The implementation support was appealing to me.	Overall	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Dynamic Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Routine Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
	3. I like the implementation support I have received.	Overall	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Dynamic Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Routine Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
FIM	4. I welcome the implementation support I have received.	Overall	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Dynamic Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Routine Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
	1. The implementation support seems implementable in our clinic/practice	Overall	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Dynamic Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Routine Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)

Measure	Item	Study Arm	Total Sample n (%)	1 Completely Disagree n (%)	2 Disagree n (%)	3 Neither Agree nor Disagree n (%)	4 Agree n (%)	5 Completely Agree n (%)
	2. The implementation support seems possible in our clinic/practice	Overall	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Dynamic Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Routine Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
	3. The implementation support seems doable in our clinic/practice	Overall	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Dynamic Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Routine Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
	4. The implementation support seems easy to use in our clinic/practice	Overall	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Dynamic Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Routine Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)

**Table 2.202    Distributional Characteristics of the Acceptability of Intervention Measure (AIM – Implementation Support) (Month 4/5), N=XX**

AIM – Implementation Support	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
Mean Score	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
<b>Study Arm</b>							
Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
T-test		XX.XX					
Degrees of Freedom		XX					
P-Value		0.XXXX					
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
T-test		XX.XX					
Degrees of Freedom		XX					
P-Value		0.XXXX					
<b>Clinic Type</b>							
University/Academia/Research	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
FQHC/Department of Health	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Nonprofit	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Private	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
<b>Provider Type</b>							
Physician	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Mid-level providers[1]	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Nurse	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Medical Assistant	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Pharmacist	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Social worker/case manager/PrEP educator/PrEP navigator	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)

AIM – Implementation Support	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
Office administrator /clinic administrator/front desk staff/scheduler	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Laboratory staff/technician/phlebotomist/other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
<b>Items</b>							
1. The implementation support has met my approval.	XX	X.X	X.XX	X.X (X.X, X.X)	X (X, X)	XX (XX.X)	(X.XX, X.XX)
2. The implementation support was appealing to me.	XX	X.X	X.XX	X.X (X.X, X.X)	X (X, X)	XX (XX.X)	(X.XX, X.XX)
3. I like the implementation support I have received.	XX	X.X	X.XX	X.X (X.X, X.X)	X (X, X)	XX (XX.X)	(X.XX, X.XX)
4. I welcome the implementation support I have received.	XX	X.X	X.XX	X.X (X.X, X.X)	X (X, X)	XX (XX.X)	(X.XX, X.XX)

[1] Mid-level providers include nurse practitioners and physician assistants.

**Table 2.203    Distributional Characteristics of the Feasibility of Intervention Measure (FIM - Implementation Support) (Month 4/5), N=XX**

FIM - Implementation Support	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
Mean Score	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
<b>Study Arm</b>							
Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
T-test		XX.XX					
Degrees of Freedom		XX					
P-Value		0.XXXX					
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
T-test		XX.XX					
Degrees of Freedom		XX					
P-Value		0.XXXX					
<b>Clinic Type</b>							
University/Academia/Research	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
FQHC/Department of Health	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
Nonprofit	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
Private	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
<b>Provider Type</b>							
Physician	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
Mid-level providers[1]	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
Nurse	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
Medical Assistant	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
Pharmacist	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
Social worker/case manager/PrEP educator/PrEP navigator	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)



FIM - Implementation Support	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
Office administrator /clinic administrator/front desk staff/scheduler	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
Laboratory staff/technician/phlebotomist/other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
<b>Items</b>							
1. The implementation support seems implementable in our clinic/practice	XX	X.X	X.XX	X.X (X.X, X.X)	X (X.X, X.X)	XX (XX.X)	(X.XX, X.XX)
2. The implementation support seems possible in our clinic/practice	XX	X.X	X.XX	X.X (X.X, X.X)	X (X.X, X.X)	XX (XX.X)	(X.XX, X.XX)
3. The implementation support seems doable in our clinic/practice	XX	X.X	X.XX	X.X (X.X, X.X)	X (X.X, X.X)	XX (XX.X)	(X.XX, X.XX)
4. The implementation support seems easy to use in our clinic/practice	XX	X.X	X.XX	X.X (X.X, X.X)	X (X.X, X.X)	XX (XX.X)	(X.XX, X.XX)

**Table 2.204 Changes from Baseline for Acceptability of Intervention Measure (AIM - Implementation Support) and Feasibility of Intervention Measure (FIM - Implementation Support) (Month 4/5), N=XX**

Measure	Study Arm	n	Mean	SD	Median (Q1, Q3)	Observed Range (min, max)	Missing n (%)	95% CI for the Mean
AIM - Implementation Support Baseline	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
AIM – Implementation Support Month 4/5	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
AIM - Implementation Support Change from Baseline to Month 4/5	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	T-test		X.XXX					
	DF		XX					
	P-Value		0.XXX					
FIM - Implementation Support Baseline	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
FIM - Implementation Support Month 4/5	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
FIM - Implementation Support Change from Baseline to Month 4/5	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	T-test		X.XXX					
	DF		XX					
	P-Value		0.XXX					

**Table 2.205 Mixed-effects Modeling of the Acceptability of Intervention Measure (AIM – Implementation Support) (Month 4/5), N=XX**

Fixed effects					
Parameter	Estimate	Standard Error	Denominator Degrees of Freedom	T	p-Value
Intercept (RI, Low)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm (DI)	X.XX	X.XXX	XX	X.XX	0.XXXX
Volume (High)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm by Volume	X.XX	X.XXX	XX	X.XX	0.XXXX
Baseline Mean Score[1]	X.XX	X.XXX	XX	X.XX	0.XXXX
Random Effects					
Covariance Parameter	Estimate	Standard Error		Z	p-Value
Site Variance ( $\tau(0,0)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Covariance ( $\tau(0,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Baseline Variance ( $\tau(1,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Residual Variance ( $\sigma^2$ )	X.XX	X.XXX	-	X.XX	0.XXXX

Note: Null model likelihood ratio test,  $\chi^2(XX) = XXX.XX$ ,  $p = 0.XXXX$ .

[1] Baseline mean score centered by site.

**Table 2.206 Mixed-effects Modeling of the Changes from Baseline to Month 4/5 in Acceptability of Intervention Measure (AIM – Implementation Support), N=XX**

Fixed effects					
Parameter	Estimate	Standard Error	Denominator Degrees of Freedom	T	p-Value
Intercept (RI, Low)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm (DI)	X.XX	X.XXX	XX	X.XX	0.XXXX
Volume (High)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm by Volume	X.XX	X.XXX	XX	X.XX	0.XXXX
Baseline Mean Score[1]	X.XX	X.XXX	XX	X.XX	0.XXXX
Random Effects					
Covariance Parameter	Estimate	Standard Error		Z	p-Value
Site Variance ( $\tau(0,0)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Covariance ( $\tau(0,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Baseline Variance ( $\tau(1,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Residual Variance ( $\sigma^2$ )	X.XX	X.XXX	-	X.XX	0.XXXX

Note: Null model likelihood ratio test,  $\chi^2(XX) = XXX.XX$ ,  $p = 0.XXXX$ .

[1] Baseline mean score centered by site.

**Table 2.207 Mixed-effects Modeling of the Feasibility of Intervention Measure (FIM – Implementation Support) (Month 4/5), N=XX**

Fixed effects					
Parameter	Estimate	Standard Error	Denominator Degrees of Freedom	T	p-Value
Intercept (RI, Low)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm (DI)	X.XX	X.XXX	XX	X.XX	0.XXXX
Volume (High)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm by Volume	X.XX	X.XXX	XX	X.XX	0.XXXX
Baseline Mean Score[1]	X.XX	X.XXX	XX	X.XX	0.XXXX
Random Effects					
Covariance Parameter	Estimate	Standard Error		Z	p-Value
Site Variance ( $\tau(0,0)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Covariance ( $\tau(0,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Baseline Variance ( $\tau(1,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Residual Variance ( $\sigma^2$ )	X.XX	X.XXX	-	X.XX	0.XXXX

Note: Null model likelihood ratio test,  $\chi^2(XX) = XXX.XX$ ,  $p = 0.XXXX$ .

[1] Baseline mean score centered by site.

**Table 2.208 Mixed-effects Modeling of the Changes from Baseline to Month 4/5 in Feasibility of Intervention Measure (FIM – Implementation Support), N=XX**

Fixed effects					
Parameter	Estimate	Standard Error	Denominator Degrees of Freedom	T	p-Value
Intercept (RI, Low)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm (DI)	X.XX	X.XXX	XX	X.XX	0.XXXX
Volume (High)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm by Volume	X.XX	X.XXX	XX	X.XX	0.XXXX
Baseline Mean Score[1]	X.XX	X.XXX	XX	X.XX	0.XXXX
Random Effects					
Covariance Parameter	Estimate	Standard Error		Z	p-Value
Site Variance ( $\tau(0,0)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Covariance ( $\tau(0,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Baseline Variance ( $\tau(1,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Residual Variance ( $\sigma^2$ )	X.XX	X.XXX	-	X.XX	0.XXXX

Note: Null model likelihood ratio test,  $\chi^2(XX) = XXX.XX$ ,  $p = 0.XXXX$ .

[1] Baseline mean score centered by site.

**Table 2.301 Summary of Acceptability of Intervention Measure (AIM - Telehealth) and Feasibility of Intervention Measure (FIM - Telehealth) Items (Month 4/5), N=XX**

Measure	Item	Study Arm	Total Sample n (%)	1 Completely Disagree n (%)	2 Disagree n (%)	3 Neither Agree nor Disagree n (%)	4 Agree n (%)	5 Completely Agree n (%)
AIM	1. Telehealth for APREUDE delivery in our clinic/practice meets my approval.	Overall	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Dynamic Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Routine Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
	2. Telehealth for APREUDE delivery in our clinic/practice is appealing to me.	Overall	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Dynamic Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Routine Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
	3. I like using telehealth for APREUDE delivery in our clinic/practice.	Overall	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Dynamic Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Routine Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
	4. I welcome telehealth for APREUDE delivery in our clinic/practice.	Overall	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Dynamic Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Routine Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
FIM	1. Telehealth for APREUDE delivery seems implementable	Overall	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)

Measure	Item	Study Arm	Total Sample n (%)	1 Completely Disagree n (%)	2 Disagree n (%)	3 Neither Agree nor Disagree n (%)	4 Agree n (%)	5 Completely Agree n (%)
	in our clinic/practice.							
		Dynamic Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Routine Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
	2. Telehealth for APREITUDE delivery seems possible in our clinic/practice	Overall	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Dynamic Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Routine Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
	3. Telehealth for APREITUDE delivery seems doable in our clinic/practice.	Overall	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Dynamic Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Routine Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
	4. Telehealth for APREITUDE delivery seems easy to use in our clinic/practice.	Overall	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Dynamic Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Routine Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)



**Table 2.302    Distributional Characteristics of the Acceptability of Intervention Measure (AIM – Telehealth) (Month 4/5), N=XX**

AIM – TELEHEALTH	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
Mean Score	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
<b>Study Arm</b>							
Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
T-test		X.XXX					
Degrees of Freedom		XX					
P-Value		0.XXX					
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
T-test		X.XXX					
Degrees of Freedom		XX					
P-Value		0.XXX					
<b>Clinic Type</b>							
University/Academia/Research	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
FQHC/Department of Health	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Nonprofit	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Private	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
<b>Provider Type</b>							
Physician	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Mid-level providers[1]	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Nurse	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Medical Assistant	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Pharmacist	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Social worker/case manager/PrEP educator/PrEP navigator	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)

AIM – TELEHEALTH	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
Office administrator /clinic administrator/front desk staff/scheduler	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Laboratory staff/technician/phlebotomist/other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
<b>Items</b>							
1. Telehealth for APREITUDE in our clinic/practice meets my approval.	XX	X.X	X.XX	X.X (X.X, X.X)	X (X, X)	XX (XX.X)	(X.XX, X.XX)
2. Telehealth for APREITUDE in our clinic/practice is appealing to me.	XX	X.X	X.XX	X.X (X.X, X.X)	X (X, X)	XX (XX.X)	(X.XX, X.XX)
3. I like using telehealth for APREITUDE in our clinic/practice.	XX	X.X	X.XX	X.X (X.X, X.X)	X (X, X)	XX (XX.X)	(X.XX, X.XX)
4. I welcome telehealth for APREITUDE in our clinic/practice.	XX	X.X	X.XX	X.X (X.X, X.X)	X (X, X)	XX (XX.X)	(X.XX, X.XX)

[1] Mid-level providers include nurse practitioners and physician assistants.

**Table 2.303    Distributional Characteristics of the Feasibility of Intervention Measure (FIM - Telehealth) (Month 4/5), N=XX**

FIM - TELEHEALTH	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
Mean Score	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
<b>Study Arm</b>							
Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
T-test		X.XXX					
Degrees of Freedom		XX					
P-Value		0.XXX					
<b>Site Volume</b>							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
T-test		X.XXX					
Degrees of Freedom		XX					
P-Value		0.XXX					
<b>Clinic Type</b>							
University/Academia/Research	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
FQHC/Department of Health	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Nonprofit	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Private	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
<b>Provider Type</b>							
Physician	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Mid-level providers[1]	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Nurse	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Medical Assistant	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Pharmacist	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Social worker/case manager/PrEP educator/PrEP navigator	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)

FIM - TELEHEALTH	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
Office administrator /clinic administrator/front desk staff/scheduler	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Laboratory staff/technician/phlebotomist/other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
<b>Items</b>							
1. Telehealth for APRETUDE seems implementable in our clinic/practice	XX	X.X	X.XX	X.X (X.X, X.X)	X (X, X)	XX (XX.X)	(X.XX, X.XX)
2. Telehealth for APRETUDE seems possible in our clinic/practice	XX	X.X	X.XX	X.X (X.X, X.X)	X (X, X)	XX (XX.X)	(X.XX, X.XX)
3. Telehealth for APRETUDE seems doable in our clinic/practice	XX	X.X	X.XX	X.X (X.X, X.X)	X (X, X)	XX (XX.X)	(X.XX, X.XX)
4. Telehealth for APRETUDE seems easy to use in our clinic/practice	XX	X.X	X.XX	X.X (X.X, X.X)	X (X, X)	XX (XX.X)	(X.XX, X.XX)

**Table 2.304 Changes from Baseline for Acceptability of Intervention Measure (AIM - Telehealth) and Feasibility of Intervention Measure (FIM - Telehealth ) (Month 4/5), N=XX**

Measure	Study Arm	n	Mean	SD	Median (Q1, Q3)	Observed Range (min, max)	Missing n (%)	95% CI for the Mean
AIM - Telehealth Baseline	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
AIM - Telehealth Month 4/5	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
AIM - Telehealth Change from Baseline to Month 4/5	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	T-test		X.XXX					
	DF		XX					
	P-Value		0.XXX					
FIM - Telehealth Baseline	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
FIM - Telehealth Month 4/5	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
FIM - Telehealth Change from Baseline to Month 4/5	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	X (X.X%)	(X.XXX, X.XXX)
	T-test		X.XXX					
	DF		XX					
	P-Value		0.XXX					

**Table 2.305 Mixed-effects Modeling of the Acceptability of Intervention Measure (AIM – Telehealth) (Month 4/5), N=XX**

Fixed effects					
Parameter	Estimate	Standard Error	Denominator Degrees of Freedom	T	p-Value
Intercept (RI, Low)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm (DI)	X.XX	X.XXX	XX	X.XX	0.XXXX
Volume (High)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm by Volume	X.XX	X.XXX	XX	X.XX	0.XXXX
Baseline Mean Score[1]	X.XX	X.XXX	XX	X.XX	0.XXXX
Random Effects					
Covariance Parameter	Estimate	Standard Error		Z	p-Value
Site Variance ( $\tau(0,0)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Covariance ( $\tau(0,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Baseline Variance ( $\tau(1,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Residual Variance ( $\sigma^2$ )	X.XX	X.XXX	-	X.XX	0.XXXX

Note: Null model likelihood ratio test,  $\chi^2(XX) = XXX.XX$ ,  $p = 0.XXXX$ .

[1] Baseline mean score centered by site.

**Table 2.306 Mixed-effects Modeling of the Changes from Baseline to Month 4/5 in Acceptability of Intervention Measure (AIM – Telehealth), N=XX**

Fixed effects					
Parameter	Estimate	Standard Error	Denominator Degrees of Freedom	T	p-Value
Intercept (RI, Low)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm (DI)	X.XX	X.XXX	XX	X.XX	0.XXXX
Volume (High)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm by Volume	X.XX	X.XXX	XX	X.XX	0.XXXX
Baseline Mean Score[1]	X.XX	X.XXX	XX	X.XX	0.XXXX
Random Effects					
Covariance Parameter	Estimate	Standard Error		Z	p-Value
Site Variance ( $\tau(0,0)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Covariance ( $\tau(0,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Baseline Variance ( $\tau(1,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Residual Variance ( $\sigma^2$ )	X.XX	X.XXX	-	X.XX	0.XXXX

Note: Null model likelihood ratio test,  $\chi^2(XX) = XXX.XX$ ,  $p = 0.XXXX$ .

[1] Baseline mean score centered by site.

**Table 2.307 Mixed-effects Modeling of the Feasibility of Intervention Measure (FIM – Telehealth) (Month 4/5), N=XX**

Fixed effects					
Parameter	Estimate	Standard Error	Denominator Degrees of Freedom	T	p-Value
Intercept (RI, Low)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm (DI)	X.XX	X.XXX	XX	X.XX	0.XXXX
Volume (High)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm by Volume	X.XX	X.XXX	XX	X.XX	0.XXXX
Baseline Mean Score[1]	X.XX	X.XXX	XX	X.XX	0.XXXX
Random Effects					
Covariance Parameter	Estimate	Standard Error		Z	p-Value
Site Variance ( $\tau(0,0)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Covariance ( $\tau(0,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Baseline Variance ( $\tau(1,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Residual Variance ( $\sigma^2$ )	X.XX	X.XXX	-	X.XX	0.XXXX

Note: Null model likelihood ratio test,  $\chi^2(XX) = XXX.XX$ ,  $p = 0.XXXX$ .

[1] Baseline mean score centered by site.



**Table 2.308 Mixed-effects Modeling of the Changes from Baseline to Month 4/5 in Feasibility of Intervention Measure (FIM – Telehealth), N=XX**

Fixed effects					
Parameter	Estimate	Standard Error	Denominator Degrees of Freedom	T	p-Value
Intercept (RI, Low)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm (DI)	X.XX	X.XXX	XX	X.XX	0.XXXX
Volume (High)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm by Volume	X.XX	X.XXX	XX	X.XX	0.XXXX
Baseline Mean Score[1]	X.XX	X.XXX	XX	X.XX	0.XXXX
Random Effects					
Covariance Parameter	Estimate	Standard Error		Z	p-Value
Site Variance ( $\tau(0,0)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Covariance ( $\tau(0,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Baseline Variance ( $\tau(1,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Residual Variance ( $\sigma^2$ )	X.XX	X.XXX	-	X.XX	0.XXXX

Note: Null model likelihood ratio test,  $\chi^2(XX) = XXX.XX$ ,  $p = 0.XXXX$ .

[1] Baseline mean score centered by site.

Table 2.309 Summary of Feasibility and Acceptability of Telehealth (Month 4/5), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
14	Does your clinic/practice use any form of telehealth for APRETUDE delivery?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
17	What telehealth services does your clinic/practice provide for APRETUDE?				
		Video consultation: using videoconferencing technology to facilitate a patient visit with both physician and patient present at the same time.	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Telephone consultation and visits	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Remote monitoring of patient health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Online appointment scheduling: ability for patients to make appointments without interacting with staff	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Patient portal conversations: ability for patients to send messages in an online portal	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		At-home testing services: providers order tests and send to patient's home to complete	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Sending and receiving patient reported outcomes questionnaires (e.g., quality of life, health behaviors), via an online system	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Online prescription refill requests	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Online portal for patients to access medical documents, such as visit summaries and test results	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Text messaging with patients about care	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Email reminders to patients about upcoming visits	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Text reminders	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Automated phone call reminder	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Staff phone call reminder	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Sending motivational reminders to help patients persist on APRETUDE	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Sending cabotegravir oral lead in to patient's home	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Insurance/benefits verification	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
18	"How easy or difficult is it to use the following telehealth systems to provide APRETUDE services to your patients?"				
	Video consultation	Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't use this system	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Telephone consultation	Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't use this system	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Remote monitoring of patients	Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't use this system	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Online appointment scheduling	Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't use this system	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Patient portal conversations: ability for patients to send messages to providers	Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't use this system	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	At-home testing services	Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't use this system	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Send and receiving patient reported outcomes questionnaires (e.g., quality of life, health behaviors), via an online system	Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't use this system	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Online prescription refills	Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't use this system	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Online portal for patients to access medical documents, such as visit summaries and test results	Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Somewhat Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't use this system	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Text messaging with patients about care	Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't use this system	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Email reminders to patient about upcoming visits	Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't use this system	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Text reminders	Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't use this system	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Automated phone call reminders	Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't use this system	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Staff phone call reminder	Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't use this system	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Sending motivational reminders to help patients persist on APREUDE	Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Somewhat Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't use this system	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Sending cabotegravir oral lead in to patient's home	Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't use this system	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Insurance/benefits verification	Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't use this system	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
19	In the last 6 months, what proportion of your APRETUDE visits would you estimate were via telehealth (e.g., tele-consults, video)?				
		None (0%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Few (1-30%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Some (31-65%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Most (66%-99%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		All (100%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
20	Why is telehealth not used by your clinic/practice?				
		Do not know how to use telehealth	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Telehealth is too expensive	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Telehealth is too impersonal	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Telehealth does not allow staff to do the necessary physical exams	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Concerns about telehealth privacy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Lack of patient access to computers and/or the internet	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 2.310 Summary of Telehealth Services/Systems Used (Month 4/5), N=XX

21. Which of the following telehealth services/systems is your clinic/practice using to deliver APREUDE during the PILLAR study?	Total Sample n (%)	Yes, my clinic's service/system n (%)	Yes, services/systems offered through PILLAR study n (%)	No n (%)	I don't know n (%)
<b>A. Online system for scheduling/rescheduling consultations and injection appointments</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>					
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>					
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>					
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>					
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>B. Video/virtual consultations for initial and follow-up visits</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>					
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>					
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>					
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



21. Which of the following telehealth services/systems is your clinic/practice using to deliver APREUDE during the PILLAR study?	Total Sample n (%)	Yes, my clinic's service/system n (%)	Yes, services/systems offered through PILLAR study n (%)	No n (%)	I don't know n (%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>					
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>C. Injection Administration: home health nurse to administer injection</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>					
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>					
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>					
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>					
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

21. Which of the following telehealth services/systems is your clinic/practice using to deliver APREUDE during the PILLAR study?	Total Sample n (%)	Yes, my clinic's service/system n (%)	Yes, services/systems offered through PILLAR study n (%)	No n (%)	I don't know n (%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>D. Injection appointment reminders: text, digital, email</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>					
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>					
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>					
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>					
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>E. HIV testing services: at home nurse testing</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>					
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>					
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

21. Which of the following telehealth services/systems is your clinic/practice using to deliver APREUDE during the PILLAR study?	Total Sample n (%)	Yes, my clinic's service/system n (%)	Yes, services/systems offered through PILLAR study n (%)	No n (%)	I don't know n (%)
<b>Clinic Type</b>					
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>					
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator/clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 2.311 Summary of Ease of Use of Telehealth Services/Systems Used (Month 4/5), N=XX

22. How easy or difficult has each of the telehealth services/systems been for your clinic/practice to implement for the delivery of APREUDE?	Total Sample n (%)	Very easy n (%)	Somewhat easy n (%)	Neutral n (%)	Somewhat Difficult n (%)	Very difficult n (%)	I have not personally used this n (%)
<b>A. Online system for scheduling/rescheduling consultations and injection appointments</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>							
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>							
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>							
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>							
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

22. How easy or difficult has each of the telehealth services/systems been for your clinic/practice to implement for the delivery of APREUDE?	Total Sample n (%)	Very easy n (%)	Somewhat easy n (%)	Neutral n (%)	Somewhat Difficult n (%)	Very difficult n (%)	I have not personally used this n (%)
<b>B. Video/virtual consultations for initial and follow-up visits</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>							
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>							
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>							
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>							
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>C. Injection Administration: home health nurse to administer injection</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>							

22. How easy or difficult has each of the telehealth services/systems been for your clinic/practice to implement for the delivery of APREUDE?	Total Sample n (%)	Very easy n (%)	Somewhat easy n (%)	Neutral n (%)	Somewhat Difficult n (%)	Very difficult n (%)	I have not personally used this n (%)
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>							
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>							
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>							
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>D. Injection appointment reminders: text, digital, email</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>							
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

22. How easy or difficult has each of the telehealth services/systems been for your clinic/practice to implement for the delivery of APREUDE?	Total Sample n (%)	Very easy n (%)	Somewhat easy n (%)	Neutral n (%)	Somewhat Difficult n (%)	Very difficult n (%)	I have not personally used this n (%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>							
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>							
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>							
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>E. HIV testing services: at home nurse testing</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>							
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>							

22. How easy or difficult has each of the telehealth services/systems been for your clinic/practice to implement for the delivery of APREUDE?	Total Sample n (%)	Very easy n (%)	Somewhat easy n (%)	Neutral n (%)	Somewhat Difficult n (%)	Very difficult n (%)	I have not personally used this n (%)
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>							
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>							
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



Table 2.312 Summary of Helpfulness of Services/Systems Used (Month 4/5), N=XX

23. How helpful or unhelpful has each of the telehealth services/systems been to the delivery of APREUDE in your clinic/practice?	Total Sample n (%)	Very easy n (%)	Somewhat easy n (%)	Neutral n (%)	Somewhat Difficult n (%)	Very difficult n (%)	I have not personally used this n (%)
<b>A. Online system for scheduling/rescheduling consultations and injection appointments</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>							
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>							
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>							
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>							
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

23. How helpful or unhelpful has each of the telehealth services/systems been to the delivery of APREUDE in your clinic/practice?	Total Sample n (%)	Very easy n (%)	Somewhat easy n (%)	Neutral n (%)	Somewhat Difficult n (%)	Very difficult n (%)	I have not personally used this n (%)
<b>B. Video/virtual consultations for initial and follow-up visits</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>							
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>							
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>							
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>							
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>C. Injection Administration: home health nurse to administer injection</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>							

23. How helpful or unhelpful has each of the telehealth services/systems been to the delivery of APREUDE in your clinic/practice?	Total Sample n (%)	Very easy n (%)	Somewhat easy n (%)	Neutral n (%)	Somewhat Difficult n (%)	Very difficult n (%)	I have not personally used this n (%)
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>							
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>							
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>							
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>D. Injection appointment reminders: text, digital, email</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>							
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

23. How helpful or unhelpful has each of the telehealth services/systems been to the delivery of APREUDE in your clinic/practice?	Total Sample n (%)	Very easy n (%)	Somewhat easy n (%)	Neutral n (%)	Somewhat Difficult n (%)	Very difficult n (%)	I have not personally used this n (%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>							
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>							
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>							
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>E. HIV testing services: at home nurse testing</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>							
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>							

23. How helpful or unhelpful has each of the telehealth services/systems been to the delivery of APREUDE in your clinic/practice?	Total Sample n (%)	Very easy n (%)	Somewhat easy n (%)	Neutral n (%)	Somewhat Difficult n (%)	Very difficult n (%)	I have not personally used this n (%)
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>							
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>							
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 2.313 Summary of Satisfaction of Services/Systems Used (Month 4/5), N=XX

24. How satisfied or dissatisfied have you been with each of the telehealth services/systems for delivering APREUDE in your clinic/practice?	Total Sample n (%)	Very satisfied n (%)	Somewhat satisfied n (%)	Neither satisfied nor dissatisfied n (%)	Somewhat satisfied n (%)	Very satisfied n (%)	I have not personally used this n (%)
<b>A. Online system for scheduling/rescheduling consultations and injection appointments</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>							
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>							
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>							
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>							
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

24. How satisfied or dissatisfied have you been with each of the telehealth services/systems for delivering APREUDE in your clinic/practice?	Total Sample n (%)	Very satisfied n (%)	Somewhat satisfied n (%)	Neither satisfied nor dissatisfied n (%)	Somewhat satisfied n (%)	Very satisfied n (%)	I have not personally used this n (%)
<b>B. Video/virtual consultations for initial and follow-up visits</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>							
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>							
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>							
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>							
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator/clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>C. Injection Administration: home health nurse to administer injection</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>							

24. How satisfied or dissatisfied have you been with each of the telehealth services/systems for delivering APREUDE in your clinic/practice?	Total Sample n (%)	Very satisfied n (%)	Somewhat satisfied n (%)	Neither satisfied nor dissatisfied n (%)	Somewhat satisfied n (%)	Very satisfied n (%)	I have not personally used this n (%)
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>							
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>							
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>							
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>D. Injection appointment reminders: text, digital, email</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>							
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



24. How satisfied or dissatisfied have you been with each of the telehealth services/systems for delivering APREUDE in your clinic/practice?	Total Sample n (%)	Very satisfied n (%)	Somewhat satisfied n (%)	Neither satisfied nor dissatisfied n (%)	Somewhat satisfied n (%)	Very satisfied n (%)	I have not personally used this n (%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>							
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>							
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>							
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>E. HIV testing services: at home nurse testing</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>							
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>							

24. How satisfied or dissatisfied have you been with each of the telehealth services/systems for delivering APREUDE in your clinic/practice?	Total Sample n (%)	Very satisfied n (%)	Somewhat satisfied n (%)	Neither satisfied nor dissatisfied n (%)	Somewhat satisfied n (%)	Very satisfied n (%)	I have not personally used this n (%)
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>							
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>							
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 2.401 Summary of Utility of Proposed Implementation Strategies (Month 4/5), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
25	Have you used the following in the implementation of APRETUDE into your practice/clinic?				
25A	Frequently Asked Questions Brochure	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
25B	Readiness Consideration	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
25C	Get Started Overview-Init/Adm Guide	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
25D	Injection Education Video	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
25E	Provider Website – location where all materials and videos on APRETUDE for the study is located	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
25F	Patient Materials	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
25G	Implementation Guidance Video	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
25H	Appointment Scheduler	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
25I	Pre-scheduled Appointment Guidance	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
25J	Designated Injection Days Guidance	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
25K	Drop-in Injection Visits Guidance	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
25L	Transport Support to Patient Appt	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
25M	Monthly Implement Facilitation Call	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
25N	Group Implement Facilitation Calls	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
25O	Document on How Discuss Sex Health	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
25P	PILLAR Spot	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
26	How often have you used the following in the implementation of APRETUDE into your practice/clinic?				
26A	Frequent Ask Question Brochure	Rarely	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Sometimes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Often	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		All the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
26B	Readiness Consideration	Rarely	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Sometimes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Often	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		All the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
26C	Getting Started Overview	Rarely	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Sometimes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Often	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		All the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
26D	Injection Education Video	Rarely	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Sometimes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Often	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		All the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
26F	Patient Materials	Rarely	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Sometimes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Often	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		All the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
26G	Implementation Guidance Video	Rarely	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Sometimes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Often	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		All the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
26H	Appointment Scheduler	Rarely	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Sometimes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Often	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		All the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
26I	Pre-scheduled Appt Guidance	Rarely	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Sometimes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Often	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		All the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
26J	Designated Inj Days Guidance	Rarely	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Sometimes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Often	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		All the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
26K	Drop-in Inj Visits Guidance	Rarely	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Sometimes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Often	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		All the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
26L	Transport Support to Pt Appt	Rarely	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Sometimes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Often	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		All the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
26M	Monthly Implement Facilit Call	Rarely	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Sometimes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Often	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		All the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
26N	Group Implement Facilit Calls	Rarely	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Sometimes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Often	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		All the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
26O	Doc on How Discuss Sex Health	Rarely	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Sometimes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Often	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		All the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
26P	PILLAR Spot	Rarely	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Sometimes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Often	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		All the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
27	How useful are the following in the implementation of APRETUDE into your practice/clinic?				
27A	Frequently Asked Questions Brochure	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
27B	Readiness Consideration	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
27C	Getting Started Overview-Init/Adm Guide	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
27D	Injection Education Video	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
27E	Provider Website	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
27F	Patient Materials	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
27G	Implementation Guidance Video	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
27H	Appointment Scheduler	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
27I	Pre-scheduled Appointment Guidance	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
27J	Designated Injection Days Guidance	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
27K	Drop-in Injection Visits Guidance	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		A little useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
27L	Provide Transport Support to Patient Appt	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
27M	Monthly Implementation Facilitation Call	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
27N	Group Implementation Facilitation Calls	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
27O	Document on How to Discuss Sexual Health	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
27P	PILLAR Spot	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 2.501 Summary of Perceived Barriers to Delivering APRETUDE to Patients (Month 4/5), N=XX**

52. Please indicate how concerned you would be about each of the following being a barrier or challenge to delivering APRETUDE to patients based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
<b>A. Patients' ability to keep appointments</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

52. Please indicate how concerned you would be about each of the following being a barrier or challenge to delivering APREUDE to patients based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
<b>B. Patients' injection-related pain/soreness</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>C. Risk of drug resistance for patients not adherent to injections</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

52. Please indicate how concerned you would be about each of the following being a barrier or challenge to delivering APREUDE to patients based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>D. Cost of APREUDE</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						

52. Please indicate how concerned you would be about each of the following being a barrier or challenge to delivering APREUDE to patients based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>E. Keeping a patient engaged and motivated to continue APREUDE</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

52. Please indicate how concerned you would be about each of the following being a barrier or challenge to delivering APREUDE to patients based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>F. Identifying eligible individuals for APREUDE</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

52. Please indicate how concerned you would be about each of the following being a barrier or challenge to delivering APREUDE to patients based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>G. Worried that a patient will feel stigmatized if offered APREUDE</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						

52. Please indicate how concerned you would be about each of the following being a barrier or challenge to delivering APREUDE to patients based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>H. Patients' willingness to travel every 2 months for an injection appointment</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



52. Please indicate how concerned you would be about each of the following being a barrier or challenge to delivering APREUDE to patients based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>I. Patient lack of belief in the efficacy of APREUDE</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

52. Please indicate how concerned you would be about each of the following being a barrier or challenge to delivering APREUDE to patients based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 2.502 Summary of Perceptions of Administering APRETUDE (Month 4/5), N=XX

53. Please indicate how concerned you would be about each of the following being a barrier or challenge to APRETUDE administration based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
<b>A. Difficulty of giving the gluteal medial injection</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator/clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

53. Please indicate how concerned you would be about each of the following being a barrier or challenge to APRETUDE administration based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
<b>B. Understanding how to manage patients who miss an injection dose</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>C. How to transition patients off of APRETUDE who want to stop taking it (e.g., should other PrEP be offered)</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

53. Please indicate how concerned you would be about each of the following being a barrier or challenge to APREUDE administration based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>D. Understanding how to use oral PrEP medication for a <u>planned</u> missed injection visit</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						

53. Please indicate how concerned you would be about each of the following being a barrier or challenge to APRETUDE administration based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>E. Understanding how to restart APRETUDE after a missed injection</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

53. Please indicate how concerned you would be about each of the following being a barrier or challenge to APREUDE administration based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>F. Managing the oral lead-in phase of APREUDE before starting injections if needed</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

53. Please indicate how concerned you would be about each of the following being a barrier or challenge to APREUDE administration based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>G. Ability to provide adherence counseling and support when injection dosing visits are missed</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						



53. Please indicate how concerned you would be about each of the following being a barrier or challenge to APREUDE administration based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 2.503 Summary of Perceived Barriers to Managing Delivery of APRETUDE (Month 4/5), N=XX**

54. Please indicate how concerned you would be about each of the following being a barrier or challenge to APRETUDE delivery based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
<b>A. Management of scheduling injection appointments every 2 months during correct injection (i.e., dosing) windows</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

54. Please indicate how concerned you would be about each of the following being a barrier or challenge to APRETUDE delivery based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>B. Management of rescheduling appointments during correct injection (i.e., dosing) windows</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

54. Please indicate how concerned you would be about each of the following being a barrier or challenge to APRETUDE delivery based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
<b>C. Ability to schedule/reschedule patients who missed APRETUDE visits within correct injection (i.e., dosing) windows</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator/clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

54. Please indicate how concerned you would be about each of the following being a barrier or challenge to APRETUDE delivery based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
<b>D. Ability to identify and flag missed injection visits to providers (in a timely manner)</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>E. Ability to manage patients presenting to APRETUDE injection</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

54. Please indicate how concerned you would be about each of the following being a barrier or challenge to APREUDE delivery based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
<b>appointments with other care needs that need to be addressed</b>						
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>F. Persistence to follow up with patient on missed appointments</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						

54. Please indicate how concerned you would be about each of the following being a barrier or challenge to APREUDE delivery based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>G. Provider time to discuss HIV prevention with all eligible patients</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

54. Please indicate how concerned you would be about each of the following being a barrier or challenge to APREUDE delivery based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>H. Ability to provide HIV screening as indicated at each injection visit and provide rapid intervention/follow-up based on results status</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



54. Please indicate how concerned you would be about each of the following being a barrier or challenge to APREUDE delivery based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>I. HIV monitoring requirements associated with APREUDE</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

54. Please indicate how concerned you would be about each of the following being a barrier or challenge to APREUDE delivery based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 2.504 Summary of Perceived Resourcing Barriers to Support Delivery of APRETUDE (Month 4/5), N=XX**

55. Please indicate how concerned you would be about each of the following potentially being a barrier or challenge to APRETUDE delivery based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
<b>A. Staff resourcing to ensure appropriate clinic flow</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

55. Please indicate how concerned you would be about each of the following potentially being a barrier or challenge to APREUDE delivery based on your current expectations and knowledge.						
	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
<b>B. Number of exam rooms for injections</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>C. Clinic staff to administer injections</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

55. Please indicate how concerned you would be about each of the following potentially being a barrier or challenge to APREUDE delivery based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>D. Staff preparation (i.e., education, training, in-services) to implement APREUDE</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						

55. Please indicate how concerned you would be about each of the following potentially being a barrier or challenge to APREUDE delivery based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>E. Staff time to provide counseling and support to patients, such as answering questing between visit, keeping patients motivated</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						

55. Please indicate how concerned you would be about each of the following potentially being a barrier or challenge to APRETUDE delivery based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>F. Staff belief in the efficacy of APRETUDE</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

55. Please indicate how concerned you would be about each of the following potentially being a barrier or challenge to APREUDE delivery based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



**Table 2.505 Summary of Perceptions of Clinic/Practice Culture and Environment (Month 4/5), N=XX**

56. How much do you agree or disagree with the following statements about your clinic/practice?	Total Sample n (%)	Completely Disagree n (%)	Disagree n (%)	Neither agree nor disagree n (%)	Agree n (%)	Completely Agree n (%)
<b>A. People at all levels openly talk about what is and isn't working</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>B. Most people in this clinic are willing to change how they do things in response to feedback from others</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>C. It is hard to get things to change in our clinic</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>D. People in this clinic operate as a real team</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation						
<b>Site Volume</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low						
<b>E. Staff members often show signs of stress and strain</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

56. How much do you agree or disagree with the following statements about your clinic/practice?	Total Sample n (%)	Completely Disagree n (%)	Disagree n (%)	Neither agree nor disagree n (%)	Agree n (%)	Completely Agree n (%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>F. We regularly take time to consider ways to improve how we do things</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>G. Leadership strongly supports clinic change efforts</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 2.506 Summary of Barriers to PrEP Provisioning (Month 4/5), N=XX

87. Indicate your level of agreement with the following statements:	Total Sample n (%)	Completely Disagree n (%)	Disagree n (%)	Neither agree nor disagree n (%)	Agree n (%)	Completely Agree n (%)
<b>A. The use of PrEP will cause patients to engage in riskier behaviors</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>B. Providing PrEP endorses the risk behaviors of users</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>C. Only people who engage in risky behavior need PrEP</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>D. Only people with many sexual partners need PrEP</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation						
<b>Site Volume</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low						
<b>E. All sexually active people can benefit from PrEP</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

87. Indicate your level of agreement with the following statements:	Total Sample n (%)	Completely Disagree n (%)	Disagree n (%)	Neither agree nor disagree n (%)	Agree n (%)	Completely Agree n (%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>F. Providing PrEP will result in an increase in sexually transmitted diseases among patients</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>G. People do not need PrEP if they act responsibly</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 2.507 Distributional Characteristics of Barriers to PrEP Provisioning (Month 4/5), N=XX

87. Indicate your level of agreement with the following statements:	Study Arm	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
<b>A. The use of PrEP will cause patients to engage in riskier behaviors</b>	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
	T-test		X.XXX					
	DF		XX					
	P-Value		0.XXX					
<b>B. Providing PrEP endorses the risk behaviors of users</b>	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
	T-test		X.XXX					
	DF		XX					
	P-Value		0.XXX					
<b>C. Only people who engage in risky behavior need PrEP</b>	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
	T-test		X.XXX					
	DF		XX					
	P-Value		0.XXX					
<b>D. Only people with many sexual partners need PrEP</b>	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
	T-test		X.XXX					
	DF		XX					
	P-Value		0.XXX					
<b>E. All sexually active people can benefit from PrEP</b>	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)

87. Indicate your level of agreement with the following statements:	Study Arm	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
	T-test		X.XXX					
	DF		XX					
	P-Value		0.XXX					
<b>F. Providing PrEP will result in an increase in sexually transmitted diseases among patients</b>	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
	T-test		X.XXX					
	DF		XX					
	P-Value		0.XXX					
<b>G. People do not need PrEP if they act responsibly</b>	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
	T-test		X.XXX					
	DF		XX					
	P-Value		0.XXX					
<b>Total Score</b>	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
	T-test		X.XXX					
	DF		XX					
	P-Value		0.XXX					

**Table 2.508 Shift from Baseline to Month 4/5 in Summary of Perceived Barriers to Delivering APRETUDE to Patients (Month 4/5), N=XX**

52. Please indicate how concerned you would be about each of the following being a barrier or challenge to delivering APRETUDE to patients based on your current expectations and knowledge.									
A. Patients' ability to keep appointments									
Study Arm	N	Baseline	M4/5						
			Extremely Concerned	Moderately Concerned	Somewhat Concerned	Slightly Concerned	Not at all Concerned	Missing	Total
DI	XX	Extremely Concerned	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)
		Moderately Concerned	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)
		Somewhat Concerned	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)
		Slightly Concerned	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)
		Not at all Concerned	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)
		Missing	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)
		Total	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)
RI	XX	Extremely Concerned	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)

		<b>Moderately Concerned</b>	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)
		<b>Somewhat Concerned</b>	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)
		<b>Slightly Concerned</b>	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)
		<b>Not at all Concerned</b>	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)
		<b>Missing</b>	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)
		<b>Total</b>	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)

Note 1: Shift tables will be created as above for items 52b through 52i.

Missing: BL = missing item at BL. M 4/5 = missing item at M 4/5.

Percentage calculations:

Column total %: numerator= number selecting respective response at M 4/5, denominator = number responding at M 4/5

Row total %: numerator= number selecting respective response at BL, denominator = number responding at BL

Cell %: numerator = number selecting respective combination of BL and M 4/5 responses, denominator=number of participants responding at BL.

Total: N = number of participants that completed the question at either BL or M 4/5

### Table 2.509 Shift from Baseline to Month 4/5 in Summary of Perceptions of Administering APRETUDE (Month 4/5), N=XX

Note 1: Shift tables will be created as shown for Table 2.508 for items 53a through 53g.

Missing: BL = missing item at BL. M 4/5 = missing item at M 4/5.

Percentage calculations:

Column total %: numerator= number selecting respective response at M 4/5, denominator = number responding at M 4/5

Row total %: numerator= number selecting respective response at BL, denominator = number responding at BL

Cell %: numerator = number selecting respective combination of BL and M 4/5 responses, denominator=number of participants responding at BL.

Total: N = number of participants that completed the question at either BL or M 4/5



### Table 2.510 Shift from Baseline to Month 4/5 in Summary of Perceived Barriers to Managing Delivery of APRETUDE (Month 4/5), N=XX

Note 1: Shift tables will be created as shown for Table 2.508 for items 54a through 54i.

Missing: BL = missing item at BL. M 4/5 = missing item at M 4/5.

Percentage calculations:

Column total %: numerator= number selecting respective response at M 4/5, denominator = number responding at M 4/5

Row total %: numerator= number selecting respective response at BL, denominator = number responding at BL

Cell %: numerator = number selecting respective combination of BL and M 4/5 responses, denominator=number of participants responding at BL.

Total: N = number of participants that completed the question at either BL or M 4/5

### Table 2.511 Shift from Baseline to Month 4/5 in Summary of Perceived Resourcing Barriers to Support Delivery of APRETUDE (Month 4/5), N=XX

Note 1: Shift tables will be created as shown for Table 2.508 for items 55a through 55f.

Missing: BL = missing item at BL. M 4/5 = missing item at M 4/5.

Percentage calculations:

Column total %: numerator= number selecting respective response at M 4/5, denominator = number responding at M 4/5

Row total %: numerator= number selecting respective response at BL, denominator = number responding at BL

Cell %: numerator = number selecting respective combination of BL and M 4/5 responses, denominator=number of participants responding at BL.

Total: N = number of participants that completed the question at either BL or M 4/5

### Table 2.512 Shift from Baseline to Month 4/5 in Summary of Perceptions of Clinic/Practice Culture and Environment (Month 4/5), N=XX

Note 1: Shift tables will be created as shown for Table 2.508 for items 56a through 56g.

Missing: BL = missing item at BL. M 4/5 = missing item at M 4/5.

Percentage calculations:

Column total %: numerator= number selecting respective response at M 4/5, denominator = number responding at M 4/5

Row total %: numerator= number selecting respective response at BL, denominator = number responding at BL

Cell %: numerator = number selecting respective combination of BL and M 4/5 responses, denominator=number of participants responding at BL.

Total: N = number of participants that completed the question at either BL or M 4/5

**Table 2.513 Shift from Baseline to Month 4/5 in Summary of Barriers to PrEP Provisioning (Month 4/5), N=XX**

Note 1: Shift tables will be created as shown for Table 2.508 for items 87a through 87g.

Missing: BL = missing item at BL. M 4/5 = missing item at M 4/5.

Percentage calculations:

Column total %: numerator= number selecting respective response at M 4/5, denominator = number responding at M 4/5

Row total %: numerator= number selecting respective response at BL, denominator = number responding at BL

Cell %: numerator = number selecting respective combination of BL and M 4/5 responses, denominator=number of participants responding at BL.

Total: N = number of participants that completed the question at either BL or M 4/5

Table 2.601 Summary of the Sexual Health Assessment Tool (Month 4/5), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
28	Has your clinic/practice started to use the Sexual Health Assessment?				
		No And Not Planning To Use The Sexual Health Assessment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No But Planning To Use The Sexual Health Assessment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
29	Who in your clinic/practice is or will be responsible for distributing the Sexual Health Assessment to patients?				
		Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Nurse practitioner/physician assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Medical assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Social worker/case manager	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Peer educator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
30	Who in your clinic/practice is or will be responsible for reviewing and discussing the results of the Sexual Health Assessment with patients?				
		Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Nurse practitioner/physician assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Medical assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Social worker/case manager	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Peer educator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The results are or will not be discussed with patients	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
31	How often have you used the Sexual Health Assessment in your clinic/practice?				
		Rarely	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Sometimes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Often	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		All the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
32	"Please indicate your level of agreement with the following statements about the Sexual Health Assessment."				
	The Sexual Health Assessment is/will be easy to implement in my clinic/practice	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The Sexual Health Assessment is/will be an easy way to identify individuals interested in PrEP	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The Sexual Health Assessment helps/will help to facilitate conversations about PrEP with patients	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
33	Why is the Sexual Health Assessment not used by your clinic/practice?	Already have a similar assessment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Does not integrate with the EMR	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The assessment is difficult to administer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Concerns about patient privacy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The assessment does not ask the right questions	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The assessment takes too much time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The assessment is not needed	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 2.602 Summary of the PrEP Communication Tool (Month 4/5), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
34	Has your clinic/practice started to use PrEP Options Communication Tool?				
		No and not planning to use the PrEP Options Communication Tool	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No but planning to use the PrEP Options Communication Tool	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
35	Who in your clinic/practice is or will be responsible for using the PrEP Options Communication Tool with patients?				
		Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Nurse practitioner/physician assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Medical assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Social worker/case manager	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Peer educator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
36	How often have you used the PrEP Options Communication Tool in your clinic/practice?				
		Rarely	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Sometimes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Often	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		All the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
37	Please indicate your level of agreement with the following statements about the PrEP Options Communication Tool				

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
	The PrEP Options Communication Tool is/will be easy to implement in my clinic/practice	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The PrEP Options Communication Tool helps/will help to facilitate conversations about PrEP with patients	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
38	Why is the PrEP Options Communication Tool not used by your clinic/practice?	Already have a similar tool	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Do not have time in a clinical visit to use the tool	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Do not understand the information in the tool	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Tool does not provide the right information	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Tool is not needed	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



Table 2.701 Summary of the Optional Oral Lead-in Phase of APRETUDE (Month 4/5), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
73	How do you start your patients with APRETUDE?				
		Directly with injection	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		With optional oral lead-in using oral cabotegravir	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		With oral PrEP (TDF/FTC or TAF/FTC)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
74	“Of all your patients who have been prescribed APRETUDE, please estimate the percentage that started:”				
	Directly with injection who switched from oral PrEP	N	XX	XX	XX
		Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)
		Median	XX.X	XX.X	XX.X
		Q1, Q3	X.X, X.X	X.X, X.X	X.X, X.X
		Range (Min, Max)	XX (XX, XX)	XX (XX, XX)	XX (XX, XX)
	Directly with injection who are new to PrEP	N	XX	XX	XX
		Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)
		Median	XX.X	XX.X	XX.X
		Q1, Q3	X.X, X.X	X.X, X.X	X.X, X.X
		Range (Min, Max)	XX (XX, XX)	XX (XX, XX)	XX (XX, XX)
	With optional oral lead-in (oral Cabotegravir)	N	XX	XX	XX
		Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)
		Median	XX.X	XX.X	XX.X
		Q1, Q3	X.X, X.X	X.X, X.X	X.X, X.X
		Range (Min, Max)	XX (XX, XX)	XX (XX, XX)	XX (XX, XX)
	With oral PrEP (TDF/FTC or TAF/FTC)	N	XX	XX	XX
		Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)
		Median	XX.X	XX.X	XX.X
		Q1, Q3	X.X, X.X	X.X, X.X	X.X, X.X
		Range (Min, Max)	XX (XX, XX)	XX (XX, XX)	XX (XX, XX)
	Other	N	XX	XX	XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)
		Median	XX.X	XX.X	XX.X
		Q1, Q3	X.X, X.X	X.X, X.X	X.X, X.X
		Range (Min, Max)	XX (XX, XX)	XX (XX, XX)	XX (XX, XX)
75	What sources of information have you drawn upon in assessing whether oral lead-in is needed or not?				
		Scientific literature	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Independent Medical Education	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Data from ViiV/GSK	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Scientific conferences	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Clinic rounds	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		CDC guidelines	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other medical colleagues	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other sources	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
76	What are the main factors that drive your decision to use oral lead-in or not?				
		The ability to assess the safety/tolerability of APREUDE in all patients	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The ability to assess the safety/tolerability of APREUDE in patients with a history of allergy/drug intolerance	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The availability of more data from clinical trials using an oral lead-in phase	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The ability to increase drug concentration before starting the injections	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Being cautious with a new medication	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Providing patient with protection against HIV until the injection arrives	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Patient request	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Enough data exists from clinical trials to start patients with injection without oral lead in	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Provide patients with immediate protection with a long acting method by not using oral lead in	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
77	How influential are patient preferences in the decision of whether or not to use an oral lead-in phase?				
		Very influential	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Influential	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat influential	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not very influential	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all influential	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
78	Have any of your patients missed injection visit(s)?				
		No, none of my patients have missed their injection visits	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes, some of my patients have had planned missed visits	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes, some of my patients have had unplanned missed visits	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
79	For patients who have missed an injection visit, what protection were they given/offered until they received their next injection?				
		Cabotegravir oral tablets	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		TDF/FTC	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		TAF/FTC	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Provision of condoms	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Risk reduction education	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		None	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Do not know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
80	For patients who plan to miss an injection, what protection do you plan on offering them until they receive their next injection?				
		Cabotegravir oral tablets	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		TDF/FTC	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		TAF/FTC	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Provision of condoms	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Risk reduction education	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		None	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Do not know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
81	How easy or difficult was it to start patients on oral PrEP for a missed injection visit?				
		Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Somewhat difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
82	How acceptable was it to start patients on oral PrEP after a missed injection visit?				
		Very acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little Acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all Acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
83	Before initiating a patient on PrEP, what type of HIV test do you primarily use?				
	Oral PrEP	HIV-1 RNA, qualitative test	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV-1 RNA, quantitative test (e.g. viral load)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV antigen/antibody test (laboratory) 4 <sup>th</sup> gen lab	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV antigen/ antibody test (rapid test) 4 <sup>th</sup> gen rapid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV antibody test (rapid test) 3 <sup>rd</sup> gen rapid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	APREUDE	HIV-1 RNA, qualitative test	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV-1 RNA, quantitative test (e.g. viral load)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV antigen/antibody test (laboratory) 4 <sup>th</sup> gen lab	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV antigen/ antibody test (rapid test) 4 <sup>th</sup> gen rapid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV antibody test (rapid test) 3 <sup>rd</sup> gen rapid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
84	Before initiating a patient on PrEP, what type of HIV test have you ever used?				
	Oral PrEP	HIV-1 RNA, qualitative test	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV-1 RNA, quantitative test (e.g. viral load)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV antigen/antibody test (laboratory) 4 <sup>th</sup> gen lab	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV antigen/ antibody test (rapid test) 4 <sup>th</sup> gen rapid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV antibody test (rapid test) 3 <sup>rd</sup> gen rapid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	APREUDE	HIV-1 RNA, qualitative test	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		HIV-1 RNA, quantitative test (e.g. viral load)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV antigen/antibody test (laboratory) 4 <sup>th</sup> gen lab	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV antigen/ antibody test (rapid test) 4 <sup>th</sup> gen rapid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV antibody test (rapid test) 3 <sup>rd</sup> gen rapid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
85	For follow-up visits for patients who are on PrEP, what type of HIV test do you primarily use?				
	Oral PrEP	HIV-1 RNA, qualitative test	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV-1 RNA, quantitative test (e.g. viral load)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV antigen/antibody test (laboratory) 4 <sup>th</sup> gen lab	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV antigen/ antibody test (rapid test) 4 <sup>th</sup> gen rapid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV antibody test (rapid test) 3 <sup>rd</sup> gen rapid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	APREUDE	HIV-1 RNA, qualitative test	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV-1 RNA, quantitative test (e.g. viral load)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV antigen/antibody test (laboratory) 4 <sup>th</sup> gen lab	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV antigen/ antibody test (rapid test) 4 <sup>th</sup> gen rapid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV antibody test (rapid test) 3 <sup>rd</sup> gen rapid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
86	For follow-up visits for patients who are on PrEP, what type of HIV test have you ever used?				
	Oral PrEP	HIV-1 RNA, qualitative test	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV-1 RNA, quantitative test (e.g. viral load)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV antigen/antibody test (laboratory) 4 <sup>th</sup> gen lab	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV antigen/ antibody test (rapid test) 4 <sup>th</sup> gen rapid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV antibody test (rapid test) 3 <sup>rd</sup> gen rapid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	APREUDE	HIV-1 RNA, qualitative test	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		HIV-1 RNA, quantitative test (e.g. viral load)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV antigen/antibody test (laboratory) 4 <sup>th</sup> gen lab	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV antigen/ antibody test (rapid test) 4 <sup>th</sup> gen rapid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV antibody test (rapid test) 3 <sup>rd</sup> gen rapid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 2.801 Summary of Perceived Number of APREUDE Patients Clinic/Practice Can Manage Per Week on an Ongoing Basis (Month 4/5), N=XX**

57. How many APREUDE patients do you think your clinic/practice can manage per week on an ongoing basis?	Total Sample n (%)	0-10 Patients n (%)	11-25 Patients n (%)	26-50 Patients n (%)	51-100 Patients n (%)	101-200 Patients n (%)	>200 Patients n (%)	I don't know n=xx (%)
<b>Total Sample</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>								
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>								
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 2.802    Distributional Characteristics of People in Clinic Trained and Prepared to Give APREUDE Injections (Month 4/5), N=XX**

58. Approximately how many people in your clinic are trained and prepared to give APREUDE injections?	Total Sample n (%)	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum and Maximum)	Percent Missing	95% Confidence Interval	I don't know n (%)
<b>Total Sample</b>	XX (XX.X%)	X.X	X.XX	X.X (X.X, X.X)	XX (XX, XX)	XX.X%	X.XX (X.XX, X.XX)	XX (XX.X%)
<b>Study Arm</b>								
Dynamic Implementation	XX (XX.X%)	X.X	X.XX	X.X (X.X, X.X)	XX (XX, XX)	XX.X%	X.XX (X.XX, X.XX)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	X.X	X.XX	X.X (X.X, X.X)	XX (XX, XX)	XX.X%	X.XX (X.XX, X.XX)	XX (XX.X%)
<b>Site Volume</b>								
High	XX (XX.X%)	X.X	X.XX	X.X (X.X, X.X)	XX (XX, XX)	XX.X%	X.XX (X.XX, X.XX)	XX (XX.X%)
Low	XX (XX.X%)	X.X	X.XX	X.X (X.X, X.X)	XX (XX, XX)	XX.X%	X.XX (X.XX, X.XX)	XX (XX.X%)



**Table 2.803**    **Distributional Characteristics of Estimated Number of Staff Needed Per Week to Incorporate APREUDE into Clinic/Practice for Approximately 25 People (Month 4/5), N=XX**

48. How much staff in total do you estimate is/will be needed per week to incorporate APREUDE into your clinic/practice for approximately 25 people?	Total Sample n (%)	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum and Maximum)	Percent Missing	95% Confidence Interval	I don't know n (%)
<b>Total Sample</b>	XX (XX.X%)	X.X	X.XX	X.X (X.X, X.X)	XX (XX, XX)	XX.X%	X.XX (X.XX, X.XX)	XX (XX.X%)
<b>Study Arm</b>								
Dynamic Implementation	XX (XX.X%)	X.X	X.XX	X.X (X.X, X.X)	XX (XX, XX)	XX.X%	X.XX (X.XX, X.XX)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	X.X	X.XX	X.X (X.X, X.X)	XX (XX, XX)	XX.X%	X.XX (X.XX, X.XX)	XX (XX.X%)
<b>Site Volume</b>								
High	XX (XX.X%)	X.X	X.XX	X.X (X.X, X.X)	XX (XX, XX)	XX.X%	X.XX (X.XX, X.XX)	XX (XX.X%)
Low	XX (XX.X%)	X.X	X.XX	X.X (X.X, X.X)	XX (XX, XX)	XX.X%	X.XX (X.XX, X.XX)	XX (XX.X%)

**Table 2.804 Summary of Estimated Percentage of Staff Time/Full-Time Equivalent Hours Needed Per Week to Incorporate APRETUDE into Clinic/Practice for Approximately 25 People (Month 4/5), N=XX**

60. How much staff time/full-time equivalent hours (FTE) do you estimate is/will be needed per week to incorporate APRETUDE into your clinic/practice for approximately 25 people?	Total Sample n (%)	1-20% FTE or 0.4 – 8hrs of staff time n (%)	21-40% FTE or 8.4 – 16hrs of staff time n (%)	41-60% FTE or 16.4 – 24 hrs of staff time n (%)	61-80% FTE or 24.4 – 32hrs of staff time n (%)	81-100% FTE or 32.4 – 40hrs of staff time n (%)	I don't know n (%)
<b>Total Sample</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>							
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>							
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 2.805 Summary of Plans to Create New Roles/Positions in Clinic to Coordinate the APREITUDE Program (Month 4/5), N=XX**

61. Have you created or do you plan to create new role(s)/new position(s) in your clinic to coordinate the APREITUDE program?	Total Sample n (%)	Yes n (%)	No n (%)	Maybe n (%)	I don't know n (%)
<b>Total Sample</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>					
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>					
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 2.806 Summary of Number of New Roles/Positions in Clinic to Coordinate the APRETUDE Program (Month 4/5), N=XX**

62. How many new role(s)/new position(s) have been created or will be created in your clinic to coordinate the APRETUDE program? [1]	Total Sample n (%)	1 n (%)	2 n (%)	3 n (%)	4 n (%)	5 n (%)	More than 5 n (%)	I don't know n (%)
<b>Total Sample</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>								
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>								
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

[1] Only includes SSPs who responded 'yes' or 'maybe' to 'Do you plan to create new role(s)/new position(s) in your clinic to coordinate the APRETUDE program?'

**Table 2.807 Summary of How Clinic/Practice Plans to Track Patients on APRETUDE (Month 4/5), N=XX**

63. How is the clinic/practice tracking patients on APRETUDE?	Total Sample n (%)	Use a spreadsheet such as MS Excel n (%)	Assign specific staff to track patients n (%)	Have providers track their own patients n (%)	Create alerts in electronic medical records (EMRs) n (%)	Other [1] n (%)	I don't know n (%)
<b>Total Sample</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>							
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>							
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

[1] Other responses include: xxxxx

**Table 2.808 Summary of How Clinic/Practice Responds to Patients who Do Not Show for a Regularly Scheduled Appointment (Month 4/5), N=XX**

64. What does your clinic/practice do if a patient does not show for a APREUDE visit?	Total Sample n (%)	Phone the patient to reschedule n (%)	Text the patient to reschedule n (%)	Email the patient to reschedule n (%)	Send the patient a postal letter to reschedule n (%)	Wait until the patient contacts the clinic/practice to reschedule n (%)	Charge the patient a fee for not showing up n (%)	I don't know/not applicable to role n (%)	Other [1] n (%)
<b>Total Sample</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>									
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>									
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

[1] Other responses include: xxxxx

**Table 2.809 Summary of Whether Clinic/Practice has Specific Person in Charge of Following Up on No-Shows (Month 4/5), N=XX**

65. Is there a specific person in charge of following up on no-shows for APREUDE appointments?	Total Sample n (%)	Yes n (%)	No n (%)	I don't know n (%)
<b>Total Sample</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>				
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>				
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 2.810 Summary of Type of Systems Clinic has in Place to Remind Patients of Upcoming Appointments (Month 4/5), N=XX**

69. How do you remind patients of an upcoming APREUDE appointment?[1]	Total Sample n (%)	Phone Call from Staff n (%)	Automated Phone call n (%)	Text Message n (%)	Email n (%)	Postal Mail n (%)	Phone App Notification n (%)	Other [2] n (%)
<b>Total Sample</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>								
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>								
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

[1] Responses are not mutually exclusive; participants can select all that apply

[2] Other responses included: xxxxx



Table 2.811 Summary of Type of Systems Clinic has in Place to Offer Upcoming Appointments (Month 4/5), N=XX

70. How do you plan to offer appointments for APREUDE injections?	Total Sample	Study Arm		Site Volume	
	n (%)	Dynamic n (%)	Routine n (%)	High Volume n (%)	Low Volume n (%)
Appointments each day of the week	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Appointments only on certain days of the week	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Appointments spread out over the month	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Injection only appointments	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Allow patients to drop-in for injections on any day without an appointment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Allow patients to drop-in with little advanced notice (e.g., 24 hour notice)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Allow patients to drop-in on a specific injection day without an appointment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
After hours appointments	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Appointments each day of the week	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Before hours appointment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Weekend appointments	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Home nursing appointments	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mobile clinic option	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Alternate site appointments	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Depends on the schedule of the injection nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Depends on the schedule of the APREUDE provider	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

[1] Responses are not mutually exclusive; participants can select all that apply

[2] Other responses include : xxxxx

Table 2.812 Summary of Implementing APRETUDE in Practice (Month 4/5), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
67	APRETUDE must be administered within a two-week injection window every two months after the loading doses.				
		Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Have not rescheduled any injections thus far	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
68	How easy or difficult has it been to reschedule appointments for APRETUDE injections?				
		Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Have not rescheduled any injections thus far	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
69	How do you remind patients of an upcoming APRETUDE appointment?				
		Phone call from Staff	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Automated phone call	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Text message	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Email	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Postal Mail	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Phone app notification	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
70	How does your practice/clinic currently offer appointments for APRETUDE injections?				
		Appointments each day of the week	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Appointments only on certain days of the week	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Appointments spread out over the month	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Injection-only appointments	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Allow patients to drop-in for injections on any day without an appointment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Allow patients to drop-in with little advance notice (e.g., 24 hr notice)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Allow patients to drop-in on a specific injection day without an appointment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		After hours appointments	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Before hours appointment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Weekend appointments	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Home nursing appointments	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Mobile clinic option	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Alternate site appointments	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Depends on the schedule of the injection nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Depends on the schedule of the APRETUDE provider	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Unsure	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
71	How easy or difficult has it been to implement APRETUDE into your current workflow?				
		Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Have not rescheduled any injections thus far	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
72	How do you feel about implementing APRETUDE at your clinic/practice?				
		Extremely positive	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Positive	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat positive	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little positive	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all positive	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 2.901 Quarterly Site Reporting

Question		Total	Dynamic Implementation	Routine Implementation
14. How many HIV PrEP seeking persons did the clinic/practice see in the last 3 months?				
<b>Baseline</b>	N	XX	XX	XX
	Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)
	Median	XX.X	XX.X	XX.X
	Q1, Q3	XX.X, XX.X	XX.X, XX.X	XX.X, XX.X
	Min-Max	X, X	X, X	X, X
<b>Quarter X*</b>	N	XX	XX	XX
	Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)
	Median	XX.X	XX.X	XX.X
	Q1, Q3	XX.X, XX.X	XX.X, XX.X	XX.X, XX.X
	Min-Max	X, X	X, X	X, X
15. How many patients would you estimate initiated any type of PrEP – oral or injectable – at the clinic/practice in the last 3 months?				
<b>Baseline</b>	N	XX	XX	XX
	Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)
	Median	XX.X	XX.X	XX.X
	Q1, Q3	XX.X, XX.X	XX.X, XX.X	XX.X, XX.X
	Min-Max	X, X	X, X	X, X
<b>Quarter X*</b>	N	XX	XX	XX
	Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)
	Median	XX.X	XX.X	XX.X
	Q1, Q3	XX.X, XX.X	XX.X, XX.X	XX.X, XX.X
	Min-Max	X, X	X, X	X, X
16. How many patients would you estimate initiated APREUDE in the last 3 months at the clinic/practice?				
<b>Baseline</b>	N	XX	XX	XX
	Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)
	Median	XX.X	XX.X	XX.X

Question		Total	Dynamic Implementation	Routine Implementation
	Q1, Q3	XX.X, XX.X	XX.X, XX.X	XX.X, XX.X
	Min-Max	X, X	X, X	X, X
<b>Quarter X*</b>	N	XX	XX	XX
	Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)
	Median	XX.X	XX.X	XX.X
	Q1, Q3	XX.X, XX.X	XX.X, XX.X	XX.X, XX.X
	Min-Max	X, X	X, X	X, X
17. Of all patients who have been prescribed PrEP at your clinic/practice, how many would you estimate have completed the Sexual Health Assessment provided by the PILLAR study?				
<b>Baseline</b>	N	XX	XX	XX
	Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)
	Median	XX.X	XX.X	XX.X
	Q1, Q3	XX.X, XX.X	XX.X, XX.X	XX.X, XX.X
	Min-Max	X, X	X, X	X, X
<b>Quarter X*</b>	N	XX	XX	XX
	Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)
	Median	XX.X	XX.X	XX.X
	Q1, Q3	XX.X, XX.X	XX.X, XX.X	XX.X, XX.X
	Min-Max	X, X	X, X	X, X

NOTE: reporting is not compiled on schedule with Month 4/5 or Month 12/13 collections, but is instead collected quarterly

\*To be populated for each quarter separately depending on available of quarterly data.

## 7 Tables for Month 12/13 Analysis

Table 3.001	Demographic Characteristics of New Staff Study Participants (Month 12/13), N=XX .....	266
Table 3.002	Demographic Characteristics of Longitudinal* Study Participants (Month 12/13), N=XX ....	268
Table 3.003	Characteristics of New Staff Study Participants (Month 12/13), N=XX.....	269
Table 3.004	Characteristics of Longitudinal* Staff Study Participants (Month 12/13), N=XX .....	271
Table 3.005	Summary of Confidence with Skills (Month 12/13), N=XX.....	273
Table 3.006	Staff Study Participants' Perceptions Regarding APRETUDE (Month 12/13), N=XX.....	275
Table 3.007	Summary of Experiences with the Acquisition Process (Month 12/13), N=XX .....	279
Table 3.101	Summary of Acceptability of Intervention Measure (AIM – APRETUDE) and Feasibility of Intervention Measure (FIM – APRETUDE ) Items (Month 12/13), N=XX .....	293
Table 3.102	Distributional Characteristics of the Acceptability of Intervention Measure (AIM – APRETUDE) (Month 12/13), N=XX .....	295
Table 3.103	Distributional Characteristics of the Feasibility of Intervention Measure (FIM – APRETUDE) (Month 12/13), N=XX .....	297
Table 3.104	Changes from Baseline for Acceptability of Intervention Measure (AIM – APRETUDE) and Feasibility of Intervention Measure (FIM – APRETUDE ) (Month 12/13), N=XX .....	299
Table 3.105	Mixed-effects Modeling of the Acceptability of Intervention Measure (AIM – APRETUDE) (Month 12/13), N=XX .....	300
Table 3.106	Mixed-effects Modeling of the Changes from Baseline to Month 12/13 in Acceptability of Intervention Measure (AIM – APRETUDE), N=XX .....	301
Table 3.107	Mixed-effects Modeling of the Feasibility of Intervention Measure (FIM – APRETUDE) (Month 12/13), N=XX .....	302
Table 3.108	Mixed-effects Modeling of the Changes from Baseline to Month 12/13 in Feasibility of Intervention Measure (FIM – APRETUDE), N=XX.....	303
Table 3.201	Summary of Acceptability of Intervention Measure (AIM – Implementation Support) and Feasibility of Intervention Measure (FIM – Implementation Support) Items (Month 12/13), N=XX .....	304
Table 3.202	Distributional Characteristics of the Acceptability of Intervention Measure (AIM – Implementation Support) (Month 12/13), N=XX.....	306
Table 3.203	Distributional Characteristics of the Feasibility of Intervention Measure (FIM – Implementation Support) (Month 12/13), N=XX.....	308
Table 3.204	Changes from Baseline to Acceptability of Intervention Measure (AIM – Implementation Support) and Feasibility of Intervention Measure (FIM – Implementation Support ) (Month 12/13), N=XX .....	310
Table 3.205	Mixed-effects Modeling of the Acceptability of Intervention Measure (AIM – Implementation Support) (Month 12/13), N=XX.....	311
Table 3.206	Mixed-effects Modeling of the Changes from Baseline to Month 12/13 in Acceptability of Intervention Measure (AIM – Implementation Support), N=XX .....	312
Table 3.207	Mixed-effects Modeling of the Feasibility of Intervention Measure (FIM – Implementation Support) (Month 12/13), N=XX.....	313

Table 3.208	Mixed-effects Modeling of the Changes from Baseline to Month 12/13 in Feasibility of Intervention Measure (FIM – Implementation Support), N=XX.....	314
Table 3.301	Summary of Acceptability of Intervention Measure (AIM – Telehealth) and Feasibility of Intervention Measure (FIM – Telehealth) Items (Month 12/13), N=XX.....	315
Table 3.302	Distributional Characteristics of the Acceptability of Intervention Measure (AIM – Telehealth) (Month 12/13), N=XX .....	317
Table 3.303	Distributional Characteristics of the Feasibility of Intervention Measure (FIM – Telehealth) (Month 12/13), N=XX .....	319
Table 3.304	Changes from Baseline for Acceptability of Intervention Measure (AIM – Telehealth) and Feasibility of Intervention Measure (FIM – Telehealth) (Month 12/13), N=XX.....	321
Table 3.305	Mixed-effects Modeling of the Acceptability of Intervention Measure (AIM – Telehealth) (Month 12/13), N=XX .....	322
Table 3.306	Mixed-effects Modeling of the Changes from Baseline to Month 12/13 in Acceptability of Intervention Measure (AIM – Telehealth), N=XX.....	323
Table 3.307	Mixed-effects Modeling of the Feasibility of Intervention Measure (FIM – Telehealth) (Month 12/13), N=XX .....	324
Table 3.308	Mixed-effects Modeling of the Changes from Baseline to Month 12/13 in Feasibility of Intervention Measure (FIM – Telehealth), N=XX.....	325
Table 3.309	Summary of Feasibility and Acceptability of Telehealth (Month 12/13), N=XX.....	326
Table 3.310	Summary of Telehealth Services/Systems Used (Month 12/13), N=XX.....	332
Table 3.311	Summary of Ease of Use of Telehealth Services/Systems Used (Month 12/13), N=XX .....	336
Table 3.312	Summary of Helpfulness of Services/Systems Used (Month 12/13), N=XX.....	342
Table 3.313	Summary of Satisfaction of Services/Systems Used (Month 12/13), N=XX .....	348
Table 3.401	Summary of Utility of Proposed Implementation Strategies (Month 12/13), N=XX.....	353
Table 3.501	Summary of Perceived Barriers to Delivering APRETUDE to Patients (Month 12/13), N=XX.....	359
Table 3.502	Summary of Perceptions of Administering APRETUDE (Month 12/13), N=XX.....	368
Table 3.503	Summary of Perceived Barriers to Managing Delivery of APRETUDE (Month 12/13), N=XX.....	376
Table 3.504	Summary of Perceived Resourcing Barriers to Support Delivery of APRETUDE (Month 12/13), N=XX .....	387
Table 3.505	Summary of Perceptions of Clinic/Practice Culture and Environment (Month 12/13), N=XX.....	394
Table 3.506	Summary of Barriers to PrEP Provisioning (Month 12/13), N=XX.....	396
Table 3.507	Distributional Characteristics of Barriers to PrEP Provisioning (Month 12/13), N=XX.....	398
Table 3.508	Shift from Month 4/5 to Month 12/13 in Summary of Perceived Barriers to Delivering APRETUDE to Patients (Month 12/13), N=XX .....	400
Table 3.509	Shift from Month 4/5 to Month 12/13 in Summary of Perceptions of Administering APRETUDE (Month 12/13), N=XX .....	401
Table 3.510	Shift from Month 4/5 to Month 12/13 in Summary of Perceived Barriers to Managing Delivery of APRETUDE (Month 12/13), N=XX .....	402



Table 3.511	Shift from Month 4/5 to Month 12/13 in Summary of Perceived Resourcing Barriers to Support Delivery of APREUDE (Month 12/13), N=XX.....	402
Table 3.512	Shift from Month 4/5 to Month 12/13 in Summary of Perceptions of Clinic/Practice Culture and Environment (Month 12/13), N=XX .....	402
Table 3.513	Shift from Month 4/5 to Month 12/13 in Summary of Barriers to PrEP Provisioning (Month 12/13), N=XX .....	403
Table 3.601	Summary of the Sexual Health Assessment Tool (Month 12/13), N=XX.....	404
Table 3.602	Summary of the PrEP Communication Tool (Month 12/13), N=XX.....	407
Table 3.701	Summaries of the Optional Oral Lead-in Phase of APREUDE (Month 12/13), N=XX.....	409
Table 3.702	Assessment of Alternate Sites of Administration of APREUDE (Month 12/13), N=XX .....	415
Table 3.801	Summary of Perceived Number of APREUDE Patients Clinic/Practice Can Manage Per Week on an Ongoing Basis (Month 12/13), N=XX .....	421
Table 3.802	Distributional Characteristics of Reported Number of People in Clinic Trained and Prepared to Give APREUDE Injections (Month 12/13), N=XX .....	422
Table 3.803	Distributional Characteristics of Estimated Number of Staff Needed Per Week to Incorporate APREUDE into Clinic/Practice for Approximately 25 People (Month 12/13), N=XX.....	423
Table 3.804	Summary of Estimated Percentage of Staff Time/Full-Time Equivalent Hours Needed Per Week to Incorporate APREUDE into Clinic/Practice for Approximately 25 People (Month 12/13), N=XX .....	424
Table 3.805	Summary of Plans to Create New Roles/Positions in Clinic to Coordinate the APREUDE Program (Month 12/13), N=XX.....	425
Table 3.806	Summary of Number of New Roles/Positions in Clinic to Coordinate the APREUDE Program (Month 12/13), N=XX.....	426
Table 3.807	Summary of How Clinic/Practice Plans to Track Patients on APREUDE (Month 12/13), N=XX.....	427
Table 3.808	Summary of How Clinic/Practice Responds to Patients who Do Not Show for a Regularly Scheduled Appointment (Month 12/13), N=XX.....	428
Table 3.809	Summary of Whether Clinic/Practice has Specific Person in Charge of Following Up on No-Shows (Month 12/13), N=XX .....	429
Table 3.810	Summary of Type of Systems Clinic has in Place to Remind Patients of Upcoming Appointments (Month 12/13), N=XX.....	430
Table 3.811	Summary of Type of Systems Clinic has in Place to Offer Upcoming Appointments (Month 12/13), N=XX .....	431
Table 3.812	Summary of Implementing APREUDE in Practice (Month 12/13), N=XX .....	432
Table 3.813.	Test for Differences of Implementation Arm by Site Volume on Feasibility of Intervention Measure, APREUDE (Month 12/13), N=XX.....	435
Table 3.814.	Test for Differences of Implementation Arm by Site Volume on Feasibility of Intervention Measure, Implementation Support (Month 12/13), N=XX .....	435
Table 3.815.	Test for Differences of Implementation Arm by Site Volume on Feasibility of Intervention Measure, Telehealth (Month 12/13), N=XX.....	435

Table 3.816. Test for Differences of Implementation Arm by Site Volume on Acceptability of Intervention Measure, APRETUDE (Month 12/13), N=XX.....	435
Table 3.817. Test for Differences of Implementation Arm by Site Volume on Acceptability of Intervention Measure, Implementation Support (Month 12/13), N=XX .....	435
Table 3.818. Test for Differences of Implementation Arm by Site Volume on Acceptability of Intervention Measure, Telehealth (Month 12/13), N=XX.....	436

Table 3.001 Demographic Characteristics of New Staff Study Participants (Month 12/13), N=XX

Question Number	Characteristic	Study Arm		
		Total (N=XX)	Dynamic Implementation (N=XX)	Routine Implementation (N=XX)
		n (%)	n (%)	n (%)
<b>99</b>	<b>Gender</b>			
	Cisgender Male	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Cisgender Female	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Transgender Man	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Transgender Woman	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Nonbinary	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Gender Queer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other Gender	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>100</b>	<b>Age (years)</b>			
	N	XX	XX	XX
	Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)
	Median	XX.X	XX.X	XX.X
	Q1, Q3	XX, XX	XX, XX	XX, XX
	Min-Max	XX.X, XX.X	XX.X, XX.X	XX.X, XX.X
	Missing	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>100</b>	<b>Age (years), High Volume</b>			
	N	XX	XX	XX
	Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)
	Median	XX.X	XX.X	XX.X
	Q1, Q3	XX, XX	XX, XX	XX, XX
	Min-Max	XX.X, XX.X	XX.X, XX.X	XX.X, XX.X
	Missing	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>100</b>	<b>Age (years), Low Volume</b>			
	N	XX	XX	XX
	Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)
	Median	XX.X	XX.X	XX.X
	Q1, Q3	XX, XX	XX, XX	XX, XX
	Min-Max	XX.X, XX.X	XX.X, XX.X	XX.X, XX.X
	Missing	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>100</b>	<b>Age</b>			
	18-25	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	26-35	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Characteristic	Study Arm		
		Total (N=XX)	Dynamic Implementation (N=XX)	Routine Implementation (N=XX)
		n (%)	n (%)	n (%)
	66-49	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	50+	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>101</b>	<b>Race</b>			
	White/Caucasian	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Black	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Asian	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Native American	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Pacific Islander	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Mixed Race	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other Race	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I Prefer not to Answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>102</b>	<b>Ethnicity</b>			
	Hispanic/Latinx	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Non-Hispanic/Latinx	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 3.002 Demographic Characteristics of Longitudinal\* Study Participants (Month 12/13), N=XX**

Question Number	Characteristic	Study Arm		
		Total (N=XX)	Dynamic Implementation (N=XX)	Routine Implementation (N=XX)
		n (%)	n (%)	n (%)
<b>99</b>	<b>Gender</b>			
	Cisgender Male	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Cisgender Female	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Transgender Man	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Transgender Woman	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Nonbinary	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Gender Queer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other Gender	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>100</b>	<b>Age (years)</b>			
	N	XX	XX	XX
	Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)
	Median	XX.X	XX.X	XX.X
	Q1, Q3	XX, XX	XX, XX	XX, XX
	Min-Max	XX.X, XX.X	XX.X, XX.X	XX.X, XX.X
	Missing	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>100</b>	<b>Age (years), High Volume</b>			
	N	XX	XX	XX
	Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)
	Median	XX.X	XX.X	XX.X
	Q1, Q3	XX, XX	XX, XX	XX, XX
	Min-Max	XX.X, XX.X	XX.X, XX.X	XX.X, XX.X
	Missing	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>100</b>	<b>Age (years), Low Volume</b>			
	N	XX	XX	XX
	Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)
	Median	XX.X	XX.X	XX.X
	Q1, Q3	XX, XX	XX, XX	XX, XX
	Min-Max	XX.X, XX.X	XX.X, XX.X	XX.X, XX.X
	Missing	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>100</b>	<b>Age</b>			
	18-25	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	26-35	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Characteristic	Study Arm		
		Total (N=XX)	Dynamic Implementation (N=XX)	Routine Implementation (N=XX)
		n (%)	n (%)	n (%)
	66-49	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	50+	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>101</b>	<b>Race</b>			
	White/Caucasian	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Black	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Asian	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Native American	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Pacific Islander	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Mixed Race	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other Race	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I Prefer not to Answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>102</b>	<b>Ethnicity</b>			
	Hispanic/Latinx	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Non-Hispanic/Latinx	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Prefer not to answer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

\* Longitudinal = SSPs who completed any portion of any questionnaire at Baseline, Month 4/5 and Month 12/13

**Table 3.003 Characteristics of New Staff Study Participants (Month 12/13), N=XX**

Question Number	Characteristic	Study Arm		
		Total (N=XX)	Dynamic Implementation (N=XX)	Routine Implementation (N=XX)
		n (%)	n (%)	n (%)
<b>1</b>	<b>Provider Type</b>			
	Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Nurse Practitioner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Physician Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Social worker/case manager	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Office administrator/clinic administrator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Laboratory staff/technician/phlebotomist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Characteristic	Study Arm		
	Front desk staff/ Scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>2</b>	<b>Personally Administer Injections</b>			
	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>3</b>	<b>Prescribe Medications as part of role</b>			
	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>4</b>	<b>Currently Provide PrEP Counseling</b>			
	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>103</b>	<b>Specialty</b>			
	Infectious disease specialist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Internal medicine/ primary care/general doctor/ family practitioner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	HIC Specialist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Immunologist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Women's health/obstetricians and gynecologists	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Endocrinologist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other[2]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>104</b>	<b>Length of Time practicing Medicine</b>			
	<1 year	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	1–5 years	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	6–10 years	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	11-15 years	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	16-20 years	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	>21 years	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

[1] Other responses include: xxx

[2] Other responses include: xxx

Table 3.004 Characteristics of Longitudinal\* Staff Study Participants (Month 12/13), N=XX

Question Number	Characteristic	Study Arm		
		Total (N=XX)	Dynamic Implementation (N=XX)	Routine Implementation (N=XX)
		n (%)	n (%)	n (%)
<b>1</b>	<b>Provider Type</b>			
	Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Nurse Practitioner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Physician Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Social worker/case manager	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Office administrator/clinic administrator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Laboratory staff/technician/phlebotomist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Front desk staff/ Scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>2</b>	<b>Personally Administer Injections</b>			
	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>3</b>	<b>Prescribe Medications as part of role</b>			
	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>4</b>	<b>Currently Provide PrEP Counseling</b>			
	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>103</b>	<b>Specialty</b>			
	Infectious disease specialist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Internal medicine/ primary care/general doctor/ family practitioner	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	HIC Specialist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Immunologist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Women's health/obstetricians and gynecologists	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Endocrinologist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Other[2]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>104</b>	<b>Length of Time practicing Medicine</b>			
	<1 year	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	1–5 years	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



Question Number	Characteristic	Study Arm		
	6–10 years	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	11-15 years	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	16-20 years	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	>21 years	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

\* Longitudinal = SSPs who completed any portion of any questionnaire at Baseline, Month 4/5 and Month 12/13

[1] Other responses include: xxx

[2] Other responses include: xxx

Table 3.005 Summary of Confidence with Skills (Month 12/13), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
5	“Please rate your level of confidence for each skill listed.”				
	Talking to Patient About Sexual History	Not At All Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A Little Bit Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not Applicable To My Role	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Screening a patient to determine whether they are an appropriate candidate for PrEP	Not At All Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A Little Bit Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not Applicable To My Role	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Answering Patient’s Questions About PrEP	Not At All Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A Little Bit Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not Applicable To My Role	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Suggesting PrEP to a Patient	Not At All Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A Little Bit Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not Applicable To My Role	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Counseling Pt Other Method of protection	Not At All Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A Little Bit Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Very Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not Applicable To My Role	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Monitoring a Patient on PrEP	Not At All Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A Little Bit Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Confident	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not Applicable To My Role	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 3.006 Staff Study Participants' Perceptions Regarding APRETUDE (Month 12/13), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
6	In your opinion, APRETUDE is appropriate for which individuals?				
		Are sexually active	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		have been sexually active with 1 or more partners in the last 6 months	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		are currently adherent on daily oral PrEP	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		are non-adherent on daily oral PrEP	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		use PrEP on demand (i.e., event-based PrEP, PrEP 2-1-1)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		could benefit from PrEP but do not want to use daily PrEP	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		have previously used and discontinued daily PrEP	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		feel stigmatized about taking oral PrEP	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		request APRETUDE spontaneously	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		have sex without a condom	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		engage in anal sex	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		have a sexual partner living with HIV	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		live in areas with high HIV prevalence	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		currently have or recently (within the past 6 months) have had an STI other than HIV	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		are in monogamous relationships	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		inject drugs	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		have sex with a person/people who inject drugs	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		experience stigma around using HIV prevention	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		are concerned about taking pills every day	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		experience stress or anxiety over adherence of a daily pill regimen	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		have more chaotic lifestyles (e.g., variable work schedules, frequent travel, balancing work and school)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		have more structured lifestyles (e.g., regular work hours, little to no unplanned travels)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		have difficulty planning or organizing	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		have stable income and stable housing	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		experience homelessness or are unstably housed	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		have psychiatric comorbidities	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		have sex with someone who has recently been in jail/prison	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		are incarcerated, temporarily incarcerated, or recently released from incarcerated	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
7	Are Individuals with specific demographics more appropriate for APREITUDE?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
8	In your opinion, what are the demographics of the individuals who are appropriate for APREITUDE?				
		Patients <35 years old	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Patients 35-50 years old	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Patients >50 years old	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Black transgender men	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Black transgender women	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Black cisgender women	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Black cisgender men	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Black non-binary individuals	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Black men who have sex with men	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		White transgender men	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		White transgender women	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		White cisgender women	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		White cisgender men	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		White non-binary individuals	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		White men who have sex with men	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Latinx transgender men	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Latinx transgender women	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Latinx cisgender women	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Latinx cisgender men	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Latinx non-binary individuals	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Latinx men who have sex with men	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other transgender men of color	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other transgender women of color	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other cisgender women of color	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other cisgender men of color	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other non-binary individuals of color	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other men who have sex with men of color	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
9	Has any of the patients at this clinic/practice asked for (or about) APRETUDE?				

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
10	Are you or this clinic/practice proactively informing patients about APREUDE?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
11	How are you or this clinic/practice informing patients about APREUDE?				
		Provision of educational materials	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		During consultation with patient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Through peer educators	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Referring patients to PrEP providers	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Posters in the clinic/practice	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Flyers in the clinic/practice	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Mentions on the clinic/practice's website	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Mentions on social media	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 3.007 Summary of Experiences with the Acquisition Process (Month 12/13), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
42	Are you involved in any of part of the benefits verification and acquisition process for APREUDE, such as completing enrollment forms, sending documents to insurance companies, purchasing APREUDE?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
43	Is your clinic/practice using ViiV Connect to acquire APREUDE?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
44	Do You Personally Use ViiV Connect?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
45	How are your providers or clinic/practice acquiring APREUDE?				
		Buy-and-Bill – purchases APREUDE from a wholesaler or specialty distributor and bills the primary third-party payer.	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		White Bagging – submits prescription to a specialty pharmacy within ViiV's specialty pharmacy network and the specialty pharmacy processes the claim and ships APREUDE for administration.	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Clear Bagging – internal pharmacy maintains inventory of the medication, processes the claim, and delivers the medication.	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
46	Who in your clinic/practice is primarily responsible for completing the insurance benefits verification process for APREITUDE?				
		Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Nurse practitioner/physician assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Speciality pharmacy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Medical assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Social worker/case manager	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Dedicated administrator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		APREITUDE coordinator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
47	On average, how long does it take to complete the APREITUDE enrollment form?				
		1-5 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		6-10 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		11-15 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		16-20 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		21-25 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		26-30 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		31+ minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		I have not completed this form	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
48	On average, how long has it taken to receive confirmation of benefits verification for APRETUDE?				
		1-2 days	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		3-4 days	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		5-6 days	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		7-8 days	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		9-10 days	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		11-15 days	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		16-20 days	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		20-30 days	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		31-40 days	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		41-60 days	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		61+ days	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
49	On average, how long has it taken for patients to receive APRETUDE from the point of benefits verification?				
		1-2 days	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		3-4 days	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		5-6 days	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		7-8 days	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		9-10 days	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		11-15 days	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		16-20 days	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		21-30 days	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
50	"For each item, please indicate how concerned you are about each of the following based on your current expectations, understanding and knowledge of ViiV Connect."				
	Authorization wait times	Extremely concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Moderately concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Slightly concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Understanding status of authorization	Extremely concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Moderately concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Slightly concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Understanding how to seek assistance	Extremely concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Moderately concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Slightly concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Amount of paperwork	Extremely concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Moderately concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Slightly concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Clarity on coverage approval	Extremely concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Moderately concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Slightly concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Ensuring medication comes to the right place (e.g., clinic/practice, pharmacy)	Extremely concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Moderately concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Slightly concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Potential loss of enthusiasm for APREUDE by patients	Extremely concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Moderately concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Slightly concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Potential patient dissatisfaction with clinic staff	Extremely concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Moderately concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Slightly concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Staff dissatisfaction with the acquisition process	Extremely concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Moderately concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Slightly concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Potential disruption of clinic flow	Extremely concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Moderately concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Slightly concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Time-consuming process	Extremely concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Moderately concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Slightly concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Inequitable access for eligible patients	Extremely concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Moderately concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Slightly concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Not at all concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
51	“Please indicate how much you agree or disagree with each of the following statements.”				
	I understand how to use ViiV Connect (skip applicable if Q44=yes)	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I understand how to complete the APREUDE forms in ViiV Connect (skip applicable if Q44=yes)	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Completing the benefits enrollment forms is easy (skip applicable if Q42=yes)	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The live support for ViiV Connect is helpful (skip applicable if Q43=yes)	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I am knowledgeable about the patient savings card for APRETUDE for patients (skip applicable if Q42=yes)	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The benefits verification process of ViiV Connect is time consuming (RC) (skip applicable if Q43=yes)	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I am satisfied with the benefits verification process (skip applicable if Q42=yes)	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	It has been easy to acquire APRETUDE for patients (skip applicable if Q42=yes)	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I know what to do if I am having trouble acquiring APREITUDE for patients (skip applicable if Q42=yes)	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	I am knowledgeable about the patient assistance program for APREITUDE (skip applicable if Q42=yes)	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
52	How helpful or unhelpful has each type of support been to your clinic/practice in using ViiV Connect?"				
	ViiV Connect Services and Support information (e.g., ViiV Connect Brochure, Provider Portal Brochure)	Not at all helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Did not use it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	ViiV Connect Enrollment information (annotated enrollment forms, enrollment form)	Not at all helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Did not use it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Acquisition Guides (e.g., ordering guide, buy and bill checklist, specialty pharmacy checklist)	Not at all helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Did not use it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Billing, Coding and reimbursement information (e.g., prior authorization checklist, reimbursement guide)	Not at all helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Did not use it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Benefits Verification – understanding summary of benefits (illustrated form highlights patient benefit summary and how to read it)	Not at all helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Did not use it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Live support (e.g., access coordinators)	Not at all helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Did not use it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Video for patients on what is ViiV Connect (DI)	Not at all helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Did not use it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
	A video for providers describing what is ViiV Connect (DI)	Not at all helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Did not use it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Patient informational material about ViiV Connect and the acquisition process	Not at all helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Did not use it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Medication Acquisition Tracker – web-based tool to track patients' benefits acquisition journey from enrollment to medication receipt at the clinic/practice (DI)	Not at all helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Did not use it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
	APRETUDE Payer Information found on the PILLAR Spot: spreadsheet updated on a weekly basis and gives providers information on which payers are covering APRETUDE and under what type of benefit	Not at all helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Did not use it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
53	How helpful or unhelpful has receiving the list of payers/insurers who cover the medication and when coverage began has been to your clinic/practice?				
		Not at all helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very helpful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Did not use it	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
54	I would recommend ViiV Connect to other providers and clinics/practices to aid in the acquisition of ViiV medications.				
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



**Table 3.101 Summary of Acceptability of Intervention Measure (AIM – APRETUDE) and Feasibility of Intervention Measure (FIM – APRETUDE ) Items (Month 12/13), N=XX**

Measure	Item	Study Arm	Total Sample n (%)	1 Completely Disagree n (%)	2 Disagree n (%)	3 Neither Agree nor Disagree n (%)	4 Agree n (%)	5 Completely Agree n (%)
AIM	1. APRETUDE in our clinic/practice meets my approval.	Overall	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Dynamic Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Routine Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
	2. APRETUDE in our clinic/practice is appealing to me.	Overall	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Dynamic Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Routine Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
	3. I like APRETUDE in our clinic/practice.	Overall	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Dynamic Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Routine Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
FIM	1. I welcome APRETUDE in our clinic/practice.	Overall	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Dynamic Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Routine Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
	2. APRETUDE seems implementable in our clinic/practice.	Overall	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Dynamic Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Routine Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
	2. APRETUDE seems possible in our clinic/practice.	Overall	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Dynamic Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Routine Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)

Measure	Item	Study Arm	Total Sample n (%)	1 Completely Disagree n (%)	2 Disagree n (%)	3 Neither Agree nor Disagree n (%)	4 Agree n (%)	5 Completely Agree n (%)
		Dynamic Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Routine Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
	3. APREITUDE seems doable in our clinic/practice.	Overall	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Dynamic Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Routine Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
	4. APREITUDE seems easy to use in our clinic/practice	Overall	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Dynamic Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Routine Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)

**Table 3.102    Distributional Characteristics of the Acceptability of Intervention Measure (AIM – APREUDE) (Month 12/13), N=XX**

AIM – APREUDE	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
Mean Score	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Study Arm							
Dynamic Intervention	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Routine Intervention	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
T-test Degrees of Freedom P-Value		X.XXX XX 0.XXXX					
Site Volume							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
T-test Degrees of Freedom P-Value		X.XXX XX 0.XXXX					
Clinic Type							
University/Academia/Research	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
FQHC/Department of Health	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Nonprofit	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Private	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Provider Type							
Physician	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Mid-level providers[1]	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Nurse	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Medical Assistant	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Pharmacist	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Social worker/case manager/PrEP educator/PrEP navigator	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)



AIM – APREITUDE	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
Office administrator /clinic administrator/front desk staff/scheduler	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Laboratory staff/technician/phlebotomist/other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Items							
1. APREITUDE in our clinic/practice meets my approval.	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XX, X.XX)
2. APREITUDE in our clinic/practice is appealing to me.	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XX, X.XX)
3. I like APREITUDE in our clinic/practice.	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XX, X.XX)
4. I welcome APREITUDE in our clinic/practice.	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XX, X.XX)

[1] Mid-level providers include nurse practitioners and physician assistants.

**Table 3.103    Distributional Characteristics of the Feasibility of Intervention Measure (FIM – APREUDE) (Month 12/13), N=XX**

FIM – APREUDE	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
Mean Score	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Study Arm							
Dynamic Intervention	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Routine Intervention	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
T-test Degrees of Freedom P-Value		X.XXX XX 0.XXXX					
Site Volume							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
T-test Degrees of Freedom P-Value		X.XXX XX 0.XXXX					
Clinic Type							
University/Academia/Research	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
FQHC/Department of Health	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Nonprofit	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Private	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Provider Type							
Physician	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Mid-level providers[1]	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Nurse	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Medical Assistant	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Pharmacist	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Social worker/case manager/PrEP educator/PrEP navigator	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)

FIM – APREITUDE	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
Office administrator /clinic administrator/front desk staff/scheduler	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Laboratory staff/technician/phlebotomist/other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Items							
1. APREITUDE seems implementable in our clinic/practice.	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XX, X.XX)
2. APREITUDE seems possible in our clinic/practice.	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XX, X.XX)
3. APREITUDE seems doable in our clinic/practice.	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XX, X.XX)
4. APREITUDE seems easy to use in our clinic/practice	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XX, X.XX)

[1] Mid-level providers include nurse practitioners and physician assistants.

**Table 3.104 Changes from Baseline for Acceptability of Intervention Measure (AIM – APRETUDE) and Feasibility of Intervention Measure (FIM – APRETUDE ) (Month 12/13), N=XX**

Measure	Study Arm	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
AIM - APRETUDE Baseline	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
AIM - APRETUDE Month 12/13	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
AIM - APRETUDE Change from Baseline to Month 12/13	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
	T-test		X.XXX					
	DF		XX					
	P-Value		0.XXX					
FIM - APRETUDE Baseline	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
FIM - APRETUDE Month 12/13	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
FIM - APRETUDE Change from Baseline to Month 12/13	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
	T-test		X.XXX					
	DF		XX					
	P-Value		0.XXX					

**Table 3.105 Mixed-effects Modeling of the Acceptability of Intervention Measure (AIM – APREUDE) (Month 12/13), N=XX**

Fixed effects					
Parameter	Estimate	Standard Error	Denominator Degrees of Freedom	T	p-Value
Intercept (RI, Low)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm (DI)	X.XX	X.XXX	XX	X.XX	0.XXXX
Volume (High)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm by Volume	X.XX	X.XXX	XX	X.XX	0.XXXX
Baseline Mean Score[1]	X.XX	X.XXX	XX	X.XX	0.XXXX
Random Effects					
Covariance Parameter	Estimate	Standard Error		Z	p-Value
Site Variance ( $\tau(0,0)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Covariance ( $\tau(0,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Baseline Variance ( $\tau(1,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Residual Variance ( $\sigma^2$ )	X.XX	X.XXX	-	X.XX	0.XXXX

Note: Null model likelihood ratio test,  $\chi^2(XX) = XXX.XX$ ,  $p = 0.XXXX$ .

[1] Baseline mean score centered by site.

**Table 3.106 Mixed-effects Modeling of the Changes from Baseline to Month 12/13 in Acceptability of Intervention Measure (AIM – APRETUDE), N=XX**

Fixed effects					
Parameter	Estimate	Standard Error	Denominator Degrees of Freedom	T	p-Value
Intercept (RI, Low)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm (DI)	X.XX	X.XXX	XX	X.XX	0.XXXX
Volume (High)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm by Volume	X.XX	X.XXX	XX	X.XX	0.XXXX
Baseline Mean Score[1]	X.XX	X.XXX	XX	X.XX	0.XXXX
Random Effects					
Covariance Parameter	Estimate	Standard Error		Z	p-Value
Site Variance ( $\tau(0,0)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Covariance ( $\tau(0,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Baseline Variance ( $\tau(1,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Residual Variance ( $\sigma^2$ )	X.XX	X.XXX	-	X.XX	0.XXXX

Note: Null model likelihood ratio test,  $\chi^2(XX) = XXX.XX$ ,  $p = 0.XXXX$ .

[1] Baseline mean score centered by site.

**Table 3.107 Mixed-effects Modeling of the Feasibility of Intervention Measure (FIM – APRETUDE) (Month 12/13), N=XX**

Fixed effects					
Parameter	Estimate	Standard Error	Denominator Degrees of Freedom	T	p-Value
Intercept (RI, Low)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm (DI)	X.XX	X.XXX	XX	X.XX	0.XXXX
Volume (High)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm by Volume	X.XX	X.XXX	XX	X.XX	0.XXXX
Baseline Mean Score[1]	X.XX	X.XXX	XX	X.XX	0.XXXX
Random Effects					
Covariance Parameter	Estimate	Standard Error		Z	p-Value
Site Variance ( $\tau(0,0)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Covariance ( $\tau(0,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Baseline Variance ( $\tau(1,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Residual Variance ( $\sigma^2$ )	X.XX	X.XXX	-	X.XX	0.XXXX

Note: Null model likelihood ratio test,  $\chi^2(XX) = XXX.XX$ ,  $p = 0.XXXX$ .

[1] Baseline mean score centered by site.

**Table 3.108 Mixed-effects Modeling of the Changes from Baseline to Month 12/13 in Feasibility of Intervention Measure (FIM – APRETUDE), N=XX**

Fixed effects					
Parameter	Estimate	Standard Error	Denominator Degrees of Freedom	T	p-Value
Intercept (RI, Low)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm (DI)	X.XX	X.XXX	XX	X.XX	0.XXXX
Volume (High)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm by Volume	X.XX	X.XXX	XX	X.XX	0.XXXX
Baseline Mean Score[1]	X.XX	X.XXX	XX	X.XX	0.XXXX
Random Effects					
Covariance Parameter	Estimate	Standard Error		Z	p-Value
Site Variance ( $\tau(0,0)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Covariance ( $\tau(0,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Baseline Variance ( $\tau(1,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Residual Variance ( $\sigma^2$ )	X.XX	X.XXX	-	X.XX	0.XXXX

Note: Null model likelihood ratio test,  $\chi^2(XX) = XXX.XX$ ,  $p = 0.XXXX$ .

[1] Baseline mean score centered by site.



**Table 3.201 Summary of Acceptability of Intervention Measure (AIM – Implementation Support) and Feasibility of Intervention Measure (FIM – Implementation Support) Items (Month 12/13), N=XX**

Measure	Item	Study Arm	Total Sample n (%)	1 Completely Disagree n (%)	2 Disagree n (%)	3 Neither Agree nor Disagree n (%)	4 Agree n (%)	5 Completely Agree n (%)
AIM	1. The implementation support has met my approval.	Overall	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Dynamic Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Routine Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
	2. The implementation support was appealing to me.	Overall	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Dynamic Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Routine Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
	3. I like the implementation support I have received.	Overall	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Dynamic Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Routine Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
FIM	4. I welcome the implementation support I have received.	Overall	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Dynamic Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Routine Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
	1. The implementation support seems implementable in our clinic/practice	Overall	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Dynamic Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Routine Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)

Measure	Item	Study Arm	Total Sample n (%)	1 Completely Disagree n (%)	2 Disagree n (%)	3 Neither Agree nor Disagree n (%)	4 Agree n (%)	5 Completely Agree n (%)
	2. The implementation support seems possible in our clinic/practice	Overall	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Dynamic Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Routine Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
	3. The implementation support seems doable in our clinic/practice	Overall	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Dynamic Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Routine Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
	4. The implementation support seems easy to use in our clinic/practice	Overall	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Dynamic Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Routine Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)

**Table 3.202    Distributional Characteristics of the Acceptability of Intervention Measure (AIM – Implementation Support) (Month 12/13), N=XX**

AIM – Implementation Support	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
Mean Score	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Study Arm							
Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
T-test Degrees of Freedom P-Value		X.XXX XX 0.XXX					
Site Volume							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
T-test Degrees of Freedom P-Value		X.XXX XX 0.XXX					
Clinic Type							
University/Academia/Research	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
FQHC/Department of Health	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Nonprofit	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Private	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Provider Type							
Physician	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Mid-level providers[1]	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Nurse	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Medical Assistant	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Pharmacist	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Social worker/case manager/PrEP educator/PrEP navigator	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)

AIM – Implementation Support	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
Office administrator /clinic administrator/front desk staff/scheduler	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Laboratory staff/technician/phlebotomist/other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Items							
1. The implementation support has met my approval.	XX	X.X	X.XX	X.X (X.X, X.X)	X.X (X, X.)	XX (XX.X)	(X.XX, X.XX)
2. The implementation support was appealing to me.	XX	X.X	X.XX	X.X (X.X, X.X)	X.X (X, X)	XX (XX.X)	(X.XX, X.XX)
3. I like the implementation support I have received.	XX	X.X	X.XX	X.X (X.X, X.X)	X.X (X, X)	XX (XX.X)	(X.XX, X.XX)
4. I welcome the implementation support I have received.	XX	X.X	X.XX	X.X (X.X, X.X)	X.X (X, X)	XX (XX.X)	(X.XX, X.XX)

[1] Mid-level providers include nurse practitioners and physician assistants.

**Table 3.203    Distributional Characteristics of the Feasibility of Intervention Measure (FIM – Implementation Support) (Month 12/13), N=XX**

FIM – Implementation Support	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
Mean Score	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
Study Arm							
Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
T-test Degrees of Freedom P-Value		X.XXX XX 0.XXX					
Site Volume							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
T-test Degrees of Freedom P-Value		X.XXX XX 0.XXX					
Clinic Type							
University/Academia/Research	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
FQHC/Department of Health	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
Nonprofit	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
Private	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
Provider Type							
Physician	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
Mid-level providers[1]	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
Nurse	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
Medical Assistant	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
Pharmacist	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
Social worker/case manager/PrEP educator/PrEP navigator	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)

FIM – Implementation Support	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
Office administrator /clinic administrator/front desk staff/scheduler	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
Laboratory staff/technician/phlebotomist/other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
Items							
1. The implementation support seems implementable in our clinic/practice	XX	X.X	X.XX	X.X (X.X, X.X)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XX, X.XX)
2. The implementation support seems possible in our clinic/practice	XX	X.X	X.XX	X.X (X.X, X.X)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XX, X.XX)
3. The implementation support seems doable in our clinic/practice	XX	X.X	X.XX	X.X (X.X, X.X)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XX, X.XX)
4. The implementation support seems easy to use in our clinic/practice	XX	X.X	X.XX	X.X (X.X, X.X)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XX, X.XX)

**Table 3.204 Changes from Baseline to Acceptability of Intervention Measure (AIM – Implementation Support) and Feasibility of Intervention Measure (FIM – Implementation Support ) (Month 12/13), N=XX**

Measure	Study Arm	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
AIM – Implementation Support Baseline	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
AIM - Implementation Support Month 12/13	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
AIM - Implementation Support Change from Baseline to Month 12/13	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
	T-test		X.XXX					
	DF		XX					
	P-Value		0.XXX					
FIM - Implementation Support Baseline	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
FIM - Implementation Support Month 12/13	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
FIM - Implementation Support Change from Baseline to Month 12/13	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
	T-test		X.XXX					
	DF		XX					
	P-Value		0.XXX					

**Table 3.205 Mixed-effects Modeling of the Acceptability of Intervention Measure (AIM – Implementation Support) (Month 12/13), N=XX**

Fixed effects					
Parameter	Estimate	Standard Error	Denominator Degrees of Freedom	T	p-Value
Intercept (RI, Low)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm (DI)	X.XX	X.XXX	XX	X.XX	0.XXXX
Volume (High)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm by Volume	X.XX	X.XXX	XX	X.XX	0.XXXX
Baseline Mean Score[1]	X.XX	X.XXX	XX	X.XX	0.XXXX
Random Effects					
Covariance Parameter	Estimate	Standard Error		Z	p-Value
Site Variance ( $\tau(0,0)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Covariance ( $\tau(0,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Baseline Variance ( $\tau(1,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Residual Variance ( $\sigma^2$ )	X.XX	X.XXX	-	X.XX	0.XXXX

Note: Null model likelihood ratio test,  $\chi^2(XX) = XXX.XX$ ,  $p = 0.XXXX$ .

[1] Baseline mean score centered by site.



**Table 3.206 Mixed-effects Modeling of the Changes from Baseline to Month 12/13 in Acceptability of Intervention Measure (AIM – Implementation Support), N=XX**

Fixed effects					
Parameter	Estimate	Standard Error	Denominator Degrees of Freedom	T	p-Value
Intercept (RI, Low)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm (DI)	X.XX	X.XXX	XX	X.XX	0.XXXX
Volume (High)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm by Volume	X.XX	X.XXX	XX	X.XX	0.XXXX
Baseline Mean Score[1]	X.XX	X.XXX	XX	X.XX	0.XXXX
Random Effects					
Covariance Parameter	Estimate	Standard Error		Z	p-Value
Site Variance ( $\tau(0,0)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Covariance ( $\tau(0,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Baseline Variance ( $\tau(1,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Residual Variance ( $\sigma^2$ )	X.XX	X.XXX	-	X.XX	0.XXXX

Note: Null model likelihood ratio test,  $\chi^2(XX) = XXX.XX$ ,  $p = 0.XXXX$ .

[1] Baseline mean score centered by site.

**Table 3.207 Mixed-effects Modeling of the Feasibility of Intervention Measure (FIM – Implementation Support) (Month 12/13), N=XX**

Fixed effects					
Parameter	Estimate	Standard Error	Denominator Degrees of Freedom	T	p-Value
Intercept (RI, Low)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm (DI)	X.XX	X.XXX	XX	X.XX	0.XXXX
Volume (High)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm by Volume	X.XX	X.XXX	XX	X.XX	0.XXXX
Baseline Mean Score[1]	X.XX	X.XXX	XX	X.XX	0.XXXX
Random Effects					
Covariance Parameter	Estimate	Standard Error		Z	p-Value
Site Variance ( $\tau(0,0)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Covariance ( $\tau(0,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Baseline Variance ( $\tau(1,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Residual Variance ( $\sigma^2$ )	X.XX	X.XXX	-	X.XX	0.XXXX

Note: Null model likelihood ratio test,  $\chi^2(XX) = XXX.XX$ ,  $p = 0.XXXX$ .

[1] Baseline mean score centered by site.

**Table 3.208 Mixed-effects Modeling of the Changes from Baseline to Month 12/13 in Feasibility of Intervention Measure (FIM – Implementation Support), N=XX**

Fixed effects					
Parameter	Estimate	Standard Error	Denominator Degrees of Freedom	T	p-Value
Intercept (RI, Low)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm (DI)	X.XX	X.XXX	XX	X.XX	0.XXXX
Volume (High)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm by Volume	X.XX	X.XXX	XX	X.XX	0.XXXX
Baseline Mean Score[1]	X.XX	X.XXX	XX	X.XX	0.XXXX
Random Effects					
Covariance Parameter	Estimate	Standard Error	-	Z	p-Value
Site Variance ( $\tau(0,0)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Covariance ( $\tau(0,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Baseline Variance ( $\tau(1,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Residual Variance ( $\sigma^2$ )	X.XX	X.XXX	-	X.XX	0.XXXX

Note: Null model likelihood ratio test,  $\chi^2(XX) = XXX.XX$ ,  $p = 0.XXXX$ .

[1] Baseline mean score centered by site.

**Table 3.301 Summary of Acceptability of Intervention Measure (AIM – Telehealth) and Feasibility of Intervention Measure (FIM – Telehealth) Items (Month 12/13), N=XX**

Measure	Item	Study Arm	Total Sample n (%)	1 Completely Disagree n (%)	2 Disagree n (%)	3 Neither Agree nor Disagree n (%)	4 Agree n (%)	5 Completely Agree n (%)
AIM	1. Telehealth for APREITUDE delivery in our clinic/practice meets my approval.	Overall	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Dynamic Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Routine Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
	2. Telehealth for APREITUDE delivery in our clinic/practice is appealing to me.	Overall	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Dynamic Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Routine Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
	3. I like using telehealth for APREITUDE delivery in our clinic/practice.	Overall	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Dynamic Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Routine Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
FIM	4. I welcome telehealth for APREITUDE delivery in our clinic/practice.	Overall	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Dynamic Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Routine Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
	1. Telehealth for APREITUDE delivery seems implementable in our clinic/practice.	Overall	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Dynamic Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Routine Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
	2. Telehealth for APREITUDE delivery	Overall	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Dynamic Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Routine Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)

Measure	Item	Study Arm	Total Sample n (%)	1 Completely Disagree n (%)	2 Disagree n (%)	3 Neither Agree nor Disagree n (%)	4 Agree n (%)	5 Completely Agree n (%)
	seems possible in our clinic/practice							
		Dynamic Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Routine Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
	3. Telehealth for APREITUDE delivery seems doable in our clinic/practice.	Overall	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Dynamic Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Routine Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
	4. Telehealth for APREITUDE delivery seems easy to use in our clinic/practice.	Overall	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Dynamic Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)
		Routine Implementation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX (XX.X)

**Table 3.302    Distributional Characteristics of the Acceptability of Intervention Measure (AIM – Telehealth) (Month 12/13), N=XX**

AIM – TELEHEALTH	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
Mean Score	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Study Arm							
Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
T-test Degrees of Freedom P-Value		X.XXX XX 0.XXX					
Site Volume							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
T-test Degrees of Freedom P-Value		X.XXX XX 0.XXX					
Clinic Type							
University/Academia/Research	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
FQHC/Department of Health	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Nonprofit	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Private	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Provider Type							
Physician	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Mid-level providers[1]	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Nurse	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Medical Assistant	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Pharmacist	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Social worker/case manager/PrEP educator/PrEP navigator	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)

AIM – TELEHEALTH	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
Office administrator /clinic administrator/front desk staff/scheduler	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Laboratory staff/technician/phlebotomist/other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X)	(X.XXX, X.XXX)
Items							
1. Telehealth for APREITUDE in our clinic/practice meets my approval.	XX	X.X	X.XX	X.X (X.X, X.X)	X (X, X)	XX (XX.X)	(X.XX, X.XX)
2. Telehealth for APREITUDE in our clinic/practice is appealing to me.	XX	X.X	X.XX	X.X (X.X, X.X)	X (X, X)	XX (XX.X)	(X.XX, X.XX)
3. I like using telehealth for APREITUDE in our clinic/practice.	XX	X.X	X.XX	X.X (X.X, X.X)	X (X, X)	XX (XX.X)	(X.XX, X.XX)
4. I welcome telehealth for APREITUDE in our clinic/practice.	XX	X.X	X.XX	X.X (X.X, X.X)	X (X, X)	XX (XX.X)	(X.XX, X.XX)

[1] Mid-level providers include nurse practitioners and physician assistants.

**Table 3.303    Distributional Characteristics of the Feasibility of Intervention Measure (FIM – Telehealth) (Month 12/13), N=XX**

FIM – TELEHEALTH	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
Mean Score	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
Study Arm							
Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
T-test Degrees of Freedom P-Value		X.XXX XX 0.XXXX					
Site Volume							
High	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
Low	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
T-test Degrees of Freedom P-Value		X.XXX XX 0.XXXX					
Clinic Type							
University/Academia/Research	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
FQHC/Department of Health	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
Nonprofit	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
Private	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
Provider Type							
Physician	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
Mid-level providers[1]	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
Nurse	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
Medical Assistant	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
Pharmacist	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
Social worker/case manager/PrEP educator/PrEP navigator	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)



FIM – TELEHEALTH	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
Office administrator /clinic administrator/front desk staff/scheduler	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
Laboratory staff/technician/phlebotomist/other	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
Items							
1. Telehealth for APREITUDE seems implementable in our clinic/practice	XX	X.X	X.XX	X.X (X.XX, X.XX)	X (X, X)	XX (XX.X)	(X.XX, X.XX)
2. Telehealth for APREITUDE seems possible in our clinic/practice	XX	X.X	X.XX	X.X (X.XX, X.XX)	X (X, X)	XX (XX.X)	(X.XX, X.XX)
3. Telehealth for APREITUDE seems doable in our clinic/practice	XX	X.X	X.XX	X.X (X.XX, X.XX)	X (X, X)	XX (XX.X)	(X.XX, X.XX)
4. Telehealth for APREITUDE seems easy to use in our clinic/practice	XX	X.X	X.XX	X.X (X.XX, X.XX)	X (X, X)	XX (XX.X)	(X.XX, X.XX)

**Table 3.304 Changes from Baseline for Acceptability of Intervention Measure (AIM – Telehealth) and Feasibility of Intervention Measure (FIM – Telehealth) (Month 12/13), N=XX**

Measure	Study Arm	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
AIM – Telehealth Baseline	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
AIM - Telehealth Month 12/13	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
AIM - Telehealth Change from Baseline to Month 12/13	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
	T-test		X.XXX					
	DF		XX					
	P-Value		0.XXX					
FIM - Telehealth Baseline	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
FIM - Telehealth Month 12/13	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
FIM - Telehealth Change from Baseline to Month 12/13	Dynamic Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XX	X.XXX	X.XX (X.XX, X.XX)	X.X (X.X, X.X)	XX (XX.X%)	(X.XXX, X.XXX)
	T-test		X.XXX					
	DF		XX					
	P-Value		0.XXX					

**Table 3.305 Mixed-effects Modeling of the Acceptability of Intervention Measure (AIM – Telehealth) (Month 12/13), N=XX**

Fixed effects					
Parameter	Estimate	Standard Error	Denominator Degrees of Freedom	T	p-Value
Intercept (RI, Low)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm (DI)	X.XX	X.XXX	XX	X.XX	0.XXXX
Volume (High)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm by Volume	X.XX	X.XXX	XX	X.XX	0.XXXX
Baseline Mean Score[1]	X.XX	X.XXX	XX	X.XX	0.XXXX
Random Effects					
Covariance Parameter	Estimate	Standard Error		Z	p-Value
Site Variance ( $\tau(0,0)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Covariance ( $\tau(0,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Baseline Variance ( $\tau(1,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Residual Variance ( $\sigma^2$ )	X.XX	X.XXX	-	X.XX	0.XXXX

Note: Null model likelihood ratio test,  $\chi^2(XX) = XXX.XX$ ,  $p = 0.XXXX$ .

[1] Baseline mean score centered by site.

**Table 3.306 Mixed-effects Modeling of the Changes from Baseline to Month 12/13 in Acceptability of Intervention Measure (AIM – Telehealth), N=XX**

Fixed effects					
Parameter	Estimate	Standard Error	Denominator Degrees of Freedom	T	p-Value
Intercept (RI, Low)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm (DI)	X.XX	X.XXX	XX	X.XX	0.XXXX
Volume (High)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm by Volume	X.XX	X.XXX	XX	X.XX	0.XXXX
Baseline Mean Score[1]	X.XX	X.XXX	XX	X.XX	0.XXXX
Random Effects					
Covariance Parameter	Estimate	Standard Error		Z	p-Value
Site Variance ( $\tau(0,0)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Covariance ( $\tau(0,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Baseline Variance ( $\tau(1,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Residual Variance ( $\sigma^2$ )	X.XX	X.XXX	-	X.XX	0.XXXX

Note: Null model likelihood ratio test,  $\chi^2(XX) = XXX.XX$ ,  $p = 0.XXXX$ .

[1] Baseline mean score centered by site.

**Table 3.307 Mixed-effects Modeling of the Feasibility of Intervention Measure (FIM – Telehealth) (Month 12/13), N=XX**

Fixed effects					
Parameter	Estimate	Standard Error	Denominator Degrees of Freedom	T	p-Value
Intercept (RI, Low)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm (DI)	X.XX	X.XXX	XX	X.XX	0.XXXX
Volume (High)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm by Volume	X.XX	X.XXX	XX	X.XX	0.XXXX
Baseline Mean Score[1]	X.XX	X.XXX	XX	X.XX	0.XXXX
Random Effects					
Covariance Parameter	Estimate	Standard Error		Z	p-Value
Site Variance ( $\tau(0,0)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Covariance ( $\tau(0,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Baseline Variance ( $\tau(1,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Residual Variance ( $\sigma^2$ )	X.XX	X.XXX	-	X.XX	0.XXXX

Note: Null model likelihood ratio test,  $\chi^2(XX) = XXX.XX$ ,  $p = 0.XXXX$ .

[1] Baseline mean score centered by site.

**Table 3.308 Mixed-effects Modeling of the Changes from Baseline to Month 12/13 in Feasibility of Intervention Measure (FIM – Telehealth), N=XX**

Fixed effects					
Parameter	Estimate	Standard Error	Denominator Degrees of Freedom	T	p-Value
Intercept (RI, Low)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm (DI)	X.XX	X.XXX	XX	X.XX	0.XXXX
Volume (High)	X.XX	X.XXX	XX	X.XX	0.XXXX
Study Arm by Volume	X.XX	X.XXX	XX	X.XX	0.XXXX
Baseline Mean Score[1]	X.XX	X.XXX	XX	X.XX	0.XXXX
Random Effects					
Covariance Parameter	Estimate	Standard Error		Z	p-Value
Site Variance ( $\tau(0,0)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Covariance ( $\tau(0,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Baseline Variance ( $\tau(1,1)$ )	X.XX	X.XXX	-	X.XX	0.XXXX
Residual Variance ( $\sigma^2$ )	X.XX	X.XXX	-	X.XX	0.XXXX

Note: Null model likelihood ratio test,  $\chi^2(XX) = XXX.XX$ ,  $p = 0.XXXX$ .

[1] Baseline mean score centered by site.

Table 3.309 Summary of Feasibility and Acceptability of Telehealth (Month 12/13), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
16	Does your clinic/practice use any form of telehealth for APREUDE delivery?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
19	What telehealth services does your clinic/practice provide for APREUDE?				
		Video consultation: using videoconferencing technology to facilitate a patient visit with both physician and patient present at the same time.	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Telephone consultation and visits	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Remote monitoring of patient health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Online appointment scheduling: ability for patients to make appointments without interacting with staff	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Patient portal conversations: ability for patients to send messages in an online portal	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		At-home testing services: providers order tests and send to patient's home to complete	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Sending and receiving patient reported outcomes questionnaires (e.g., quality of life, health behaviors), via an online system	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Online prescription refill requests	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Online portal for patients to access medical documents, such as visit summaries and test results	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Text messaging with patients about care	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Email reminders to patients about upcoming visits	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Text reminders	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Automated phone call reminder	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Staff phone call reminder	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Sending motivational reminders to help patients persist on APREUDE	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Sending cabotegravir oral lead in to patient's home	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Insurance/benefits verification	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
20	"How easy or difficult is it to use the following telehealth systems to provide APREUDE services to your patients?"				
	Video consultation	Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't use this system	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Telephone consultation	Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't use this system	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Remote monitoring of patients	Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't use this system	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Online appointment scheduling	Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't use this system	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Patient portal conversations: ability for patients to send messages to providers	Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't use this system	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	At-home testing services	Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't use this system	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Send and receiving patient reported outcomes questionnaires (e.g., quality of life, health behaviors), via an online system	Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't use this system	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Online prescription refills	Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't use this system	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Online portal for patients to access medical documents, such as visit summaries and test results	Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't use this system	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Text messaging with patients about care	Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't use this system	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Email reminders to patient about upcoming visits	Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't use this system	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Text reminders	Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't use this system	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Automated phone call reminders	Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't use this system	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Staff phone call reminder	Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't use this system	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
	Sending motivational reminders to help patients persist on APREUDE	Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't use this system	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Sending cabotegravir oral lead in to patient's home	Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't use this system	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Insurance/benefits verification	Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't use this system	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
21	In the last 6 months, what proportion of your APREUDE visits would you estimate were via telehealth (e.g., tele-consults, video)?				
		None (0%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Few (1-30%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Some (31-65%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Most (66%-99%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		All (100%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
23	Why is telehealth not used by your clinic/practice?				
		Do not know how to use telehealth	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Telehealth is too expensive	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Telehealth is too impersonal	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Telehealth does not allow staff to do the necessary physical exams	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Concerns about telehealth privacy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Lack of patient access to computers and/or the internet	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 3.310 Summary of Telehealth Services/Systems Used (Month 12/13), N=XX

24. Which of the following telehealth services/systems is your clinic/practice using to deliver APREUDE during the PILLAR study?	Total Sample n (%)	Yes, my clinic's service/system n (%)	Yes, services/systems offered through PILLAR study n (%)	No n (%)	I don't know n (%)
<b>A. Online system for scheduling/rescheduling consultations and injection appointments</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>					
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>					
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>					
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>					
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>B. Video/virtual consultations for initial and follow-up visits</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>					
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>					
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>					
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

24. Which of the following telehealth services/systems is your clinic/practice using to deliver APREUDE during the PILLAR study?	Total Sample n (%)	Yes, my clinic's service/system n (%)	Yes, services/systems offered through PILLAR study n (%)	No n (%)	I don't know n (%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>					
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>C. Injection Administration: home health nurse to administer injection</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>					
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>					
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>					
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>					
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

24. Which of the following telehealth services/systems is your clinic/practice using to deliver APREUDE during the PILLAR study?	Total Sample n (%)	Yes, my clinic's service/system n (%)	Yes, services/systems offered through PILLAR study n (%)	No n (%)	I don't know n (%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>D. Injection appointment reminders: text, digital, email</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>					
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>					
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>					
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>					
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>E. HIV testing services: at home nurse testing</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>					
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>					
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

24. Which of the following telehealth services/systems is your clinic/practice using to deliver APREUDE during the PILLAR study?	Total Sample n (%)	Yes, my clinic's service/system n (%)	Yes, services/systems offered through PILLAR study n (%)	No n (%)	I don't know n (%)
<b>Clinic Type</b>					
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>					
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



**Table 3.311 Summary of Ease of Use of Telehealth Services/Systems Used (Month 12/13), N=XX**

25. How easy or difficult has each of the telehealth services/systems been for your clinic/practice to implement for the delivery of APREUDE?	Total Sample n (%)	Very easy n (%)	Somewhat easy n (%)	Neutral n (%)	Somewhat Difficult n (%)	Very difficult n (%)	I have not personally used this n (%)
<b>A. Online system for scheduling/rescheduling consultations and injection appointments</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>							
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>							
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>							
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>							
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

25. How easy or difficult has each of the telehealth services/systems been for your clinic/practice to implement for the delivery of APREUDE?	Total Sample n (%)	Very easy n (%)	Somewhat easy n (%)	Neutral n (%)	Somewhat Difficult n (%)	Very difficult n (%)	I have not personally used this n (%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>B. Video/virtual consultations for initial and follow-up visits</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>							
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>							
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>							
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>							
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

25. How easy or difficult has each of the telehealth services/systems been for your clinic/practice to implement for the delivery of APREUDE?	Total Sample n (%)	Very easy n (%)	Somewhat easy n (%)	Neutral n (%)	Somewhat Difficult n (%)	Very difficult n (%)	I have not personally used this n (%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>C. Injection Administration: home health nurse to administer injection</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>							
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>							
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>							
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>							
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

25. How easy or difficult has each of the telehealth services/systems been for your clinic/practice to implement for the delivery of APREUDE?	Total Sample n (%)	Very easy n (%)	Somewhat easy n (%)	Neutral n (%)	Somewhat Difficult n (%)	Very difficult n (%)	I have not personally used this n (%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>D. Injection appointment reminders: text, digital, email</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>							
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>							
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>							
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>							
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

25. How easy or difficult has each of the telehealth services/systems been for your clinic/practice to implement for the delivery of APREUDE?	Total Sample n (%)	Very easy n (%)	Somewhat easy n (%)	Neutral n (%)	Somewhat Difficult n (%)	Very difficult n (%)	I have not personally used this n (%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>E. HIV testing services: at home nurse testing</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>							
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>							
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>							
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>							
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

25. How easy or difficult has each of the telehealth services/systems been for your clinic/practice to implement for the delivery of APREUDE?	Total Sample n (%)	Very easy n (%)	Somewhat easy n (%)	Neutral n (%)	Somewhat Difficult n (%)	Very difficult n (%)	I have not personally used this n (%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 3.312 Summary of Helpfulness of Services/Systems Used (Month 12/13), N=XX

26. How helpful or unhelpful has each of the telehealth services/systems been to the delivery of APREUDE in your clinic/practice?	Total Sample n (%)	Very helpful n (%)	Helpful n (%)	Somewhat helpful n (%)	A little Helpful n (%)	Not at all helpful n (%)	I have not personally used this n (%)
<b>A. Online system for scheduling/rescheduling consultations and injection appointments</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>							
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>							
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>							
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>							
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

26. How helpful or unhelpful has each of the telehealth services/systems been to the delivery of APREUDE in your clinic/practice?	Total Sample n (%)	Very helpful n (%)	Helpful n (%)	Somewhat helpful n (%)	A little Helpful n (%)	Not at all helpful n (%)	I have not personally used this n (%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>B. Video/virtual consultations for initial and follow-up visits</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>							
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>							
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>							
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>							
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



26. How helpful or unhelpful has each of the telehealth services/systems been to the delivery of APREUDE in your clinic/practice?	Total Sample n (%)	Very helpful n (%)	Helpful n (%)	Somewhat helpful n (%)	A little Helpful n (%)	Not at all helpful n (%)	I have not personally used this n (%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>C. Injection Administration: home health nurse to administer injection</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>							
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>							
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>							
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>							
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

26. How helpful or unhelpful has each of the telehealth services/systems been to the delivery of APREUDE in your clinic/practice?	Total Sample n (%)	Very helpful n (%)	Helpful n (%)	Somewhat helpful n (%)	A little Helpful n (%)	Not at all helpful n (%)	I have not personally used this n (%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>D. Injection appointment reminders: text, digital, email</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>							
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>							
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>							
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>							
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

26. How helpful or unhelpful has each of the telehealth services/systems been to the delivery of APREUDE in your clinic/practice?	Total Sample n (%)	Very helpful n (%)	Helpful n (%)	Somewhat helpful n (%)	A little Helpful n (%)	Not at all helpful n (%)	I have not personally used this n (%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>E. HIV testing services: at home nurse testing</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>							
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>							
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>							
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>							
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

26. How helpful or unhelpful has each of the telehealth services/systems been to the delivery of APREUDE in your clinic/practice?	Total Sample n (%)	Very helpful n (%)	Helpful n (%)	Somewhat helpful n (%)	A little Helpful n (%)	Not at all helpful n (%)	I have not personally used this n (%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 3.313 Summary of Satisfaction of Services/Systems Used (Month 12/13), N=XX

27. How satisfied or dissatisfied have you been with each of the telehealth services/systems for delivering APREUDE in your clinic/practice?	Total Sample n (%)	Very satisfied n (%)	Somewhat satisfied n (%)	Neither satisfied nor dissatisfied n (%)	Somewhat dissatisfied n (%)	Very dissatisfied n (%)	I have not personally used this n (%)
<b>A. Online system for scheduling/rescheduling consultations and injection appointments</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>							
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>							
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>							
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>							
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator/clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

27. How satisfied or dissatisfied have you been with each of the telehealth services/systems for delivering APREUDE in your clinic/practice?	Total Sample n (%)	Very satisfied n (%)	Somewhat satisfied n (%)	Neither satisfied nor dissatisfied n (%)	Somewhat dissatisfied n (%)	Very dissatisfied n (%)	I have not personally used this n (%)
<b>B. Video/virtual consultations for initial and follow-up visits</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>							
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>							
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>							
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>							
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>C. Injection Administration: home health nurse to administer injection</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

27. How satisfied or dissatisfied have you been with each of the telehealth services/systems for delivering APREUDE in your clinic/practice?	Total Sample n (%)	Very satisfied n (%)	Somewhat satisfied n (%)	Neither satisfied nor dissatisfied n (%)	Somewhat dissatisfied n (%)	Very dissatisfied n (%)	I have not personally used this n (%)
<b>Study Arm</b>							
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>							
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>							
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>							
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>D. Injection appointment reminders: text, digital, email</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>							

27. How satisfied or dissatisfied have you been with each of the telehealth services/systems for delivering APREUDE in your clinic/practice?	Total Sample n (%)	Very satisfied n (%)	Somewhat satisfied n (%)	Neither satisfied nor dissatisfied n (%)	Somewhat dissatisfied n (%)	Very dissatisfied n (%)	I have not personally used this n (%)
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>							
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>							
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>							
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>E. HIV testing services: at home nurse testing</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>							
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



27. How satisfied or dissatisfied have you been with each of the telehealth services/systems for delivering APREUDE in your clinic/practice?	Total Sample n (%)	Very satisfied n (%)	Somewhat satisfied n (%)	Neither satisfied nor dissatisfied n (%)	Somewhat dissatisfied n (%)	Very dissatisfied n (%)	I have not personally used this n (%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>							
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>							
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>							
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator/clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 3.401 Summary of Utility of Proposed Implementation Strategies (Month 12/13), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
28	Have you used the following in the implementation of APRETUDE into your practice/clinic?				
28A	Frequently Asked Questions Brochure	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
28B	Readiness Consideration	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
28C	Get Started Overview-Init/Adm Guide	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
28D	Injection Education Video	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
28E	Provider Website – location where all materials and videos on APRETUDE for the study is located	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
28F	Patient Materials	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
28G	Implementation Guidance Video	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
28H	Appointment Scheduler	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
28I	Pre-scheduled Appointment Guidance	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
28J	Designated Injection Days Guidance	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
28K	Drop-in Injection Visits Guidance	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
28L	Transport Support to Patient Appt	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
28M	Monthly Implement Facilitation Call	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
28N	Group Implement Facilitation Calls	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
28O	Document on How Discuss Sex Health	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
28P	PILLAR Spot	Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
29	How often have you used the following in the implementation of APRETUDE into your practice/clinic?				
29A	Frequent Ask Question Brochure	Rarely	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Sometimes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Often	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		All the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
29B	Readiness Consideration	Rarely	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Sometimes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Often	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		All the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
29C	Getting Started Overview	Rarely	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Sometimes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Often	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		All the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
29D	Injection Education Video	Rarely	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Sometimes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Often	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		All the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
29F	Patient Materials	Rarely	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Sometimes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Often	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		All the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
29G	Implementation Guidance Video	Rarely	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Sometimes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Often	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		All the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
29H	Appointment Scheduler	Rarely	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Sometimes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Often	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		All the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
29I	Pre-scheduled Appt Guidance	Rarely	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Sometimes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Often	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		All the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
29J	Designated Inj Days Guidance	Rarely	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Sometimes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Often	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		All the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
29K	Drop-in Inj Visits Guidance	Rarely	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Sometimes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Often	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		All the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
29L	Transport Support to Pt Appt	Rarely	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Sometimes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Often	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		All the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
29M	Monthly Implement Facilit Call	Rarely	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Sometimes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Often	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		All the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
29N	Group Implement Facilit Calls	Rarely	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Sometimes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Often	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		All the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
29O	Doc on How Discuss Sex Health	Rarely	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Sometimes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Often	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		All the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
29P	PILLAR Spot	Rarely	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Sometimes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Often	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		All the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
30	How useful are the following in the implementation of APRETUDE into your practice/clinic?				
30A	Frequently Asked Questions Brochure	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
30B	Readiness Consideration	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
30C	Getting Started Overview-Init/Adm Guide	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
30D	Injection Education Video	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
30E	Provider Website	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
30F	Patient Materials	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		A little useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
30G	Implementation Guidance Video	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
30H	Appointment Scheduler	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
30I	Pre-scheduled Appointment Guidance	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
30J	Designated Injection Days Guidance	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
30K	Drop-in Injection Visits Guidance	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
30L	Provid Transport Support to Patient Appt	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
30M	Monthly Implementation Facilitation Call	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
30N	Group Implementation Facilitation Calls	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
30O	Document on How to Discuss Sexual Health	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
30P	PILLAR Spot	Not at all useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very Useful	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 3.501 Summary of Perceived Barriers to Delivering APRETUDE to Patients (Month 12/13), N=XX**

55. Please indicate how concerned you would be about each of the following being a barrier or challenge to delivering APRETUDE to patients based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
<b>A. Patients' ability to keep appointments</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator/clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



55. Please indicate how concerned you would be about each of the following being a barrier or challenge to delivering APREUDE to patients based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>B. Patients' injection-related pain/soreness</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator/clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

55. Please indicate how concerned you would be about each of the following being a barrier or challenge to delivering APREUDE to patients based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
<b>C. Risk of drug resistance for patients not adherent to injections</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>D. Cost of APREUDE</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

55. Please indicate how concerned you would be about each of the following being a barrier or challenge to delivering APREUDE to patients based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>E. Keeping a patient engaged and motivated to continue APREUDE</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						

55. Please indicate how concerned you would be about each of the following being a barrier or challenge to delivering APRETUDE to patients based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>F. Identifying eligible individuals for APRETUDE</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

55. Please indicate how concerned you would be about each of the following being a barrier or challenge to delivering APREUDE to patients based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator/clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>G. Worried that a patient will feel stigmatized if offered APREUDE</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

55. Please indicate how concerned you would be about each of the following being a barrier or challenge to delivering APREUDE to patients based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>H. Patients' willingness to travel every 2 months for an injection appointment</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						

55. Please indicate how concerned you would be about each of the following being a barrier or challenge to delivering APREUDE to patients based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>I. Patient lack of belief in the efficacy of APREUDE</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

55. Please indicate how concerned you would be about each of the following being a barrier or challenge to delivering APREUDE to patients based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



Table 3.502 Summary of Perceptions of Administering APRETUDE (Month 12/13), N=XX

56. Please indicate how concerned you would be about each of the following being a barrier or challenge to APRETUDE administration based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
<b>A. Difficulty of giving the gluteal medial injection</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator/clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

56. Please indicate how concerned you would be about each of the following being a barrier or challenge to APREITUDE administration based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
<b>B. Understanding how to manage patients who miss an injection dose</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia /Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

56. Please indicate how concerned you would be about each of the following being a barrier or challenge to APRETUDE administration based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
<b>C. How to transition patients off of APRETUDE who want to stop taking it (e.g., should other PrEP be offered)</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia /Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

56. Please indicate how concerned you would be about each of the following being a barrier or challenge to APREUDE administration based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>D. Understanding how to use oral PrEP medication for a planned missed injection visit</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator/clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

56. Please indicate how concerned you would be about each of the following being a barrier or challenge to APREITUDE administration based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
administrator/front desk staff/scheduler						
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>E. Understanding how to restart APREITUDE after a missed injection</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator/clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

56. Please indicate how concerned you would be about each of the following being a barrier or challenge to APREITUDE administration based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
administrator/front desk staff/scheduler						
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>F. Managing the oral lead-in phase of APREITUDE before starting injections if needed</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

56. Please indicate how concerned you would be about each of the following being a barrier or challenge to APREUDE administration based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>G. Ability to provide adherence counseling and support when injection dosing visits are missed</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

56. Please indicate how concerned you would be about each of the following being a barrier or challenge to APREITUDE administration based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
educator/PrEP navigator						
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



**Table 3.503 Summary of Perceived Barriers to Managing Delivery of APRETUDE (Month 12/13), N=XX**

57. Please indicate how concerned you would be about each of the following being a barrier or challenge to APRETUDE delivery based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
<b>A. Management of scheduling injection appointments every 2 months during correct injection (i.e., dosing) windows</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

57. Please indicate how concerned you would be about each of the following being a barrier or challenge to APREITUDE delivery based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>B. Management of rescheduling appointments during correct injection (i.e., dosing) windows</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

57. Please indicate how concerned you would be about each of the following being a barrier or challenge to APRETUDE delivery based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>C. Ability to schedule/reschedule patients who missed APRETUDE visits within correct injection (i.e., dosing) windows</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

57. Please indicate how concerned you would be about each of the following being a barrier or challenge to APREITUDE delivery based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>D. Ability to identify and flag missed injection visits to providers (in a timely manner)</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

57. Please indicate how concerned you would be about each of the following being a barrier or challenge to APRETUDE delivery based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>E. Ability to manage patients presenting to APRETUDE injection appointments with other care needs that need to be addressed</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

57. Please indicate how concerned you would be about each of the following being a barrier or challenge to APREUDE delivery based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>F. Persistence to follow up with patient on missed appointments</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

57. Please indicate how concerned you would be about each of the following being a barrier or challenge to APREUDE delivery based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>G. Provider time to discuss HIV prevention with all eligible patients</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

57. Please indicate how concerned you would be about each of the following being a barrier or challenge to APREITUDE delivery based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>H. Ability to provide HIV screening as indicated at each injection visit and provide rapid intervention/follow-up based on results status</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



57. Please indicate how concerned you would be about each of the following being a barrier or challenge to APRETUDE delivery based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>I. HIV monitoring requirements associated with APRETUDE</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

57. Please indicate how concerned you would be about each of the following being a barrier or challenge to APRETUDE delivery based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>J. Cost/coverage of ancillary services to provide APRETUDE</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

57. Please indicate how concerned you would be about each of the following being a barrier or challenge to APREITUDE delivery based on your current expectations and knowledge.	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 3.504 Summary of Perceived Resourcing Barriers to Support Delivery of APREUDE  
(Month 12/13), N=XX**

58. Please indicate how concerned you would be about each of the following potentially being a barrier or challenge to APREUDE delivery based on your current expectations and knowledge.						
	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
<b>A. Staff resourcing to ensure appropriate clinic flow</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

58. Please indicate how concerned you would be about each of the following potentially being a barrier or challenge to APREUDE delivery based on your current expectations and knowledge.						
	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>B. Number of exam rooms for injections</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

58. Please indicate how concerned you would be about each of the following potentially being a barrier or challenge to APREUDE delivery based on your current expectations and knowledge.						
	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>C. Clinic staff to administer injections</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

58. Please indicate how concerned you would be about each of the following potentially being a barrier or challenge to APREUDE delivery based on your current expectations and knowledge.						
	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>D. Staff preparation (i.e., education, training, in-services) to implement APREUDE</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

58. Please indicate how concerned you would be about each of the following potentially being a barrier or challenge to APREUDE delivery based on your current expectations and knowledge.						
	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>E. Staff time to provide counseling and support to patients, such as answering questing between visit, keeping patients motivated</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



58. Please indicate how concerned you would be about each of the following potentially being a barrier or challenge to APREUDE delivery based on your current expectations and knowledge.	Total Sample					
	n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>F. Staff belief in the efficacy of APREUDE</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Clinic Type</b>						
University/Academia/Research	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
FQHC/Department of Health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nonprofit	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Private	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Provider Type</b>						
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mid-level providers[1]	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

58. Please indicate how concerned you would be about each of the following potentially being a barrier or challenge to APREUDE delivery based on your current expectations and knowledge.	<div> <div></div> <div></div> <div></div> <div></div> <div></div> <div></div> </div>					
	Total Sample n (%)	Extremely concerned n (%)	Moderately concerned n (%)	Somewhat concerned n (%)	Slightly concerned n (%)	Not at all concerned n (%)
Social worker/case manager/PrEP educator/PrEP navigator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Office administrator /clinic administrator/front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Laboratory staff/technician/phlebotomist/other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 3.505 Summary of Perceptions of Clinic/Practice Culture and Environment (Month 12/13), N=XX**

59. How much do you agree or disagree with the following statements about your clinic/practice?	Total Sample n (%)	Completely Disagree n (%)	Disagree n (%)	Neither agree nor disagree n (%)	Agree n (%)	Completely Agree n (%)
<b>A. People at all levels openly talk about what is and isn't working</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>B. Most people in this clinic are willing to change how they do things in response to feedback from others</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>C. It is hard to get things to change in our clinic</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>D. People in this clinic operate as a real team</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation						
<b>Site Volume</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low						
<b>E. Staff members often show signs of stress and strain</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

59. How much do you agree or disagree with the following statements about your clinic/practice?	Total Sample n (%)	Completely Disagree n (%)	Disagree n (%)	Neither agree nor disagree n (%)	Agree n (%)	Completely Agree n (%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>F. We regularly take time to consider ways to improve how we do things</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>G. Leadership strongly supports clinic change efforts</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 3.506 Summary of Barriers to PrEP Provisioning (Month 12/13), N=XX

96. Indicate your level of agreement with the following statements:	Total Sample n (%)	Completely Disagree n (%)	Disagree n (%)	Neither agree nor disagree n (%)	Agree n (%)	Completely Agree n (%)
<b>A. The use of PrEP will cause patients to engage in riskier behaviors</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>B. Providing PrEP endorses the risk behaviors of users</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>C. Only people who engage in risky behavior need PrEP</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>D. Only people with many sexual partners need PrEP</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation						
<b>Site Volume</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low						
<b>E. All sexually active people can benefit from PrEP</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

96. Indicate your level of agreement with the following statements:	Total Sample n (%)	Completely Disagree n (%)	Disagree n (%)	Neither agree nor disagree n (%)	Agree n (%)	Completely Agree n (%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>F. Providing PrEP will result in an increase in sexually transmitted diseases among patients</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>G. People do not need PrEP if they act responsibly</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>						
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>						
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 3.507 Distributional Characteristics of Barriers to PrEP Provisioning (Month 12/13), N=XX**

96. Indicate your level of agreement with the following statements:	Study Arm	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
A. The use of PrEP will cause patients to engage in riskier behaviors	Dynamic Implementation	XX	X.XXX	X.XXXX	X.XX (X.XX, X.XX)	X.XX (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XXX	X.XXXX	X.XX (X.XX, X.XX)	X.XX (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
	T-test		X.XXX					
	DF		XX					
	P-Value		X.XXX					
B. Providing PrEP endorses the risk behaviors of users	Dynamic Implementation	XX	X.XXX	X.XXXX	X.XX (X.XX, X.XX)	X.XX (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XXX	X.XXXX	X.XX (X.XX, X.XX)	X.XX (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
	T-test		X.XXX					
	DF		XX					
	P-Value		X.XXX					
C. Only people who engage in risky behavior need PrEP	Dynamic Implementation	XX	X.XXX	X.XXXX	X.XX (X.XX, X.XX)	X.XX (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XXX	X.XXXX	X.XX (X.XX, X.XX)	X.XX (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
	T-test		X.XXX					
	DF		XX					
	P-Value		X.XXX					
D. Only people with many sexual partners need PrEP	Dynamic Implementation	XX	X.XXX	X.XXXX	X.XX (X.XX, X.XX)	X.XX (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XXX	X.XXXX	X.XX (X.XX, X.XX)	X.XX (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
	T-test		X.XXX					
	DF		XX					
	P-Value		X.XXX					
E. All sexually active people can benefit from PrEP	Dynamic Implementation	XX	X.XXX	X.XXXX	X.XX (X.XX, X.XX)	X.XX (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)

96. Indicate your level of agreement with the following statements:	Study Arm	n	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean
	Routine Implementation	XX	X.XXX	X.XXXX	X.XX (X.XX, X.XX)	X.XX (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
	T-test		X.XXX					
	DF		XX					
	P-Value		X.XXX					
F. Providing PrEP will result in an increase in sexually transmitted diseases among patients	Dynamic Implementation	XX	X.XXX	X.XXXX	X.XX (X.XX, X.XX)	X.XX (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XXX	X.XXXX	X.XX (X.XX, X.XX)	X.XX (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
	T-test		X.XXX					
	DF		XX					
	P-Value		X.XXX					
G. People do not need PrEP if they act responsibly	Dynamic Implementation	XX	X.XXX	X.XXXX	X.XX (X.XX, X.XX)	X.XX (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XXX	X.XXXX	X.XX (X.XX, X.XX)	X.XX (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
	T-test		X.XXX					
	DF		XX					
	P-Value		X.XXX					
Total Score	Dynamic Implementation	XX	X.XXX	X.XXXX	X.XX (X.XX, X.XX)	X.XX (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
	Routine Implementation	XX	X.XXX	X.XXXX	X.XX (X.XX, X.XX)	X.XX (X.XX, X.XX)	XX (XX.X)	(X.XXX, X.XXX)
	T-test		X.XXX					
	DF		XX					
	P-Value		X.XXX					



**Table 3.508 Shift from Month 4/5 to Month 12/13 in Summary of Perceived Barriers to Delivering APRETUDE to Patients (Month 12/13), N=XX**

55. Please indicate how concerned you would be about each of the following being a barrier or challenge to delivering APRETUDE to patients based on your current expectations and knowledge.									
A. Patients' ability to keep appointments									
Study Arm	N	M4/5	M12/13						
			Extremely Concerned	Moderately Concerned	Somewhat Concerned	Slightly Concerned	Not at all Concerned	Missing	Total
DI	XX	Extremely Concerned	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)
		Moderately Concerned	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)
		Somewhat Concerned	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)
		Slightly Concerned	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)
		Not at all Concerned	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)
		Missing	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)
		Total	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)
RI	XX	Extremely Concerned	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)

		<b>Moderately Concerned</b>	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)
		<b>Somewhat Concerned</b>	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)
		<b>Slightly Concerned</b>	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)
		<b>Not at all Concerned</b>	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)
		<b>Missing</b>	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)
		<b>Total</b>	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)

Note 1: Shift tables will be created as above for items 55b through 55i.

Note 2: Only includes respondents who completed surveys at respective months.

Missing: M4/5 = missing item at M4/5 but not M12/13. M12/13 = missing item at M12/13 but not M4/5.

Percentage calculations:

Column total %: numerator= number selecting respective response at M12/13, denominator = number responding at M12/13

Row total %: numerator= number selecting respective response at M4/5, denominator = number responding at M4/5

Cell %: numerator = number selecting respective combination of M4/5 and M12/13 responses, denominator=number of participants responding at M4/5.

Total: N = number of participants that completed the question at either M4/5 or M12/13

### Table 3.509 Shift from Month 4/5 to Month 12/13 in Summary of Perceptions of Administering APRETUDE (Month 12/13), N=XX

Note 1: Shift tables will be created as shown for Table 3.508 for items 56a through 56g.

Note 2: Only includes respondents who completed surveys at respective months.

Missing: M4/5 = missing item at M4/5 but not M12/13. M12/13 = missing item at M12/13 but not M4/5.

Percentage calculations:

Column total %: numerator= number selecting respective response at M12/13, denominator = number responding at M12/13

Row total %: numerator= number selecting respective response at M4/5, denominator = number responding at M4/5

Cell %: numerator = number selecting respective combination of M4/5 and M12/13 responses, denominator=number of participants responding at M4/5.

Total: N = number of participants that completed the question at either M4/5 or M12/13

### Table 3.510 Shift from Month 4/5 to Month 12/13 in Summary of Perceived Barriers to Managing Delivery of APRETUDE (Month 12/13), N=XX

Note 1: Shift tables will be created as shown for Table 3.508 for items 57a through 57i.

Note 2: Only includes respondents who completed surveys at respective months.

Missing: M4/5 = missing item at M4/5 but not M12/13. M12/13 = missing item at M12/13 but not M4/5.

Percentage calculations:

Column total %: numerator= number selecting respective response at M12/13, denominator = number responding at M12/13

Row total %: numerator= number selecting respective response at M4/5, denominator = number responding at M4/5

Cell %: numerator = number selecting respective combination of M4/5 and M12/13 responses, denominator=number of participants responding at M4/5.

Total: N = number of participants that completed the question at either M4/5 or M12/13

### Table 3.511 Shift from Month 4/5 to Month 12/13 in Summary of Perceived Resourcing Barriers to Support Delivery of APRETUDE (Month 12/13), N=XX

Note 1: Shift tables will be created as shown for Table 3.508 for items 58a through 58f.

Note 2: Only includes respondents who completed surveys at respective months.

Missing: M4/5 = missing item at M4/5 but not M12/13. M12/13 = missing item at M12/13 but not M4/5.

Percentage calculations:

Column total %: numerator= number selecting respective response at M12/13, denominator = number responding at M12/13

Row total %: numerator= number selecting respective response at M4/5, denominator = number responding at M4/5

Cell %: numerator = number selecting respective combination of M4/5 and M12/13 responses, denominator=number of participants responding at M4/5.

Total: N = number of participants that completed the question at either M4/5 or M12/13

### Table 3.512 Shift from Month 4/5 to Month 12/13 in Summary of Perceptions of Clinic/Practice Culture and Environment (Month 12/13), N=XX

Note 1: Shift tables will be created as shown for Table 3.508 for items 59a through 59g.

Note 2: Only includes respondents who completed surveys at respective months.

Missing: M4/5 = missing item at M4/5 but not M12/13. M12/13 = missing item at M12/13 but not M4/5.

Percentage calculations:

Column total %: numerator= number selecting respective response at M12/13, denominator = number responding at M12/13

Row total %: numerator= number selecting respective response at M4/5, denominator = number responding at M4/5

Cell %: numerator = number selecting respective combination of M4/5 and M12/13 responses, denominator=number of participants responding at M4/5.

Total: N = number of participants that completed the question at either M4/5 or M12/13

### Table 3.513 Shift from Month 4/5 to Month 12/13 in Summary of Barriers to PrEP Provisioning (Month 12/13), N=XX

Note 1: Shift tables will be created as shown for Table 3.508 for items 96a through 96g.

Note 2: Only includes respondents who completed surveys at respective months.

Missing: M4/5 = missing item at M4/5 but not M12/13. M12/13 = missing item at M12/13 but not M4/5.

Percentage calculations:

Column total %: numerator= number selecting respective response at M12/13, denominator = number responding at M12/13

Row total %: numerator= number selecting respective response at M4/5, denominator = number responding at M4/5

Cell %: numerator = number selecting respective combination of M4/5 and M12/13 responses, denominator=number of participants responding at M4/5.

Total: N = number of participants that completed the question at either M4/5 or M12/13

Table 3.601 Summary of the Sexual Health Assessment Tool (Month 12/13), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
31	Has your clinic/practice started to use the Sexual Health Assessment?				
		No And Not Planning To Use The Sexual Health Assessment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No But Planning To Use The Sexual Health Assessment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
32	Who in your clinic/practice is or will be responsible for distributing the Sexual Health Assessment to patients?				
		Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Nurse practitioner/physician assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Medical assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Social worker/case manager	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Peer educator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
33	Who in your clinic/practice is or will be responsible for reviewing and discussing the results of the Sexual Health Assessment with patients?				
		Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Nurse practitioner/physician assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Medical assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Social worker/case manager	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Peer educator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The results are or will not be discussed with patients	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
34	How often have you used the Sexual Health Assessment in your clinic/practice?				
		Rarely	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Sometimes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Often	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		All the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
			XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
35	"Please indicate your level of agreement with the following statements about the Sexual Health Assessment."				
	The Sexual Health Assessment is/will be easy to implement in my clinic/practice	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The Sexual Health Assessment is/will be an easy way to identify individuals interested in PrEP	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The Sexual Health Assessment helps/will help to facilitate conversations about PrEP with patients	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
36	Why is the Sexual Health Assessment not used by your clinic/practice?				
		Already have a similar assessment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Does not integrate with the EMR	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The assessment is difficult to administer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Concerns about patient privacy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The assessment does not ask the right questions	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The assessment takes too much time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The assessment is not needed	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 3.602 Summary of the PrEP Communication Tool (Month 12/13), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
37	Has your clinic/practice started to use PrEP Options Communication Tool?				
		No and not planning to use the PrEP Options Communication Tool	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No but planning to use the PrEP Options Communication Tool	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
38	Who in your clinic/practice is or will be responsible for using the PrEP Options Communication Tool with patients?				
		Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Nurse practitioner/physician assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Medical assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Social worker/case manager	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Front desk staff/scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Peer educator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
39	How often have you used the PrEP Options Communication Tool in your clinic/practice?				
		Rarely	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Sometimes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Often	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		All the time	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
40	Please indicate your level of agreement with the following statements about the PrEP Options Communication Tool				
	The PrEP Options Communication Tool is/will be easy to implement in my clinic/practice	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	The PrEP Options Communication Tool helps/will help to facilitate conversations about PrEP with patients	Completely disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither agree nor disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
41	Why is the PrEP Options Communication Tool not used by your clinic/practice?				
		Already have a similar tool	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Do not have time in a clinical visit to use the tool	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Do not understand the information in the tool	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Tool does not provide the right information	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Tool is not needed	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Table 3.701 Summaries of the Optional Oral Lead-in Phase of APRETUDE (Month 12/13), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
79	How do you start your patients with APRETUDE?				
		directly with injection	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		With optional oral lead-in using oral cabotegravir	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		With oral PrEP (TDF/FTC or TAF/FTC)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
80	"Of all your patients who have been prescribed APRETUDE, please estimate the percentage that started:"				
	Directly with injection who switched from oral PrEP	N	XX	XX	XX
		Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)
		Median	XX.X	XX.X	XX.X
		Q1, Q3	XX.X, XX.X	XX.X, XX.X	XX.X, XX.X
		Range (Min, Max)	XX (XX, XX)	XX (XX, XX)	XX (XX, XX)
	Directly with injection who are new to PrEP	N	XX	XX	XX
		Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)
		Median	XX.X	XX.X	XX.X
		Q1, Q3	XX.X, XX.X	XX.X, XX.X	XX.X, XX.X
		Range (Min, Max)	XX (XX, XX)	XX (XX, XX)	XX (XX, XX)
	With optional oral lead-in (oral Cabotegravir)	N	XX	XX	XX
		Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)
		Median	XX.X	XX.X	XX.X
		Q1, Q3	XX.X, XX.X	XX.X, XX.X	XX.X, XX.X
		Range (Min, Max)	XX (XX, XX)	XX (XX, XX)	XX (XX, XX)
	With oral PrEP (TDF/FTC or TAF/FTC)	N	XX	XX	XX
		Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)
		Median	XX.X	XX.X	XX.X
		Q1, Q3	XX.X, XX.X	XX.X, XX.X	XX.X, XX.X
		Range (Min, Max)	XX (XX, XX)	XX (XX, XX)	XX (XX, XX)
	Other	N	XX	XX	XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)
		Median	XX.X	XX.X	XX.X
		Q1, Q3	XX.X, XX.X	XX.X, XX.X	XX.X, XX.X
		Range (Min, Max)	XX (XX, XX)	XX (XX, XX)	XX (XX, XX)
81	What sources of information have you drawn upon in assessing whether oral lead-in is needed or not?				
		Scientific literature	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Independent Medical Education	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Data from ViiV/GSK	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Scientific conferences	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Clinic rounds	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		CDC guidelines	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other medical colleagues	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other sources	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
82	What are the main factors that drive your decision to use oral lead-in or not?				
		The ability to assess the safety/tolerability of APREUDE in all patients	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The ability to assess the safety/tolerability of APREUDE in patients with a history of allergy/drug intolerance	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The availability of more data from clinical trials using an oral lead-in phase	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		The ability to increase drug concentration before starting the injections	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Being cautious with a new medication	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Providing patient with protection against HIV until the injection arrives	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Patient request	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Enough data exists from clinical trials to start patients with injection without oral lead in	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Provide patients with immediate protection with a long acting method by not using oral lead in	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
83	How influential are patient preferences in the decision of whether or not to use an oral lead-in phase?				
		Very influential	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Influential	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat influential	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not very influential	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all influential	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
84	Have any of your patients missed injection visit(s)?				
		No, none of my patients have missed their injection visits	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes, some of my patients have had planned missed visits	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Yes, some of my patients have had unplanned missed visits	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
85	For patients who have missed an injection visit, what protection were they given/offered until they received their next injection?				
		Cabotegravir oral tablets	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		TDF/FTC	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		TAF/FTC	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Provision of condoms	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Risk reduction education	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		None	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Do not know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
86	For patients who plan to miss an injection, what protection do you plan on offering them until they receive their next injection?				
		Cabotegravir oral tablets	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		TDF/FTC	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		TAF/FTC	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Provision of condoms	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Risk reduction education	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		None	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Do not know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
87	How easy or difficult was it to start patients on oral PrEP for a missed injection visit?				
		Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
88	How acceptable was it to start patients on oral PrEP after a missed injection visit?				
		Very acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little Acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all Acceptable	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
89	Before initiating a patient on PrEP, what type of HIV test do you primarily use?				
	Oral PrEP	HIV-1 RNA, qualitative test	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV-1 RNA, quantitative test (e.g. viral load)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV antigen/antibody test (laboratory) 4th gen lab	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV antigen/ antibody test (rapid test) 4th gen rapid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV antibody test (rapid test) 3rd gen rapid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	APRETUDE	HIV-1 RNA, qualitative test	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV-1 RNA, quantitative test (e.g. viral load)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV antigen/antibody test (laboratory) 4th gen lab	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV antigen/ antibody test (rapid test) 4th gen rapid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV antibody test (rapid test) 3rd gen rapid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
90	Before initiating a patient on PrEP, what type of HIV test have you ever used?				
	Oral PrEP	HIV-1 RNA, qualitative test	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV-1 RNA, quantitative test (e.g. viral load)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV antigen/antibody test (laboratory) 4th gen lab	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV antigen/ antibody test (rapid test) 4th gen rapid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV antibody test (rapid test) 3rd gen rapid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	APRETUDE	HIV-1 RNA, qualitative test	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		HIV-1 RNA, quantitative test (e.g. viral load)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV antigen/antibody test (laboratory) 4th gen lab	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV antigen/ antibody test (rapid test) 4th gen rapid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV antibody test (rapid test) 3rd gen rapid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
91	For follow-up visits for patients who are on PrEP, what type of HIV test do you primarily use?				
	Oral PrEP	HIV-1 RNA, qualitative test	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV-1 RNA, quantitative test (e.g. viral load)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV antigen/antibody test (laboratory) 4th gen lab	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV antigen/ antibody test (rapid test) 4th gen rapid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV antibody test (rapid test) 3rd gen rapid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	APREUDE	HIV-1 RNA, qualitative test	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV-1 RNA, quantitative test (e.g. viral load)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV antigen/antibody test (laboratory) 4th gen lab	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV antigen/ antibody test (rapid test) 4th gen rapid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV antibody test (rapid test) 3rd gen rapid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
92	For follow-up visits for patients who are on PrEP, what type of HIV test have you ever used?				
	Oral PrEP	HIV-1 RNA, qualitative test	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV-1 RNA, quantitative test (e.g. viral load)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV antigen/antibody test (laboratory) 4th gen lab	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV antigen/ antibody test (rapid test) 4th gen rapid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV antibody test (rapid test) 3rd gen rapid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	APREUDE	HIV-1 RNA, qualitative test	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV-1 RNA, quantitative test (e.g. viral load)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV antigen/antibody test (laboratory) 4th gen lab	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		HIV antigen/ antibody test (rapid test) 4th gen rapid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		HIV antibody test (rapid test) 3rd gen rapid	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 3.702 Assessment of Alternate Sites of Administration of APRETUDE (Month 12/13), N=XX**

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
93	Have any of your APRETUDE patients received their injections at a location other than your clinic?				
		Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
94	At which locations have your APRETUDE patients received injections?				
		Another clinic	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		At home	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		An infusion center	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Retail pharmacy (e.g., CVS, Walgreens)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Community based organization	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Department of health	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
95	"Please rate how appropriate you believe each setting would be for administering APRETUDE."				
95A	HIV-specialty clinic	Very Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
95B	Primary care clinic/private practice	Very Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		A little Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
95C	Women's health practice/center	Very Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
95D	Community health center	Very Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
95E	Hospital outpatient	Very Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
95F	Retail pharmacy (e.g., CVS, Walgreens)	Very Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Not at all Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
95G	Other pharmacy	Very Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
95H	At home/home-based caring	Very Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
95I	Community based organization	Very Appropriate			
		Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
95J	Infusion center	Very Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
95K	STD/STI clinic	Very Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
95L	PrEP clinic	Very Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
95M	Department of Health Clinic	Very Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
95N	Mobile clinic	Very Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
95O	Other(s), (please specify)	Very Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all Appropriate	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
96	Indicate your level of agreement with the following statements:				
96A	The use of PrEP will cause patients to engage in riskier behaviors	Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither disagree nor agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
96B	Providing PrEP endorses the risk behaviors of users	Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither disagree nor agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
96C	Only people who engage in risky behavior need PrEP	Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither disagree nor agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
96D	Only people with many sexual partners need PrEP	Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither disagree nor agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
96E	All sexually active people can benefit from PrEP (RC)	Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither disagree nor agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
96F	Providing PrEP will result in an increase in sexually transmitted diseases among patients	Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither disagree nor agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
96G	People do not need PrEP if they act responsibly	Completely Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Disagree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither disagree nor agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Completely agree	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 3.801 Summary of Perceived Number of APREUDE Patients Clinic/Practice Can Manage Per Week on an Ongoing Basis (Month 12/13), N=XX**

60. How many APREUDE patients do you think your clinic/practice can manage per week on an ongoing basis?	Total Sample n (%)	0-10 Patients n (%)	11-25 Patients n (%)	26-50 Patients n (%)	51-100 Patients n (%)	101-200 Patients n (%)	>200 Patients n (%)	Unsure n=xx (%)
<b>Total Sample</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>								
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>								
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 3.802    Distributional Characteristics of Reported Number of People in Clinic Trained and Prepared to Give APRETUDE Injections (Month 12/13), N=XX**

61. Approximately how many people in your clinic are trained and prepared to give APRETUDE injections?	Total Sample n (%)	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum and Maximum)	Missing n (%)	95% CI for the Mean	I don't know n (%)
<b>Total Sample</b>	XX (XX%)	X.X	X.XX	X.X (X.X,X.X)	XX (XX, XX)	XX.X%	(X.XX, X.XX)	XX (XX.X%)
<b>Study Arm</b>								
Dynamic Implementation	XX (XX%)	X.X	X.XX	X.X (X.X,X.X)	XX (XX, XX)	XX.X%	(X.XX, X.XX)	XX (XX.X%)
Routine Implementation	XX (XX%)	X.X	X.XX	X.X (X.X,X.X)	XX (XX, XX)	XX.X%	(X.XX, X.XX)	XX (XX.X%)
<b>Site Volume</b>								
High	XX (XX%)	X.X	X.XX	X.X (X.X,X.X)	XX (XX, XX)	XX.X%	(X.XX, X.XX)	XX (XX.X%)
Low	XX (XX%)	X.X	X.XX	X.X (X.X,X.X)	XX (XX, XX)	XX.X%	(X.XX, X.XX)	XX (XX.X%)

**Table 3.803**    **Distributional Characteristics of Estimated Number of Staff Needed Per Week to Incorporate APREUDE into Clinic/Practice for Approximately 25 People (Month 12/13), N=XX**

62. How much staff in total do you estimate is/will be needed per week to incorporate APREUDE into your clinic/practice for approximately 25 people?	Total Sample n (%)	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum and Maximum)	Missing n (%)	95% CI for the Mean	I don't know n (%)
<b>Total Sample</b>	XX (XX%)	X.X	X.XX	X.X (X.X,X.X)	XX (XX, XX)	XX.X%	(X.XX, X.XX)	XX (XX.X%)
<b>Study Arm</b>								
Dynamic Implementation	XX (XX%)	X.X	X.XX	X.X (X.X,X.X)	XX (XX, XX)	XX.X%	(X.XX, X.XX)	XX (XX.X%)
Routine Implementation	XX (XX%)	X.X	X.XX	X.X (X.X,X.X)	XX (XX, XX)	XX.X%	(X.XX, X.XX)	XX (XX.X%)
<b>Site Volume</b>								
High	XX (XX%)	X.X	X.XX	X.X (X.X,X.X)	XX (XX, XX)	XX.X%	(X.XX, X.XX)	XX (XX.X%)
Low	XX (XX%)	X.X	X.XX	X.X (X.X,X.X)	XX (XX, XX)	XX.X%	(X.XX, X.XX)	XX (XX.X%)



**Table 3.804 Summary of Estimated Percentage of Staff Time/Full-Time Equivalent Hours Needed Per Week to Incorporate APRETUDE into Clinic/Practice for Approximately 25 People (Month 12/13), N=XX**

63. How much staff time/full-time equivalent hours (FTE) do you estimate is/will be needed per week to incorporate APRETUDE into your clinic/practice for approximately 25 people?	Total Sample n (%)	1-20% FTE or 0.4 - 8hrs of staff time n (%)	21-40% FTE or 8.4 - 16hrs of staff time n (%)	41-60% FTE or 16.4 - 24 hrs of staff time n (%)	61-80% FTE or 24.4 - 32hrs of staff time n (%)	81-100% FTE or 32.4 - 40hrs of staff time n (%)	I don't know n (%)
<b>Total Sample</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>							
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>							
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 3.805 Summary of Plans to Create New Roles/Positions in Clinic to Coordinate the APREITUDE Program (Month 12/13), N=XX**

64. Have you created or do you plan to create new role(s)/new position(s) in your clinic to coordinate the APREITUDE program?	Total Sample n (%)	Yes n (%)	No n (%)	Maybe n (%)	I don't know n (%)
<b>Total Sample</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>					
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>					
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 3.806 Summary of Number of New Roles/Positions in Clinic to Coordinate the APREUDE Program (Month 12/13), N=XX**

65. How many new role(s)/new position(s) have been or will be created in your clinic to coordinate the APREUDE program? [1]	Total Sample n (%)	1 n (%)	2 n (%)	3 n (%)	4 n (%)	5 n (%)	More than 5 n (%)	I don't know n (%)
<b>Total Sample</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>								
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>								
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

[1] Only includes SSPs who responded 'yes' or 'maybe' to 'Do you plan to create new role(s)/new position(s) in your clinic to coordinate the APREUDE program?'

**Table 3.807 Summary of How Clinic/Practice Plans to Track Patients on APRETUDE (Month 12/13), N=XX**

66. How is the clinic/practice tracking patients on APRETUDE?	Total Sample n (%)	Use a spreadsheet such as MS Excel n (%)	Assign specific staff to track patients n (%)	Have providers track their own patients n (%)	Create alerts in electronic medical records (EMRs) n (%)	Other [1] n (%)	I don't know n (%)
<b>Total Sample</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>							
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>							
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

[1] Other responses include: xxxxx

**Table 3.808 Summary of How Clinic/Practice Responds to Patients who Do Not Show for a Regularly Scheduled Appointment (Month 12/13), N=XX**

67. What does your clinic/practice do if a patient does not show for a APREUDE visit?	Total Sample n (%)	Phone the patient to reschedule n (%)	Text the patient to reschedule n (%)	Email the patient to reschedule n (%)	Send the patient a postal letter to reschedule n (%)	Wait until the patient contacts the clinic/practice to reschedule n (%)	Charge the patient a fee for not showing up n (%)	I don't know/not applicable to role n (%)	Other [1] n (%)
<b>Total Sample</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>									
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>									
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

[1] Other responses include: xxxxx

**Table 3.809 Summary of Whether Clinic/Practice has Specific Person in Charge of Following Up on No-Shows (Month 12/13), N=XX**

68. Is there a specific person in charge of following up on no-shows for APREUDE appointments?	Total Sample n (%)	Yes n (%)	No n (%)	I don't know n (%)
<b>Total Sample</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>				
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>				
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 3.810 Summary of Type of Systems Clinic has in Place to Remind Patients of Upcoming Appointments (Month 12/13), N=XX**

72. How do you remind patients of an upcoming APREUDE appointment?[1]	Total Sample n (%)	Phone Call from Staff n (%)	Automated Phone call n (%)	Text Message n (%)	Email n (%)	Postal Mail n (%)	Phone App Notification n (%)	I don't know n (%)	Other [2] n (%)
<b>Total Sample</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>									
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>									
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

[1] Responses are not mutually exclusive; participants can select all that apply

[2] Other responses included: xxxxx

Table 3.811 Summary of Type of Systems Clinic has in Place to Offer Upcoming Appointments (Month 12/13), N=XX

73. How does your practice/clinic currently offer appointments for APREUDE injections?	Total Sample	Study Arm		Site Volume	
		Dynamic Implementation	Routine Implementation	High	Low
	n (%)	n (%)	n (%)	n (%)	n (%)
Appointments each day of the week	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Appointments only on certain days of the week	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Appointments spread out over the month	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Injection only appointments	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Allow patients to drop-in for injections on any day without an appointment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Allow patients to drop-in with little advanced notice (e.g., 24 hour notice)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Allow patients to drop-in on a specific injection day without an appointment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
After hours appointments	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Before hours appointment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Weekend appointments	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Home nursing appointments	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mobile clinic option	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Alternate site appointments	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Depends on the schedule of the injection nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Depends on the schedule of the APREUDE provider	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Unsure	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

[1] Responses are not mutually exclusive; participants can select all that apply

[2] Other responses include : xxxxx



Table 3.812 Summary of Implementing APRETUDE in Practice (Month 12/13), N=XX

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
70	APRETUDE must be administered within a two-week injection window every two months after the loading doses.				
		Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Have not rescheduled any injections thus far	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
71	How easy or difficult has it been to reschedule appointments for APRETUDE injections?				
		Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Have not rescheduled any injections thus far	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
72	How do you remind patients of an upcoming APRETUDE appointment?				
		Phone call from Staff	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Automated phone call	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Text message	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Email	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Postal Mail	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Phone app notification	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
73	How does your practice/clinic currently offer appointments for APRETUDE injections?				
		Appointments each day of the week	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Appointments only on certain days of the week	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Appointments spread out over the month	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Injection-only appointments	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Allow patients to drop-in for injections on any day without an appointment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		Allow patients to drop-in with little advance notice (e.g., 24 hr notice)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Allow patients to drop-in on a specific injection day without an appointment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		After hours appointments	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Before hours appointment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Weekend appointments	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Home nursing appointments	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Mobile clinic option	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Alternate site appointments	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Depends on the schedule of the injection nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Depends on the schedule of the APRETUDE provider	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Unsure	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
74	How easy or difficult has it been to implement APRETUDE into your current workflow?				
		Very easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat easy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Neither easy nor difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Very difficult	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Have not rescheduled any injections thus far	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
75	On average, how long does an APRETUDE patient spend in the waiting room prior to an injection visit?	Up to 20 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		21-40 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		41-60 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		61-90 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		More than 90 minutes (more than 1.5 hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
76	On average, how long does an APRETUDE patient spend in the exam room during an injection visit?				
		Up to 20 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question Number	Question	Response	Total (N = XX) n (%)	Dynamic Implementation (N = XX) n (%)	Routine Implementation (N = XX) n (%)
		21-40 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		41-60 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		61-90 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		More than 90 minutes (more than 1.5 hrs)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
77	What is the observation period for a patient after an APRETUDE injection?				
		No observation period	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Up to 10 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		11-20 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		21-30 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		More than 30 minutes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
78	How do you feel about implementing APRETUDE at your clinic/practice?				
		Extremely positive	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Positive	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Somewhat positive	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		A little positive	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
		Not at all positive	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

**Table 3.813. Test for Differences of Implementation Arm by Site Volume on Feasibility of Intervention Measure, APREUDE (Month 12/13), N=XX**

Source	DF	MS	F	p
Study Arm (DI vs. RI)	X.XX	X.XXX	XX	0.XXXX
Volume (High vs. Low)	X.XX	X.XXX	XX	0.XXXX
Interaction, Arm by Volume	X.XX	X.XXX	XX	0.XXXX
Error	X.XX	X.XXX	-	-

**Table 3.814. Test for Differences of Implementation Arm by Site Volume on Feasibility of Intervention Measure, Implementation Support (Month 12/13), N=XX**

Source	DF	MS	F	p
Study Arm (DI vs. RI)	X.XX	X.XXX	XX	0.XXXX
Volume (High vs. Low)	X.XX	X.XXX	XX	0.XXXX
Interaction, Arm by Volume	X.XX	X.XXX	XX	0.XXXX
Error	X.XX	X.XXX	-	-

**Table 3.815. Test for Differences of Implementation Arm by Site Volume on Feasibility of Intervention Measure, Telehealth (Month 12/13), N=XX**

Source	DF	MS	F	p
Study Arm (DI vs. RI)	X.XX	X.XXX	XX	0.XXXX
Volume (High vs. Low)	X.XX	X.XXX	XX	0.XXXX
Interaction, Arm by Volume	X.XX	X.XXX	XX	0.XXXX
Error	X.XX	X.XXX	-	-

**Table 3.816. Test for Differences of Implementation Arm by Site Volume on Acceptability of Intervention Measure, APREUDE (Month 12/13), N=XX**

Source	DF	MS	F	p
Study Arm (DI vs. RI)	X.XX	X.XXX	XX	0.XXXX
Volume (High vs. Low)	X.XX	X.XXX	XX	0.XXXX
Interaction, Arm by Volume	X.XX	X.XXX	XX	0.XXXX
Error	X.XX	X.XXX	-	-

**Table 3.817. Test for Differences of Implementation Arm by Site Volume on Acceptability of Intervention Measure, Implementation Support (Month 12/13), N=XX**

Source	DF	MS	F	p
Study Arm (DI vs. RI)	X.XX	X.XXX	XX	0.XXXX
Volume (High vs. Low)	X.XX	X.XXX	XX	0.XXXX

Interaction, Arm by Volume	X.XX	X.XXX	XX	0.XXXX
Error	X.XX	X.XXX	-	-

**Table 3.818. Test for Differences of Implementation Arm by Site Volume on Acceptability of Intervention Measure, Telehealth (Month 12/13), N=XX**

Source	DF	MS	F	<i>p</i>
Study Arm (DI vs. RI)	X.XX	X.XXX	XX	0.XXXX
Volume (High vs. Low)	X.XX	X.XXX	XX	0.XXXX
Interaction, Arm by Volume	X.XX	X.XXX	XX	0.XXXX
Error	X.XX	X.XXX	-	-

Table 3.901 Quarterly Site Reporting

Question		Total	Dynamic Implementation	Routine Implementation
14. How many HIV PrEP seeking persons did the clinic/practice see in the last 3 months?				
<b>Baseline</b>	N	XX	XX	XX
	Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)
	Median	XX.X	XX.X	XX.X
	Q1, Q3	XX.X, XX.X	XX.X, XX.X	XX.X, XX.X
	Min-Max	X, X	X, X	X, X
<b>Quarter X*</b>	N	XX	XX	XX
	Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)
	Median	XX.X	XX.X	XX.X
	Q1, Q3	XX.X, XX.X	XX.X, XX.X	XX.X, XX.X
	Min-Max	X, X	X, X	X, X
15. How many patients would you estimate initiated any type of PrEP – oral or injectable – at the clinic/practice in the last 3 months?				
<b>Baseline</b>	N	XX	XX	XX
	Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)
	Median	XX.X	XX.X	XX.X
	Q1, Q3	XX.X, XX.X	XX.X, XX.X	XX.X, XX.X
	Min-Max	X, X	X, X	X, X
<b>Quarter X*</b>	N	XX	XX	XX
	Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)
	Median	XX.X	XX.X	XX.X
	Q1, Q3	XX.X, XX.X	XX.X, XX.X	XX.X, XX.X
	Min-Max	X, X	X, X	X, X
16. How many patients would you estimate initiated APREUDE in the last 3 months at the clinic/practice?				
<b>Baseline</b>	N	XX	XX	XX
	Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)
	Median	XX.X	XX.X	XX.X

Question		Total	Dynamic Implementation	Routine Implementation
	Q1, Q3	XX.X, XX.X	XX.X, XX.X	XX.X, XX.X
	Min-Max	X, X	X, X	X, X
<b>Quarter X*</b>	N	XX	XX	XX
	Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)
	Median	XX.X	XX.X	XX.X
	Q1, Q3	XX.X, XX.X	XX.X, XX.X	XX.X, XX.X
	Min-Max	X, X	X, X	X, X
17. Of all patients who have been prescribed PrEP at your clinic/practice, how many would you estimate have completed the Sexual Health Assessment provided by the PILLAR study?				
<b>Baseline</b>	N	XX	XX	XX
	Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)
	Median	XX.X	XX.X	XX.X
	Q1, Q3	XX.X, XX.X	XX.X, XX.X	XX.X, XX.X
	Min-Max	X, X	X, X	X, X
<b>Quarter X*</b>	N	XX	XX	XX
	Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)
	Median	XX.X	XX.X	XX.X
	Q1, Q3	XX.X, XX.X	XX.X, XX.X	XX.X, XX.X
	Min-Max	X, X	X, X	X, X

NOTE: reporting is not compiled on schedule with Month 4/5 or Month 12/13 collections, but is instead collected quarterly

\*To be populated for each quarter separately depending on available of quarterly data.

## 8 Multiple Timepoint Tables

---

The following tables combine reporting from Month 1, Month 4/5, and Month 12/13. Only items that were administered across all three timepoints are included in tables below. Stem wording is from Month 1 questionnaire; wording for the stem of some items differed between Month 1 and subsequent time points by verb tense.

Table 4.01	Summary of Staff Study Participants' Perceptions Regarding APREUDE .....	440
Table 4.02	Summary of Experiences with the Acquisition Process .....	444
Table 4.03	Summary of Perceived Number of APREUDE Patients Clinic/Practice Can Manage Per Week on an Ongoing Basis .....	451
Table 4.04	Distributional Characteristics of People in Clinic Trained and Prepared to Give APREUDE Injections .....	453
Table 4.05	Distributional Characteristics of Estimated Number of Staff Needed Per Week to Incorporate APREUDE into Clinic/Practice for Approximately 25 People .....	455
Table 4.06	Summary of Estimated Percentage of Staff Time/Full-Time Equivalent Hours Needed Per Week to Incorporate APREUDE into Clinic/Practice for Approximately 25 People .....	457
Table 4.07	Summary of Plans to Create New Roles/Positions in Clinic to Coordinate the APREUDE Program .....	459
Table 4.08	Summary of Number of New Roles/Positions in Clinic to Coordinate the APREUDE Program .....	460
Table 4.09	Summary of How Clinic/Practice Plans to Track Patients on APREUDE .....	462
Table 4.10	Summary of How Clinic/Practice Responds to Patients who Do Not Show for a Regularly Scheduled Appointment .....	463
Table 4.11	Summary of Whether Clinic/Practice has Specific Person in Charge of Following Up on No-Shows .....	465
Table 4.12	Summary of Type of Systems Clinic has in Place to Remind Patients of Upcoming Appointments .....	466
Table 4.13	Summary of Type of Systems Clinic has in Place to Offer Upcoming Appointments – Study Arm .....	468
Table 4.14	Summary of Type of Systems Clinic has in Place to Offer Upcoming Appointments – Site Volume .....	470



Table 4.01 Summary of Staff Study Participants' Perceptions Regarding APRETUDE

Question / Response	Month 1			Month 4/5			Month 12/13		
	Total	Dynamic Implementation	Routine Implementation	Total	Dynamic Implementation	Routine Implementation	Total	Dynamic Implementation	Routine Implementation
	(N = XX)	(N = XX)	(N = XX)	(N = XX)	(N = XX)	(N = XX)	(N = XX)	(N = XX)	(N = XX)
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
In your opinion, APRETUDE is appropriate for which individuals?									
Are Sexually Active	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Have Been Sexually Active With 1 Or More Partners In The Last 6 Months	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Are Currently Adherent On Daily Oral Prep	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Are Non-Adherent On Daily Oral Prep	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Use Prep On Demand (I.E., Event-Based Prep, Prep 2-1-1)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Could Benefit From Prep But Do Not Want To Use Daily Prep	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Have Previously Used And Discontinued Daily Prep	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Feel Stigmatized About Taking Oral Prep	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Request Apretude Spontaneously	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Have Sex Without A Condom	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Engage In Anal Sex	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question / Response	Month 1			Month 4/5			Month 12/13		
	Total	Dynamic Implementation	Routine Implementation	Total	Dynamic Implementation	Routine Implementation	Total	Dynamic Implementation	Routine Implementation
	(N = XX)	(N = XX)	(N = XX)	(N = XX)	(N = XX)	(N = XX)	(N = XX)	(N = XX)	(N = XX)
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
Have A Sexual Partner Living With HIV	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Live In Areas With High HIV Prevalence	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Currently Have Or Recently (Within The Past 6 Months) Have Had An STI Other Than HIV	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Are In Monogamous Relationships	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Inject Drugs	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Have Sex With A Person/People Who Inject Drugs	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Experience Stigma Around Using HIV Prevention	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Are Concerned About Taking Pills Every Day	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Experience Stress Or Anxiety Over Adherence Of A Daily Pill Regimen	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Have More Chaotic Lifestyles (E.G., Variable Work Schedules, Frequent Travel, Balancing Work And School)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Have More Structured Lifestyles (E.G., Regular Work	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question / Response	Month 1			Month 4/5			Month 12/13		
	Total	Dynamic Implementation	Routine Implementation	Total	Dynamic Implementation	Routine Implementation	Total	Dynamic Implementation	Routine Implementation
	(N = XX)	(N = XX)	(N = XX)	(N = XX)	(N = XX)	(N = XX)	(N = XX)	(N = XX)	(N = XX)
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
Hours, Little To No Unplanned Travels)									
Have Difficulty Planning Or Organizing	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Have Stable Income And Stable Housing	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Experience Homelessness Or Are Unstably Housed	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Have Psychiatric Comorbidities	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Have Sex With Someone Who Has Recently Been In Jail/Prison	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Are Incarcerated, Temporarily Incarcerated, Or Recently Released From Incarcerated	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Has any of the patients at this clinic/practice asked for (or about) APRETUDE?</b>									
Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Are you or this clinic/practice proactively informing patients about APRETUDE?</b>									

Question / Response	Month 1			Month 4/5			Month 12/13		
	Total	Dynamic Implementation	Routine Implementation	Total	Dynamic Implementation	Routine Implementation	Total	Dynamic Implementation	Routine Implementation
	(N = XX)	(N = XX)	(N = XX)	(N = XX)	(N = XX)	(N = XX)	(N = XX)	(N = XX)	(N = XX)
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
I Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>How are you or this clinic/practice informing patients about APRETUDE?</b>									
Provision Of Educational Materials	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
During Consultation With Patient	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Through Peer Educators	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Referring Patients To Prep Providers	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Posters In The Clinic/Practice	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Flyers In The Clinic/Practice	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mentions On The Clinic/Practice's Website	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mentions On Social Media	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Results from tables 1.004, 2.004, and 3.004.

Table 4.02 Summary of Experiences with the Acquisition Process

Question / Response	Month 1			Total	Month 4/5			Total	Month 12/13	
	Total	Dynamic Implementation	Routine Implementation		Dynamic Implementation	Routine Implementation	Dynamic Implementation		Routine Implementation	
	(N = XX)	(N = XX)	(N = XX)		(N = XX)	(N = XX)	(N = XX)		(N = XX)	
	n (%)	n (%)	n (%)		n (%)	n (%)	n (%)		n (%)	
Are you or will you be involved in any part of acquisition process for APREUDE, such as completing enrollment forms, prior authorization, claims, sending documents to insurance companies, and purchasing APREUDE?										
Yes	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	
No	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	
I Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	
How will your providers or clinic/practice acquire APREUDE?										
Buy-And-Bill - Purchases Apretude From A Wholesaler Or Specialty Distributor And Bills The Primary Third-Party Payer	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	
White Bagging - Submits Prescription To A Specialty Pharmacy Within ViiV's Specialty Pharmacy Network And The Specialty Pharmacy Processes The Claim And Ships Apretude For Administration	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	
Clear Bagging - Internal Pharmacy Maintains Inventory Of The Medication, Processes The Claim, And Delivers The Medication	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	

Question / Response	Month 1			Month 4/5			Month 12/13		
	Total	Dynamic Implementation	Routine Implementation	Total	Dynamic Implementation	Routine Implementation	Total	Dynamic Implementation	Routine Implementation
	(N = XX)	(N = XX)	(N = XX)	(N = XX)	(N = XX)	(N = XX)	(N = XX)	(N = XX)	(N = XX)
Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
I Don't Know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Who in your clinic/practice is responsible for completing the insurance benefits verification process for specialty medications for patients?									
Physician	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse Practitioner/ Physician Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Pharmacist	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Specialty Pharmacy	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Medical Assistant	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Social Worker/Case Manager	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Front Desk Staff/Scheduler	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Dedicated Administrator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Apretude Coordinator	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question / Response		Month 1			Month 4/5			Month 12/13		
		Total	Dynamic Implementation	Routine Implementation	Total	Dynamic Implementation	Routine Implementation	Total	Dynamic Implementation	Routine Implementation
		(N = XX)	(N = XX)	(N = XX)	(N = XX)	(N = XX)	(N = XX)	(N = XX)	(N = XX)	(N = XX)
I Don't Know		XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
For each item, please indicate how concerned you would be about each of the following based on your current expectations, understanding and knowledge of ViV Connect.										
Authorization Wait Times	Extremely Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Moderately Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Slightly Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Somewhat Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not At All Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Understanding Status of Authorization	Extremely Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Moderately Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Slightly Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Somewhat Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not At All Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Understanding how to seek assistance	Extremely Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Moderately Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question / Response		Month 1			Month 4/5			Month 12/13		
		Total	Dynamic Implementation	Routine Implementation	Total	Dynamic Implementation	Routine Implementation	Total	Dynamic Implementation	Routine Implementation
		(N = XX)	(N = XX)	(N = XX)	(N = XX)	(N = XX)	(N = XX)	(N = XX)	(N = XX)	(N = XX)
	Slightly Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Somewhat Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not At All Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Amount of paperwork	Extremely Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Moderately Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Slightly Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Somewhat Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not At All Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Clarity on Coverage Approval	Extremely Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Moderately Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Slightly Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Somewhat Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not At All Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Ensuring medication	Extremely Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)



Question / Response		Month 1			Month 4/5			Month 12/13		
		Total	Dynamic Implementation	Routine Implementation	Total	Dynamic Implementation	Routine Implementation	Total	Dynamic Implementation	Routine Implementation
		(N = XX)	(N = XX)	(N = XX)	(N = XX)	(N = XX)	(N = XX)	(N = XX)	(N = XX)	(N = XX)
<i>comes to the right place (e.g., clinic/practice, pharmacy)</i>	Moderately Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Slightly Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Somewhat Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not At All Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Potential loss of enthusiasm for APREUDE by patients	Extremely Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Moderately Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Slightly Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Somewhat Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not At All Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Potential patient dissatisfaction with clinic staff	Extremely Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Moderately Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Slightly Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Somewhat Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not At All Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question / Response		Month 1			Month 4/5			Month 12/13		
		Total	Dynamic Implementation	Routine Implementation	Total	Dynamic Implementation	Routine Implementation	Total	Dynamic Implementation	Routine Implementation
		(N = XX)	(N = XX)	(N = XX)	(N = XX)	(N = XX)	(N = XX)	(N = XX)	(N = XX)	(N = XX)
Staff dissatisfaction with the acquisition process	Extremely Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Moderately Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Slightly Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Somewhat Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not At All Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Potential Disruption of Clinic Flow	Extremely Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Moderately Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Slightly Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Somewhat Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not At All Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Time-consuming Process	Extremely Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Moderately Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Slightly Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Somewhat Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Question / Response		Month 1			Month 4/5			Month 12/13		
		Total (N = XX)	Dynamic Implementation (N = XX)	Routine Implementation (N = XX)	Total (N = XX)	Dynamic Implementation (N = XX)	Routine Implementation (N = XX)	Total (N = XX)	Dynamic Implementation (N = XX)	Routine Implementation (N = XX)
	Not At All Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Inequitable Access for Eligible Patients	Extremely Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Moderately Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Slightly Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Somewhat Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
	Not At All Concerned	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
I would recommend Viiv Connect to other providers and clinics/practices to aid in the acquisition of Viiv medications										
Agree		XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Disagree		XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Neither Agree Or Disagree		XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Completely Disagree		XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Completely Agree		XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Results from tables 1.005, 2.005, and 3.005.

Table 4.03 Summary of Perceived Number of APREUDE Patients Clinic/Practice Can Manage Per Week on an Ongoing Basis

How many APREUDE patients do you think your clinic/practice can manage per week on an ongoing basis?	Total Sample n (%)	0-10 Patients n (%)	11-25 Patients n (%)	26-50 Patients n (%)	51-100 Patients n (%)	101-200 Patients n (%)	>200 Patients n (%)	I don't know n=xx (%)
Month 1								
Total Sample	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Study Arm								
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Site Volume								
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Month 4/5								
Total Sample	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Study Arm								
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Site Volume								
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Month 12/13								
Total Sample	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Study Arm								
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Site Volume								
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Results from tables 1.801, 2. 801, and 3. 801.

Table 4.04 Distributional Characteristics of People in Clinic Trained and Prepared to Give APRETUDE Injections

Approximately how many people in your clinic are trained and prepared to give APRETUDE injections?	Total Sample n (%)	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% Confidence Interval	I don't know n (%)
<b>Month 1</b>								
<b>Total Sample</b>	XX (XX.X%)	X.X	X.XX	X.X (X.X, X.X)	XX (XX, XX)	XX (XX.X%)	(X.XX, X.XX)	XX (XX.X%)
<b>Study Arm</b>								
Dynamic Implementation	XX (XX.X%)	X.X	X.XX	X.X (X.X, X.X)	XX (XX, XX)	XX (XX.X%)	(X.XX, X.XX)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	X.X	X.XX	X.X (X.X, X.X)	XX (XX, XX)	XX (XX.X%)	(X.XX, X.XX)	XX (XX.X%)
<b>Site Volume</b>								
High	XX (XX.X%)	X.X	X.XX	X.X (X.X, X.X)	XX (XX, XX)	XX (XX.X%)	(X.XX, X.XX)	XX (XX.X%)
Low	XX (XX.X%)	X.X	X.XX	X.X (X.X, X.X)	XX (XX, XX)	XX (XX.X%)	(X.XX, X.XX)	XX (XX.X%)
<b>Month 4/5</b>								
<b>Total Sample</b>	XX (XX.X%)	X.X	X.XX	X.X (X.X, X.X)	XX (XX, XX)	XX (XX.X%)	(X.XX, X.XX)	XX (XX.X%)
<b>Study Arm</b>								
Dynamic Implementation	XX (XX.X%)	X.X	X.XX	X.X (X.X, X.X)	XX (XX, XX)	XX (XX.X%)	(X.XX, X.XX)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	X.X	X.XX	X.X (X.X, X.X)	XX (XX, XX)	XX (XX.X%)	(X.XX, X.XX)	XX (XX.X%)
<b>Site Volume</b>								
High	XX (XX.X%)	X.X	X.XX	X.X (X.X, X.X)	XX (XX, XX)	XX (XX.X%)	(X.XX, X.XX)	XX (XX.X%)
Low	XX (XX.X%)	X.X	X.XX	X.X (X.X, X.X)	XX (XX, XX)	XX (XX.X%)	(X.XX, X.XX)	XX (XX.X%)
<b>Month 12/13</b>								
<b>Total Sample</b>	XX (XX.X%)	X.X	X.XX	X.X (X.X, X.X)	XX (XX, XX)	XX (XX.X%)	(X.XX, X.XX)	XX (XX.X%)
<b>Study Arm</b>								
Dynamic Implementation	XX (XX.X%)	X.X	X.XX	X.X (X.X, X.X)	XX (XX, XX)	XX (XX.X%)	(X.XX, X.XX)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	X.X	X.XX	X.X (X.X, X.X)	XX (XX, XX)	XX (XX.X%)	(X.XX, X.XX)	XX (XX.X%)
<b>Site Volume</b>								
High	XX (XX.X%)	X.X	X.XX	X.X (X.X, X.X)	XX (XX, XX)	XX (XX.X%)	(X.XX, X.XX)	XX (XX.X%)
Low	XX (XX.X%)	X.X	X.XX	X.X (X.X, X.X)	XX (XX, XX)	XX (XX.X%)	(X.XX, X.XX)	XX (XX.X%)

Results from tables 1.802, 2.802, and 3.802.

**Table 4.05      Distributional Characteristics of Estimated Number of Staff Needed Per Week to Incorporate APRETUDE into Clinic/Practice for Approximately 25 People**

How much staff in total do you estimate will be needed per week to incorporate APRETUDE into your clinic/practice for approximately 25 people?	Total Sample n (%)	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean	I don't know n (%)
<b>Month 1</b>								
<b>Total Sample</b>	XX (XX.X%)	X.XX	X.XXX	X.XX (X.XX,X.XX)	XX.X (XX.X, XX.X)	XX (XX.X%)	(X.XX, X.XX)	XX (XX.X%)
<b>Study Arm</b>								
Dynamic Implementation	XX (XX.X%)	X.XX	X.XXX	X.XX (X.XX,X.XX)	XX.X (XX.X, XX.X)	XX (XX.X%)	(X.XX, X.XX)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	X.XX	X.XXX	X.XX (X.XX,X.XX)	XX.X (XX.X, XX.X)	XX (XX.X%)	(X.XX, X.XX)	XX (XX.X%)
<b>Site Volume</b>								
High	XX (XX.X%)	X.XX	X.XXX	X.XX (X.XX,X.XX)	XX.X (XX.X, XX.X)	XX (XX.X%)	(X.XX, X.XX)	XX (XX.X%)
Low	XX (XX.X%)	X.XX	X.XXX	X.XX (X.XX,X.XX)	XX.X (XX.X, XX.X)	XX (XX.X%)	(X.XX, X.XX)	XX (XX.X%)
<b>Month 4/5</b>								
<b>Total Sample</b>	XX (XX.X%)	X.XX	X.XXX	X.XX (X.XX,X.XX)	XX.X (XX.X, XX.X)	XX (XX.X%)	(X.XX, X.XX)	XX (XX.X%)
<b>Study Arm</b>								
Dynamic Implementation	XX (XX.X%)	X.XX	X.XXX	X.XX (X.XX,X.XX)	XX.X (XX.X, XX.X)	XX (XX.X%)	(X.XX, X.XX)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	X.XX	X.XXX	X.XX (X.XX,X.XX)	XX.X (XX.X, XX.X)	XX (XX.X%)	(X.XX, X.XX)	XX (XX.X%)
<b>Site Volume</b>								
High	XX (XX.X%)	X.XX	X.XXX	X.XX (X.XX,X.XX)	XX.X (XX.X, XX.X)	XX (XX.X%)	(X.XX, X.XX)	XX (XX.X%)
Low	XX (XX.X%)	X.XX	X.XXX	X.XX (X.XX,X.XX)	XX.X (XX.X, XX.X)	XX (XX.X%)	(X.XX, X.XX)	XX (XX.X%)
<b>Month 12/13</b>								
<b>Total Sample</b>	XX (XX.X%)	X.XX	X.XXX	X.XX (X.XX,X.XX)	XX.X (XX.X, XX.X)	XX (XX.X%)	(X.XX, X.XX)	XX (XX.X%)
<b>Study Arm</b>								
Dynamic Implementation	XX (XX.X%)	X.XX	X.XXX	X.XX (X.XX,X.XX)	XX.X (XX.X, XX.X)	XX (XX.X%)	(X.XX, X.XX)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	X.XX	X.XXX	X.XX (X.XX,X.XX)	XX.X (XX.X, XX.X)	XX (XX.X%)	(X.XX, X.XX)	XX (XX.X%)
<b>Site Volume</b>								



How much staff in total do you estimate will be needed per week to incorporate APRETUDE into your clinic/practice for approximately 25 people?	Total Sample n (%)	Mean	SD	Median (Q1, Q3)	Observed Range (Minimum, Maximum)	Missing n (%)	95% CI for the Mean	I don't know n (%)
High	XX (XX.X%)	X.XX	X.XXX	X.XX (X.XX,X.XX)	XX.X (XX.X, XX.X)	XX (XX.X%)	(X.XX, X.XX)	XX (XX.X%)
Low	XX (XX.X%)	X.XX	X.XXX	X.XX (X.XX,X.XX)	XX.X (XX.X, XX.X)	XX (XX.X%)	(X.XX, X.XX)	XX (XX.X%)

Results from tables 1.803, 2.803, and 3.803.

**Table 4.06 Summary of Estimated Percentage of Staff Time/Full-Time Equivalent Hours Needed Per Week to Incorporate APRETUDE into Clinic/Practice for Approximately 25 People**

How much staff time/full-time equivalent hours (FTE) do you estimate will be needed per week to incorporate APRETUDE into your clinic/practice for approximately 25 people?	Total Sample n (%)	1-20% FTE or 0.4 - 8hrs of staff time n (%)	21-40% FTE or 8.4 - 16hrs of staff time n (%)	41-60% FTE or 16.4 - 24 hrs of staff time n (%)	61-80% FTE or 24.4 – 32hrs of staff time n (%)	81-100% FTE or 32.4 - 40hrs of staff time n (%)	I don't know n (%)
<b>Month 1</b>							
<b>Total Sample</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>							
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>							
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Month 4/5</b>							
<b>Total Sample</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>							
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>							
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Month 12/13</b>							

How much staff time/full-time equivalent hours (FTE) do you estimate will be needed per week to incorporate APRETUDE into your clinic/practice for approximately 25 people?	Total Sample n (%)	1-20% FTE or 0.4 - 8hrs of staff time n (%)	21-40% FTE or 8.4 - 16hrs of staff time n (%)	41-60% FTE or 16.4 - 24 hrs of staff time n (%)	61-80% FTE or 24.4 - 32hrs of staff time n (%)	81-100% FTE or 32.4 - 40hrs of staff time n (%)	I don't know n (%)
<b>Total Sample</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>							
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>							
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Results from tables 1.804, 2.804, and 3.804.

**Table 4.07 Summary of Plans to Create New Roles/Positions in Clinic to Coordinate the APREUDE Program**

Do you plan to create new role(s)/new position(s) in your clinic to coordinate the APREUDE program?	Total Sample n (%)	Yes n (%)	No n (%)	Maybe n (%)	I don't know n (%)
<b>Month 1</b>					
<b>Total Sample</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>					
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>					
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Month 4/5</b>					
<b>Total Sample</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>					
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>					
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Month 12/13</b>					
<b>Total Sample</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>					
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>					
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Results from tables 1.805, 2.805, and 3.805.

**Table 4.08 Summary of Number of New Roles/Positions in Clinic to Coordinate the APREUDE Program**

How many new role(s)/new position(s) are you planning to create in your clinic to coordinate the APREUDE program?	Total Sample	1	2	3	4	5	More than 5	I don't know
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
<b>Month 1</b>								
<b>Total Sample</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>								
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>								
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Month 4/5</b>								
<b>Total Sample</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>								
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>								
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Month 12/13</b>								
<b>Total Sample</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>								
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>								
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

How many new role(s)/new position(s) are you planning to create in your clinic to coordinate the APRETUDE program?	Total Sample	1	2	3	4	5	More than 5	I don't know
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Results from tables 1.806, 2.806, and 3.806.

Table 4.09 Summary of How Clinic/Practice Plans to Track Patients on APRETUDE

How does your clinic/practice plan to track patients on APRETUDE?	Total Sample n (%)	Use a spreadsheet such as MS Excel n (%)	Assign specific staff to track patients n (%)	Have providers track their own patients n (%)	Create alerts in electronic medical records (EMRs) n (%)	Other [1] n (%)	I don't know n (%)
<b>Month 1</b>							
<b>Total Sample</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>							
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>							
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Month 4/5</b>							
<b>Total Sample</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>							
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>							
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Month 12/13</b>							
<b>Total Sample</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>							
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>							
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Results from tables 1.807, 2.807, and 3.807.

Table 4.10 Summary of How Clinic/Practice Responds to Patients who Do Not Show for a Regularly Scheduled Appointment

What does your clinic/practice do if a patient does not show for a regularly scheduled appointment?	Total Sample n (%)	Phone the patient to reschedule n (%)	Text the patient to reschedule n (%)	Email the patient to reschedule n (%)	Send the patient a postal letter to reschedule n (%)	Wait until the patient contacts the clinic/practice to reschedule n (%)	Charge the patient a fee for not showing up n (%)	I don't know/not applicable to role n (%)	Other n (%)
<b>Month 1</b>									
<b>Total Sample</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>									
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>									
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Month 4/5</b>									
<b>Total Sample</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>									
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>									
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Month 12/13</b>									
<b>Total Sample</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>									
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>									



What does your clinic/practice do if a patient does not show for a regularly scheduled appointment?	Total Sample n (%)	Phone the patient to reschedule n (%)	Text the patient to reschedule n (%)	Email the patient to reschedule n (%)	Send the patient a postal letter to reschedule n (%)	Wait until the patient contacts the clinic/practice to reschedule n (%)	Charge the patient a fee for not showing up n (%)	I don't know/not applicable to role n (%)	Other n (%)
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Results from tables 1.808, 2.808, and 3.808.

**Table 4.11 Summary of Whether Clinic/Practice has Specific Person in Charge of Following Up on No-Shows**

Is there a specific person in charge of following up on no-shows?	Total Sample n (%)	Yes n (%)	No n (%)	I don't know n (%)
<b>Month 1</b>				
<b>Total Sample</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>				
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>				
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Month 4/5</b>				
<b>Total Sample</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>				
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>				
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Month 12/13</b>				
<b>Total Sample</b>	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Study Arm</b>				
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
<b>Site Volume</b>				
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Results from tables 1.809, 2.809, and 3.809.

Table 4.12 Summary of Type of Systems Clinic has in Place to Remind Patients of Upcoming Appointments

What type of systems does your clinic have in place to remind patients of an upcoming appointment?	Total Sample n (%)	Phone Call from Staff n (%)	Automated Phone call n (%)	Text Message n (%)	Email n (%)	Postal Mail n (%)	Phone App Notification n (%)	Other n (%)
Month 1								
Total Sample	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Study Arm								
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Site Volume								
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Month 4/5								
Total Sample	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Study Arm								
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Site Volume								
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Month 12/13								
Total Sample	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Study Arm								
Dynamic Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Routine Implementation	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Site Volume								
High	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

What type of systems does your clinic have in place to remind patients of an upcoming appointment?	Total Sample n (%)	Phone Call from Staff n (%)	Automated Phone call n (%)	Text Message n (%)	Email n (%)	Postal Mail n (%)	Phone App Notification n (%)	Other n (%)
Low	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Results from tables 1.810, 2.810, and 3.810.

Table 4.13 Summary of Type of Systems Clinic has in Place to Offer Upcoming Appointments – Study Arm

How do you plan to offer appointments for APREUDE injections?	Month 1			Month 4/5			Month 12/13		
	Study Arm		Total Sample	Study Arm		Total Sample	Study Arm		Total Sample
	Dynamic Implementation	Routine Implementation		Dynamic Implementation	Routine Implementation		Dynamic Implementation	Routine Implementation	
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
Appointments each day of the week	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Appointments only on certain days of the week	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Appointments spread out over the month	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Injection-only appointments	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Allow patients to drop-in for injections on any day without an appointment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Allow patients to drop-in with little advanced notice (e.g., 24 hour notice)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Allow patients to drop-in on a specific injection day without an appointment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
After hours appointments	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

How do you plan to offer appointments for APRETUDE injections?	Month 1			Month 4/5			Month 12/13		
	Study Arm		Total Sample	Study Arm		Total Sample	Study Arm		Total Sample
	Dynamic Implementation	Routine Implementation		Dynamic Implementation	Routine Implementation		Dynamic Implementation	Routine Implementation	
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
Before hours appointment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Weekend appointments	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Home nursing appointments	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mobile clinic option	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Alternate site appointments	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Depends on the schedule of the injection nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Depends on the schedule of the APRETUDE provider	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Results from tables 1.811, 2.811, and 3.811.

Table 4.14 Summary of Type of Systems Clinic has in Place to Offer Upcoming Appointments – Site Volume

How do you plan to offer appointments for APRETUDE injections?	Total Sample n (%)	Month 1 Site Volume		Total Sample n (%)	Month 4/5 Site Volume		Total Sample n (%)	Month 12/13 Site Volume	
		High Volume n (%)	Low Volume n (%)		High Volume n (%)	Low Volume n (%)		High Volume n (%)	Low Volume n (%)
Appointments each day of the week	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Appointments only on certain days of the week	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Appointments spread out over the month	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Injection-only appointments	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Allow patients to drop-in for injections on any day without an appointment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Allow patients to drop-in with little advanced notice (e.g., 24 hour notice)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Allow patients to drop-in on a specific injection day without an appointment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
After hours appointments	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Before hours appointment	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

How do you plan to offer appointments for APRETUDE injections?	Month 1			Month 4/5			Month 12/13		
	Total Sample n (%)	Site Volume		Total Sample n (%)	Site Volume		Site Volume n (%)	Site Volume	
		High Volume n (%)	Low Volume n (%)		High Volume n (%)	Low Volume n (%)		High Volume n (%)	Low Volume n (%)
Weekend appointments	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Home nursing appointments	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Mobile clinic option	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Alternate site appointments	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Depends on the schedule of the injection nurse	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Depends on the schedule of the APRETUDE provider	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
Other	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)
I don't know	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)

Results from tables 1.811, 2.811, and 3.81